Created
August 22, 2023 14:57
-
-
Save nielsdejong/2d70dce2af5ee0938722657155538702 to your computer and use it in GitHub Desktop.
We can't make this file beautiful and searchable because it's too large.
This file contains hidden or bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
| "Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL" | |
| 1,"NCT04291703","Low Dose Antithymocyte Globulin (ATG) to Delay or Prevent Progression to Stage 3 T1D","TN28","Not yet recruiting","No Results Available","Diabetes Mellitus, Type 1","Drug: Antithymocyte Globulin|Drug: Placebo (for ATG)","Progression to Stage 3 T1D","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","12 Years to 34 Years (Child, Adult)","Phase 2","114","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","TrialNet TN28|UC4DK117009","December 2022","December 31, 2028","December 31, 2029","March 2, 2020",,"November 28, 2022",,,"https://ClinicalTrials.gov/show/NCT04291703" | |
| 2,"NCT05593081","Multicenter Study of Fulminant Type 1 Diabetes in China",,"Recruiting","No Results Available","Diabetes Mellitus, Type 1","Genetic: HLA","Change in serum hemoglobin A1c level|Change in titer of autoantibodies|Treatment options|The incidence of chronic complications of diabetes mellitus","Second Xiangya Hospital of Central South University","All","Child, Adult, Older Adult",,"240","Other","Observational","Observational Model: Other|Time Perspective: Other","F1 China","May 20, 2022","December 31, 2027","December 31, 2027","October 25, 2022",,"October 25, 2022","Quanzhou First People's Hospital, Quanzhou, Fujian, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China|The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China|Guizhou Provincial People's Hospital, Zunyi, Guangzhou, China|Hainan Provincial People's Hospital, Haikou, Hainan, China|Changsha Central Hospital, Changsha, Hunan, China|Yancheng Third People's Hospital, Yancheng, Jiangs, China|The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China|Yunnan Provincial People's Hospital, Kunming, Yunnan, China|The Second Xiangya Hospital of Central South University, Changsha, China",,"https://ClinicalTrials.gov/show/NCT05593081" | |
| 3,"NCT04616391","AHCL System Initiation in T1D Patients naïve to Technology",,"Unknown status","No Results Available","Diabetes Mellitus, Type 1","Device: insulin pump Medtronic 780G","Between group TIR difference|Between group TIR difference >70%|Between group difference in the percentage of time spent:|Between group difference in the mean glucose level|Between group difference in the glycemic variability measure by SD and CV|Between group difference in the HbA1c levels|Between group difference in the Diabetes Quality of Life (QoL) questionnaire score","Jagiellonian University|Medtronic Poland Spółka z ograniczoną odpowiedzialnością|University of Rzeszow","All","26 Years to 60 Years (Adult)","Not Applicable","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","1072.61201.8.2020","November 2, 2020","March 31, 2021","July 1, 2021","November 5, 2020",,"November 5, 2020",,,"https://ClinicalTrials.gov/show/NCT04616391" | |
| 4,"NCT04670198","A Psychosocial Education Programme for Young People With Type 1 Diabetes - the Youth Empowerment Skills (YES)","YES","Active, not recruiting","No Results Available","Diabetes Mellitus, Type 1","Behavioral: Youth Empowerment Skills|Behavioral: Waiting-list control","Glycated haemoglobin (HbA1c)|Frequency of blood glucose monitoring|Insulin adherence|Self-Management of Diabetes in Adolescence Scale (SMOD-A)|Confidence in Diabetes Self-Care Scale (CDSS)|Diabetes Quality of Life Instrument (DQOL) (adapted for youth)|Brief Illness Perception Questionnaire (IPQ-B)|Emergency care events|Hypoglycaemia and severe hypoglycaemic events|Weight|Intervention Appropriateness Measure (IAM)|Feasibility of Intervention Measure (FIM)|Acceptability of Intervention Measure (AIM)","King's College London|Guy's and St Thomas' Foundation NHS Trust|Diabetes UK","All","14 Years to 19 Years (Child, Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","D-UK 19/0006055","June 1, 2021","March 31, 2023","March 31, 2023","December 17, 2020",,"April 7, 2022","Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom|University Lewisham Hospital, London, United Kingdom|Queen Elizabeth Hospital, London, United Kingdom|King's College Hospital, London, United Kingdom|St George's University Hospital HS Foundation Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04670198" | |
| 5,"NCT02215200","ATG-GCSF in New Onset Type 1 Diabetes","ATG-GCSF","Completed","Has Results","Diabetes Mellitus, Type 1","Drug: Anti-Thymocyte Globulin (ATG)|Drug: Granulocyte colony stimulating factor (GCSF)|Drug: Placebo (for ATG)|Drug: Placebo (for GCSF)","Change in Area Under the Stimulated C-peptide Curve From Baseline to 12 Months.","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Center for Research Resources (NCRR)|Juvenile Diabetes Research Foundation|American Diabetes Association|Sanofi|The Leona M. and Harry B. Helmsley Charitable Trust|Amgen","All","12 Years to 45 Years (Child, Adult)","Phase 2","89","NIH|Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ATG-GCSF (IND)|Type 1 Diabetes TrialNet|TN19|UC4DK106993|UC4DK117009","December 2014","August 2017","August 2018","August 13, 2014","March 2, 2020","March 2, 2020","University of California - San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|Barbara Davis Center, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|University of Florida, Gainesville, Florida, United States|University of Miami, Miami, Florida, United States|University of South Florida Diabetes Center, Tampa, Florida, United States|Indiana University-Riley Hospital for Children, Indianapolis, Indiana, United States|University of Minnesota, Minneapolis, Minnesota, United States|Columbia University-Naomi Berrie Diabetes Center, New York, New York, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Vanderbilt Eskind Diabetes Clinic, Nashville, Tennessee, United States|Benaroya Research Institute, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT02215200/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT02215200/ICF_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT02215200/SAP_002.pdf","https://ClinicalTrials.gov/show/NCT02215200" | |
| 6,"NCT03400618","Carbohydrate Content in the Diet in Type 1 Diabetes",,"Recruiting","No Results Available","Diabetes Mellitus, Type 1","Other: Moderate carbohydrate diet|Other: Higher carbohydrate diet","The difference in mean glucose level|The difference in standard deviation of glucose levels|The difference in the proportion of time with high glucose levels|The difference in the proportion of time with euglycaemic levels|Weight|Total cholesterol|LDL cholesterol|HDL cholesterol|Triglycerides|Total insulin dose|Diabetes Treatment Satisfaction Questionnaire (DTSQc) score|Diabetes Treatment Satisfaction Questionnaire (DTSQs) score|Hypoglycemia confidence score","Vastra Gotaland Region","All","18 Years and older (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Carbohydrate study","March 1, 2018","December 2022","December 2022","January 17, 2018",,"November 12, 2021","NU Hospital Organization, Uddevalla, Sweden",,"https://ClinicalTrials.gov/show/NCT03400618" | |
| 7,"NCT05541484","Ketone Monitoring in T1D: Effect of SGLT2i During Usual Care and With Insulin Deficiency",,"Recruiting","No Results Available","Diabetes Mellitus, Type 1","Drug: SGLT2 inhibitor|Device: Biosense Breath Ketone Analyzer","Ketone levels measured in blood and breath in persons with T1D in persons with T1D|Ketone levels in persons with T1D during usual care versus usual care plus SGLT2i treatment","Washington University School of Medicine|Juvenile Diabetes Research Foundation","All","18 Years to 75 Years (Adult, Older Adult)","Phase 4","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","202206078","October 14, 2022","September 2023","August 2024","September 15, 2022",,"December 8, 2022","Washington University, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT05541484" | |
| 8,"NCT05575609","Anthropometric Measurements and Balance in Children With Diabetes Relation Between Anthropometric Measurements and Balance in Children With Type 1 Diabetes",,"Recruiting","No Results Available","Diabetes Mellitus, Type 1","Other: children with Diabetes Mellitus, Type 1","balance|weight anthropometric measurement|height anthropometric measurement","Cairo University","All","7 Years to 11 Years (Child)",,"50","Other","Observational","Observational Model: Other|Time Perspective: Prospective","diabetes","November 1, 2022","November 30, 2023","November 30, 2023","October 12, 2022",,"December 7, 2022","Amira Mahmoud Abd-elmonem, Giza, Egypt",,"https://ClinicalTrials.gov/show/NCT05575609" | |
| 9,"NCT05143411","Evaluation of a Mobile Application to Optimize Self-decision on Metabolic Control in Persons With Type 1 Diabetes","DM-BLUE","Completed","No Results Available","Diabetes Mellitus, Type 1","Other: PRE-test","Change in glucose levels|Change in glycemic variability","Universidad Iberoamericana|Clemson University","All","14 Years to 18 Years (Child, Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2018-2019-3C1-044","October 8, 2021","March 8, 2022","March 28, 2022","December 3, 2021",,"November 2, 2022","Universidad Iberoamericana, Santo Domingo, Distrito Nacional, Dominican Republic",,"https://ClinicalTrials.gov/show/NCT05143411" | |
| 10,"NCT04758884","Telemedicine in Patients With Type 1 Diabetes Mellitus.",,"Unknown status","No Results Available","Diabetes Mellitus, Type 1","Other: Telemedicine","To compare changes in HbA1c at 6 months in a group of patients with T1D in the reference area of the ""Hospital Comarcal de l´Alt Penedès"" followed by telemedicine versus to the usual management in consultation.|Differences in terms of HbA1c at 3 months in a group of patients with T1D followed by telemedicine versus to the usual management in consultation.|Differences in terms of Quality-of-life questionnaire designed for diabetes mellitus (EsDQOL) in a group of patients with T1D followed by telemedicine versus to the usual management in consultation.|Differences in terms of episodes of symptomatic hypoglycemia in a group of patients with T1D followed by telemedicine versus to the usual management in consultation.|Differences in terms of glucometry in a group of patients with T1D followed by telemedicine versus to the usual management in consultation.|Differences in terms of total time spent by endocrinologist in a group of patients with T1D followed by telemedicine versus to the usual management in consultation.|Differences in terms of indirect costs in a group of patients with T1D followed by telemedicine versus to the usual management in consultation.|Differences in terms of number of unplanned contacts with the specialist in a group of patients with T1D followed by telemedicine versus to the usual management in consultation.","Consorci Sanitari de l'Alt Penedès i Garraf","All","18 Years and older (Adult, Older Adult)","Not Applicable","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CSAPG-05","January 1, 2021","September 30, 2021","September 30, 2021","February 17, 2021",,"February 17, 2021","Hospital Comarcal de l'Alt Penedès, Vilafranca Del Penedès, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04758884" | |
| 11,"NCT04729296","Anti-TNFα to Delay or Prevent Progression to Stage 3 T1D",,"Withdrawn","No Results Available","Diabetes Mellitus, Type 1","Drug: Golimumab|Drug: Placebo","The primary outcome is the elapsed time from random treatment assignment to the development of diabetes (T1D) or time of last contact among those randomized","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of South Florida","All","3 Years to 46 Years (Child, Adult)","Phase 2","0","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","TN30 Anti-TNFα|2U01DK106993-02|1UC4DK117009-01","July 1, 2021","July 1, 2027","July 1, 2027","January 28, 2021",,"December 2, 2021",,,"https://ClinicalTrials.gov/show/NCT04729296" | |
| 12,"NCT04226378","Canadian Real-World Outcomes of Omnipod Initiation in People With T1D","COPPER","Completed","No Results Available","Diabetes Mellitus, Type 1","Device: Omnipod|Other: MDI","Glycated hemoglobin (A1C)|Proportion of patients achieving A1C < 7.0%|Proportion of patients achieving A1C < 8.0%|Weight|Body mass index (BMI)|Total daily dose (TDD) of insulin|Weekly incidence of hypoglycemia|Annual incidence of severe hypoglycemia","LMC Diabetes & Endocrinology Ltd.|Insulet Corporation","All","18 Years and older (Adult, Older Adult)",,"286","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","COPPER","January 20, 2020","February 9, 2020","February 9, 2020","January 13, 2020",,"February 21, 2020","LMC Healthcare, Toronto, Canada",,"https://ClinicalTrials.gov/show/NCT04226378" | |
| 13,"NCT04160156","Long-term, Implantable Sensor Improves Health Outcomes in Patients With T1D",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Device: Long term sensor","HbA1c (%)|Time in Range (%)|Time Below Range (%)|Time Above Range (%)|Mean Daily Glucose (mmol/l)|Glucose Standard Deviation (mmol/L)","University Magna Graecia","All","18 Years and older (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Long term implantable sensor","June 5, 2018","June 30, 2019","June 30, 2019","November 12, 2019",,"November 12, 2019","University Magna Graecia, Catanzaro, Italy",,"https://ClinicalTrials.gov/show/NCT04160156" | |
| 14,"NCT04978662","Sleep and Chronotype in Children With Type 1 Diabetes",,"Enrolling by invitation","No Results Available","Diabetes Mellitus, Type 1",,"sleep wake patterns measured by actigraphy|sleep disorder|chronotype|metabolic control|treatment","Marmara University|The Scientific and Technological Research Council of Turkey","All","6 Years to 18 Years (Child, Adult)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","120S789","July 6, 2021","October 2021","December 2021","July 27, 2021",,"July 27, 2021","Marmara University School of Medicine, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04978662" | |
| 15,"NCT05626712","Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes","CREATE-1","Not yet recruiting","No Results Available","Type 1 Diabetes|Diabetes Mellitus, Type 1","Biological: CELZ-201 Administration|Other: Control Group","Number of Participants with Adverse Events|Glycosylated HbA1C|Insulin Requirement|Islet Autoantibody Levels|Alloreactive Antibody Levels|C-peptide during a 4-hour MMTT","Creative Medical Technology Holdings Inc","All","18 Years to 35 Years (Adult)","Phase 1|Phase 2","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CELZ-201-001","January 1, 2023","January 31, 2025","January 31, 2026","November 25, 2022",,"November 25, 2022","Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT05626712" | |
| 16,"NCT04081883","Biosensors for Open and Closed-loop Glycemia Control in T1D Patients With Insulin Pump","DIABLO","Not yet recruiting","No Results Available","Diabetes Mellitus, Type 1","Other: Biosensor algorithm","Comparison between biosensor to CGMS responses","University Hospital, Bordeaux","All","18 Years and older (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHUBX 2018/48","January 2022","January 2023","January 2023","September 9, 2019",,"June 7, 2021","Hôpital Saint-André, Bordeaux, France",,"https://ClinicalTrials.gov/show/NCT04081883" | |
| 17,"NCT02908555","Sleep, Coping and Executive Functioning in Youth With Type 1 Diabetes","SleepT1D","Completed","No Results Available","Diabetes Mellitus, Type 1","Other: No intervention","Glycemic control|Executive functioning","Yale University","All","10 Years to 16 Years (Child)",,"40","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","1507016174","January 2016","June 15, 2018","June 15, 2018","September 21, 2016",,"July 2, 2018","Yale School of Nursing, West Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02908555" | |
| 18,"NCT01047865","Type 1 Diabetes Recurrence in Pancreas Transplants",,"Recruiting","No Results Available","Diabetes Mellitus, Type 1",,"Retrospective and prospective analysis of pancreas transplant recipients to determine frequency, and time course of autoantibody recurrence of disease. Prospective follow up to: monitor autoantibody levels, monitor and phenotype autoreactive T|Monitor autoantibody levels as well as phenotype autoreactive T cells in peripheral blood.","University of Miami","All","18 Years to 75 Years (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Cohort|Time Perspective: Other","20053039","May 2005","May 2023","May 2023","January 13, 2010",,"April 6, 2022","University of Miami Miller School of Medicine Transplant Clinic, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01047865" | |
| 19,"NCT02284009","Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus",,"Completed","Has Results","Diabetes Mellitus, Type 1","Biological: Albiglutide weekly injection|Biological: Placebo weekly injection|Biological: Insulin","Mean Change From Baseline in Time Normalized Stimulated (From Mixed Meal Tolerance Test [MMTT]) 2-hour Plasma C-peptide Area Under the Curve (AUC) at Week 52|Mean Change From Baseline in Time Normalized Stimulated (From MMTT) 2 Hour Plasma C-peptide AUC at Week 16, 28 and Week 64|Maximum Stimulated Plasma C-peptide (MMTT) at Baseline, Week 16, 28, 52 and 64|Mean Change From Baseline in Time Normalized Plasma Glucagon AUC (From MMTT) at Week 16, 28, 52 and 64|Percentage of Responders at Baseline, Weeks 4, 8, 16, 28, 40, 52 and 64|Percentage of Participants Achieving Partial Remission Status (Insulin Dose-adjusted Hemoglobin A1c (IDAA1C)<= 9.0) at Baseline, Week 4, 8, 16, 28, 40, 52 and 64|Change From Baseline in Percent HbA1c at Week 52|Percent HbA1c Over Time (at Weeks 4, 8, 16, 28, 40, 52 and 64)|Change From Baseline in Mean Daily Insulin Use at Week 4, 8, 16, 28, 40, 52 and 64|Number of Events of Participant-reported Significant Hypoglycemia, Occurring > Week 24 and <= Week 52|Time Spent With Plasma Glucose Level <= 3.9, > 3.9 to <= 10.0, and > 10.0 Measured by 72 Hour Continuous Glucose Monitoring (CGM) at Baseline, Week 28 and 52|Number of Hypoglycemic Excursions for Each Participant From 7-Point Glucose Profile at Baseline, Week 28 and 52|Greatest Magnitude of Hypoglycemic Excursions for Each Participant From 7-Point Glucose Profile at Baseline, Week 28 and 52|Number of Hyperglycemic Excursions for Each Participant From 7-Point Glucose Profile at Baseline, Week 28 and 52|Greatest Magnitude of Hyperglycemic Excursions for Each Participant From 7-Point Glucose Profile at Baseline, Week 28 and 52|Change From Baseline in Body Weight (Kilograms) at Week 52|Weight Over Time (at Weeks 2, 4, 6, 8, 16, 28, 40, 52 and 64)|Population Estimates of Pharmacokinetic (PK) Parameters: Apparent Clearance [CL/F]|Population Estimates of PK Parameters: Apparent Volume of Distribution [V/F]|Population Estimates of PK Parameters: First-order Absorption Rate Constant [Ka]","GlaxoSmithKline","All","18 Years to 30 Years (Adult)","Phase 2","67","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","110933","October 10, 2014","October 18, 2017","October 18, 2017","November 5, 2014","March 25, 2019","June 29, 2020","GSK Investigational Site, Bois-Guillaume, France|GSK Investigational Site, Caen Cedex 9, France|GSK Investigational Site, Lille Cedex, France|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Frankfurt, Hessen, Germany|GSK Investigational Site, Duesseldorf, Nordrhein-Westfalen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Latina, Lazio, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Roma, Italy|GSK Investigational Site, Alzira/Valencia, Spain|GSK Investigational Site, Badalona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Granada, Spain|GSK Investigational Site, Hospitalet de Llobregat, Spain|GSK Investigational Site, Lleida, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Málaga, Spain|GSK Investigational Site, Pama de Mallorca, Spain|GSK Investigational Site, San Juan (Alicante), Spain|GSK Investigational Site, Sevilla, Spain|GSK Investigational Site, Birmingham, United Kingdom|GSK Investigational Site, Bristol, United Kingdom|GSK Investigational Site, Cardiff, United Kingdom|GSK Investigational Site, Darlington, United Kingdom|GSK Investigational Site, Dundee, United Kingdom|GSK Investigational Site, Durham, United Kingdom|GSK Investigational Site, Glasgow, United Kingdom|GSK Investigational Site, Liverpool, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Newcastle upon Tyne, United Kingdom|GSK Investigational Site, Sheffield, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT02284009/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT02284009/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02284009" | |
| 20,"NCT05467514","Effect of Liraglutide on Subclinical Atherosclerosis in Patients With Type 1 Diabetes Mellitus",,"Active, not recruiting","No Results Available","Diabetes Mellitus, Type 1","Drug: Liraglutide","To assess the effect of liraglutide on carotid intima media thickness in patients with type 1 diabetes mellitus.|To assess the effect of liraglutide on cardiovascular risk factors, cardiometabolic markers (BMI, weight and abdominal circumference)|To assess the effect of liraglutide on cardiovascular risk factors, cardiometabolic markers. Somatometry (BMI, weight and abdominal circumference)|To assess the effect of liraglutide on cardiovascular risk factors, cardiometabolic markers Laboratory studies (total cholesterol, LDL, HDL, triglycerides, non-HDL cholesterol)|To assess the effect of liraglutide on cardiovascular risk factors, cardiometabolic markers Laboratory studies (HbA1c)|To assess the effect of liraglutide on cardiovascular risk factors, cardiometabolic markers. eGDR (Estimated glucose disposal rate)","David Sanchez Garcia|Instituto Mexicano del Seguro Social","All","15 Years to 60 Years (Child, Adult)","Phase 3","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","F-2022-1901-019","July 1, 2022","December 2022","December 2022","July 20, 2022",,"November 23, 2022","Centro Médico Nacional del Noreste Hospital de Especialidades UMAE 25, Monterrey, Nuevo León, Mexico",,"https://ClinicalTrials.gov/show/NCT05467514" | |
| 21,"NCT03722225","CHO-loading Before and High Intermittent CHO-intake During Physical Exercise in T1D",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Other: Carbohydrate loading and high intermittent carbohydrate intake during physical exercise","The percentage of the glucose values spent in target range, defined as 72-180 mg/dl.","Örebro University, Sweden","All","18 Years to 50 Years (Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","Dnr:2012/159","January 20, 2016","March 18, 2016","March 25, 2016","October 26, 2018",,"October 26, 2018",,,"https://ClinicalTrials.gov/show/NCT03722225" | |
| 22,"NCT01194245","Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus",,"Completed","Has Results","Diabetes Mellitus, Type 1","Drug: Insulin lispro|Drug: recombinant human hyaluronidase PH20|Drug: Insulin aspart|Drug: Insulin glulisine|Drug: Insulin glargine","Change From Baseline in Glycosylated Hemoglobin A1C (HbA1c) at the End of Each Treatment Period|Mean Daily Insulin Dose|Percentage of Participants Meeting Glucose Targets|Rates of Hypoglycemia at the End of Each Treatment Period|Change From Baseline in Body Weight at the End of Each Treatment Period|Mean Daily Postprandial Glucose (PPG) Excursions","Halozyme Therapeutics","All","18 Years and older (Adult, Older Adult)","Phase 2","135","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HALO-117-205","August 2010","August 2011","August 2011","September 2, 2010","August 19, 2014","February 26, 2019","AMCR Institute, Inc., Escondido, California, United States|Scripps Whittier Diabetes Institute, La Jolla, California, United States|Mills-Peninsula Health Services, San Mateo, California, United States|Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|Center for Diabetes and Endocrine Care, Hollywood, Florida, United States|Diabetes Research Institute, Miami, Florida, United States|Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States|Mid-America Diabetes Associates, Wichita, Kansas, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|Medstar Research Institute, Hyattsville, Maryland, United States|Henry Ford Health System, Detroit, Michigan, United States|International Diabetes Center, Minneapolis, Minnesota, United States|Mercury Street Medical, Butte, Montana, United States|Desert Endocrinology, Henderson, Nevada, United States|UT Southwestern Medical Center at Dallas, Dallas, Texas, United States|Texas Diabetes and Endocrinology, Round Rock, Texas, United States|Cetero Research-San Antonio, San Antonio, Texas, United States|West Olympia Internal Medicine, Olympia, Washington, United States|University of Washington School of Medicine, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01194245" | |
| 23,"NCT04524949","IMCY-0098 Proof of ACtion in Type 1 Diabetes (IMPACT Study)","IMPACT","Recruiting","No Results Available","Diabetes Mellitus, Type 1","Drug: IMCY-0098 450 μg|Drug: IMCY-0098 1350 μg|Drug: Placebo","Change in stimulated C-peptide response during the first two hours of a mixed meal tolerance test (MMTT) from baseline to 48 weeks between IMCY-0098 and placebo groups|Changes in stimulated C-peptide response during the first two hours of a MMTT for the two doses of IMCY-0098 versus placebo|Difference in Dried Blood Spots (DBS) fasted C-peptide between treatment and placebo groups|Changes in DBS C-peptide measurements at each visit comparing each dose with placebo|Effects of each dose of IMCY-0098 on HbA1c|Effects of each dose of IMCY-0098 on hypoglycaemic events|Effects of each dose of IMCY-0098 on diabetic ketoacidosis (DKA) episodes|Effects of each dose of IMCY-0098 on daily total insulin dose|Effects of each dose of IMCY-0098 on Continuous Glucose Monitoring (CGM) measures|Impact of IMCY-0098 at each dose on autoantibodies against GAD65, IA 2, ZnT8 and insulin over time|To evaluate the safety features of IMCY-0098 during treatment period|To evaluate the safety features of IMCY-0098 during the whole study duration|To evaluate the safety features of IMCY-0098 on lymphocytes ratio","Imcyse SA","All","18 Years to 44 Years (Adult)","Phase 2","108","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IMCY-T1D-003|2020-001317-20","December 29, 2020","September 2024","September 2024","August 24, 2020",,"September 23, 2022","University of Alabama at Birmingham, Birmingham, Alabama, United States|Barbara Davis Center, Aurora, Colorado, United States|University of Chicago, Chicago, Illinois, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|Princess Alexandra Hospital, Brisbane, Australia|Royal Melbourne Hospital, Melbourne, Australia|St. Vincent's Hospital, Melbourne, Australia|Royal North Shore Hospital, Sydney, Australia|Université Libre de Bruxelles - Hôpital Erasme - ULB, Brussels, Belgium|UZ Brussels, Brussels, Belgium|Katholieke Universiteit Leuven UZ Gasthuisberg, Leuven, Belgium|Ospedale San Raffaele S.r.l., Milan, Italy|AOU Pisana - Ospedale Cisanello, Pisa, Italy|Hospital of Lithuanian University of Health Sciences Kauno Klinikos, Kaunas, Lithuania|Klaipeda university hospital, Klaipeda, Lithuania|Vilnius university hospital Santaros klinikos, Vilnius, Lithuania|UMC - University Children's Hospital, Ljubljana, Slovenia|Department of clinical sciences, CRC/Malmö, Lund University, Lund, Sweden|Addenbrooke's Hospital, Cambridge, United Kingdom|University Hospital of Wales, Cardiff, United Kingdom|Royal Infirmary of Edinburgh, Edinburgh, United Kingdom|Royal Devon and Exeter Hospital, Exeter, United Kingdom|St James´s University Hospital, Leeds, United Kingdom|Leicester General Hospital, Leicester, United Kingdom|Guy's and St Thomas' Hospital, London, United Kingdom|Royal London Hospital, London, United Kingdom|St George's Hospital, London, United Kingdom|Royal Victoria Infirmary, Newcastle, United Kingdom|Churchill Hospital, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04524949" | |
| 24,"NCT02139943","A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM)",,"Completed","Has Results","Diabetes Mellitus, Type 1","Drug: Canagliflozin 100 mg|Drug: Canagliflozin 300 mg|Drug: Placebo","Percentage of Participants With Hemoglobin A1c (HbA1c) Reduction Greater Than or Equal to (>=) 0.4 Percent (%) and no Increase in Body Weight|Percentage of Participants With Adverse Events","Janssen Research & Development, LLC","All","25 Years to 65 Years (Adult, Older Adult)","Phase 2","352","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR104173|2013-005078-24|28431754DIA2004","May 2014","June 2015","June 2015","May 16, 2014","July 18, 2016","July 18, 2016","Little Rock, Arkansas, United States|Concord, California, United States|La Jolla, California, United States|Los Angeles, California, United States|Los Gatos, California, United States|Northridge, California, United States|Orange, California, United States|San Francisco, California, United States|Temecula, California, United States|Tustin, California, United States|Ventura, California, United States|Walnut Creek, California, United States|Denver, Colorado, United States|Miami, Florida, United States|Palm Harbor, Florida, United States|Atlanta, Georgia, United States|Honolulu, Hawaii, United States|Council Bluffs, Iowa, United States|Des Moines, Iowa, United States|Baton Rouge, Louisiana, United States|Rockville, Maryland, United States|Billings, Montana, United States|Omaha, Nebraska, United States|El Paso, Nevada, United States|Las Vegas, Nevada, United States|Nashua, New Hampshire, United States|Billings, New York, United States|Smithtown, New York, United States|Morehead City, North Carolina, United States|Columbus, Ohio, United States|Mentor, Ohio, United States|Philadelphia, Pennsylvania, United States|Greer, South Carolina, United States|Bloomington, Tennessee, United States|Arlington, Texas, United States|Austin, Texas, United States|Dallas, Texas, United States|El Paso, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Schertz, Texas, United States|Tomball, Texas, United States|Ogden, Utah, United States|Salt Lake City, Utah, United States|Spokane, Washington, United States|Milwaukee, Wisconsin, United States|Calgary, Alberta, Canada|London, Ontario, Canada|Oakville, Ontario, Canada|Thornhill, Ontario, Canada|Toronto, Ontario, Canada|Laval, Quebec, Canada|Sainte-Foy, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02139943" | |
| 25,"NCT05530369","The Link Between ""Time In Range"" Versus HbA1c and the Presence of Chronic COmplications in Type 1 Diabetes: a Longitudinal Study","TIRCO","Completed","No Results Available","Diabetes Mellitus, Type 1",,"Time In Range (TIR, 70-180 mg/dL)|Diabetic eye disease|Nephropathy|Neuropathy|HbA1c (%)|Mean glucose (mg/dl)","University Hospital, Antwerp","All","18 Years and older (Adult, Older Adult)",,"479","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TIRCO","September 1, 2014","November 30, 2021","August 30, 2022","September 7, 2022",,"September 30, 2022",,,"https://ClinicalTrials.gov/show/NCT05530369" | |
| 26,"NCT03091673","Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients",,"Completed","Has Results","Diabetes Mellitus, Type 1","Drug: Glucagon","Change in Plasma Glucose|Time for Plasma Glucose to Increase by ≥25 mg/dL|Plasma Glucagon Area Under the Curve|Plasma Glucagon Cmax|Plasma Glucagon Tmax","Xeris Pharmaceuticals|The Emmes Company, LLC","All","2 Years to 17 Years (Child)","Phase 3","31","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XSGP-302","March 27, 2017","September 7, 2017","September 27, 2017","March 27, 2017","November 16, 2018","December 11, 2018","Stanford University, Stanford, California, United States|Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|University of Florida, Gainesville, Florida, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Women & Children's Hospital of Buffalo, Buffalo, New York, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT03091673/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT03091673/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03091673" | |
| 27,"NCT00290979","Efficacy and Safety of Insulin Glulisine in Type 1 Diabetes Mellitus",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: insulin glulisine","Non-inferiority in the efficacy and safety of HMR1964 as compared with Insulin lispro|6-month safety data","Sanofi","All","18 Years and older (Adult, Older Adult)","Phase 3","250","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EFC6167","December 2004",,,"February 13, 2006",,"August 26, 2009","Sanofi-Aventis, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT00290979" | |
| 28,"NCT04061746","Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells",,"Recruiting","No Results Available","Diabetes Mellitus, Type 1","Biological: Mesenchymal Stem Cells (MSCs)|Other: Placebo Infusion (Plasmalyte A with 0.5% human serum albumin)","12 month Change in C-peptide area under the curve after a 2-hour MMTT|6 Month Change in C-Peptide area under the curve after a 2-hour MMTT|6 Month peak C-peptide after a 2-hour MMTT|1 year peak C-peptide after a 2-hour MMTT|Change in 24-hour insulin dose per kilogram between baseline and 1 year measurements","Medical University of South Carolina|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 30 Years (Adult)","Phase 1","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","00085542|R01DK118529-01A1","February 13, 2020","March 31, 2025","March 31, 2026","August 20, 2019",,"March 31, 2022","Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04061746" | |
| 29,"NCT03755479","Evaluation of Minimed 670G in T1D Patients on Multiple Daily Injection",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Device: Hybrid Closed Loop Insulin Pump Minimed 670G","Achieving glucose values more than 67% in Time in Range (70-180 mg/dl)|Change in HbA1c|Glucose values above Range (>180 mg/dl)|Time spend in Auto Mode","Sidra Medical and Research Center","All","6 Years to 17 Years (Child)",,"30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1810033883","February 1, 2019","August 8, 2019","August 11, 2019","November 28, 2018",,"September 6, 2019","Sidra Medicine, Doha, Qa, Qatar",,"https://ClinicalTrials.gov/show/NCT03755479" | |
| 30,"NCT05351879","Evaluation of a Booster Administration of GAD-alum (Diamyd®) in Individuals With Type 1 Diabetes",,"Active, not recruiting","No Results Available","Diabetes Mellitus, Type 1","Biological: GAD-alum (Diamyd) 40 μg/mL","Number of Clinically Significant Abnormal Results from Physical examinations, including neurological and Vital Signs assessments|Injection site reactions|Occurrence of AEs and SAEs|Number of Clinically Significant Abnormal Results From Laboratory measurements (hematology, clinical chemistry) and Urine analysis.|Change in Stimulated C-peptide During a MMTT|Change in HbA1c|Change in daily exogenous insulin consumption|Change in insulin-dose-adjusted HbA1c (IDAA1c)|Change in time in glycemic target range 3.9 to 10 mmol/L|Change in time in hyperglycemic range > 10 mmol/L","Linkoeping University|Diamyd Medical AB","All","Child, Adult, Older Adult","Phase 1|Phase 2","6","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DIAGNODE-B","May 9, 2022","November 2023","November 2023","April 28, 2022",,"October 10, 2022","Kliniska Forskningsenheten (Hudmottagningen), Universitetssjukhuset Linköping, Linköping, Sweden",,"https://ClinicalTrials.gov/show/NCT05351879" | |
| 31,"NCT03144869","Physical Activity Monitoring Paediatric Type 1 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Behavioral: physical activity monitor and feedback","Recruitment|Adherence|Retention|Data completion|Occurrence of adverse events|Acceptability|Demographics|Clinical information|Parental self-efficacy for diabetes management|Parental fear of hypoglycaemia","Sheffield Hallam University|Sheffield Children's NHS Foundation Trust","All","7 Years to 11 Years (Child)","Not Applicable","13","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","CA16015","September 1, 2017","August 1, 2018","August 1, 2018","May 9, 2017",,"September 6, 2018","Sheffield Children's Hospital NHS Foundation Trust, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03144869" | |
| 32,"NCT05483803","Digital Health Intervention for Caregivers Emotional and Self-management Support of Children With Type 1 Diabetes","CARING T1D","Active, not recruiting","No Results Available","Diabetes Mellitus, Type 1","Behavioral: Adhera® Caring digital intervention for Type 1 Diabetes","Sub-study 1: Qualitative data of psychological burdens experienced as caregivers of children with type 1 diabetes and barriers/facilitators for adopting the digital health solution|Sub-study 2: Changes on caregiver's positive mood|Emotional outcome: Changes on caregiver's distress|Emotional outcome: Changes on caregiver's general wellbeing|Emotional outcome: Changes on caregiver's perceived self-efficacy|Health-related Quality of Life (HrQoL): Changes on the child's HRQoL|Life-style outcome: Adherence to Mediterranean diet|Life-style outcome: physical activity (APALQ)|Knowledge of the disease and its treatment.|Behavioral outcome: objectively measured children's metabolic control to the treatment|Behavioral outcome: Usability","Adhera Health, Inc.|Hospital Miguel Servet|Novo Nordisk A/S","All","Child, Adult, Older Adult","Not Applicable","100","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other","CAR-22-001|U1111-1280-9100","October 1, 2022","May 2023","July 2023","August 2, 2022",,"November 17, 2022","Hospital Miguel Servet, Zaragoza, Aragon, Spain",,"https://ClinicalTrials.gov/show/NCT05483803" | |
| 33,"NCT03111433","Efficacy of Coenzyme q10 in Pediatrics With Type 1 Diabetes Mellitus",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Dietary Supplement: Coenzyme Q10|Drug: Insulin","change in soluble interacellular adhesion molecule level","Ain Shams University","All","8 Years to 18 Years (Child, Adult)","Phase 2","49","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PHCL136","March 19, 2017","January 20, 2018","January 20, 2018","April 12, 2017",,"April 3, 2018","Ainshams university pediatric's hospital, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT03111433" | |
| 34,"NCT02343146","Healthy Eating, Physical Activity, and Glycemic Control in Young Children With T1D",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Behavioral: Type One Training (TOT)","Glycemic Control/HbA1c|Child eating as measured by Remote Food Photography by the parent","Randi Streisand|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Children's National Research Institute","All","21 Years to 99 Years (Adult, Older Adult)","Not Applicable","46","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other","5649|DP3DK103998","December 2015","May 2019","August 2019","January 21, 2015",,"August 2, 2019","Children's Research Institute, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT02343146" | |
| 35,"NCT02693964","Bone and Vascular Health in Postmenopausal Women With Type 1 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Other: Bone density and carotid ultrasound","Difference in bone mineral density between postmenopausal women with type 1 diabetes and controls|Difference in carotid intima media thickness between postmenopausal women with type 1 diabetes and controls|Differences in biomarkers (1): e.g. (bone specific alkaline phosphatase, Procollagen I Intact N-Terminal (P1NP), osteocalcin, C-terminal telopeptide (CTX): (Continued in Outcome 4)|Differences in biomarkers (2): (Continued from Outcome 3) e.g. IL-2, IL-6 (Interleukin 2 and 6) and Tumor necrosis factor (TNF-alfa) between postmenopausal women with T1D and controls.|Correlation between biomarkers with cardiovascular risk measures (carotid intima media thickness)","University of Colorado, Denver","Female","45 Years and older (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","15-1854","March 2016","July 2017","July 31, 2017","February 29, 2016",,"January 28, 2020","Barbara Davis Center for Diabetes, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT02693964" | |
| 36,"NCT05428943","OPT101 in Type 1 Diabetes Patients",,"Recruiting","No Results Available","Diabetes Mellitus, Type 1","Drug: OPT101","Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Serum samples collected to determine AUC0-t|Serum samples collected to determine Cmax|Serum samples collected to determine CL/F|Serum samples collected to determine t1/2|Serum samples collected to determine HbA1C from baseline pre mixed meal tolerance test|Serum samples collected to determine c-peptide post mixed meal tolerance test|Serum samples collected to determine glucose levels (mmol/L) pre and post mixed meal tolerance test","Op-T LLC","All","18 Years to 60 Years (Adult)","Phase 1","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","OPT101-100-20","September 27, 2022","October 2022","October 2022","June 23, 2022",,"September 26, 2022","Diablo Clinical Research Center, Walnut Creek, California, United States|Rainier Clinical Research Center, Renton, Washington, United States",,"https://ClinicalTrials.gov/show/NCT05428943" | |
| 37,"NCT02365740","Postprandial Blood Glucose Control and Gastric Emptying in Type 1 Diabetes: Pathogenetic Factors and Therapeutic Options",,"Unknown status","No Results Available","Diabetes Mellitus, Type 1","Other: gastric emptying test|Other: gut hormones determination|Other: Continuous Glucose Monitoring|Drug: Insulin single bolus|Drug: Insulin double-wave bolus","gastric emptying measure|gut hormones dosage|Continuous Glucose Monitoring|postprandial glucose variability after single insulin bolus|postprandial glucose variability after double-wave insulin bolus","Federico II University","All","18 Years to 55 Years (Adult)","Not Applicable","80","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","248/13","November 2014","November 2015","November 2016","February 19, 2015",,"February 19, 2015","Dept. of ""Medicina Clinica e Chirurgia"" of Federico II University, Naples, Italy",,"https://ClinicalTrials.gov/show/NCT02365740" | |
| 38,"NCT04043260","DreaMed Advisor Pro System in Subjects With Type 1 Diabetes Treated With MDI Therapy",,"Completed","No Results Available","Insulin-dependent Diabetes Mellitus|Diabetes Mellitus, Type 1","Device: Advisor Pro","Percentage of readings below 54 mg/dl|Percentage of readings within range of 70-180 mg/dl|Change in HbA1C post study treatment","DreaMed Diabetes","All","18 Years to 65 Years (Adult, Older Adult)","Not Applicable","35","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR-0998","November 27, 2019","February 28, 2021","April 30, 2021","August 2, 2019",,"August 17, 2021","Schneider MC, Petah Tikva, Israel",,"https://ClinicalTrials.gov/show/NCT04043260" | |
| 39,"NCT02402439","Treatment of Type I Diabetes by Islet Transplantation Into the Gastric Submucosa Study Protocol",,"Active, not recruiting","No Results Available","Diabetes Mellitus, Type 1","Drug: Islet cells|Procedure: Islet transplantation into the gastrointestinal submucosa","Insulin independence|Changes in HbA1c|Changes (reduction) in insulin requirements|Incidence of adverse events","Andrew Posselt|University of California, San Francisco","All","18 Years to 70 Years (Adult, Older Adult)","Phase 1","3","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IGS","March 2016","April 30, 2023","April 30, 2023","March 30, 2015",,"August 24, 2022","University of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT02402439" | |
| 40,"NCT01883804","Effect of Methyldopa on MHC Class II Antigen Presentation in Type 1 Diabetes",,"Completed","Has Results","Diabetes Mellitus, Type 1","Drug: Methyldopa","The Change From Baseline of DQ8 Antigen Presentation by Peripheral Blood Mononuclear Cells After 6 Weeks of Methyldopa Treatment.|The Change in C-Peptide AUC Following a MMTT From Baseline to Study Completion.|The Change in Hemoglobin A1c From Baseline to Study Completion.|The Change in Insulin Use From Baseline to Study Completion.","University of Colorado, Denver|Juvenile Diabetes Research Foundation","All","18 Years to 46 Years (Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13-1408","June 2013","February 2016","February 2016","June 21, 2013","March 29, 2018","January 18, 2022","Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT01883804" | |
| 41,"NCT05585983","INfluenza VaccInation To Mitigate typE 1 Diabetes","INVITED","Recruiting","No Results Available","Diabetes Mellitus, Type 1","Biological: Vaxigrip Tetra Sanofi Pasteur Europe","Change in fasting residual β cell (C-peptide) function.|Change in HbA1c|Change in insulin requirements.|Time-In-Range of blood glucose.|Variation of blood glucose.","Aarhus University Hospital","All","7 Years to 17 Years (Child)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","INVITED-2022","December 14, 2022","April 1, 2025","June 1, 2026","October 19, 2022",,"December 16, 2022","Aarhus University Hospital, Aarhus, Denmark",,"https://ClinicalTrials.gov/show/NCT05585983" | |
| 42,"NCT05262387","A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 Diabetes",,"Recruiting","No Results Available","Diabetes Mellitus, Type 1","Drug: Lyumjev|Drug: Humalog","Change From Baseline in Plasma Glucose (PG) From the Start to the End of Exercise for Each Treatment Arm|Change From Baseline in Postprandial Plasma Glucose (PPG) Excursion During Mixed-Meal Tolerance Test (MMTT) for Each Treatment Arm","Eli Lilly and Company","All","18 Years to 55 Years (Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","17278|I8B-MC-ITSU","February 14, 2022","March 7, 2023","March 7, 2023","March 2, 2022",,"December 28, 2022","LMC Clinical Research Inc. (Bayview), Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT05262387" | |
| 43,"NCT00097292","TrialNet Pathway to Prevention of T1D",,"Recruiting","No Results Available","Diabetes Mellitus, Type 1",,"Development of type 1 diabetes|Metabolic and Autoantibody Assessments","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institute of Allergy and Infectious Diseases (NIAID)|National Center for Research Resources (NCRR)|American Diabetes Association","All","30 Months to 45 Years (Child, Adult)",,"75000","NIH|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NHStudy (IND)|UC4DK117009|UC4DK106993","February 2004","July 2025","July 2025","November 22, 2004",,"February 21, 2022","Childrens Hospital of Orange County, Orange, California, United States|University of California San Francisco, San Francisco, California, United States|Stanford University Medical Center, Stanford, California, United States|Barbara Davis Center for Childhood Diabetes, Denver, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|University of Florida, Gainesville, Florida, United States|Emory Children's Center, Atlanta, Georgia, United States|Riley Hospital for Children, Indiana University, Indianapolis, Indiana, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|The Children's Mercy Hospital, Kansas City, Missouri, United States|Columbia University, New York, New York, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States|University of Texas Medical Center at Dallas, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Benaroya Research Institute, Seattle, Washington, United States|Walter and Eliza Hall Institute, Parkville, Victoria, Australia|The Hospital for Sick Children, Toronto, Ontario, Canada|University of Turku, Turku, Finland|Vita-Salute San Raffaele University, Milan, Italy|University of Bristol, Bristol, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00097292" | |
| 44,"NCT00623610","Beta-Cell Transplantation in Pre-Uremic Patients With Type 1 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Procedure: islet cell grafts","Evidence of clinically relevant beta cell function.","AZ-VUB|Vrije Universiteit Brussel|Universitaire Ziekenhuizen KU Leuven|Universiteit Antwerpen|Erasme University Hospital","All","18 Years to 65 Years (Adult, Older Adult)","Phase 1|Phase 2","36","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BK-Tx-04","September 2000","October 2005","October 2005","February 26, 2008",,"February 26, 2008","Universitair Ziekenhuis and Diabetes Research Center - Brussels Free University-VUB, Brussels, Belgium|Department of Endocrinology and Nephrology, UZ Gasthuisberg, Katholieke Universiteit Leuven -KUL, Leuven, Belgium",,"https://ClinicalTrials.gov/show/NCT00623610" | |
| 45,"NCT05594706","Anhydroglucitol in Children With Type 1 Diabetes",,"Not yet recruiting","No Results Available","Diabetes Mellitus, Type 1","Other: Measurement of blood levels of 1,5-anhydroglucitol","Correlation of 1,5-anhydroglucitol levels in newly diagnosed patients with indirect markers of beta-cell function and mass|Correlation of 1,5-anhydroglucitol levels in patients with longstanding disease with indirect markers of beta-cell function and mass","University Hospital, Geneva|University of Geneva, Switzerland","All","2 Years to 18 Years (Child, Adult)",,"60","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2022-01684","January 1, 2023","December 31, 2024","December 31, 2024","October 26, 2022",,"October 28, 2022",,,"https://ClinicalTrials.gov/show/NCT05594706" | |
| 46,"NCT02637154","Motivational Interview in Adolescents With Poorly Controlled Type 1 Diabetes",,"Unknown status","No Results Available","Diabetes Mellitus, Type 1","Behavioral: Motivational Interviewing|Behavioral: Standard Education","Change in HbA1C values (mmol/mol)|Change in glycaemic variability|Influence of changes in markers of vascular health (IMT)|Influence of changes in markers of vascular health (PWV)|Influence of changes in bone mineral density (BMD)|Influence of changes in quality of life|Influence of changes in markers of inflammation (IL-6 - pg/ml)|Influence of changes in markers of inflammation (high-sensitive-c-reactive-protein CRP - mg/l).|Influence of changes in insulin-like-growth-factor IGF-I levels|Influence of changes in markers of bone turnover (serum aminoterminal propeptide of type I collagen (PINP - ng/ml)).|Influence of changes in vitamin D status (25-hydroxy-D) ng/ml|Influence of changes in marker of bone turnover: osteocalcin (ng/ml)|Influence of changes in marker of bone turnover: aminoterminal telopeptide of type I collagen (INTP - ng/ml)","Helsinki University Central Hospital","All","12 Years to 16 Years (Child)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","MoHa","October 15, 2015","September 2018","December 2018","December 22, 2015",,"August 3, 2018","Helsinki University Central Hospital, Pediatric Diabetes Unit Espoo, Espoo, Finland|Helsinki University Central Hospital, Pediatric Endocrinology Unit, Helsinki, Finland|Oulu University Hospital, Pediatric Endocrinology Unit, Oulu, Finland",,"https://ClinicalTrials.gov/show/NCT02637154" | |
| 47,"NCT02632383","Young With Diabetes Type 1 - Test of an mHealth App",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Device: Young with Diabetes - app","Glycemic control measured by HbA1c|Problem areas in diabetes measured by PAID-20|Perceived competences in diabetes measured by PCD-questionnaire|Health Care Climate measured by HCCQ-questionnaire","Nordsjaellands Hospital|Herlev Hospital|Steno Diabetes Center Copenhagen|Zealand University Hospital","All","14 Years to 22 Years (Child, Adult)","Not Applicable","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","1","December 2015","March 28, 2017","March 28, 2017","December 16, 2015",,"April 10, 2017","Steno Diabetes Center, Gentofte, Denmark|Pediatric and Adolescent Department, Herlev Hospital, Herlev, Denmark|Department of Cardiology, Nephrology and Endocrinology, Nordsjællands Hospital, Hillerød, Hillerød, Denmark|Pediatric and Adolescent Department, Nordsjællands Hospital, Hillerød, Hillerød, Denmark|Department of Endocrinology, Køge Hospital, Køge, Denmark|Pediatric Department, Roskilde Hospital, Roskilde, Denmark",,"https://ClinicalTrials.gov/show/NCT02632383" | |
| 48,"NCT01421147","A Study in Adults With Type 1 Diabetes","ELEMENT 1","Completed","Has Results","Diabetes Mellitus, Type 1","Drug: LY2963016|Drug: Lantus|Drug: Insulin Lispro","Change From Baseline up to 24 Weeks in Hemoglobin A1c (HbA1c)|Change From Baseline in Insulin Antibody Levels|Change From Baseline in Hemoglobin A1c (HbA1c)|7-Point Self-Monitored Blood Glucose (SMBG) Profiles|Glycemic Variability of Fasting Blood Glucose|Change From Baseline in Body Weight|Adult Low Blood Sugar Survey (ALBSS)|Insulin Treatment Satisfaction Questionnaire (ITSQ)|Insulin Dose Per Body Weight (U/kg) (Total and by Component [Basal and Bolus (Lispro)])|Insulin Dose - Units [Total and by Component [Basal and Bolus (Lispro)])|Percentage of Participants With Hemoglobin A1c (HbA1c) <7.0% and HbA1c ≤6.5%|Incidence of Hypoglycemic Events|Rate Per 30 Days of Hypoglycemic Events","Eli Lilly and Company|Boehringer Ingelheim","All","18 Years and older (Adult, Older Adult)","Phase 3","536","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13712|I4L-MC-ABEB|2011-000829-73","August 2011","August 2012","April 2013","August 22, 2011","October 9, 2014","October 9, 2014","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, Alabama, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hollywood, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Port Richey, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Palm Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roswell, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Springfield, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Des Moines, Iowa, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Topeka, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lexington, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Metairie, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kalamazoo, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Omaha, Nebraska, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nashua, New Hampshire, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mineola, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Hyde Park, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Syracuse, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Asheville, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Austin, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brussels, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leuven, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liège, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fulda, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St. Ingbert-Oberwürzbach, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Haidari/Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Thessaloniki, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Budapest, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Debrecen, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salgotarjan, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kumamoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miyazaki, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nagasaki, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guadalajara, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monterrey, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Puebla, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampico, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Krakow, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lodz, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Szczecin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bucharest, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Galati, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Iasi, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oradea, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Timisoara, Romania",,"https://ClinicalTrials.gov/show/NCT01421147" | |
| 49,"NCT04236895","PK/PD Biosimilarity Study of Gan & Lee Insulin Glargine Injection vs.US & EU Lantus® in Type 1 Diabetes Mellitus Patients",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: Gan & Lee Insulin Glargine Injection","PK endpoint|PD endpoint|Secondary PK endpoint|Exploratory PK endpoint|Secondary PD endpoint|Exploratory PD endpoint|Safety endpoints","Gan and Lee Pharmaceuticals, USA","Male","18 Years to 64 Years (Adult)","Phase 1","114","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GL-GLA-CT1002","July 10, 2018","November 28, 2018","November 28, 2018","January 22, 2020",,"January 22, 2020","Profil Mainz GmbH & Co. KG, Mainz, Germany|Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany",,"https://ClinicalTrials.gov/show/NCT04236895" | |
| 50,"NCT03374462","Type 1 Diabetes Telemedicine",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Behavioral: Telemedicine Intervention","Improvement in A1C Levels|Increased visit frequency|Impact on high-cost health care utilization|Feasibility of home-based telemedicine|Acceptability of home-based telemedicine","University of California, Davis","All","1 Year to 17 Years (Child)","Not Applicable","59","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","1125857","November 27, 2017","April 1, 2019","October 31, 2019","December 15, 2017",,"February 21, 2020","University of California-Davis, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT03374462" | |
| 51,"NCT04848480","A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)","ONWARDS 6","Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: insulin icodec|Drug: insulin degludec|Drug: insulin aspart","Change in HbA1c (glycated haemoglobin)|Change in fasting plasma glucose (FPG)|Time in range 3.9-10.0 mmol/L (70-180 mg/dL) using continuous glucose monitoring (CGM) system, Dexcom G6|Change in DTSQs (Diabetes Treatment Satisfaction Questionnaire) in total treatment satisfaction|Change in HbA1c|Number of severe hypoglycaemic episodes (level 3)|Number of clinically significant hypoglycaemic episodes (level 2) (below 3.0 mmol/L (54 mg/dL), confirmed by BG meter)|Number of clinically significant hypoglycaemic episodes (level 2) (below 3.0 mmol/L (54 mg/dL), confirmed by BG meter) or severe hypoglycaemic episodes (level 3)|Number of nocturnal clinically significant hypoglycaemic episodes (level 2) (below 3.0 mmol/L (54 mg/dL), confirmed by BG meter) or severe hypoglycaemic episodes (level 3)|Time spent below 3.0 mmol/L (54 mg/dL) using continuous glucose monitoring (CGM) system, Dexcom G6|Time spent greater than 10 mmol/L (180 mg/dL) using continuous glucose monitoring (CGM) system, Dexcom G6|Mean total weekly insulin dose|Change in body weight","Novo Nordisk A/S","All","18 Years and older (Adult, Older Adult)","Phase 3","583","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NN1436-4625|U1111-1251-7315|2020-002374-27","April 30, 2021","April 28, 2022","December 2, 2022","April 19, 2021",,"December 28, 2022","Novo Nordisk Investigational Site, Concord, California, United States|Novo Nordisk Investigational Site, Fresno, California, United States|Novo Nordisk Investigational Site, La Jolla, California, United States|Novo Nordisk Investigational Site, La Mesa, California, United States|Novo Nordisk Investigational Site, San Mateo, California, United States|Novo Nordisk Investigational Site, Denver, Colorado, United States|Novo Nordisk Investigational Site, Fleming Island, Florida, United States|Novo Nordisk Investigational Site, Fort Lauderdale, Florida, United States|Novo Nordisk Investigational Site, Port Charlotte, Florida, United States|Novo Nordisk Investigational Site, Saint Augustine, Florida, United States|Novo Nordisk Investigational Site, Lawrenceville, Georgia, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Topeka, Kansas, United States|Novo Nordisk Investigational Site, Rockville, Maryland, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Nashua, New Hampshire, United States|Novo Nordisk Investigational Site, Albany, New York, United States|Novo Nordisk Investigational Site, Wilmington, North Carolina, United States|Novo Nordisk Investigational Site, Greenville, South Carolina, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Amarillo, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Live Oak, Texas, United States|Novo Nordisk Investigational Site, Renton, Washington, United States|Novo Nordisk Investigational Site, Graz, Austria|Novo Nordisk Investigational Site, Innsbruck, Austria|Novo Nordisk Investigational Site, Saint Stefan, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Winnipeg, Manitoba, Canada|Novo Nordisk Investigational Site, St. Johns, Newfoundland and Labrador, Canada|Novo Nordisk Investigational Site, Halifax, Nova Scotia, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Laval, Quebec, Canada|Novo Nordisk Investigational Site, Berlin, Germany|Novo Nordisk Investigational Site, Essen, Germany|Novo Nordisk Investigational Site, Falkensee, Germany|Novo Nordisk Investigational Site, Lingen, Germany|Novo Nordisk Investigational Site, Ludwigshafen, Germany|Novo Nordisk Investigational Site, Lübeck, Germany|Novo Nordisk Investigational Site, Münster, Germany|Novo Nordisk Investigational Site, Oldenburg I. Holst, Germany|Novo Nordisk Investigational Site, Saint Ingbert-Oberwürzbach, Germany|Novo Nordisk Investigational Site, Ahmedabad, Gujarat, India|Novo Nordisk Investigational Site, Kozhikode, Kerala, India|Novo Nordisk Investigational Site, New Dehli, New Delhi, India|Novo Nordisk Investigational Site, Hyderabad, India|Novo Nordisk Investigational Site, New Delhi, India|Novo Nordisk Investigational Site, Thriruvananthapuram, India|Novo Nordisk Investigational Site, Catanzaro, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Perugia, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, Rome, Italy|Novo Nordisk Investigational Site, Koriyama-shi, Fukushima, Japan, Japan|Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido, Hokkaido, Japan, Japan|Novo Nordisk Investigational Site, Kumamoto-shi, Kumamoto, Japan, Japan|Novo Nordisk Investigational Site, Chuo-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Kanagawa, Japan|Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Apeldoorn, Netherlands|Novo Nordisk Investigational Site, Arnhem, Netherlands|Novo Nordisk Investigational Site, Rotterdam, Netherlands|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Saint Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, St. Petersburg, Russian Federation|Novo Nordisk Investigational Site, Voronezh, Russian Federation|Novo Nordisk Investigational Site, Yaroslavl, Russian Federation|Novo Nordisk Investigational Site, Barcelona, Spain|Novo Nordisk Investigational Site, Málaga, Spain|Novo Nordisk Investigational Site, Oviedo, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Adana, Turkey|Novo Nordisk Investigational Site, Aydin, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Kayseri, Turkey|Novo Nordisk Investigational Site, Malatya, Turkey|Novo Nordisk Investigational Site, Bristol, United Kingdom|Novo Nordisk Investigational Site, Cambridge, United Kingdom|Novo Nordisk Investigational Site, Derby, United Kingdom|Novo Nordisk Investigational Site, Edinburgh, United Kingdom|Novo Nordisk Investigational Site, Guildford, United Kingdom|Novo Nordisk Investigational Site, Oxford, United Kingdom|Novo Nordisk Investigational Site, Stevenage, United Kingdom|Novo Nordisk Investigational Site, Swansea, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04848480" | |
| 52,"NCT01184703","Low Glycemic Index Diet in Patients With Type 1 Diabetes","LGID1","Completed","No Results Available","Diabetes Mellitus, Type 1","Other: Low GI food","HbA1c|LDL-cholesterol","Steno Diabetes Center Copenhagen","All","20 Years to 65 Years (Adult, Older Adult)","Phase 3","65","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","GI-project_1","June 2007","August 2009","December 2009","August 19, 2010",,"September 6, 2010","Steno Diabetes Center, Gentofte, Denmark",,"https://ClinicalTrials.gov/show/NCT01184703" | |
| 53,"NCT02814123","Effect of Basal-Bolus Closed-Loop Co-Administration of Insulin and Pramlintide on Improving the Glycemic Control in Type 1 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Other: 24-hour inpatient intervention","Percentage of time of plasma glucose levels spent in target range. Target range is defined to be between 3.9 and 10.0 mmol/L of fast-acting insulin-plus-pramlintide closed-loop delivery vs. fast-acting insulin-alone closed-loop delivery.|Percentage of time of plasma glucose levels spent in target range. Target range is defined to be between 3.9 and 10.0 mmol/L of regular insulin-plus-pramlintide closed-loop delivery vs. fast-acting insulin-alone closed-loop delivery.|Percentage of time of plasma glucose levels spent in target range, comparing fast-acting insulin-plus-pramlintide closed-loop delivery vs. regular insulin-plus-pramlintide closed-loop delivery.|Percentage of time (8:00-8:00) of plasma glucose levels spent: a. 3.9-7.8 mmol/L; b. 3.9-10 mmol/L; c. <3.9 mmol/L; d. <3.3 mmol/L; e. <2.8 mmol/L; f. >7.8 mmol/L; g. >10 mmol/L; h. >13.9 mmol/L; i. >16.7 mmol/L|Percentage of overnight time (23:00-8:00) of plasma glucose levels: a. 3.9-7.8 mmol/L; b. 3.9-10 mmol/L; c. <3.9 mmol/L; d. <3.3 mmol/L; e. <2.8 mmol/L; f. >7.8 mmol/L; g. >10 mmol/L; h. >13.9 mmol/L; i. >16.7 mmol/L|Standard deviation of glucose levels as a measure of glucose variability.|Total insulin delivery.|Total pramlintide delivery.|Mean plasma glucose level during: a. the overall study period; b. overnight period.|Mean plasma insulin concentration.|Mean plasma glucagon concentration.|Mean plasma amylin concentration.|Number of subjects experiencing hypoglycemia requiring oral treatment during: a. the overall study period; b. the night.|Gastrointestinal symptoms during the treatment optimization (i.e., the minimum 10 days prior to the 24-hour closed-loop visits) and during the 24-hour closed-loop visits.","McGill University|Juvenile Diabetes Research Foundation","All","18 Years and older (Adult, Older Adult)","Phase 2","28","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MAP-1","January 13, 2017","July 8, 2018","July 8, 2018","June 27, 2016",,"February 17, 2020","McGill University Health Centre, Montréal, Quebec, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT02814123/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT02814123/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT02814123" | |
| 54,"NCT00590876","The Impact of Pancreatic Islet Cell Allotransplantation on Cognitive Function in Type 1 Diabetes Mellitus",,"Completed","No Results Available","Diabetes Mellitus, Type 1",,"fMRI","Yale University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Juvenile Diabetes Research Foundation","All","18 Years to 55 Years (Adult)",,"36","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","DK66108a_0304025134|R37DK020495|DK20495","December 2008","July 2011","July 2011","January 11, 2008",,"October 27, 2011","Yale University School of Medicine, New Haven, Connecticut, United States|University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00590876" | |
| 55,"NCT01123083","Trial of Otelixizumab for Adolescents and Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-2","DEFEND-2","Completed","Has Results","Diabetes Mellitus, Type 1","Biological: Otelixizumab|Biological: Placebo","Change From Baseline in 2 Hour Mixed Meal-stimulated C-peptide Area Under Curve (AUC) (Normalized for 120-minute Time Interval) at Month 12|Change From Baseline in 2 Hour Mixed Meal-stimulated C-peptide AUC (Normalized for 120-minute Time Interval) at Week 12 and 6 Months|Change From Baseline in Stimulated C-Peptide Mean AUC at Week 12, Month 6, 12 and 18|Number of Participants With Responder Status|Change From Baseline in Mean Daily Insulin Use Over 7 Consecutive Days During the 2 Weeks Prior to the Assessment|Change From Baseline in HbA1c Levels Over 7 Consecutive Days During the 2 Weeks Prior to the Assessment|Average Number of Severe Hypoglycemic Events and Documented Symptomatic Hypoglycemic Events From Baseline to Month 12|Percentage of Participants With Change From Baseline in Severe Hypoglycemic Events and Documented Symptomatic Hypoglycemic Events at Month 12|Composite Rank Sum: HbA1c and Exogenous Insulin Use at 6 and 12 Months|Composite Rank Sum: C-Peptide AUC, HbA1c and Exogenous Insulin Use at 6 and 12 Months","GlaxoSmithKline|Juvenile Diabetes Research Foundation","All","12 Years to 17 Years (Child)","Phase 3","179","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","115494|TRX4018","May 17, 2010","March 9, 2012","March 9, 2012","May 14, 2010","September 15, 2017","September 15, 2017","GSK Investigational Site, Roma, Italy",,"https://ClinicalTrials.gov/show/NCT01123083" | |
| 56,"NCT02092051","CGM Treatment in Patients With Type 1 Diabetes Treated With Insulin Injections",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Device: Continuous glucose monitoring with DexCom G4 platina","Difference in HbA1c between week 26 and week 69|Difference in mean glucose level measured by CGM between week 23-26 and 66-69|Difference in mean amplitude glucose excursion (MAGE) measured by CGM between week 23-26 and week 66-69|Difference in standard deviation of glucose levels measured by CGM between week 23-26 and week 66-69|Difference in DTSQs scores between weeks 26 and 69|DTSQc score at week 69|Difference in WHO 5 scores between weeks 26 and 69|Difference in SWE-HFS scores between weeks 26 and 69|Difference in SWE-PAID-20 scores between weeks 26 and 69|Difference in the proportion of time with low glucose levels measured by CGM during two weeks between week 23-26 and week 66-69 measured by CGM (below 3.0 mmol/l and below 4.0 mmol/l respectively)|Difference in the proportion of time with high glucose levels measured by CGM during two weeks between week 23-26 and week 66-69 measured by CGM (above 10.0 mmol/l and above 13.9 mmol/l respectively)|Difference in the proportion of time with euglycaemic levels measured by CGM during two weeks between weeks 23-26 and weeks 66-69 (5.5-10.0 mmol/l and 3.9-10.0 mmol/l respectively)|Difference in the proportion of patients reducing their HbA1c by 5 mmol/mol (0.5% in DCCT) or more|Difference in the proportion of patients lowering their HbA1c 10 mmol/mol (1% in DCCT) or more|Difference in the mean number of severe hypoglycaemic events between weeks 1-26 and weeks 43-69 defined as unconsciousness due to hypoglycaemia or need of assistance from another person to resolve the hypoglycaemia","Vastra Gotaland Region|DexCom, Inc.","All","18 Years and older (Adult, Older Adult)","Not Applicable","161","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CGMMDI","January 2014","June 2016","June 2016","March 19, 2014",,"January 10, 2017","Alingsås Hospital, Alingsås, Sweden|Angered Hospital, Angered, Sweden|Helsingborg Hospital, Helsingborg, Sweden|Öbackakliniken, Härnösand, Sweden|Centralhospital Kristianstad, Kristianstad, Sweden|Halland's Hospital Kungsbacka, Kungsbacka, Sweden|Malmö University Hospital, Malmö, Sweden|Motala Hospital, Motala, Sweden|Vrinnevisjukhuset, Norrköping, Sweden|Södersjukhuset, Stockholm, Sweden|Trelleborg Hospital, Trelleborg, Sweden|Uddevalla Hospital, Uddevalla, Sweden|Academic Hospital Uppsala, Uppsala, Sweden|Ängelholm Hospital, Ängelholm, Sweden|University Hospital Örebro, Örebro, Sweden",,"https://ClinicalTrials.gov/show/NCT02092051" | |
| 57,"NCT03362151","A Clinical Study to Investigate and Compare the Impact of High Protein Pasta, Lower Protein Pasta and White Rice on Blood Sugar Control in People With Type 1 Diabetes Mellitus (T1DM)",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Other: Regular pasta|Other: High protein pasta|Other: White rice","Delta glucose (maximum rise from baseline glucose) mg/dL|Incremental area under the curve (area)|Time to peak glucose level (minutes)|percent time glucose <70 mg/dL","Sansum Diabetes Research Institute|Harvard University","All","18 Years to 75 Years (Adult, Older Adult)","Not Applicable","14","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB17-1316","January 1, 2018","August 2, 2018","August 2, 2018","December 5, 2017",,"September 5, 2018","Sansum Diabetes Research Institute, Santa Barbara, California, United States",,"https://ClinicalTrials.gov/show/NCT03362151" | |
| 58,"NCT02663661","Insulin-Glucose-Glucagon Network: Defining a Type 1 Diabetes Progression Index",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Procedure: Metabolic Challenge Admission|Other: CGM home test","Test the hypothesis that immunological abnormalities are associated with abnormally high glucagon responses to a meal and reduced glucagon responses to insulin induced hypoglycemia.|Correlate metrics derived from a minimally-invasive Continuous Glucose Monitor (CGM) home test with glucagon responses to a meal and hypoglycemia measured in the hospital.","University of Virginia|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","12 Years to 45 Years (Child, Adult)","Not Applicable","73","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","18568|DP3DK106907-01","March 16, 2016","June 30, 2019","June 30, 2019","January 26, 2016",,"July 23, 2019","University of Virginia, Center for Diabetes Technology, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02663661" | |
| 59,"NCT05097339","cArdiopulmonary exerCise Test Assessing Multiple bIOmarkers iN Type 1 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 1",,"Change in glucose concentration during and after morning Aerobic and Symptom Limited Maximal Exercise Test|Change in lactate concentration during and after morning Aerobic and Symptom Limited Maximal Exercise Test|Change in ketone concentration during and after morning Aerobic and Symptom Limited Maximal Exercise Test","University Hospital, Antwerp|Indigo Diabetes NV|Université Montpellier|Campus Bio-Medico University|University of Padova","Male","18 Years to 40 Years (Adult)",,"21","Other|Industry","Observational","Observational Model: Other|Time Perspective: Prospective","ACTION1","May 10, 2019","May 13, 2020","May 13, 2020","October 28, 2021",,"October 28, 2021","Antwerp University Hospital, Edegem, Antwerp, Belgium",,"https://ClinicalTrials.gov/show/NCT05097339" | |
| 60,"NCT04753099","Telehealth Family Coaching With Type 1 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Behavioral: occupation-based coaching","Quality of Life survey to measure physical health, psychological health, social relationships, and environmental health.|family-centered participation goals|time-in-range|hemoglobin a1c number|parental competence with managing child's care","Creighton University|DexCom, Inc.","All","2 Years to 12 Years (Child)","Not Applicable","16","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Telehealth Coaching","October 9, 2020","May 5, 2021","May 5, 2021","February 15, 2021",,"May 27, 2021","Creighton University, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT04753099" | |
| 61,"NCT01890954","Optimizing Closed-Loop Control of Type 1 Diabetes Mellitus in Adolescents",,"Completed","Has Results","Diabetes Mellitus, Type 1","Device: Diabetes Assistant (DiAs)","Percent of Time Spent Near Normoglycemia","University of Virginia","All","13 Years to 18 Years (Child, Adult)","Not Applicable","17","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16890","August 2013","February 2014","February 2014","July 2, 2013","April 15, 2015","September 13, 2022","University of Virginia Center for Diabetes Technology, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01890954" | |
| 62,"NCT02423993","Education Effectiveness for Type 1 Diabetes Mellitus on Insulin Pump Therapy","EASEDIAP","Completed","Has Results","Diabetes Mellitus, Type 1","Behavioral: Education by structured programme|Device: CSII|Device: CGM-RT|Procedure: Screening for Complications|Procedure: Glycaemic control assessment|Procedure: QoL assessment|Procedure: Knowledge assessment","HbA1c|Severe Hypoglycaemia Frequency|Quality of Life (ADDQoL Questionnaire)|Nonsevere Hypoglycaemia Frequency|Glycaemic Variability|Treatment Compliance ( Frequency of SMBG and Bolus Calculator Use)|Quality of Life (SF36 Questionnaire)","Endocrinology Research Centre, Moscow","All","18 Years to 65 Years (Adult, Older Adult)","Not Applicable","77","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","101-01-2010","October 2009","October 2012","February 2013","April 22, 2015","January 11, 2016","January 11, 2016",,,"https://ClinicalTrials.gov/show/NCT02423993" | |
| 63,"NCT02038764","A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes",,"Completed","Has Results","Diabetes Mellitus, Type 1","Drug: Placebo|Biological: PF-06342674 Dose A|Biological: PF-06342674 Dose B|Biological: PF-06342674 Dose C|Biological: PF-06342674 Dose D","Number of Participants With Dose Limiting or Intolerable Treatment Related Adverse Events (AEs)|Number of Participants With All-Causality Treatment Emergent Adverse Events(TEAEs)|Number of Participants With Treatment-Related TEAEs|Number of Participants With All-Causality TEAEs Listed by Common Terminology Criteria for Adverse Events (CTCAE) Grade|Number of Participants With All-Causality Treatment-Emergent Hypoglycemic Adverse Events|Number of Participants With All-Causality Treatment-Emergent Hypoglycemic Adverse Events Listed by CTCAE Grade|Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)|Number of Participants With Vital Signs That Met the Criteria for Potential Clinical Concern(Absolute Values)|Number of Participants With Vital Signs That Met the Criteria for Potential Clinical Concern(Decreases From Baseline)|Number of Participants With Vital Signs That Met the Criteria for Potential Clinical Concern(Increases From Baseline)|Number of Participants With Electrocardiogram(ECG) Data That Met the Criteria for Potential Clinical Concern(Absolute Value)|Number of Participants With Electrocardiogram(ECG) Data That Met the Criteria for Potential Clinical Concern(Increases From Baseline)|Number of Participants With Serum Anti-PF-06342674 Antibody Response Listed by Visit|Area Under Concentration-Time Curve From Time Zero to Time Tau(AUCtau) on Day 1 and Day 71|Apparent Oral Clearance (CL/F) on Day 71|Maximum Observed Plasma Concentration (Cmax) on Day 1 and Day 71|Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 1 and Day 71|Plasma Decay Half-Life (t1/2) on Day 71|Apparent Volume of Distribution (Vz/F) on Day 71|Accumulation Ratio (Rac) on Day 71","Pfizer","All","18 Years and older (Adult, Older Adult)","Phase 1","37","Industry","Interventional","Allocation: Randomized|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","B4351003","June 4, 2014","September 13, 2016","September 13, 2016","January 17, 2014","August 3, 2018","August 3, 2018","VA San Diego Healthcare System (Drug Shipment), San Diego, California, United States|Veterans Administration San Diego Healthcare System, San Diego, California, United States|University of California, San Francisco, San Francisco, California, United States|Barbara Davis Center, Aurora, Colorado, United States|Yale School of Medicine, New Haven, Connecticut, United States|Yale New Haven Hospital - Investigational Drug Services, New Haven, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Duchossois Center for Advanced Medicine, Chicago, Illinois, United States|The University of Chicago Medical Center, Chicago, Illinois, United States|University of Chicago Clinical Resource Center, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Umass Memorial Medical Center, Worcester, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|University Of Minnesota Fairview Pharmacy Services, Minneapolis, Minnesota, United States|University Of Minnesota Medical School, Minneapolis, Minnesota, United States|Barnes- Jewish HOSP Att: Kathryn Vehe, Saint Louis, Missouri, United States|Washington University - Center for Advanced Medicine, Saint Louis, Missouri, United States|Washington University, Saint Louis, Missouri, United States|Duke Clinical Research Unit, Durham, North Carolina, United States|Duke University Health Systems (DUHS) Investigational Drug Services, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02038764" | |
| 64,"NCT05107544","Metabolic Effect of High Intensity Interval Training (HIIT) in Adolescents With Type 1 Diabetes",,"Active, not recruiting","No Results Available","Diabetes Mellitus, Type 1","Other: HIGH INTENSITY INTERVAL TRAINING","Time change in range|Change in hemoglobin A1c|Change in cholesterol|Change in triglycerides|Changes in systolic blood pressure|Changes in body composition|Changes in waist circumference|Changes in aerobic capacity|Change in heart rate|Change in resistance strength|Change in total insulin dose|Frequency of hypoglycemia episodes during the training|Change in mood of adolescents","Hospital Las Higueras|Hospital Guillermo Grant Benavente|Centro de Vida Saludable, Universidad de Concepción","All","12 Years to 19 Years (Child, Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-12-67","September 4, 2021","November 4, 2022","December 4, 2022","November 4, 2021",,"August 31, 2022","Hospital Las Higueras, Talcahuano, Concepcion, Chile",,"https://ClinicalTrials.gov/show/NCT05107544" | |
| 65,"NCT04270942","At-Risk for Type 1 Diabetes Extension Study",,"Recruiting","No Results Available","Diabetes Mellitus, Type 1","Biological: teplizumab","Safety and tolerability of teplizumab treatment|Pharmacokinetics of Teplizumab|Immunogenicity of Teplizumab|Loss of C-peptide Produced by Pancreatic Beta Cells in Individuals with Recent Diagnosis of type 1 diabetes|Clinical Parameter 1 of Diabetes Management|Clinical Parameter 2 of Diabetes Management|Clinical Parameter 3 of Diabetes Management|Change in T-cell Subpopulations","Provention Bio, Inc.","All","Child, Adult, Older Adult","Phase 2","30","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRV-031-002","March 2, 2020","August 2024","August 2024","February 17, 2020",,"September 28, 2022","Clinical Site, Aurora, Colorado, United States|Clinical Site, New Haven, Connecticut, United States|Clinical Site, Gainesville, Florida, United States|Clinical Site, Nashville, Tennessee, United States|Clinical site, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04270942" | |
| 66,"NCT05429359","cArdiopulmonary exerCise Test Assessing Multiple biOmarkers and Hormones iN Type 1 diabetEs Under Different Circumstances","ACT-ONE","Not yet recruiting","No Results Available","Diabetes Mellitus, Type 1","Other: CPET: CardioPulmonary Exercise Test for CSII users|Other: AEX1: Aerobic Exercise Test 1 for CSII users|Other: AEX2: Aerobic Exercise Test 2 for CSII users|Other: CPET: CardioPulmonary Exercise Test for MDI users|Other: AEX1: Aerobic Exercise Test 1 for MDI users|Other: AEX2: Aerobic Exercise Test 2 for MDI users","CGM outcomes during and after morning exercise|Change in glucose concentration in venous blood during and after morning exercise test|Change in lactate concentration in venous blood during and after morning exercise test|Change in ketone concentration in venous blood during and after morning exercise test|Change in cortisol concentration in venous blood during and after morning exercise test|Change in growth hormone concentration in venous blood during and after morning exercise test","University Hospital, Antwerp|Universiteit Antwerpen|York University","All","18 Years to 60 Years (Adult)","Not Applicable","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","ACT-ONE","October 1, 2022","August 31, 2023","March 31, 2024","June 23, 2022",,"September 6, 2022",,,"https://ClinicalTrials.gov/show/NCT05429359" | |
| 67,"NCT05434754","Keeping in Touch (KiT) With Youth as They Transition to Adult Type 1 Diabetes Care","KiT","Not yet recruiting","No Results Available","Diabetes Mellitus, Type 1","Other: eHealth Tool","To test the effect of a text message-based T1D transition intervention compared to control at 12 months in the Self-Efficacy for Diabetes management scale. A higher score indicates better self-efficacy.|Compare text message-based T1D transition intervention to control at 6 months in the Self-Efficacy for Diabetes management scale. Higher score indicates better self efficacy.|To compare diabetes self-efficacy in the intervention vs. control group at baseline. A higher score indicates better self efficacy.|Evaluate the impact of this text message-based intervention compared to usual care at 12 months using the Readiness Assessment of Emerging Adults with Type 1 Diabetes Diagnosed in Youth (READDY) Tool. Higher scores indicating more confidence|Evaluate the impact of this text message-based intervention compared to usual care at 6 months using the Readiness Assessment of Emerging Adults with Type 1 Diabetes Diagnosed in Youth (READDY) Tool. Higher scores indicating more confidence|To compare transition readiness in the intervention and control groups at baseline using the Readiness Assessment of Emerging Adults with Type 1 Diabetes Diagnosed in Youth (READDY) Tool. Higher scores indicating more confidence|Evaluate the impact of this text message-based intervention compared to usual care at 12 months on self-reported Barriers to Diabetes Adherence in Adolescence questionnaire (BDA) Stigma subscale|Evaluate the impact of this text message-based intervention compared to usual care at 6 months on self-reported Barriers to Diabetes Adherence in Adolescence questionnaire (BDA) Stigma subscale|To compared perceived stigma of living with T1D between the intervention and control groups at baseline using the self-reported Barriers to Diabetes Adherence in Adolescence questionnaire (BDA) Stigma subscale|Evaluate the impact of this text message-based intervention compared to usual care at 12 months using self-reported A1c values|Evaluate the impact of this text message-based intervention compared to usual care at 6 months using self-reported A1c|To compare A1c between the intervention and control groups at baseline by measuring self-reported A1c|Evaluate the impact of this text message-based intervention compared to usual care on number of diabetes-related ED visits during the 12 months of intervention|To compare the number of diabetes-related ED visits in the 24 months prior to enrolment in the intervention vs. control group at baseline|Evaluate the impact of this text message-based intervention compared to usual care on number of diabetes-related hospitalizations and length of diabetes-related hospitalizations during the 12 months of intervention|Number of diabetes-related hospitalizations and length of diabetes-related hospitalizations 24 months prior to intervention for both intervention and control populations to describe baseline characteristics|Evaluate the impact of this text message-based intervention compared to usual care on number of diabetes-related physician visits during the 12 months of intervention|Number of diabetes-related physician visits at baseline for both intervention and control populations 24 months prior to describe baseline characteristics|Evaluate the impact of this text message-based intervention compared to usual care on number of diabetes drug and devices claims during the 12 months of intervention|Number of diabetes drug and devices claims 24 months prior to enrolment to describe baseline characteristics|Evaluate the impact of this text message-based intervention costs compared to usual care costs","The Hospital for Sick Children|Trillium Health Partners|University Health Network, Toronto","All","17 Years to 19 Years (Child, Adult)","Not Applicable","267","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","3986","December 2022","March 2024","March 2025","June 28, 2022",,"October 26, 2022","Oak Valley Health, Markham, Ontario, Canada|Trillium Health Partners, Mississauga, Ontario, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|The Hospital for Sick Children, Toronto, Ontario, Canada|McGill University Health Center, Montréal, Quebec, Canada|Saint Justine Hospital, Montréal, Quebec, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT05434754/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT05434754" | |
| 68,"NCT05660941","Automated Fully Closed-Loop Insulin Delivery in Type 1 Diabetes With Ultra-Rapid Lispro (ACOLYTE Study)","ACOLYTE","Not yet recruiting","No Results Available","Diabetes Mellitus, Type 1","Drug: Lispro","Time in range|Area under curve|Time below target|Time above target|Mean glucose and glycaemic variability|Insulin dose|Time above and below significant sensor glucose levels","Manchester University NHS Foundation Trust","All","18 Years to 99 Years (Adult, Older Adult)","Not Applicable","26","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B01661","March 1, 2023","March 1, 2024","March 1, 2024","December 21, 2022",,"December 21, 2022",,,"https://ClinicalTrials.gov/show/NCT05660941" | |
| 69,"NCT04944316","Effect of a Dietary Intervention on Insulin Requirements in Type 1 Diabetes","T1D","Recruiting","No Results Available","Diabetes Mellitus, Type 1","Behavioral: Dietary intervention","Total Insulin Dose|Glycemic Control|Glycemic Variability|24-hour Carbohydrate to Insulin Ratio|Body Weight|Concentration of Plasma Lipids|High-sensitivity C-reactive Protein (hs-CRP)|Tumor necrosis factor - α (TNF-α)|Interleukin (IL) - 1 (IL-1) and interleukin-6 (IL-6)","Physicians Committee for Responsible Medicine","All","18 Years and older (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment","Pro00048903","January 19, 2022","December 30, 2022","December 31, 2022","June 29, 2021",,"April 19, 2022","Physicians Committee for Responsible Medicine, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT04944316" | |
| 70,"NCT04545151","Verapamil SR in Adults With Type 1 Diabetes","Ver-A-T1D","Recruiting","No Results Available","Diabetes Mellitus, Type 1","Drug: Verapamil SR 120 mg|Drug: Placebo","Area under the stimulated C-peptide response curve|Proinsulin, Insulin, Pro-IAPP and Proglucagon secretion|Fasting C-peptide|DBS C-peptide|Change in HbA1c|Severe hypoglycaemic episodes|DKA|Change in insulin requirements|Change in T1D associated autoantibodies|Continous glucose monitoring (CGM)","Medical University of Graz|Juvenile Diabetes Research Foundation","All","18 Years to 45 Years (Adult)","Phase 2","138","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Ver-A-T1D|2020-000435-45","February 8, 2021","February 2024","February 2024","September 10, 2020",,"July 5, 2022","Medical University of Graz, Department of Internal Medicine Division of Endocrinology and Metabolism, Graz, Styria, Austria|Universitair Ziekenhuis Brussel, Brussels, Belgium|Université Libre de Bruxelles/ Hôpital Erasme, Brussels, Belgium|Universitair Ziekenhuis Antwerpen, Edegem, Belgium|Katholieke Universiteit Leuven, Leuven, Belgium|Institut National de la Santé et de la Recherche Médicale, Paris, France|HKA Hannover, Hanover, Germany|Universität Ulm, Ulm, Germany|Università Vita-Salute San Raffaele, Milano, Italy|Università degli Studi di Siena, Siena, Italy|Slaski Uniwersytet Medyczny w Katowicach, Katowice, Poland|Lunds Universität, Lund, Sweden|Queen Elizabeth Hospital, Birmingham, United Kingdom|Southmead Hospital, Bristol, United Kingdom|Addenbrokes Hospital, Cambridge, United Kingdom|University Hospital of Wales, Cardiff, United Kingdom|Bart's Hospital QMUL, London, United Kingdom|Guy's Hospital, London, United Kingdom|Queens Medical Centre, Nottingham, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom|OCDEM, John Radcliffe Hospital, Oxford, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom|Singleton Hospital, Swansea, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04545151" | |
| 71,"NCT02909829","Safety and Efficacy of Artificial Pancreas With and Without a Meal Detection Module on Glycemic Control in Adolescents With Type 1 Diabetes After a Missed Bolus",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Device: Closed Loop Delivery|Device: Closed Loop Delivery with Meal Detection Module|Device: Conventional Pump Therapy","AUCinc: The incremental area under the curve (as compared to pre-meal glucose value) of the postprandial glucose excursions for the lunch meal.|AUCinc: The incremental area under the curve (as compared to pre-meal glucose value) of the postprandial glucose excursions: a. >10.0 mmol/L; b. >13.9 mmol/L; c. >16.7 mmol/L|Percentage of postprandial time of sensor glucose measurements spent: a. <3.9 mmol/L; b. between 3.9 and 7.8 mmol/L; c. between 3.9 and 10.0 mmol/L; d. >10.0 mmol/L; e. >13.9 mmol/L; f. >16.7 mmol/L.|Mean sensor glucose concentration.|Total insulin delivery|Glucose concentration as measured by CGM at 2 hours (120 min) post-meal.|Incremental glucose concentration as measured by CGM at 2 hours (120 min) post-meal.|Incremental postprandial peak of glucose concentration as measured by CGM.|Number of hyperglycemic events > 18.0mmol/L.|1. Glucose concentration as measured by CGM at 5 hours (300 min) post-meal. Glucose concentration as measured by CGM at 5 hours (300 min) post-meal","McGill University","All","12 Years to 18 Years (Child, Adult)","Not Applicable","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Missed Bolus 9h","October 31, 2017","October 11, 2019","October 11, 2019","September 21, 2016",,"May 27, 2020","McGill University Health Centre, Montréal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02909829" | |
| 72,"NCT03835195","Comprehensive Care in Type 1 Diabetes and Associated Outcomes","AIDDA","Completed","No Results Available","Diabetes Mellitus, Type 1","Other: Diabetes Disease Management Program|Other: Usual Care Process","Differences in HbA1C value after the intervention|Proportion of patients diagnosed with dyslipidemia after the intervention|Proportion of patients with hypoglycaemia after the intervention|Number of hospitalizations associated with diabetes, after the intervention|Proportion of patients diagnosed with hypertension after the intervention|Difference in the body mass index after the intervention","Universidad de Antioquia","All","15 Years and older (Child, Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","AIDDA","June 1, 2018","February 28, 2019","March 28, 2019","February 8, 2019",,"June 6, 2019","Clínica Integral de Diabetes, Medellín, Antioquia, Colombia",,"https://ClinicalTrials.gov/show/NCT03835195" | |
| 73,"NCT04612257","Assessing Closed-loop Insulin Delivery in Children With Type 1 Diabetes.",,"Unknown status","No Results Available","Diabetes Mellitus, Type 1","Other: Insulin-alone closed-loop","Time in range|Specific time in range|Specific nighttime time in range|Mean glucose levels|Standard deviation of glucose levels and insulin delivery|Coefficient of variance of glucose levels and insulin delivery|Total insulin delivery","McGill University|Eli Lilly and Company","All","2 Years to 13 Years (Child)","Phase 2","20","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-5584","June 18, 2019","December 31, 2021","June 30, 2022","November 2, 2020",,"November 2, 2020","McGill University Health Centre Research Institute, Montréal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT04612257" | |
| 74,"NCT04311164","Steno Tech Explore: A Study of Insulin Pump Users With Type 1 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Other: Questionnaire-based survey|Other: No intervention given.","Glycated Hemoglobin A1c (HbA1c)|Other diabetes-relevant biomarkers|General diabetes and insulin pump-specific behavior|Psychological well-being|Diabetes distress|Hypoglycemia anxiety|Technology-specific satisfaction|Educational, time and risk preferences","Steno Diabetes Center Copenhagen|Nordsjaellands Hospital","All","18 Years and older (Adult, Older Adult)",,"770","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","Steno Tech Explore","May 15, 2020","October 15, 2020","October 15, 2020","March 17, 2020",,"February 1, 2021","Steno Diabetes Center Copenhagen, Gentofte, Denmark|Nordsjællands Hospital Hillerød, Hillerød, Denmark","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT04311164/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04311164" | |
| 75,"NCT04443153","Adapting Diabetes Treatment Expert Systems to Patient in Type 1 Diabetes","DSS-2","Recruiting","No Results Available","Diabetes Mellitus, Type 1","Device: Personalized Feedback|Device: Decision Support System|Device: Sensor Augmented Mode","Glycemic Outcomes|percent time in clinical hypoglycemia|percent time below recommended threshold|percent time in target range|percent time above range|percent time above 250 mg/dL|average gycemia|Low Blood Glucose Index|High Blood Glucose Index","University of Virginia|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years and older (Adult, Older Adult)","Not Applicable","100","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","200007|2R01DK051562-19A1","September 4, 2020","August 1, 2023","August 1, 2023","June 23, 2020",,"January 26, 2022","University of Virginia Center for Diabetes Technology, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT04443153" | |
| 76,"NCT04354142","A Novel Carbohydrate Counting Smartphone App for Youth With Type 1 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Device: iSpy","Carbohydrate (CHO) Counting Accuracy|Carbohydrate (CHO) Counting Efficiency (Time to count)|Change in Quality of Life: Self Care Inventory Questionnaire|Change in Quality of Life: Diabetes Questionnaire|Change in Quality of Life: Quality of Life for Youth|Change in Quality of Life: Global Quality of Life|Implementation outcomes: Accrual/Attrition Rates|Implementation outcomes: Engagement|Implementation outcomes: Acceptability","The Hospital for Sick Children|The Physicians' Services Incorporated Foundation","All","10 Years to 17 Years (Child)","Not Applicable","46","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","1000054297","July 12, 2018","January 27, 2020","January 27, 2020","April 21, 2020",,"April 21, 2020","The Hospital for Sick Children, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04354142" | |
| 77,"NCT02464033","EDCR Study - Etanercept Diamyd Combination Regimen -Open Trial to Evaluate Safety in Children With Type 1 Diabetes",,"Completed","Has Results","Diabetes Mellitus, Type 1","Drug: GAD-Alum|Drug: Vitamin D|Drug: Etanercept","Number of Patients With Reactions of the Injection Site as an Assessment of the Tolerability|Number of Patients With Any Abnormal Findings From Physical Examinations After Baseline|Number of Patients With Clinically Significant Laboratory Findings|GAD65AB Titer Measured to Evaluate the Tolerability (Main Study Period)|Number of Patients With an Infection Reported as Adverse Event Related to Study Treatment|C-peptide: Area Under the Curve (AUC 0-120 Min) During an MMTT, Change From Baseline|Number of Patients With a Stimulated Maximum C-peptide Level Above 0.2 Nmol/L|Hemoglobin A1c (HbA1c), Change From Baseline|Exogenous Insulin Dose Per kg Body Weight and 24 Hours, Change From Baseline|C-peptide: Stimulated, 90 Minute Value, Change From Baseline|C-peptide Fasting Concentration, Change From Baseline|Spontaneous IL-17a Secretion|GAD65-induced IL-4 Secretion|GAD65-induced IL-13 Secretion|GAD65-induced IFN-gamma Secretion|GAD65-induced TNF-alpha Secretion|GAD65-induced GM-CSF Secretion|GAD65-induced MIP-1b Secretion|GAD65-induced MCP-1 Secretion","Johnny Ludvigsson|Swedish Child Diabetes Foundation|Ostergotland County Council, Sweden|Diamyd Medical AB|Linkoeping University","All","8 Years to 18 Years (Child, Adult)","Phase 2","20","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EDCR IIa","May 2015","February 25, 2019","February 25, 2019","June 8, 2015","September 25, 2019","March 29, 2021","Helsingborg Hospital, Helsingborg, Sweden|Linköping University Hospital, Linköping, Sweden|Lund University Hospital, Lund, Sweden|Skåne University Hospital, UMAS, Malmö, Sweden|Sachsska, Södersjukhuset, Stockholm, Sweden|Uddevalla Hospital, Uddevalla, Sweden|Västerås Hospital, Västerås, Sweden|Örebro University Hospital, Örebro, Sweden","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT02464033/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02464033" | |
| 78,"NCT05262595","A Study to Look at How Insulin NNC0471-0119 Works in the Body in People With Type 1 Diabetes When Injected by Insulin Pump",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: NNC0471-0119 A|Drug: NNC0471-0119 B|Drug: NNC0471-0119 D|Drug: Faster aspart","AUC (NNC0471-0119,0-30min,basal-corrected)/AUC (NNC0471-0119,0-t,basal-corrected)|AUC (NNC0471-0119,0-t,basal-corrected)|AUC (NNC0471-0119,0-30min,basal-corrected)|AUC (NNC0471-0119,2h-t,basal-corrected)|AUC (NNC0471-0119,2h-t,basal-corrected)/AUC (NNC0471-0119,0-t,basal-corrected)|Cmax,NNC0471-0119,basal-corrected: Maximum observed basal-corrected serum NNC0471-0119 concentration|Number of adverse events (AEs)|AUC (GIR,0-t,basal-corrected)|AUC (GIR,0-1h,basal-corrected)|AUC (GIR,0-1h,basal-corrected/AUC (GIR,0-t,basal-corrected)|GIRmax,basal-corrected: Maximum observed basal-corrected GIR","Novo Nordisk A/S","All","18 Years to 24 Years (Adult)","Phase 1","19","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NN1471-4752|U1111-1260-0359|2020-005145-16","March 3, 2022","August 29, 2022","September 5, 2022","March 2, 2022",,"October 17, 2022","Novo Nordisk Investigational Site, Graz, Austria",,"https://ClinicalTrials.gov/show/NCT05262595" | |
| 79,"NCT00187564","Pilot Study on the Effect of Oral Controlled-Release Alpha-Lipoic Acid on Oxidative Stress in Adolescents With Type 1 Diabetes Mellitus",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: controlled-release oral alpha-lipoic acid","1. protein carbonyl (measurement of oxidized protein)|2. Thiobarbituric Acid Reactive Substances (TBARS) (measurement of oxidized lipid)|3. 8-Oxo-dG/8-Oxo-dA (measurement of oxidized DNA)|4. Trolox equivalent antioxidant capacity (TEAC) (measurement of total antioxidant status)|1. Hb A1c|2. Urine albumin/creatinine ratio","University of California, San Francisco","All","8 Years to 21 Years (Child, Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","H7023-25421","August 2004",,"October 2005","September 16, 2005",,"May 6, 2008","UCSF Division of Pediatric Endocrinology, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT00187564" | |
| 80,"NCT03698396","Islet Transplant in Patients With Type I Diabetes",,"Recruiting","No Results Available","Diabetes Mellitus, Type 1","Biological: Allogenic Islet Cell Transplantation","Incidence of procedure related adverse events|Proportion of subjects with HbA1c less than or equal to 7.0%|Proportion of subjects free of severe hypoglycemic events between 6 and 12 months from the time of first islet cell infusion or from the time insulin therapy is withdrawn|Insulin independence achieved","Kenneth Brayman, MD|University of Virginia","All","18 Years and older (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","170020","August 1, 2019","November 1, 2021","December 1, 2023","October 9, 2018",,"July 30, 2020","University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03698396" | |
| 81,"NCT04655690","A Study to Look at How Safe Insulin NNC0471-0119 is and How it Works in People With Type 1 Diabetes Mellitus",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: NNC0471-0119|Drug: Fast-acting insulin aspart","Number of adverse events (AEs)|Number of hypoglycaemic episodes|AUCNNC0471-0119,0-30 min/AUCNNC0471-0119,0-t: Ratio of the area under the serum NNC0471-0119 concentration-time curve from 0-30 min and 0-t, where t is the last observed time point with insulin concentration above lower limit of quantification (LLOQ).|AUCNNC0471-0119,2h-t/AUCNNC0471-0119,0-t: Ratio of the area under the serum NNC0471-0119 concentration-time curve from 2 hours to t and 0 to t, where t is the last observed time point with insulin concentration above LLOQ.|AUCNNC0471-0119, 0-t: Area under the serum NNC0471-0119 concentration-time curve from 0 to t, where t is the last observed time point with insulin concentration above LLOQ.|Cmax,NNC0471-0119: Maximum observed serum NNC0471- 0119 concentration|tmax,NNC0471-0119: Time to maximum observed serum NNC0471-0119 concentration|t½, NNC0471-0119: Terminal half-life for NNC0471-0119","Novo Nordisk A/S","All","18 Years to 55 Years (Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NN1471-4612|U1111-1247-7440|2020-000665-16","November 9, 2020","November 26, 2021","November 26, 2021","December 7, 2020",,"January 2, 2023","Novo Nordisk Investigational Site, Graz, Austria",,"https://ClinicalTrials.gov/show/NCT04655690" | |
| 82,"NCT02352974","GAD-Alum (Diamyd) Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes (DIAGNODE-1)","DIAGNODE","Completed","Has Results","Diabetes Mellitus, Type 1","Drug: GAD-Alum|Drug: Vitamin D","Number of Subjects With Injection Site Reactions Month 1|Number of Subjects With Injection Site Reactions Month 2|Number of Subjects With Injection Site Reactions Month 3|Number of Subjects With Injection Site Reactions Month 32|Mean Change in C-peptide AUC (Area Under the Curve) (Mean 120min) Value, Month 15|Mean Change in C-peptide AUC(Mean 120min) Value, Month 30|Mean Change in C-peptide AUC(Mean 120min) Value, Month 43|Mean Change in C-peptide 90-minute Value, Month 15|Mean Change in C-peptide 90-minute Value, Month 30|Mean Change in C-peptide 90-minute Value, Month 43|Mean Change in Fasting C-peptide Value, Month 15|Mean Change in Fasting C-peptide Value, Month 30|Mean Change in Fasting C-peptide Value, Month 43|Mean Change in HbA1c, Month 15|Mean Change in HbA1c, Month 30|Mean Change in HbA1c, Month 43|External Insulin Dose, Baseline|External Insulin Dose, Month 15|External Insulin Dose, Month 30|External Insulin Dose, Month 43|Mean IDAA1c Values, Baseline|Mean IDAA1c Values, Month 15|Mean IDAA1c Values, Month 30|Mean IDAA1c Values, Month 43","Johnny Ludvigsson|Swedish Child Diabetes Foundation|Ostergotland County Council, Sweden|Diamyd Medical AB|Linkoeping University","All","12 Years to 30 Years (Child, Adult)","Phase 1","12","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DIAGNODE-1","January 2015","October 2019","October 2019","February 2, 2015","April 27, 2020","April 27, 2020","Linköping University, Linköping, Sweden","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT02352974/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02352974" | |
| 83,"NCT04878419","Acceptability of Virtual Educational Intervention for Adolescents and Young Adults With Type 1 Diabetes Mellitus",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Other: Virtual Educational Program","Acceptability of interactive virtual educational module no. 1|Acceptability of interactive virtual educational module no. 2|Acceptability of interactive virtual educational module no. 3|Acceptability of interactive virtual educational module no. 4|Acceptability of interactive virtual educational module no. 5|Acceptability of interactive virtual educational module no. 6|Acceptability of interactive virtual educational module no. 7|Acceptability of interactive virtual educational module no. 8|Acceptability of interactive virtual educational module no. 9|Acceptability of interactive virtual educational module no. 10|Acceptability of interactive virtual educational module no. 11|Overall acceptability of entire interactive virtual educational program|Attrition Rate|Recruitment Rate|Change in subjective diabetes self-efficacy of participants|Change in participants' diabetes related knowledge|Change in participants' diabetes related distress|Change in participants' Time In Range|Change in participants' HBA1C|Correlation of outcome expectation on degree of change in participants subjective diabetes self-efficacy after the educational intervention.|Correlation of outcome expectation on degree of change in participants diabetes related knowledge after the educational intervention.|Correlation of outcome expectation on degree of change in participants diabetes related distress after the educational intervention.|Correlation of outcome expectation on degree of change in participants HBA1C after the educational intervention.|Correlation of outcome expectation on degree of change in participants Time in Range after the educational intervention.","University Hospitals Cleveland Medical Center|Case Western Reserve University","All","16 Years to 21 Years (Child, Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","STUDY20210264","June 17, 2021","January 20, 2022","May 1, 2022","May 7, 2021",,"October 28, 2022","University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04878419" | |
| 84,"NCT04579341","Probiotics Supplementation Effect on Glucose Homeostasis in Children With Type 1 Diabetes",,"Unknown status","No Results Available","Diabetes Mellitus, Type 1","Dietary Supplement: probiotics","glycemic control","Ain Shams University","All","5 Years to 18 Years (Child, Adult)","Not Applicable","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Probiotics","January 21, 2018","October 28, 2020","November 10, 2020","October 8, 2020",,"October 8, 2020","Ain Shams University, Cairo, Ramses, Egypt|Ain Shams University, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT04579341" | |
| 85,"NCT04201171","The Impact of Different CSII and CGM Systems on Different Clinical Outcome Variables in Children and Adolescents With Type 1 Diabetes. An Observational Study Form the Norwegian Childhood Diabetes Registry (NCDR)",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Device: CSII and CGM","HbA1c|DKA|SH|HRQOL","Helse Fonna|Oslo University Hospital|Helse Vest|University of Bergen|Haukeland University Hospital","All","0 Years to 18 Years (Child, Adult)",,"2749","Other","Observational","Observational Model: Cohort|Time Perspective: Other","2016/1613","January 1, 2017","December 31, 2017","December 31, 2017","December 17, 2019",,"October 6, 2021",,,"https://ClinicalTrials.gov/show/NCT04201171" | |
| 86,"NCT04664205","Isoenergetic High Intensity Interval Training and Moderate Intensity Training in Adults With Type I Diabetes","HI1T","Completed","No Results Available","Diabetes Mellitus, Type 1","Other: High Intensity Interval Exercise|Other: Moderate Intensity Continuous Exercise","Change in Carbohydrate Metabolism|Change in Fat Metabolism|Change in Continuous Glucose (Area Under the Curve)","University of North Carolina, Chapel Hill|North Carolina Diabetes Research Center","All","18 Years to 51 Years (Adult)","Not Applicable","14","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","20-3100","February 1, 2021","September 15, 2022","September 15, 2022","December 11, 2020",,"December 6, 2022","Applied Physiology Laboratory, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04664205" | |
| 87,"NCT02790645","Telemedicine Program in Type 1 Diabetes and CSII",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Other: Group 2a. Telemedicine program|Other: Group 1a. Control|Other: Group 1b.Telemedicine program|Other: Group 2b. Control","Assessment of clinical and metabolic parameters (glycosylated hemoglobin-HbA1c- and glycemic variability-SD-).|Assessment of inflammatory markers (hs-CRP).|Assessment of inflammatory markers (IL-6).|Assessment of inflammatory markers (TNF-α).|Assessment of inflammatory markers (MCP-1).|Assessment of redox markers (CAT).|Assessment of redox markers (TBARS).|Assessment of redox markers (oxidized LDL).|Assessment of quality of life with the DQOL|Assessment of depression with the BDI-II|Assessment of anxiety with the STAI|Assessment of distress related to diabetes with the DDS|Assessment of treatment satisfaction with the DTSQ|Assessment of fear of hypoglycemia with the FH-15|Assessment of cost-effectiveness with a structured interview designed by our research group of direct and indirect costs.","Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud|Ministerio de Economía y Competitividad, Spain|Andaluz Health Service|Roche Pharma AG","All","16 Years to 85 Years (Child, Adult, Older Adult)","Not Applicable","51","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSII TELEMEDICINE PROGRAM","September 2012","April 2016","September 19, 2016","June 6, 2016",,"July 13, 2017",,,"https://ClinicalTrials.gov/show/NCT02790645" | |
| 88,"NCT05134987","A Multiple Dose Study Investigating Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0363-0845 in Participants With Type 1 Diabetes Pharmacokinetics and Pharmacodynamics: How Insulin NNC0363-0845 is Transported Throughout the Body and How It Works",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: NNC0363-0845|Drug: Insulin detemir","AUCPG,0.5-2h Area under the plasma glucose-time curve at steady concentrations|AUCPG,0-1h Area under the plasma glucose-time curve at steady concentrations|AUCPG,0-2hArea under the plasma glucose-time curve at steady concentrations|AUCPG,0-4h Area under the plasma glucose-time curve at steady concentrations|∆PGav,0-1h Mean change in plasma glucose at steady concentrations|∆PGav,0-2h Mean change in plasma glucose at steady concentrations|Number of adverse events","Novo Nordisk A/S","All","18 Years to 64 Years (Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NN1845-4886|U1111-1266-4162|2021-003271-33","December 1, 2021","May 6, 2022","May 6, 2022","November 26, 2021",,"November 4, 2022","Novo Nordisk Investigational Site, Graz, Austria",,"https://ClinicalTrials.gov/show/NCT05134987" | |
| 89,"NCT04333823","Adolescent Type 1 Diabetes Treatment With SGLT2i for hyperglycEMia & hyPerfilTration Trial","ATTEMPT","Recruiting","No Results Available","Diabetes Mellitus, Type 1","Drug: Dapagliflozin 5mg|Drug: Placebo","Measured Glomerular Filtration Rate (mGFR)|Glycated Hemoglobin A1c (HbA1c)|Adverse events|Diabetes Ketoacidosis (DKA)|Hypoglycemic events|Urinary and Genitourinary Tract Infections|Blood Glucose Profile|Glycemic Variability|Weight|Body Mass Index (BMI)|Maturation|Total Daily Insulin Dose (TDID)","The Hospital for Sick Children|Canadian Institutes of Health Research (CIHR)|Juvenile Diabetes Research Foundation","All","12 Years to 18 Years (Child, Adult)","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CTO1940","December 11, 2020","May 2023","May 2023","April 3, 2020",,"November 2, 2022","Children's Hospital Colorado Anschutz Medical Campus, Aurora, Colorado, United States|London Health Sciences Centre Children's Hospital, London, Ontario, Canada|The Hospital for Sick Children, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04333823" | |
| 90,"NCT04186195","Psychosocial Factors Affecting Glycemic Control in Children and Adolescents With Type 1 Diabetes Mellitus",,"Completed","No Results Available","Diabetes Mellitus, Type 1",,"Children's type 1 diabetes glycemic control|Parents' divorce rate|Parent's type 1 diabetes glycemic status","Tampere University Hospital","All","1 Year to 16 Years (Child)",,"191","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","R19096","November 3, 2020","December 30, 2021","December 30, 2021","December 4, 2019",,"May 17, 2022","Tampere University Hospital, Tampere, Finland",,"https://ClinicalTrials.gov/show/NCT04186195" | |
| 91,"NCT04049110","Dapagliflozin in Physical Exercise in Type 1 Diabetes",,"Recruiting","No Results Available","Diabetes Mellitus, Type 1","Drug: Forxiga 10mg|Drug: Placebo","Mean Amplitude of Glucose Excursions (MAGE) after physical exercise|Area under the curve for glucagon-like peptide I before, during and after physical exercise|Area under the curve for glucagon before, during and after physical exercise","University Hospital Inselspital, Berne","All","18 Years to 65 Years (Adult, Older Adult)","Phase 3","24","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CUI_002_02","September 15, 2020","March 30, 2023","March 30, 2023","August 7, 2019",,"November 8, 2022","Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT04049110" | |
| 92,"NCT03143816","Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study-STAT Study","STAT","Completed","Has Results","Diabetes Mellitus, Type 1","Drug: Technosphere insulin","Change in Time in Range (%) (70-180 mg/dl) With TI on CGM|Change in Post-prandial Glucose Excursion (mg/dl) (1-4 Hours After Meals) With TI|Change in Glucose Variability (GV) (mg/dl) (Standard Deviation and/or Coefficient Variation)|The Area Under the Curve Calculation (AUC) (Min*mg/dl) in the PPBG and PPGE,|Change in HbA1c (%) in One-month Treatment|Change in Above the Target Time (%) (>180 mg/dl) on CGM|Hypoglycemia Frequency (%) (Below the Target <70mg/dl) on CGM","University of Colorado, Denver|Atlanta Diabetes Associates|University of Southern California|Rainier Clinical Research Center|Mannkind Corporation","All","18 Years to 70 Years (Adult, Older Adult)","Phase 4","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-0427","September 30, 2017","December 15, 2017","January 31, 2018","May 8, 2017","February 22, 2022","February 22, 2022","Barbara Davis Center, Aurora, Colorado, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT03143816/Prot_SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT03143816/ICF_002.pdf","https://ClinicalTrials.gov/show/NCT03143816" | |
| 93,"NCT04428658","Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes",,"Recruiting","No Results Available","Diabetes Mellitus, Type 1","Behavioral: Supplemental video visits|Behavioral: Standard of Care|Behavioral: Supplemental remote monitoring","Glycemic control|Healthcare utilization|Patient-reported outcomes","University of California, Davis","All","5 Years to 18 Years (Child, Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1616262","September 15, 2022","January 1, 2024","January 1, 2024","June 11, 2020",,"September 30, 2022","University of California-Davis, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT04428658" | |
| 94,"NCT03260998","ECG Changes in Children and Adolescents With Type 1 Diabetes",,"Unknown status","No Results Available","Diabetes Mellitus, Type 1","Diagnostic Test: electrocardiogram","corrected QT dispersion","Assiut University","All","Child, Adult, Older Adult",,"120","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","ECGCCATD","August 2017","August 2018","January 2019","August 24, 2017",,"August 29, 2017",,,"https://ClinicalTrials.gov/show/NCT03260998" | |
| 95,"NCT04161976","A Study of LY900027 Given by Insulin Pump to Participants With Type 1 Diabetes Mellitus",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: LY900027|Drug: Insulin Lispro","Pharmacokinetics (PK): Pharmacokinetics (PK): Area Under the Insulin Lispro Curve (AUC) 0 to 5 hours after Bolus Administration Prior to a Mixed Meal Tolerance Text (MMTT)|PK: Maximum Observed Insulin Lispro Concentration (Cmax)|Pharmacodynamics (PD): Incremental Area Under the Plasma Glucose Curve Above Baseline Between 0-5 hours After Bolus Infusion|PD: Total Daily Insulin Dose|Duration Until Catheter Failure","Eli Lilly and Company","All","18 Years to 64 Years (Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","17489|J2H-MC-IUAA|2019-002318-37","December 27, 2019","July 14, 2020","July 14, 2020","November 13, 2019",,"August 5, 2020","Profil Institut für Stoffwechselforschung, Neuss, Nordrhein-Westfalen, Germany",,"https://ClinicalTrials.gov/show/NCT04161976" | |
| 96,"NCT05069545","A Research Study Looking at How the Use of NovoPen® 6 for Treatment With Tresiba® & Fiasp® Affects the Blood Sugar Level in Patients With Type 1 Diabetes as Part of Local Clinical Practice","CONNECT 1","Enrolling by invitation","No Results Available","Diabetes Mellitus, Type 1","Drug: Insulin degludec|Drug: Fast-acting insulin aspart","Change in time in range (3.9-10 mmol/L)|Change in time in hyperglycaemia/above range Level 1 (10.1 - 13.9 mmol/L)|Change in time in hyperglycaemia/above range Level 2 (greater than 13.9 mmol/L)|Change in time in hypoglycaemia/below range Level 1 (3.0-3.8 mmol/L)|Change in time in hypoglycaemia/below range Level 2 (below 3.0 mmol/L)|Change in mean glucose|Change in glucose variability (% coefficient of variability)|Change in Glucose Management Indicator|Change in HbA1c (Glycated haemoglobin)|T1-DDS (Diabetes Distress Scale for Adults with Type1 Diabetes), change in QoL (Quality of Life)|DHSS (Digital Health Solution Satisfaction)-Patient|DHSS-HCP(Health Care Professional)","Novo Nordisk A/S","All","18 Years and older (Adult, Older Adult)",,"227","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","DV3325-4759|U1111-1255-5564","October 12, 2021","March 5, 2024","March 5, 2024","October 6, 2021",,"December 20, 2022","Novo Nordisk Investigational Site, Bonheiden, Belgium|Novo Nordisk Investigational Site, Bruxelles, Belgium|Novo Nordisk Investigational Site, Bruxelles, Belgium|Novo Nordisk Investigational Site, Edegem, Belgium|Novo Nordisk Investigational Site, Leuven, Belgium|Novo Nordisk Investigational Site, Liège, Belgium|Novo Nordisk Investigational Site, Aarhus N, Denmark|Novo Nordisk Investigational Site, Herning, Denmark|Novo Nordisk Investigational Site, København, Denmark|Novo Nordisk Investigational Site, Silkeborg, Denmark|Novo Nordisk Investigational Site, Caen, France|Novo Nordisk Investigational Site, Corbeil Essonnes, France|Novo Nordisk Investigational Site, MONTPELLIER cedex 5, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Pierre-Bénite, France|Novo Nordisk Investigational Site, TOULOUSE cedex, France|Novo Nordisk Investigational Site, Vandoeuvre Les Nancy, France|Novo Nordisk Investigational Site, Borås, Sweden|Novo Nordisk Investigational Site, Malmö, Sweden|Novo Nordisk Investigational Site, Stockholm, Sweden|Novo Nordisk Investigational Site, Sundsvall, Sweden|Novo Nordisk Investigational Site, Uppsala, Sweden|Novo Nordisk Investigational Site, Örebro, Sweden",,"https://ClinicalTrials.gov/show/NCT05069545" | |
| 97,"NCT05096325","YpsoPump Occlusion Detection Algorithm: Collection of Real-world Data for In-silico Evaluation of a New Software Algorithm to Refine Occlusion Detection in Subjects With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Device: YpsoPump® insulin pump system","Difference in the number of occlusion alarms generated by the new software algorithm compared to the currently implemented occlusion detection system.|Retrospective description of the number of occlusions detected including the FIR Filter evaluation|Qualitative evaluation of the false positive alarms|Qualitative assessement of the state of the adhesive tapes after study completion","Ypsomed AG|Diabetes Center Berne Research AG","All","18 Years and older (Adult, Older Adult)",,"40","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","YPU107","January 3, 2022","March 1, 2022","March 1, 2022","October 27, 2021",,"March 22, 2022","Institut für Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm, Ulm, Germany|Universitätsklinik für Diabetologie, Endokrinologie Ernährungsmedizin & Metabolismus, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT05096325" | |
| 98,"NCT03763474","Euglyca Application in Children and Adolescents With Type 1 Diabetes Mellitus",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Combination Product: Euglyca application","Level of glycosylated hemoglobin in the 2 groups|Change from Baseline glycosylated hemoglobin at 3 months in the 2 groups|Change from 3 months glycosylated hemoglobin at 6 months in the 2 groups|Change from 6 months glycosylated hemoglobin at 12 months in the 2 groups|Percentage of Normoglycemias in the 2 groups|Diabetes Treatment Satisfaction Questionnaire (DTSQ) score in the 2 groups","Aristotle University Of Thessaloniki","All","6 Years to 18 Years (Child, Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","Euglyca application","April 1, 2017","September 1, 2018","September 1, 2018","December 4, 2018",,"December 5, 2018","Endocrine Unit of 3rd Department of Pediatrics of Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki, Greece","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT03763474/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03763474" | |
| 99,"NCT01103817","Influence of Vitamin D on Vascular Function in Adolescents and Young Adults With Type 1 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Dietary Supplement: Vitamin D","Comparison of Endothelial Function|Change in Endothelial Function after Treatment with Vitamin D|Monitoring of Vitamin D Levels in Vitamin D deficient subjects|Monitoring of Calcium Creatine Ratio in Vitamin D deficient subjects|Comparison of Systemic Blood Pressure|Comparison of Urinary Albumin/Creatinine Ratio","The Hospital for Sick Children","All","12 Years to 18 Years (Child, Adult)","Phase 2","33","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1000014567","March 2010","January 2011","January 2011","April 15, 2010",,"June 1, 2016","The Hospital for Sick Children, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01103817" | |
| 100,"NCT05646017","Effect of Heatwave Over Glycemic Control in Patients With T1D",,"Not yet recruiting","No Results Available","Type 1 Diabetes","Device: Intermittenly scanned continuous glucose monitoring","Change in Time in range|Change in Adherence to Flash 1|Change in Adherence to Flash 2|Change in Time below range 1 (TBR1)|Change in Time below range 2 (TBR2)|Change in Time above range 1 (TAR1)|Change in Time above range 2 (TAR2)|Change in Coefficient of variation percentage (CV)|Change in Glucose management index|Change in Time in hypoglycemia|Change in Hypoglycemia frequency","Castilla-La Mancha Health Service","All","18 Years to 99 Years (Adult, Older Adult)",,"2701","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","C-566","December 15, 2022","January 1, 2023","January 31, 2023","December 12, 2022",,"December 12, 2022","La Mancha-Centro Hospital, Alcázar De San Juan, Ciudad Real, Spain|Santa Barbara Hospital, Puertollano, Ciudad Real, Spain|Valdepeñas General Hospital, Valdepeñas, Ciudad Real, Spain|Virgen del Prado Hospital, Talavera De La Reina, Toledo, Spain|Albacete University Hospital, Albacete, Spain|Ciudad Real General University Hospital, Ciudad Real, Spain|Virgen de la Luz University Hospital, Cuenca, Spain|Guadalajara University Hospital, Guadalajara, Spain|Toledo University Hospital, Toledo, Spain",,"https://ClinicalTrials.gov/show/NCT05646017" | |
| 101,"NCT04035031","Effects of Dapagliflozin on Hormonal Glucose Homeostasis in Type 1 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: Forxiga 10mg|Drug: Placebo","Area under the curve for glucagon-like peptide I in oral glucose tolerance test clamp|Area under the curve for glucagon-like peptide I in euglycemic, hyperinsulinemic clamp|Area under the curve for ketone body concentrations in euglycemic, hyperinsulinemic clamp following dapagliflozin compared with placebo|Area under the curve for ketone body concentrations in oral glucose tolerance test clamp following dapagliflozin compared with placebo|Area under the curve for free fatty acids in euglycemic, hyperinsulinemic clamp following dapagliflozin compared with placebo|Area under the curve for free fatty acids in oral glucose tolerance test clamp following dapagliflozin compared with placebo|Area under the curve for glucagon in euglycemic, hyperinsulinemic clamp following dapagliflozin compared with placebo|Area under the curve for glucagon in oral glucose tolerance test clamp following dapagliflozin compared with placebo|Area under the curve for somatostatin in euglycemic, hyperinsulinemic clamp following dapagliflozin compared with placebo|Area under the curve for somatostatin in oral glucose tolerance test clamp following dapagliflozin compared with placebo","University Hospital Inselspital, Berne","All","18 Years to 65 Years (Adult, Older Adult)","Phase 3","13","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","CUI_002_01","January 9, 2020","November 12, 2020","November 12, 2020","July 29, 2019",,"March 26, 2021","Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT04035031" | |
| 102,"NCT01785108","DIABGAD - Trial to Preserve Insulin Secretion in Type 1 Diabetes Using GAD-Alum (Diamyd) in Combination With Vitamin D and Ibuprofen",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Biological: GAD-Alum (Diamyd) 20 µg|Biological: GAD-Alum (Diamyd) 20 µg X 2|Drug: Vitamin D|Drug: Ibuprofen","Change in C-peptide (90 minute value and AUC mean 0-120 min) during a Mixed Meal Tolerance Test from baseline to month 6, 15 and 30|Proportion of patients with a stimulated maximum C-peptide level above 0.2 nmol/L|Hemoglobin A1c (HbA1c), change between baseline and subsequent visits|Exogenous insulin dose per kg body weight and 24 hours, change between baseline and subsequent visits|Th2-deviation of cell-mediated immune response seen, e.g. as increased ratio of IL-5, 10, 13 in comparison with IFN-gamma, TNF-alfa, IL-1 beta, IL-17, and increase of T-regulatory cells|Decrease in inflammatory markers, e.g. TNF-alfa, IL-1 beta, IL-2, IL-17|Fasting C-peptide, change between baseline and month 6, 15 and 30","Johnny Ludvigsson|Swedish Child Diabetes Foundation|The Research Council of South East Sweden (FORSS)|Diamyd Medical AB|Linkoeping University","All","10 Years to 18 Years (Child, Adult)","Phase 2","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DIABGAD-1","February 2013","March 2017","March 2017","February 7, 2013",,"August 23, 2017","Halmstad Hospital, Halmstad, Sweden|Astrid Lindgren Children's Hospital - Huddinge, Huddinge, Sweden|Kalmar Hospital, Kalmar, Sweden|Linköping University, Linköping, Sweden|Lund University Hospital, Lund, Sweden|Skåne University Hospital, UMAS, Malmö, Sweden|Sachsska, Södersjukhuset, Stockholm, Sweden|Astrid Lindgren Children's Hospital, Stockholm, Sweden|Uddevalla Hospital, Uddevalla, Sweden|Örebro University Hospital, Örebro, Sweden",,"https://ClinicalTrials.gov/show/NCT01785108" | |
| 103,"NCT04414280","The Impact of Hybrid Closed-loop Insulin Delivery in Type 1 Diabetes on Glycemic Control and PROMs","INRANGE","Recruiting","No Results Available","Diabetes Mellitus, Type 1","Device: Medtronic MiniMed 670G|Device: Medtronic MiniMed 780G|Device: Tandem Control-IQ","Time in range|Time in level 2 hypoglycemia|Time in level 1 hypoglycemia|Time below range|Time above range|Time in level 1 hyperglycemia|Glycemic variability|Mean glucose concentration|HbA1c|Correlation between sex (male/female) and change in HbA1c|Correlation between educational attainment (measured by a questionnaire with multiple options) and change in HbA1c|Correlation between cohabitation (yes/no) and change in HbA1c|Correlation between duration of diabetes (years) and change in HbA1c|Correlation between chronic diabetic complications (measured by a questionnaire with multiple options) and change in HbA1c|Correlation between total daily dose of insulin (units per day) and change in HbA1c|Number of low glucose events|Quality of life measured by the Short Form Health Survey 36-item (SF-36) version 2 questionnaire (scale: 0 (low quality of life) - 100 (high quality of life))|Hypoglycemia awareness measured by the Clarke hypoglycemia awareness survey (scale: unaware (≥4 times ""R"" or once ""U"") or aware (<4 times ""R""))|Hypoglycemia awareness measured by the Gold-scale (scale: 1 (aware) - 7 (unaware))|Fear of hypoglycemia measured by the Hypoglycemia Fear Survey, version II (HFS-II) questionnaire, behaviour (scale: 0 (less adapted behaviour) - 40 (more adapted behaviour))|Fear of hypoglycemia measured by the Hypoglycemia Fear Survey, version II (HFS-II) questionnaire, worry (scale: 0 (not worried) - 72 (very worried))|Distress due to diabetes measured by the Problem Areas In Diabetes survey, short form (PAID-SF) questionnaire (scale: 0 (no distress) - 20 (very distressed))|Treatment satisfaction measured by the Diabetes Treatment Satisfaction Questionnaire, status (DTSQs. Scale: 0 (low satisfaction) - 36 (high satisfaction))|Treatment satisfaction measured by a self-developed questionnaire about expectations towards the use of the Medtronic MiniMed 670G system (multiple choice)|Impact of diabetes and device satisfaction by the Diabetes Impact and Device Satisfaction Scale (scale: device satisfaction = 7 (not satisfied) - 70 (very satisfied); diabetes impact = 4 (low impact) - 40 (high impact))|Fear of hypoglycemia measured by the Hypoglycemia Fear Survey for children (HFS-C) questionnaire, worry (scale: 0 (not worried) - 60 (very worried))|Fear of hypoglycemia measured by the Hypoglycemia Fear Survey for children (HFS-C) questionnaire, behaviour (scale: 0 (less adapted behaviour) - 40 (more adapted behaviour))|The Diabetes Quality of Life for Youth (DQOLY) questionnaire|Questionnaire for parents of children and adolescents with diabetes, a part of the HAPPI-D QOL Protocol (Hvidøre, Adolescent, Parent, Professional, Instrument, Diabetes)|The Parent's fear of hypoglycemia scale - modified version of the Hypoglycemia Fear Survey for use with parents","Universitaire Ziekenhuizen KU Leuven","All","6 Years and older (Child, Adult, Older Adult)",,"1150","Other","Observational","Observational Model: Cohort|Time Perspective: Other","S63351","March 12, 2020","December 31, 2024","December 31, 2024","June 4, 2020",,"December 21, 2022","UZ Leuven, Leuven, Vlaams-Brabant, Belgium|OLVZ Aalst, Aalst, Belgium|GZA Ziekenhuizen - campus Sint-Vincentius, Antwerpen, Belgium|Hôpital d'Arlon, Arlon, Belgium|Imeldaziekenhuis, Bonheiden, Belgium|AZ Sint-Jan - campus Sint-Jan, Brugge, Belgium|Hôpital Erasme, Bruxelles, Belgium|UZ Antwerpen, Edegem, Belgium|ZOL - campus Sint-Jan, Genk, Belgium|Jessa Ziekenhuis - campus Salvator, Hasselt, Belgium|UZ Brussel, Jette, Belgium|AZ Groeninge - campus kennedylaan, Kortrijk, Belgium|CHR de La Citadelle, Liège, Belgium|CHU de Liège - site du Sart Tilman, Liège, Belgium|Az Damiaan, Oostende, Belgium|AZ Delta - campus Wilgenstraat Roeselare, Roeselare, Belgium|AZ Nikolaas, Sint-Niklaas, Belgium|GZA Ziekenhuizen - campus Sint-Augustinus, Wilrijk, Belgium",,"https://ClinicalTrials.gov/show/NCT04414280" | |
| 104,"NCT03481374","Cardiovascular Autonomic Neuropathy in Patients With Type 1 Diabetes Mellitus.",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Diagnostic Test: autonomic function testing","VO2 max","Hasselt University|Jessa Hospital","All","18 Years and older (Adult, Older Adult)","Not Applicable","79","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","CVDIABMEL-1","July 1, 2016","March 31, 2017","March 31, 2017","March 29, 2018",,"April 17, 2018","Jessa Ziekenhuis, Hasselt, Belgium",,"https://ClinicalTrials.gov/show/NCT03481374" | |
| 105,"NCT04276207","A Study of LY900014 Versus Insulin Lispro (Humalog) on High Blood Sugar in Participants With Type 1 Diabetes Who Use Insulin Pumps",,"Completed","Has Results","Diabetes Mellitus, Type 1","Drug: LY900014|Drug: Insulin Lispro","Time to Recovery From Hyperglycemia Following Administration of LY900014 and Insulin Lispro (Humalog) After Missed Meal Bolus|Time to Recovery From Hyperglycemia Following Administration of LY900014 and Insulin Lispro (Humalog) After Pump Suspension|Pharmacodynamics (PD): Maximum Observed Plasma Glucose (PGmax) Following Administration of LY900014 and Insulin Lispro (Humalog)|Pharmacokinetics (PK): Time to Maximum Observed Insulin Lispro Concentration (Tmax) Following Administration of LY900014 and Insulin Lispro (Humalog)","Eli Lilly and Company","All","18 Years to 64 Years (Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","17277|I8B-MC-ITST|2019-003493-13","February 25, 2020","August 10, 2020","August 10, 2020","February 19, 2020","August 25, 2021","August 25, 2021","Profil Mainz GmbH & Co. KG, Mainz, Rheinland-Pfalz, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT04276207/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT04276207/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04276207" | |
| 106,"NCT03815006","Flash-glucose Monitoring in Sub-optimally Controlled Type 1 Diabetes (FLASH-UK)","FLASH-UK","Completed","No Results Available","Diabetes Mellitus, Type 1","Device: Free Style Libre 2","HbA1c Level at 24 weeks|HbA1c Level at 12 weeks|Percentage with HbA1c ≤ 53 mmol/mol (7.0%) at 12 weeks|Percentage with HbA1c ≤ 53 mmol/mol (7.0%) at 24 weeks|Sensor based - Time spent in the target glucose range between 3.9 to 10.0 mmol/l|Sensor based - Time spent below target glucose (<3.9mmol/l)|Sensor based - Time spent above target glucose (10.0 mmol/l)|Sensor based - Average glucose levels|Sensor based - Standard deviation glucose levels|Sensor based - Coefficient of variation glucose levels|Sensor based - time with sensor glucose levels < 3.5 mmol/l|Sensor based - time with sensor glucose levels < 2.8 mmol/l|Sensor based - time with sensor glucose levels in the significant hyperglycaemia|Sensor based - AUC of glucose below 3.0mmol/l|Total daily average insulin dose|Daily average basal insulin dose|Daily average bolus dose|Average number of boluses of rapid acting insulin|Number of Freestyle Libre scans per day|Frequency of severe hypoglycaemic episodes|Frequency of significant ketosis events|Nature and severity of other adverse events|Type 1 Diabetes Distress Scale Score|EQ-5D-5L Quality of Life questionnaire Score|Patient Health Questionnaire Score|Diabetes fear of injecting and self-testing questionnaire Score|The revised Diabetes Eating Problem Survey score|Average number of days of Libre usage per week|Diabetes Treatment Satisfaction Questionnaire score|Glucose Monitoring Satisfaction Survey score","Manchester University NHS Foundation Trust|University Hospitals of Derby and Burton NHS Foundation Trust|Cambridge University Hospitals NHS Foundation Trust|Portsmouth Hospitals NHS Trust|University Hospital Birmingham NHS Foundation Trust|Norfolk and Norwich University Hospitals NHS Foundation Trust|University of Manchester|Diabetes UK|Clinical Trials Unit, Manchester|BHR Limited|East Suffolk and North Essex NHS Foundation Trust|The Adam Practice, Dorset","All","16 Years and older (Child, Adult, Older Adult)","Not Applicable","156","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B00373","January 9, 2020","October 10, 2021","October 10, 2021","January 24, 2019",,"August 23, 2022","The Adam Practice, Poole, Dorset, United Kingdom|College of Medical and Dental Sciences University of Birmingham, Birmingham, United Kingdom|Addenbrooke's Hospital, Cambridge, United Kingdom|University Hospitals of Derby and Burton NHS Foundation Trust, Derby, United Kingdom|Ipswich Hospital, Ipswich, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom|Queen Alexandra Hospital, Portsmouth, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03815006" | |
| 107,"NCT03156179","Study of Calcium Metabolism in Teenage Girls With Type 1 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Diagnostic Test: calcium isotope analysis","fractional calcium absorption|Estimated calcium retention","University of Rochester|Cornell University","Female","9 Years to 18 Years (Child, Adult)",,"22","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","56744","September 1, 2015","December 31, 2016","December 31, 2016","May 17, 2017",,"May 17, 2017","Univeristy of Rochester Medical Center, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT03156179" | |
| 108,"NCT04052919","Cardiac Dysfunction in Adolescents With Type 1 Diabetes: Contribution of Daily-life Glucoregulation and Impact on Cardiorespiratory Exercise Capacity","GIIADMT1","Completed","No Results Available","Diabetes Mellitus, Type 1","Other: Cardiac dysfunction in adolescents with type 1 diabetes","transthoracic echocardiography|glycemic control|body composition|HbA1C level|BMI (Body Mass Index)|Height|weight|Physical activity questionaire","Hasselt University|Jessa Hospital","All","12 Years to 18 Years (Child, Adult)","Not Applicable","19","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","GIIADMT1","February 1, 2018","August 1, 2019","August 1, 2019","August 12, 2019",,"August 12, 2019","Jessa Ziekenhuis, Hasselt, Belgium",,"https://ClinicalTrials.gov/show/NCT04052919" | |
| 109,"NCT03682237","Optimizing Metabolic Control in Type 1 Diabetes - The Automatic Bolus Calculator Flash Study",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Device: Carbohydrate counting, automated bolus calculation|Device: Flash glucose monitoring (FGM)","Time in normoglycemia|HbA1c|Severe hypoglycemia|Hypoglycemia|Diabetes distress|Diabetes treatment satisfaction|Diabetes empowerment|Diabetes quality of life|Blinded FGM hypoglycemia|Blinded FGM hyperglycemia|Blinded FGM glycemic variability|Personality traits|Total insulin dose|Total basal insulin dose|Insulin boluses|Body weight|Urinary albumin/excretion rate","Steno Diabetes Center Copenhagen|Hillerod Hospital, Denmark|Hvidovre University Hospital|Bispebjerg Hospital|Rigshospitalet, Denmark|Frederiksberg University Hospital|Amager Hospital","All","18 Years and older (Adult, Older Adult)","Not Applicable","184","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-17040573","October 1, 2018","October 26, 2020","October 26, 2020","September 24, 2018",,"October 28, 2020","Steno Diabetes Center Copenhagen, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT03682237" | |
| 110,"NCT00105352","Improving Metabolic Assessments in Type 1 Diabetes Mellitus Clinical Trials",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Procedure: Mixed Meal Tolerance Test|Procedure: Glucagon Stimulation Test","Stimulated C-peptide response derived from the 2-hour MMTT and the glucagon stimulation test (GST)|Time to peak C-peptide on MMTT, and the peak and AUC values from each test|Co-efficient of reproducibility of the MMTT, and the GST, provided from the duplicate tests within the same individuals","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Juvenile Diabetes Research Foundation|National Center for Research Resources (NCRR)","All","8 Years to 35 Years (Child, Adult)","Not Applicable","120","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","MMTTGST (IND) (completed)","November 2004",,"November 2005","March 14, 2005",,"June 2, 2016","Children's Hospital Los Angeles, Los Angeles, California, United States|University of California San Francisco, San Francisco, California, United States|Stanford University Medical Center, Stanford, California, United States|Barbara Davis Center for Childhood Diabetes, University of Colorado, Denver, Colorado, United States|University of Florida, Gainesville,, Florida, United States|University of Miami School of Medicine, Miami, Florida, United States|Riley Hospital for Children, Indiana University, Indianapolis, Indiana, United States|Joslin Diabetes Center/ Children's Hospital Boston, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Naomi Berrie Diabetes Center, Columbia University, New York, New York, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|University of Texas Medical Center at Dallas, Dallas, Texas, United States|Benaroya Research Institute, Seattle, Washington, United States|Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia|University of Toronto, Toronto, Ontario, Canada|University of Turku, Turku, Finland|Vita-Salute San Raffaele University, Milan, Italy|University of Bristol, Bristol, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00105352" | |
| 111,"NCT03032354","Probiotics in Newly Recognized Type 1 Diabetes",,"Unknown status","No Results Available","Diabetes Mellitus, Type 1","Drug: Lactobacillus rhamnosus GG and Bifidobacterium lactis BB12|Other: Placebo, (Placebo group)","Area under the curve (AUC) during fasting and at 30,60,90,120 min following the start of the meal|Insulin requirement (U / kg body mass )|HbA1c|Weight in kilograms|Number of participants with abnormal laboratory values and/or adverse events that are related to treatment ( eg.abdominal pain, diarrhea , constipation , vomiting,flatulence)|Occurrence of other autoimmune diseases|Height in meters|BMI in kg/m2|BMI score|severe hypoglycemia|ketoacidosis|Fasting c- peptide concentrations in ng/ml","Medical University of Warsaw","All","8 Years to 17 Years (Child)","Phase 4","96","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AgaLidka","July 15, 2017","December 2018","December 2018","January 26, 2017",,"July 11, 2017",,,"https://ClinicalTrials.gov/show/NCT03032354" | |
| 112,"NCT02351466","Type 1 Diabetes and the Brain in Children",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Other: Observational","Changes in total and regional gray and white matter volumes and white matter microstructure.|Measures of activation of frontal-parietal networks and functional connectivity of resting state networks using blood oxygen level dependent (BOLD)-functional MRI.|Changes in Neurocognitive metrics including IQ as well as executive and visual-spatial memory.","Nemours Children's Clinic|Stanford University|Washington University School of Medicine|Yale University|University of Iowa","All","7 Years to 16 Years (Child)",,"221","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","588973","March 2015","November 2018","December 2018","January 30, 2015",,"October 22, 2020","Stanford University, Palo Alto, California, United States|Yale University, New Haven, Connecticut, United States|Nemours Childrens Clinic, Jacksonville, Florida, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|Washington University, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02351466" | |
| 113,"NCT03895515","Effect of Fiasp® in Type 1 Diabetes Treatment",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: Fiasp®","Change in percentage of time spent in glycaemic target range (TIR)|Change in mean sensor glucose|Change in glycaemic variability (GV) (measured as coefficient of variation [CV])|Change in percentage of time spent in level 1 hyperglycaemia (greater than 10.0 mmol/L)|Change in percentage of time spent in level 2 hyperglycaemia (greater than 13.9 mmol/L)|Change in percentage of time spent in level 2 hypoglycaemia (lesser than 3.0 mmol/L)|Change in percentage of time spent in level 1 hypoglycaemia (lesser than 3.9 mmol/L)|Proportion with CV lesser than 36%|Change in Glycated Haemoglobin A1c (HbA1c)","Novo Nordisk A/S","All","Child, Adult, Older Adult",,"178","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","NN1218-4510|U1111-1228-4256","January 3, 2020","December 21, 2020","December 21, 2020","March 29, 2019",,"April 7, 2022","Novo Nordisk Investigational Site, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT03895515" | |
| 114,"NCT02846545","A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes","T1GER","Completed","Has Results","Diabetes Mellitus, Type 1","Biological: Golimumab|Biological: Placebo","Active Treatment Period: C-peptide Area Under the Concentration-time Curve (AUC) Calculated From a 4 Hour Mixed Meal Tolerance Test (MMTT) at Week 52|Active Treatment Period: Change From Baseline in Insulin Use in Units Per Kilogram Body Weight Per Day|Active Treatment Period: Change From Baseline in Glycosylated Haemoglobin (HbA1c) at Week 52|Hypoglycemic Event Rates|Active Treatment Period: C-peptide Area Under the Concentration-time Curve (AUC) Calculated From a 4 Hour Mixed Meal Tolerance Test (MMTT) Over Time|Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) as a Measure of Safety and Tolerability|Percentage of Participants With Serious Adverse Events|Percentage of Participants With Severe Infections Through Week 52 and Week 104|Active Treatment Period: Percentage of Participants With Study Agent Injection Site Reactions Up to Week 52|Serum Golimumab Concentrations|Number of Participants With Antibodies to Golimumab|Titers of Antibodies to Golimumab","Janssen Research & Development, LLC","All","6 Years to 21 Years (Child, Adult)","Phase 2","84","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR108187|CNTO148DML2001|2021-000189-13","August 26, 2016","May 21, 2019","January 5, 2021","July 27, 2016","July 14, 2022","December 22, 2022","Little Rock, Arkansas, United States|Newport Beach, California, United States|Sacramento, California, United States|San Diego, California, United States|San Francisco, California, United States|Walnut Creek, California, United States|Aurora, Colorado, United States|New Haven, Connecticut, United States|Doral, Florida, United States|Gainesville, Florida, United States|Atlanta, Georgia, United States|Columbus, Georgia, United States|Boise, Idaho, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|Lexington, Kentucky, United States|Louisville, Kentucky, United States|Baton Rouge, Louisiana, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Worcester, Massachusetts, United States|Morristown, New Jersey, United States|Bronx, New York, United States|Buffalo, New York, United States|Mentor, Ohio, United States|Philadelphia, Pennsylvania, United States|Sioux Falls, South Dakota, United States|Dallas, Texas, United States|San Antonio, Texas, United States|Schertz, Texas, United States|Webster, Texas, United States|Seattle, Washington, United States|Tacoma, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT02846545/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT02846545/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02846545" | |
| 115,"NCT03199716","Parent Mentors to Improve Adherence to Type I Diabetes Care Regimen in Adolescents",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Other: Parent mentors","Daily frequency of blood glucose monitoring (BGM)|HbA1c levels","University of California, Davis|Children's Miracle Network","All","10 Years to 15 Years (Child)","Not Applicable","27","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","615897","September 2014","March 23, 2017","March 23, 2017","June 27, 2017",,"June 12, 2019","UC Davis Pediatrics Endocrinology, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT03199716" | |
| 116,"NCT01222078","Investigating Re-Dosing With Otelixizumab in Adults With Newly-Diagnosed Type 1 Diabetes Mellitus",,"Terminated","Has Results","Diabetes Mellitus, Type 1","Biological: otelixizumab","Number of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs)|Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)|Mean Change From Baseline in Respiration Rate|Mean Change From Baseline in Temperature|Mean Change From Baseline in Heart Rate|Number of Participants With Values Outside the Normal Range for Vitals|Mean Change From Baseline in Value of Albumin and Total Protein|Mean Change From Baseline in Value of Alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, Creatinine Kinase, Follicle Stimulating Hormone, Gamma Glutamyl Tranferase and Lactate Dehydrogenase|Mean Change From Baseline in Value of Direct Bilirubin, Total Bilirubin, Creatinine and Uric Acid|Mean Change From Baseline in Value of Calcium, Chloride, Carbon Dioxide Content/Bicarbonate, Glucose, Potassium, Magnesium, Sodium, Inorganic Phosphorus and Urea/Blood Urea Nitrogen|Mean Change From Baseline in Value of Estradiol|Mean Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Platelet Count and White Blood Cell Count|Mean Change From Baseline in Glycosylated Hemoglobin Value|Mean Change From Baseline in Hemoglobin Value|Mean Change From Baseline in Red Blood Cell Count|Mean Epstein-Barr Virus (EBV) Viral Load|Mean Change in Total Lymphocyte Count|Mean Change in CD4+ and CD8+ T-cell Counts|Mean Change in Circulating Peripheral T Lymphocytes|Mean Change in Circulating Peripheral CD4+ and CD8+ Subset Counts|Mean Serum Levels of Anti-otelixizumab Binding Antibodies|Proportion of Anti-otelixizumab Neutralizing Antibodies|Mean Circulating Peripheral T Lymphocytes Count|Mean Circulating CD4+ and CD8+ Subset Counts|Mean Saturation of CD3 Antigen on Peripheral Blood T Cells|Mean Individual Serum Concentrations of Otelixizumab|Maximum Observed Serum Concentration (Cmax) of Otelixizumab|Time to Cmax (Tmax) of Otelixizumab|Area Under the Serum Concentration-time Curve [AUC(0-tlast)] of Otelixizumab|Time of Last Observed Quantifiable Concentration (Tlast) of Otelixizumab|Terminal Phase Half-life (Thalf) of Otelixizumab","GlaxoSmithKline","All","18 Years to 45 Years (Adult)","Phase 2","1","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","113390|2010-019157-17","November 22, 2010","May 19, 2011","May 19, 2011","October 18, 2010","June 16, 2017","October 30, 2020","GSK Investigational Site, Paris Cedex 18, France|GSK Investigational Site, Leipzig, Sachsen, Germany",,"https://ClinicalTrials.gov/show/NCT01222078" | |
| 117,"NCT05614089","Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings","HumAn-1","Not yet recruiting","No Results Available","Diabetes Mellitus, Type 1|Type 1 Diabetes","Drug: Insulin Glargine|Drug: NPH or premixed 70/30 (human insulin)","Time-in-serious hypoglycemia|Time-in-range (TIR)|Time-in-hypoglycemia|Time-above-range|Nocturnal hypoglycemic events|Glycemic control (HbA1c)|Rate of severe hypoglycemic events|Rate of Diabetic Ketoacidosis|Quality of Life (e.g. PedsQL Pediatric Quality of Life Inventory)","Jing Luo|The Leona M. and Harry B. Helmsley Charitable Trust|University of Pittsburgh","All","7 Years to 25 Years (Child, Adult)","Phase 4","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY21110122","January 2023","October 30, 2024","November 30, 2024","November 14, 2022",,"December 1, 2022","BIRDEM Hospital, Dhaka, Bangladesh|Bugando Medical Center, Mwanza, Tanzania|Sekou-Toure Hospital, Mwanza, Tanzania","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT05614089/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT05614089/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT05614089" | |
| 118,"NCT03358394","Mindfulness-based Arabic Guided Self-help for Parents of Children With Type 1 Diabetes",,"Unknown status","No Results Available","Diabetes Mellitus, Type 1","Behavioral: A human-interventional study","Generalized Anxiety Disorder Scale (GAD-7)|The Patient Health Questionnaire (PHQ-9).|Mindfulness","SHAHAH ALTAMMAR|University of Sheffield","All","18 Years and older (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other","Reference Number 016511","October 26, 2017","February 26, 2018","May 16, 2018","November 30, 2017",,"December 6, 2017","Shahah Altammar, Kuwait, Kuwait",,"https://ClinicalTrials.gov/show/NCT03358394" | |
| 119,"NCT05181917","Carbohydrate Count Aided by a Simulation in People With Type 1 Diabetes Mellitus. A Protocol for a Clinical Trial",,"Not yet recruiting","No Results Available","Diabetes Mellitus, Type 1","Behavioral: STUDIA app","TIme in range|Hyperglycemic crisis:|Hypoglycemia|Prediction capacity of the model of postprandial glucose values","Hospital Pablo Tobón Uribe|Universidad de Antioquia","All","18 Years to 75 Years (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2021.004","November 2022","May 2023","August 2023","January 10, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05181917" | |
| 120,"NCT05205928","Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care","SEMA-AP","Recruiting","No Results Available","Type 1 Diabetes|Diabetes Mellitus, Type 1","Drug: Outpatient therapy: 8 weeks of drug therapy with usual treatment + 5 weeks of closed-loop therapy","Percentage of time of plasma glucose levels spent in target range (semaglutide vs placebo)|Percentage of time spent in the following ranges of glucose levels between 3.9 and 7.8 mmol/L|Percentage of time spent in the following ranges of glucose levels: below 3.9 and 3.0 mmol/L|Percentage of time spent in the following ranges of glucose levels: above 7.8, 10, and 13.9 mmol/L|Mean glucose level|Standard deviation of glucose levels as a measure of glucose variability|Percentage coefficient of variation of glucose levels|Proportion of participants with TIR between 3.9 - 10.0 mol/L ≥ 70%|Glycated hemoglobin|Average scores between interventions based on quality of life questionnaires|Blood pressure and heart rate|Measured of body mass: weight, body mass index, waist circumference, hip circumference, waist-to-hip ratio|Lipid profile, specifically: LDL-cholesterol, HDL-cholesterol, triglycerides|Biochemical analyses (exploratory)|Urine albumin-creatinine ratio|Glucagon, C-peptide, Paracetamol absorption after mixed meal tolerance test (in first 15 participants)","McGill University Health Centre/Research Institute of the McGill University Health Centre","All","18 Years and older (Adult, Older Adult)","Phase 2|Phase 3","28","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2022-8097","August 2, 2022","December 30, 2024","December 30, 2024","January 25, 2022",,"October 5, 2022","Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT05205928" | |
| 121,"NCT03522870","Effects of Novel Flash Glucose Monitoring System on Glycemic Control in Adult Patients With Type 1 Diabetes Mellitus",,"Recruiting","No Results Available","Diabetes Mellitus, Type 1","Device: Flash glucose monitoring system|Device: SMBG","Glycosylated Hemoglobin A1c|Time in Range|Time in Hypoglycemia|Time in Hyperglycaemia|Percentage of HbA1c in Range|Standard deviation of glucose|Mean glucose levels|The area under the curve of hypoglycemia/ hyperglycaemia|Frequency in hypoglycemia/ hyperglycaemia|Frequency in severe hypoglycaemia|Frequency in adverse events about device|Frequency in using FGM|Frequency in SMBG|Total daily dose of insulin|The Diabetes Distress Scale (DDS)|Hypoglycaemia Fear Scale(HFS)|EQ-5D-5L","Sun Yat-sen University","All","18 Years and older (Adult, Older Adult)","Not Applicable","104","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2017YFC1309601","May 1, 2018","December 30, 2021","December 30, 2021","May 11, 2018",,"March 24, 2021","The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03522870" | |
| 122,"NCT03816761","Research Study to Look at Fast-acting Insulin Aspart With the Insulin Pump System 'iLet™' in Adults With Type 1 Diabetes",,"Completed","Has Results","Diabetes Mellitus, Type 1","Drug: Fast-acting insulin aspart|Device: iLet™","Time in Low Interstitial Glucose (Defined as Below 54 mg/dL [3 mmol/L]) From Initiation of Treatment (Day 1) to End of Treatment (Day 7) (Percentage)|Time in Low Interstitial Glucose (Defined as Below 54 mg/dL [3 mmol/L]) From Initiation of Treatment (Day 1) to End of Treatment (Day 7) (Percentage) - Median|Number of Treatment Emergent Severe Hypoglycaemic Episodes|Number of Self-manageable (Able to Self-treat) Treatment Emergent Hypoglycaemic Episodes That Require Oral Carbohydrate Intervention Per Day|Number of Treatment Emergent Overall Hypoglycaemic Episodes Classified According to the American Diabetes Association (ADA) Definition|Number of Treatment Emergent Overall Hypoglycaemic Episodes Classified According to the Novo Nordisk Classification|Number of Treatment Emergent Daytime Hypoglycaemic Episodes Classified According to the American Diabetes Association (ADA) Definition|Number of Treatment Emergent Daytime Hypoglycaemic Episodes Classified According to the Novo Nordisk Classification|Number of Treatment Emergent Nocturnal Hypoglycaemic Episodes Classified According to the American Diabetes Association (ADA) Definition|Number of Treatment Emergent Nocturnal Hypoglycaemic Episodes Classified According to the Novo Nordisk Classification|Time in Interstitial Glucose Range Was Defined as 70-180 mg/dL (3.9-10 mmol/L) From Initiation of Treatment (Day 1) to End of Treatment (Day 7) (Percentages)|Mean Interstitial-glucose Level|Number of Treatment Emergent Adverse Events|Number of Treatment Emergent Infusion Site Reactions|Total Insulin Dose Per Day","Novo Nordisk A/S","All","18 Years to 75 Years (Adult, Older Adult)","Phase 2","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","NN1218-4360|U1111-1205-1788","February 25, 2019","May 31, 2019","June 10, 2019","January 25, 2019","June 11, 2020","June 11, 2020","Novo Nordisk Investigational Site, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT03816761/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03816761" | |
| 123,"NCT04269668","An Open-label, Two-center, Randomized, Cross-over Study to Evaluate the Safety and Efficacy of Glycemic Control Using Hybrid-closed Loop vs. Advanced Hybrid Closed-loop in Young Subjects With Type 1 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Device: Medtronic Minimed 670G 3.0 HCL|Device: Medtronic Minimed 670G 4.0 AHCL","Percentage of time of glucose sensor readings within 70 to 180 mg/dl|Percentage of time of glucose sensor readings below 54 mg/dl|Percentage of time of glucose levels spent below 70 mg/dl|Percentage of time of glucose levels spent above 180 mg/dl|Average glucose sensor readings|Standard deviation of glucose sensor readings|Fasting blood glucose levels|HbA1c change|Amount of total insulin delivery|Amount of basal insulin delivery|Amount of bolus insulin delivery|Serious Adverse Events (SAE)|Serious Adverse Device Events (SADE)|Unanticipated Adverse Device effects (UADE)|Incidence of Severe Hypoglycemia|incidence of DKA","Rabin Medical Center|GIF|Medtronic","All","7 Years to 14 Years (Child)","Not Applicable","28","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RMC077719ctil","July 19, 2020","February 20, 2021","March 20, 2021","February 17, 2020",,"February 22, 2022","Diabetes -Zentrum fuer kinder und jugendliche, Hannover, Germany|Schneider Children's Medical Center of Israel, Petach-Tikva, Israel",,"https://ClinicalTrials.gov/show/NCT04269668" | |
| 124,"NCT03449433","A Meal Test Study of LY900014 in Participants With Type 1 Diabetes Mellitus",,"Completed","Has Results","Diabetes Mellitus, Type 1","Drug: LY900014|Drug: Insulin Lispro|Drug: Insulin Aspart","Pharmacokinetics (PK): Insulin Lispro or Insulin Aspart Area Under the Concentration Curve From Zero to Seven Hours (AUC 0-7h) Following Administration of Each Study Arm|Pharmacodynamics (PD): Change From Baseline Area Under the Concentration Curve of Glucose Relative to a Mixed Meal Tolerance Test (MMTT)","Eli Lilly and Company","All","18 Years to 70 Years (Adult, Older Adult)","Phase 1","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","16911|I8B-MC-ITSL|2017-003459-47","March 15, 2018","August 14, 2018","August 14, 2018","February 28, 2018","April 30, 2020","April 30, 2020","Profil Institut für Stoffwechselforschung, Neuss, Nordrhein-Westfalen, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT03449433/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT03449433/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03449433" | |
| 125,"NCT03544892","The Effects of a Low Carbohydrate, Non-Ketogenic Diet Versus Standard Diabetes Diet on Glycemic Control in Type 1 Diabetes","T1DLoCHO","Terminated","No Results Available","Diabetes Mellitus, Type 1","Other: Low carbohydrate diet|Other: Standard of care diet","Time in Range|Mean Glucose|Standard deviation of glucose|Mean amplitude of glycemic excursions|Time in hypoglycemia|Time in hyperglycemia|Change in HbA1c|Coefficient of Variation|Severe hypoglycemia|Total daily insulin dose|Total daily basal insulin 24 hour|Total daily bolus insulin 24 hour|Body weight|Body Mass Index (BMI)|Systolic Blood Pressure (mm Hg)|Diastolic Blood Pressure (mm Hg)|Pulse, per minute|Energy Intake (kcal/day)|Daily carbohydrate intake (total carbohydrate, g/day)|Percent energy intake as Carbohydrate|Daily protein intake (total protein, g/day) and Daily fat intake (total fat, g/day)|Fat quality intake (% total fat as monounsaturated, polyunsaturated, saturated, omega-3)|Standard Lipid Panel|LDL-P (nmol/L)|HDL-P (umol/L)|VLDL-P|LDL size|HDL size|VLDL size|High-sensitive C-reactive protein (hs-CRP)|Plasma lipopolysaccharide|Serum Ketones (beta-hydroxybutyrate)|Type 1 Diabetes Nutrition Knowledge Survey|Diet Quality","University of Oklahoma","All","18 Years to 30 Years (Adult)","Not Applicable","11","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","8840","May 1, 2018","June 28, 2019","June 28, 2019","June 4, 2018",,"January 13, 2020","University of Oklahoma Harold Hamm Diabetes Center, Tulsa, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT03544892" | |
| 126,"NCT03407118","A Study of LY900014 in Japanese Participants With Type 1 Diabetes Mellitus",,"Completed","Has Results","Diabetes Mellitus, Type 1","Drug: LY900014|Drug: Insulin Lispro","Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve Zero to 10 Hours (AUC 0-10h) Following Administration of Each Treatment Arm|Glucodynamics (GD): Total Amount of Glucose Infused (Gtot) Over Duration of Clamp Following Administration of Each Treatment Arm","Eli Lilly and Company","All","18 Years and older (Adult, Older Adult)","Phase 1","31","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","16645|I8B-MC-ITRZ","February 17, 2018","June 23, 2018","July 12, 2018","January 23, 2018","May 1, 2020","May 1, 2020","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Fukuoka, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT03407118/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT03407118/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03407118" | |
| 127,"NCT03335371","Evaluation of TTP399 in Patients With Type 1 Diabetes","SimpliciT1","Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: TTP399|Drug: Placebo Oral Tablet","Change in HbA1c from baseline at 12 weeks|Adverse Events|Time in target glycemic range (70-180 mg/dL)|Time in hyperglycemic range (Level 1 > 180 mg/dL, Level 2 (>250 mg/dL)|Time in hypoglycemic range (Level 1 < 70 mg/dL, Level 2 < 54 mg/dL)|Change from baseline in total daily insulin dose|Change from baseline of meal time bolus insulin","vTv Therapeutics|Juvenile Diabetes Research Foundation","All","18 Years to 70 Years (Adult, Older Adult)","Phase 1|Phase 2","115","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TTP399-203|JDRF#2-IND-2018-500","October 25, 2017","December 20, 2019","January 6, 2020","November 7, 2017",,"November 27, 2020","USC Westside Center for Diabetes, Beverly Hills, California, United States|AMCR Institute, Escondido, California, United States|University of Colorado Barbara Davis Center, Aurora, Colorado, United States|Atlanta Diabetes Associate, Atlanta, Georgia, United States|Rocky Mountain Diabetes Center, Idaho Falls, Idaho, United States|Iowa Diabetes Research, West Des Moines, Iowa, United States|Mountain Diabetes and Endocrine Center, Asheville, North Carolina, United States|UNC Diabetes Care Center, Chapel Hill, North Carolina, United States|Duke University Diabetes Research Clinic, Durham, North Carolina, United States|Diabetes & Endocrinology Consultants, Morehead City, North Carolina, United States|PMG Research of Wilmington, Wilmington, North Carolina, United States|Wake Forest, Winston-Salem, North Carolina, United States|Intend Research, Norman, Oklahoma, United States|Dallas Diabetes Research Center, Dallas, Texas, United States|University of Washington Medicine Diabetes Institute, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03335371" | |
| 128,"NCT03723759","A Research Study Looking at How Faster Aspart Injected in Double Concentration Works in the Body of People With Type 1 Diabetes Mellitus",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: Faster Aspart 200 U/mL|Drug: Faster aspart 100 U/mL","AUCIAsp,0h-t - Area under the serum insulin aspart concentration-time curve from 0 to t hours after investigational medicinal product (IMP) administration, where t is end of exposure|AUCIAsp,0-1h - Area under the serum insulin aspart concentration-time curve from 0 to 1 hour after IMP administration|AUCIAsp,0-2h - Area under the serum insulin aspart concentration-time curve from 0 to 2 hours after IMP administration|AUCIAsp,0-inf - Area under the serum insulin aspart concentration-time curve from 0 hours after IMP administration to infinity|Cmax,IAsp - Maximum observed serum insulin aspart concentration|tmax,IAsp - Time to maximum observed serum insulin aspart concentration|Number of adverse events in the treatment emergent period|Number of local reactions at the injection site in the treatment emergent period|Number of hypoglycaemic episodes in the treatment emergent period","Novo Nordisk A/S","All","18 Years to 64 Years (Adult)","Phase 1","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NN1200-4431|U1111-1209-2099|2018-000593-30","October 26, 2018","March 21, 2019","March 27, 2019","October 30, 2018",,"March 18, 2020","Novo Nordisk Investigational Site, Neuss, Germany",,"https://ClinicalTrials.gov/show/NCT03723759" | |
| 129,"NCT00678886","Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1","DEFEND-1","Completed","Has Results","Diabetes Mellitus, Type 1","Biological: otelixizumab infusion plus physician determined standard of care|Biological: placebo infusion plus physician determined standard of care","Change From Baseline in 2-hour Mixed Meal Stimulated C-peptide Area Under Curve [AUC] (Normalized for 120-minute Time Interval) at Month 12|Number of Participants Who Were Responders for (Glycosylated Hemoglobin) HbA1c/Insulin Use Response at Week 12 and Months 6 and 12|Mean Daily Insulin Use at Week 12 and Months 6 and 12.|HbA1c Level at Week 12 and Months 6 and 12|Number of Hypoglycemic Events Defined by Hypoglycemic Event Categories From Baseline Upto Month 12|Number of Participants With Hypoglycemic Events Defined by Hypoglycemic Event Categories From Baseline Upto Month 12|Number of Hypoglycemic Excursions (<=70 mg/dL) With Most Complete Glucose at Week 12 and Months 6 and 12.|Magnitude of Greatest Hypoglycemic Excursions With Most Complete Glucose at Week 12 and Months 6 and 12.|Number of Participants With Hypoglycemic Excursions With Most Complete Glucose at Week 12 and Months 6 and 12|Number of Hyperglycemic Excursions With Most Complete Glucose at Week 12 and Months 6 and 12.|Magnitude of Greatest Hyperglycemic Excursions With Most Complete Glucose at Week 12 and Months 6 and 12.|Number of Participants With Hyperglycemic Excursions With Most Complete Glucose at Week 12 and Months 6 and 12|Change From Baseline in Average Daily Risk Range (ADRR) at Week 12 and Months 6 and 12.|Composite Rank Summary for HbA1c and Exogenous Insulin Use at Month 6 and Month 12|Composite Rank Summary for C-Peptide AUC, HbA1c and Exogenous Insulin Use at Month 6 and Month 12|Change From Baseline in Level of Cytokines Interleukin (IL-6), IL-10 and Tumor Necrosis Factor-alpha (TNF-a) at Day 1, Day 4, Day 8|Percent Change From Baseline in Circulating Peripheral Lymphocytes CD4+CD25+FoxP3+ T Cells and CD4+CD25hiFoxP3+ T Cells in Type 1 Diabetes Mellitus (TIDM) up to Month 12|Percent Change From Baseline in Cell-bound Otelixizumab on CD4+ T Cells at Day 1, Day 4, Day 8|Percent Change From Baseline in CD3/TCR Saturation on CD4+ T Cells and CD8+ T Cells at Day 1, Day 4, Day 8|Percent Change From Baseline in CD3/TCR Modulation on CD4+ T Cells and CD8+ T Cells at Day 1, Day 4, Day 8","GlaxoSmithKline|Juvenile Diabetes Research Foundation","All","12 Years to 45 Years (Child, Adult)","Phase 3","272","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","115495|TRX4006","July 29, 2008","January 31, 2012","January 31, 2012","May 16, 2008","October 3, 2017","October 3, 2017","GSK Investigational Site, Birmingham, Alabama, United States|GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Costa Mesa, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Orange, California, United States|GSK Investigational Site, Riverside, California, United States|GSK Investigational Site, Santa Ana, California, United States|GSK Investigational Site, Torrance, California, United States|GSK Investigational Site, Walnut Creek, California, United States|GSK Investigational Site, Aurora, Colorado, United States|GSK Investigational Site, Washington, D.C., District of Columbia, United States|GSK Investigational Site, Boca Raton, Florida, United States|GSK Investigational Site, Jupiter, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Pembroke Pines, Florida, United States|GSK Investigational Site, Trinity, Florida, United States|GSK Investigational Site, Winter Park, Florida, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Honolulu, Hawaii, United States|GSK Investigational Site, Boise, Idaho, United States|GSK Investigational Site, Idaho Falls, Idaho, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Baltimore, Kansas, United States|GSK Investigational Site, Topeka, Kansas, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Worcester, Massachusetts, United States|GSK Investigational Site, Detroit, Michigan, United States|GSK Investigational Site, Kalamazoo, Michigan, United States|GSK Investigational Site, Gulfport, Mississippi, United States|GSK Investigational Site, Columbia, Missouri, United States|GSK Investigational Site, Kansas City, Missouri, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Neptune City, New Jersey, United States|GSK Investigational Site, Buffalo, New York, United States|GSK Investigational Site, Mineola, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Rochester, New York, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Dayton, Ohio, United States|GSK Investigational Site, Mentor, Ohio, United States|GSK Investigational Site, Tulsa, Oklahoma, United States|GSK Investigational Site, Eugene, Oregon, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Langhorne, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Rapid City, South Dakota, United States|GSK Investigational Site, Chattanooga, Tennessee, United States|GSK Investigational Site, Memphis, Tennessee, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Hurst, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Schertz, Texas, United States|GSK Investigational Site, Ogden, Utah, United States|GSK Investigational Site, Tacoma, Washington, United States|GSK Investigational Site, Calgary, Alberta, Canada|GSK Investigational Site, Oakville, Ontario, Canada|GSK Investigational Site, Smiths Falls, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Pointe-Claire, Quebec, Canada|GSK Investigational Site, Arhus C, Denmark|GSK Investigational Site, Tampere, Finland|GSK Investigational Site, Turku, Finland|GSK Investigational Site, Heidelberg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Bad Nauheim, Hessen, Germany|GSK Investigational Site, Bad Lauterberg, Niedersachsen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Latina, Lazio, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Monserrato, Sardegna, Italy|GSK Investigational Site, Palermo, Sicilia, Italy|GSK Investigational Site, Milano, Italy|GSK Investigational Site, Roma, Italy|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Gerona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Sant Joan, Spain|GSK Investigational Site, Tarrasa, Barcelona, Spain|GSK Investigational Site, Göteborg, Sweden|GSK Investigational Site, Halmstad, Sweden|GSK Investigational Site, Harnosand, Sweden|GSK Investigational Site, Karlskrona, Sweden|GSK Investigational Site, Karlstad, Sweden|GSK Investigational Site, Kristianstad, Sweden|GSK Investigational Site, Motala, Sweden|GSK Investigational Site, Stockholm, Sweden|GSK Investigational Site, Umeå, Sweden|GSK Investigational Site, Växjö, Sweden|GSK Investigational Site, Bath, Somerset, United Kingdom|GSK Investigational Site, Blackburn, United Kingdom|GSK Investigational Site, Bristol, United Kingdom|GSK Investigational Site, Hull, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Newcastle upon Tyne, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00678886" | |
| 130,"NCT00737763","Beta Cell Rescue in New Onset Type 1 Diabetes With Efalizumab","BRiTE","Withdrawn","No Results Available","Diabetes Mellitus, Type 1","Drug: efalizumab|Drug: placebo","The primary endpoint for this study will be the difference from baseline in the body's ability to respond to a Mixed Meal Tolerance Test at 12 months after enrollment.","Emory University|Juvenile Diabetes Research Foundation|Genentech, Inc.","All","12 Years to 35 Years (Child, Adult)","Phase 2","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB0007365|BRiTE Trial for T1DM","October 2008","November 2009","November 2009","August 20, 2008",,"May 12, 2014",,,"https://ClinicalTrials.gov/show/NCT00737763" | |
| 131,"NCT02953249","Wound Healing After Tooth Extraction in Individuals With Type 1 Diabetes Mellitus",,"Unknown status","No Results Available","Diabetes Mellitus, Type 1",,"Wound healing change after tooth extraction through epithelialization|Number of participants with abnormal laboratory values|Adverse events that are related to the surgery|Salivary flow|Epidermal Grow Factor (EGF)|Radiographic analysis of bone repair","University of Sao Paulo","All","18 Years and older (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","51979315.7.0000.0075","September 2016","June 2017","May 2019","November 2, 2016",,"November 2, 2016","Dental School of University of Sao Paulo, Sao Paulo, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT02953249" | |
| 132,"NCT03182426","Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)",,"Active, not recruiting","No Results Available","Diabetes Mellitus, Type 1","Drug: Plerixafor|Drug: Alemtuzumab|Drug: Anakinra|Drug: Etanercept|Drug: Liraglutide","Change of 2-hour mixed meal stimulated C-peptide AUC|Rate of Serious Adverse Event/Medical Event of Special Interest|""Responder"" status|Exogenous insulin usage|Proportion of subjects with HbA1c ≤6.5%|Proportion of subjects with HbA1c ≤7.0%|Proportion of subjects free from severe hypoglycaemia|Proportion of subjects progressing to complete beta cell loss|Autoantibodies associated with T1DM|T1DM T-cell autoreactivity|T-cell phenotyping","University of Alberta|Alberta Innovates Health Solutions","All","18 Years to 45 Years (Adult)","Phase 1|Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00053082","August 15, 2017","December 30, 2025","December 31, 2025","June 9, 2017",,"July 7, 2022","University of Alberta, Edmonton, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT03182426" | |
| 133,"NCT02820558","Neuropeptide Therapy of Recent Onset Type 1 Diabetes",,"Unknown status","No Results Available","Diabetes Mellitus, Type 1","Drug: Substance P","Stage A Safety: Side effects reported for entire cohort|C-Peptide Levels (small cohort)|C-Peptide Levels (large cohort)","Vanilloid Genetics Inc.","All","10 Years to 18 Years (Child, Adult)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VanilloidGenetics-001-13","May 2016","December 2022","December 2022","July 1, 2016",,"May 21, 2020","Hospital for Sick Children, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02820558" | |
| 134,"NCT00575159","A Study to Assess the Safety of Single Doses of GSK189075 in Subjects With Type 1 Diabetes Mellitus",,"Completed","Has Results","Diabetes Mellitus, Type 1","Drug: GSK189075|Drug: placebo","Number of Participants With All Adverse Events (AE) and Serious Adverse Events (SAE)|Number of Participants With Hypoglycemia Episodes/Events|Change From Baseline Vital Signs: Systolic and Diastolic Blood Pressure (SBP and DBP)|Change From Baseline Vital Signs: Heart Rate|Number of Participants With Abnormal Electrocardiogram (ECG) Findings|Number of Participants With Abnormal Clinical Chemistry Data|Number of Participants With Abnormal Hematology Data|Summary of Urine Osmolality|Mean Creatinine Clearance|Summary of Fluid Balance|Mean of Derived Plasma Glucose Parameters|Incremental Adjusted Weighted Means of Plasma Glucose AUC(0-4) and AUC(0-10) on Day 1|Urinary Glucose Excretion (UGE) for Timed Subintervals up to 24 Hours Post Dose (0-24 H)|Percent of Filtered Glucose in the Urine.|Mean Total Urine Volume 0-24 H|Mean Creatinine Clearance 0-24 H|Area Under the Plasma Concentration vs. Time Curve (AUC) From Time Zero (Time of Dosing) to the Last Time Point With Measurable Analyte Concentration, AUC(0-last), AUC From Time Zero to Infinite Time, AUC(0-inf) of GSK189075 Over Period|Maximum Observed Plasma Concentration (Cmax) of GSK189075 Over Period|Time to Maximum Observed Plasma Concentration (Tmax) and Terminal Half Life, (T1/2) of GSK189075 Over Period|AUC From Time Zero to 4 Hours Post Dose, AUC(0-4) for GSK189074 Over Period|Oral Clearance (CL/F) Over Period|The Metabolite to Parent AUC Ratio, AUCmetabolite/AUCparent Ratio for GSK189074 Over Period|The Metabolite to Parent AUC Ratio, AUCmetabolite/AUCparent Ratio for GSK279782 Over Period","GlaxoSmithKline","All","18 Years to 55 Years (Adult)","Phase 2","10","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","KGI107465","March 31, 2008","December 18, 2008","December 18, 2008","December 18, 2007","October 9, 2017","October 9, 2017","GSK Investigational Site, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT00575159" | |
| 135,"NCT03723772","A Research Study of How Different Doses of a New Medicine NNC0148-0287 C (Insulin 287) Work on the Blood Sugar in People With Type 1 Diabetes When it is Taken Once a Week",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: Insulin icodec|Drug: IGlar U100","AUCI287,τ,SS - Area under the serum insulin 287 concentration-time curve during one dosing interval at steady state|AUCGIR,16-52h,SS (for insulin 287) - Area under the glucose infusion rate-time curve at steady state|AUCGIR,138-168h,SS (for insulin 287) - Area under the glucose infusion rate-time curve at steady state|GIRmax,16-52h, SS (for insulin 287) - Maximum observed glucose infusion rate at steady state|GIRmax,138-168h, SS (for insulin 287) - Maximum observed glucose infusion rate at steady state|AUCGIR,0-24h,SS (for insulin glargine) - Area under the glucose infusion rate-time curve at steady state|GIRmax,0-24h, SS (for insulin glargine) - Maximum observed glucose infusion rate at steady state|AUCI287,0-168h,FD (from insulin 287) - Area under the serum insulin 287 concentration-time curve after the first dose|Cmax,I287,FD (for insulin 287) - Maximum observed serum insulin 287 concentration after the first dose|tmax,I287,FD (for insulin 287) - Time to maximum observed serum insulin 287 concentration after the first dose|Cmax,I287,SS (for insulin 287) - Maximum observed serum insulin 287 concentration after the last dose|tmax,I287,SS (for insulin 287) - Time to maximum observed serum insulin 287 concentration after the last dose|t½,I287,SS (for insulin 287) - Terminal half-life for insulin 287 at steady state|CI287,trough (for insulin 287) - Serum insulin 287 trough concentration|AUCIGlar,τ,SS (for insulin glargine) - Area under the serum insulin glargine concentration-time curve during one dosing interval at steady state|Cmax,IGlar,SS (for insulin glargine) - Maximum observed serum insulin glargine concentration at steady state|tmax,IGlar,SS (for insulin glargine) - Time to maximum observed serum insulin glargine concentration at steady state|CIGlar,trough (for insulin glargine) - Serum insulin glargine trough concentration|Number of adverse events (AEs)|Number of hypoglycaemic episodes|Change in anti-insulin 287 antibody level|Change in anti-insulin 287 antibody titres|Positive cross-reactive anti-human insulin antibodies","Novo Nordisk A/S","All","18 Years to 64 Years (Adult)","Phase 1","66","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NN1436-4225|U1111-1204-8909|2017-004528-31","November 29, 2018","June 26, 2020","June 26, 2020","October 30, 2018",,"November 10, 2021","Novo Nordisk Investigational Site, Neuss, Germany",,"https://ClinicalTrials.gov/show/NCT03723772" | |
| 136,"NCT00451321","TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)","TTEDD","Terminated","Has Results","Diabetes Mellitus, Type 1","Drug: Otelixizumab","Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Cytokine Release AE|Number of Participants With Abnormal Hematology Values of Potential Clinical Concern (PCC)|Number of Participants With Abnormal Clinical Chemistry Values of PCC|Number of Participants With Abnormal Urinalysis Dipstick Results|Mean Overall Maximum Cytokines Level|Number of Participants With Positive Epstein Barr Virus (EBV) Viral Load|Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration (AUClast) of Otelixizumab|Maximum Plasma Drug Concentration (Cmax) of Otelixizumab|Time of Last Quantifiable Drug Concentration (Tlast) and Time of Occurrence of Maximum Plasma Drug Concentration (Tmax) of Otelixizumab|Mean Lymphocytes Subsets (CD19+ B Cells, CD4+CD25hiFoxP3+ T Cells, CD8+CD25+FoxP3+ T Cells) Count|Mean Lymphocytes Subsets (CD4+ T Cells, CD8+ T Cells) Count|Mean CD4+/CD8+ Ratio|Percent Lymphocytes Subsets (CD25+CD8+Tregs) Count|Amounts of Cell-bound Otelixizumab on CD4+ and CD8+ T Cells|Saturation of CD4+ and CD8+ T Cells With Otelixizumab|CD3/TCR Complexes on CD4+ and CD8+ T Cells|Number of Participants With Detectable Anti-otelixizumab Antiglobulin Response|Number of Participants With Use of Analgesics, Antihistamines and IV Hydration as Concomitant Medication During Dosing Days|Change From Baseline in Percent Glycosylated Hemoglobin (HbA1c)","GlaxoSmithKline|Juvenile Diabetes Research Foundation","All","12 Years to 45 Years (Child, Adult)","Phase 2","88","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","115493|TRX4005","July 31, 2006","December 1, 2011","December 1, 2011","March 23, 2007","November 13, 2017","November 13, 2017","GSK Investigational Site, Birmingham, Alabama, United States|GSK Investigational Site, Walnut Creek, California, United States|GSK Investigational Site, Aurora, Colorado, United States|GSK Investigational Site, Washington, D.C., District of Columbia, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Pinellas Park, Florida, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Worcester, Massachusetts, United States|GSK Investigational Site, Kalamazoo, Michigan, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Gulfport, Mississippi, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Mentor, Ohio, United States|GSK Investigational Site, Rapid City, South Dakota, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00451321" | |
| 137,"NCT02786953","Sleep Promotion to Improve Diabetes Management in Adolescents With T1D",,"Completed","Has Results","Diabetes Mellitus, Type 1","Behavioral: Sleep Promotion","Sleep Quality: Baseline|Sleep Quality 3 Months|Glycemic Control (HbA1c) Baseline|Glycemic Control (HbA1c) 3 or 6 Months|Sleep Duration: Baseline|Sleep Duration: 3 Months|Quality of Life (PedsQL)|Adherence (Self Care Inventory) Parent|Adherence (Self Care Inventory) Teen","Vanderbilt University Medical Center","All","13 Years to 17 Years (Child)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","151271","October 19, 2017","October 23, 2018","February 5, 2019","June 1, 2016","October 18, 2019","January 18, 2020","Vanderbilt University Medical Center, Nashville, Tennessee, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT02786953/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02786953" | |
| 138,"NCT01280682","Immune Intervention With Rituximab to Preserve Beta Cell Function in Early Onset Type 1 Diabetes",,"Unknown status","No Results Available","Diabetes Mellitus, Type 1","Drug: rituximab","CD19+ cells|C-peptide level|glycated hemoglobin level|insulin dose","Nanjing Medical University","All","8 Years to 45 Years (Child, Adult)","Phase 4","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2010-SR-021","July 2010","December 2012","December 2013","January 21, 2011",,"January 21, 2011","First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT01280682" | |
| 139,"NCT03556098","Glucose-dependent Insulinotropic Polypeptide as a Safeguard Against Hypoglycemia in Patients With Type 1 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: glucose-dependent insulinotropic peptide|Drug: Glucose-Dependent Insulin-Releasing Hormone[3-30]|Drug: Saline Solution","plasma glucose concentration|Glucose regulatory hormones|Incretin hormones|GIP[3-30]|Free fatty acids (FFA)|Blood analysis of paracetamol as an assessment of gastric emptying|Fat mRNA|Fat Lipoprotein lipase (LPL)|Fat Perilipin 4|Fat Fatty acid binding protein 4 (FABP4)|Fat Hormonse-sensitive lipase (HSL)|Fat Vascular endothelial growth factor 4 (VEGF-A)|Fat GIP receptor (GIPR)|Blood pressure|Pulse","Steno Diabetes Center Copenhagen","Male","18 Years to 70 Years (Adult, Older Adult)","Not Applicable","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","H-18002707","February 22, 2019","February 11, 2020","February 11, 2020","June 14, 2018",,"May 10, 2021","Steno Diabetes Center Copenhagen, Clinical Metabolic Physiology, Hellerup, Denmark",,"https://ClinicalTrials.gov/show/NCT03556098" | |
| 140,"NCT03557892","Sensor-augmented Pump Versus Multiple Daily Injections With Degludec as Basal Insulin for Insulin Therapy in Type 1 Diabetes",,"Completed","Has Results","Diabetes Mellitus, Type 1","Device: CGM+CSII|Device: MDI with degludec","HbA1c|Severe Hypoglycemia|Local Reactions","Azienda Ospedaliero-Universitaria Careggi","All","18 Years to 75 Years (Adult, Older Adult)","Not Applicable","28","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","T1DM001","April 1, 2018","December 20, 2019","January 2, 2020","June 15, 2018","July 21, 2022","July 26, 2022","Diabetologia AOU Careggi, Firenze, Italy","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT03557892/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03557892" | |
| 141,"NCT03766854","A Research Study of How Different Amounts of a New Medicine NNC0148-0287 C (Insulin 287) Works on the Blood Sugar of People Who Are Japanese With Type 1 Diabetes When Given Once a Week",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: insulin icodec|Drug: Insulin glargine U100","AUCI287τ,SS - Area under the serum insulin 287 concentration-time curve during one dosing interval at steady state|Number of adverse events (AEs)|Number of hypoglycaemic episodes|Change in antiinsulin 287 antibody level|Change in antiinsulin 287 antibody titres|Positive cross-reactive anti-human insulin antibodies|AUCI287,0-168,FD - Area under the serum insulin 287 concentration-time curve after the first dose|tmax,I287,FD - Time to maximum observed serum insulin 287 concentration after the first dose|Cmax,I287,FD - Maximum observed serum insulin 287 concentration after the first dose|tmax,I287,SS - Time to maximum observed serum insulin 287 concentration after the last dose|Cmax,I287,SS - Maximum observed serum insulin 287 concentration after the last dose|t1/2,I287,SS - Terminal half-life for insulin 287 at steady state|CI287,trough - Serum insulin 287 trough concentration|AUCIGlar,τ,SS - Area under the serum IGlar concentration-time curve during one dosing interval at steady state|Cmax,IGlar,SS - Maximum observed serum IGlar concentration at steady state|tmax,IGlar,SS - Time to maximum observed serum IGlar concentration at steady state|CIGlar,trough - Serum IGlar trough concentration|AUCGIR,24-48h,SS - Area under the glucose infusion rate-time curve at steady state|GIRmax,24-48h, SS - Maximum observed glucose infusion rate at steady state|AUCGIR,150-168h,SS - Area under the glucose infusion rate-time curve at steady state|GIRmax,150-168h,SS - Maximum observed glucose infusion rate at steady state|AUCGIR,0-24h,SS - Area under the glucose infusion rate-time curve at steady state|GIRmax,0-24h,SS - Maximum observed glucose infusion rate at steady state","Novo Nordisk A/S","All","20 Years to 64 Years (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NN1436-4422|U1111-1211-7635","December 7, 2018","December 9, 2019","December 9, 2019","December 6, 2018",,"March 8, 2021","Novo Nordisk Investigational Site, Fukuoka, Japan",,"https://ClinicalTrials.gov/show/NCT03766854" | |
| 142,"NCT03166124","A Study of LY900014 in Elderly and Younger Adult Participants With Type 1 Diabetes Mellitus",,"Completed","Has Results","Diabetes Mellitus, Type 1","Drug: LY900014|Drug: Insulin Lispro","Pharmacokinetics: Insulin Lispro Area Under the Concentration Versus Time Curve (AUC) for Each Treatment Arm|Total Amount of Glucose Infused (Gtot) Over Duration of Clamp for Each Treatment Arm","Eli Lilly and Company","All","18 Years and older (Adult, Older Adult)","Phase 1","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","16637|I8B-MC-ITRR","May 24, 2017","November 18, 2017","November 18, 2017","May 24, 2017","April 30, 2020","April 30, 2020","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Mainz, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Neuss, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT03166124/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT03166124/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03166124" | |
| 143,"NCT03455816","Clinical Study to Evaluate the Bio-Psychosocial Impact of Mobile App for Diabetes Type 1 (""SOCIAL DIABETES"")",,"Unknown status","No Results Available","Diabetes Mellitus, Type 1","Device: Social Diabetes App|Device: Usual clinical monitoring group (Control group)","glycosylated hemoglobin|Quality of life assessment: Diabetes Quality of Life (DQoL) questionnaire.|Mean blood glucose|Standard deviation|Number of mild hypoglycaemia|Number of severe hypoglycaemia|Number of hyperglycemia|Episodes of ketosis|Episodes of ketoacidosis|Number of hospital admissions for glycemic decompensation|Fear of hypoglycemia: Questionnaire FH-15|Diabetes treatment satisfaction questionnaire ( DTSQ)|Diabetes distress scale. DDS|Scale of adherence to treatment in patients with diabetes type 1","Soledad Ruiz de Adana|Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud","All","18 Years to 65 Years (Adult, Older Adult)","Not Applicable","148","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Social Diabetes","July 7, 2017","June 2018","December 2018","March 7, 2018",,"March 13, 2018","Regional University Hospital of Málaga, Málaga, Spain",,"https://ClinicalTrials.gov/show/NCT03455816" | |
| 144,"NCT02755064","Relationship Between Gastric Emptying and Glycemic Variability in Type 1 Diabetes Mellitus",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: Erythromycin lactobionate|Drug: Placebo IV|Drug: [13C]-Spirulina|Drug: Erythromycin Ethylsuccinate Suspension|Drug: Placebo Suspension","Relationship between gastric emptying and glycemia|Number of subjects with delayed gastric emptying","Adil Bharucha|Mayo Clinic","All","Child, Adult, Older Adult","Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","08-008620|UL1TR000135","June 2010","November 2013","November 2013","April 28, 2016",,"April 28, 2016","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02755064" | |
| 145,"NCT03668808","Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones.","SafrTravlT1D","Completed","Has Results","Diabetes Mellitus, Type 1","Drug: Insulin Degludec|Drug: Insulin Glargine|Device: TRESIBA® FLEXTOUCH®|Device: LANTUS® SOLOSTAR® INSULIN PEN","Continuous Glucose Monitoring - Time in Range (70-140 mg/dl)|Continuous Glucose Monitoring - Time in Range (70-180 mg/dl)|Mean ± SD CGM Glucose (mg/dl)|CGM % Time <70 mg/dl|CGM % Time 70-180 mg/dl|CGM % Time >180 mg/dl|CGM - Coefficient of Variation (CV)|CGM Fasting Blood Glucose (FBG)|Liverpool Jet-Lag Questionnaire|Sleep Quantity Measured by ActiGraph|Sleep Efficiency Measured by ActiGraph","Sansum Diabetes Research Institute|Novo Nordisk A/S","All","18 Years to 65 Years (Adult, Older Adult)","Phase 4","25","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ISS-001227|U1111-1210-7350","November 16, 2018","September 19, 2020","September 19, 2020","September 13, 2018","June 2, 2022","November 1, 2022","Sansum Diabetes Research Institute, Santa Barbara, California, United States|inControl Diabetes Center, Honolulu, Hawaii, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT03668808/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03668808" | |
| 146,"NCT03751007","A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recently Diagnosed Type 1 Diabetes Mellitus (T1D)",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Biological: AG019 - Low Dose|Drug: Teplizumab|Drug: Placebo-AG019|Drug: Placebo-Teplizumab|Biological: AG019 - High Dose|Biological: AG019 - Low or High Dose","Number of participants with treatment-related adverse events assessed by the investigator, review of lab reports and information provided by the participant during site visits and/or participant diary during treatment with AG019 alone or with teplizumab|Immune marker cell count in systemic circulation.|Cytokines/chemokines in systemic circulation.|AG019 in systemic circulation|L. Lactis-secreted hPINS or hIL-10 in systemic circulation|AG019 in feces","Precigen Actobio T1D, LLC|Intrexon Actobiotics NV, d/b/a Precigen Actobio|TFS Trial Form Support","All","12 Years to 40 Years (Child, Adult)","Phase 1|Phase 2","42","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AG019-T1D-101|2017-002871-24","October 27, 2018","October 13, 2021","October 13, 2021","November 23, 2018",,"November 10, 2021","University of Alabama, Birmingham, Birmingham, Alabama, United States|University of California, San Francisco, San Francisco, California, United States|Coastal Metabolic Research Centre, Ventura, California, United States|University of Colorado, Aurora, Colorado, United States|Yale Center for Clinical Investigation, New Haven, Connecticut, United States|University of Miami, Miami, Florida, United States|University of South Florida, Tampa, Florida, United States|Barry J Reiner, MD, LLC, Baltimore, Maryland, United States|University of Minnesota Health, Minneapolis, Minnesota, United States|University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, United States|Sanford Children's Specialty Clinic, Sioux Falls, South Dakota, United States|University Diabetes and Endocrine Consultants, Chattanooga, Tennessee, United States|Texas Diabetes & Endocrinology, P.A., Austin, Texas, United States|Research Institute of Dallas, Dallas, Texas, United States|Benaroya Research Institute, Seattle, Washington, United States|UZ Brussel, Brussels, Belgium|UZ Antwerpen, Edegem, Belgium|UZ Leuven, Leuven, Belgium",,"https://ClinicalTrials.gov/show/NCT03751007" | |
| 147,"NCT02772783","Dietary Glycemic Index, Brain Function and Food Intake in Patients With Type 1 Diabetes Mellitus",,"Completed","Has Results","Diabetes Mellitus, Type 1","Other: high GI meal|Other: low GI meal|Drug: euglycemic insulin clamp|Drug: primed-variable insulin infusion","Nucleus Accumbens Blood Flow|Blood Flow in Other Brain Areas Involved in Intake Regulation - Dorsal Caudate|Blood Flow in Other Brain Areas Involved in Intake Regulation - Ventrolateral Striatum|Functional Connectivity of Nucleus Accumbens, Hypothalamus and Other Brain Areas Involved in Intake Regulation","Boston Children's Hospital|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital","Male","18 Years to 45 Years (Adult)","Not Applicable","15","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","IRB-P00022176|IRB- 2016P000079","July 2016","May 2018","May 2018","May 16, 2016","June 18, 2021","June 18, 2021","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT02772783/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02772783" | |
| 148,"NCT00286962","Study to Compare Intraperitoneal Insulin to Subcutaneous Insulin Administration in Type 1 Diabetes Mellitus",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Device: MIP 2007C implantable insulin pump|Device: continuous subcutaneous insulin infusion (CSII) or MDI","incidence of hypoglycemia; data taken from patient diaries during either study arm.|glycemic control; glycosylated hemoglobin (HbA1c) measurement at baseline, end of entry phase, start of both study arms, halfway through study arms, end of study arms.|average daily insulin usage; as taken from patient diaries for both study arms|frequency of adverse events; as taken from patient diaries for both study arms|frequency of clinically significant abnormal laboratory values and device complications; as taken from patient diaries for both study arms|Quality of life; score on a quality of life scale at baseline and end of either study arm|Treatment satisfaction; score on treatment satisfaction scale at baseline and end of either study arm|daily glucose excursions; measured with continuous glucose monitoring system (CGMS) at baseline, halfway through and at the end of both study arms","Medical Research Foundation, The Netherlands|Medtronic","All","18 Years to 70 Years (Adult, Older Adult)","Phase 3","24","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IC-06-01-SL|04.0211p","February 2006","April 2008","April 2008","February 6, 2006",,"April 11, 2008","Isala Klinieken, Zwolle, Netherlands",,"https://ClinicalTrials.gov/show/NCT00286962" | |
| 149,"NCT03056456","A Study of LY900014 Administered in Participants With Type 1 Diabetes Using an Insulin Pump",,"Completed","Has Results","Diabetes Mellitus, Type 1","Drug: LY900014|Drug: Insulin Lispro (Humalog)","Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve From Time Zero to 5 Hours(h) (AUC [0-5 h]) Following Administration of Each Study Arm With a Standard Single-wave Bolus|Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve From Time Zero to 5 Hours (AUC [0-5 h]) of Following Administration of Each Study Arm With a Standard Dual-wave Bolus|Glucodynamics (GD): Change From Baseline Area Under the Concentration Curve From Time Zero to 5 Hours (AUC [0-5h]) of Glucose Relative to Mixed Meal Tolerance Test Following Administration of Each Study Arm With a Standard Single-wave Bolus|Glucodynamics (GD): Change From Baseline Area Under the Concentration Curve From Time Zero to 5 Hours (AUC [0-5 h]) of Glucose Relative to MMTT Following Administration of Each Study Arm With a Standard Dual-wave Bolus","Eli Lilly and Company","All","18 Years to 70 Years (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","16727|I8B-MC-ITSC|2016-004093-18","February 23, 2017","June 19, 2017","June 19, 2017","February 17, 2017","May 1, 2020","May 1, 2020","For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Neuss, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Neuss, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT03056456/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT03056456/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03056456" | |
| 150,"NCT03220425","Evaluation of the Efficacy and Safety of Insulin Detemir Compared With That of NPH Insulin in Subjects With Type 1 Diabetes.",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: Insulin detemir|Drug: NPH insulin","The change in the level of glycosylated haemoglobin(HbA1c)","Novo Nordisk A/S","All","18 Years and older (Adult, Older Adult)","Phase 3","752","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","NN304-1335","February 1, 2001","November 12, 2001","November 12, 2001","July 18, 2017",,"July 18, 2017","Novo Nordisk Investigational Site, Broadmeadow, New South Wales, Australia|Novo Nordisk Investigational Site, Ashford, Australia|Novo Nordisk Investigational Site, Box Hill, Australia|Novo Nordisk Investigational Site, Clayton, Australia|Novo Nordisk Investigational Site, Garran, Australia|Novo Nordisk Investigational Site, Ringwood, Australia|Novo Nordisk Investigational Site, Stones Corner, Australia|Novo Nordisk Investigational Site, Woodville, Australia|Novo Nordisk Investigational Site, Bornem, Belgium|Novo Nordisk Investigational Site, Edegem, Belgium|Novo Nordisk Investigational Site, Gent, Belgium|Novo Nordisk Investigational Site, Leuven, Belgium|Novo Nordisk Investigational Site, Luxembourg, Belgium|Novo Nordisk Investigational Site, Fredericia, Denmark|Novo Nordisk Investigational Site, Frederiksberg, Denmark|Novo Nordisk Investigational Site, Hvidovre, Denmark|Novo Nordisk Investigational Site, København, Denmark|Novo Nordisk Investigational Site, Middelfart, Denmark|Novo Nordisk Investigational Site, Odense, Denmark|Novo Nordisk Investigational Site, Vejle, Denmark|Novo Nordisk Investigational Site, Århus C, Denmark|Novo Nordisk Investigational Site, Espoo, Finland|Novo Nordisk Investigational Site, Helsinki, Finland|Novo Nordisk Investigational Site, Joensuu, Finland|Novo Nordisk Investigational Site, Kemi, Finland|Novo Nordisk Investigational Site, Vantaa, Finland|Novo Nordisk Investigational Site, ANGERS cedex 09, France|Novo Nordisk Investigational Site, Avignon, France|Novo Nordisk Investigational Site, Bondy, France|Novo Nordisk Investigational Site, Corbeil Essonnes, France|Novo Nordisk Investigational Site, LA ROCHELLE cedex, France|Novo Nordisk Investigational Site, Le Creusot, France|Novo Nordisk Investigational Site, MONTPELLIER cedex 5, France|Novo Nordisk Investigational Site, Narbonne, France|Novo Nordisk Investigational Site, NEVERS cedex, France|Novo Nordisk Investigational Site, Paris Cedex 10, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Poitiers, France|Novo Nordisk Investigational Site, Rennes, France|Novo Nordisk Investigational Site, Dublin, Ireland|Novo Nordisk Investigational Site, Dublin, Ireland|Novo Nordisk Investigational Site, Amersfoort, Netherlands|Novo Nordisk Investigational Site, Apeldoorn, Netherlands|Novo Nordisk Investigational Site, Brunssum, Netherlands|Novo Nordisk Investigational Site, Den Haag, Netherlands|Novo Nordisk Investigational Site, Eindhoven, Netherlands|Novo Nordisk Investigational Site, Haarlem, Netherlands|Novo Nordisk Investigational Site, Hengelo, Netherlands|Novo Nordisk Investigational Site, Utrecht, Netherlands|Novo Nordisk Investigational Site, Bergen, Norway|Novo Nordisk Investigational Site, Jessheim, Norway|Novo Nordisk Investigational Site, Kongsvinger, Norway|Novo Nordisk Investigational Site, Oslo, Norway|Novo Nordisk Investigational Site, Oslo, Norway|Novo Nordisk Investigational Site, Sarpsborg, Norway|Novo Nordisk Investigational Site, Stavanger, Norway|Novo Nordisk Investigational Site, Stord, Norway|Novo Nordisk Investigational Site, Trondheim, Norway|Novo Nordisk Investigational Site, Falun, Sweden|Novo Nordisk Investigational Site, Helsingborg, Sweden|Novo Nordisk Investigational Site, Karlstad, Sweden|Novo Nordisk Investigational Site, Lund, Sweden|Novo Nordisk Investigational Site, Skövde, Sweden|Novo Nordisk Investigational Site, Stockholm, Sweden|Novo Nordisk Investigational Site, Umeå, Sweden|Novo Nordisk Investigational Site, Uppsala, Sweden|Novo Nordisk Investigational Site, Värnamo, Sweden|Novo Nordisk Investigational Site, Örebro, Sweden|Novo Nordisk Investigational Site, Abergavenny, United Kingdom|Novo Nordisk Investigational Site, Blackburn, United Kingdom|Novo Nordisk Investigational Site, Bolton, United Kingdom|Novo Nordisk Investigational Site, Bristol, United Kingdom|Novo Nordisk Investigational Site, Cosham, United Kingdom|Novo Nordisk Investigational Site, Derby, United Kingdom|Novo Nordisk Investigational Site, Gillingham, United Kingdom|Novo Nordisk Investigational Site, Glasgow, United Kingdom|Novo Nordisk Investigational Site, Glasgow, United Kingdom|Novo Nordisk Investigational Site, Guildford, United Kingdom|Novo Nordisk Investigational Site, Kettering, United Kingdom|Novo Nordisk Investigational Site, Livingstone, United Kingdom|Novo Nordisk Investigational Site, Llantrisant, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Newcastle, United Kingdom|Novo Nordisk Investigational Site, Northampton, United Kingdom|Novo Nordisk Investigational Site, Norwich, United Kingdom|Novo Nordisk Investigational Site, Nottingham, United Kingdom|Novo Nordisk Investigational Site, Oxford, United Kingdom|Novo Nordisk Investigational Site, Sheffield, United Kingdom|Novo Nordisk Investigational Site, Sidcup, United Kingdom|Novo Nordisk Investigational Site, Stevenage, United Kingdom|Novo Nordisk Investigational Site, Taunton, United Kingdom|Novo Nordisk Investigational Site, York, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03220425" | |
| 151,"NCT03445377","Comparison of Real-tiMe ContInuous gLucosE moNitoriNg With Self-monitorIng of Blood Glucose in Young AduLts With Type 1 diabeteS","MILLENNIALS","Completed","No Results Available","Diabetes Mellitus, Type 1","Device: Real-time continuous glucose monitoring|Device: Self-monitoring of blood glucose","Sensor Glucose readings within target range|Sensor Glucose readings below target range|Sensor Glucose readings above target range|HbA1c at 8 weeks|Average variation of glucose levels|Standard deviation variation of glucose levels|Coefficient variation of glucose levels|The time with sensor glucose levels < 3.5 mmol/l , 3.0 and <2.8 mmol/l|The time with sensor glucose levels in the significant hyperglycaemia (glucose levels > 16.7 mmol/l)|AUC of glucose below 3.5mmol/l|Total daily insulin dose","Manchester University NHS Foundation Trust|DexCom, Inc.","All","16 Years to 297 Months (Child, Adult)","Not Applicable","32","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","R04778","July 16, 2018","June 28, 2020","June 28, 2020","February 26, 2018",,"March 16, 2021","Manchester Diabetes Centre, Manchester University NHS Foundation Trust, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03445377" | |
| 152,"NCT02803892","Monotherapy With Rapamycin in Long-standing Type 1 Diabetes","MONORAPA","Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: rapamycin|Drug: Vildagliptin|Drug: Placebo 1|Drug: Placebo 2","Change from Baseline C-peptide response in the MMTT|Change from Baseline C-peptide after the MMTT|Change from Baseline insulin requirement|Change from Baseline fasting C-peptide|Change from Baseline HbA1c|Adverse Events (AEs) related to the immunosuppression|Adverse Events (AEs) and Serious Adverse Events (SAEs)","Piemonti Lorenzo|Italian Diabetes Foundation|Ospedale San Raffaele","All","18 Years and older (Adult, Older Adult)","Phase 2","55","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","DRI-2/2014 MONORAPA","May 2016","December 2018","March 2019","June 17, 2016",,"November 4, 2020","IRCCS San Raffaele Scientific Institute, Milan, Italy",,"https://ClinicalTrials.gov/show/NCT02803892" | |
| 153,"NCT02877680","Strengths-Based Behavioral mHealth App for Parents of Adolescents With Type 1 Diabetes-Pilot Study","T1DoingWell","Completed","Has Results","Diabetes Mellitus, Type 1","Behavioral: T1Doing Well","Feasibility of Study Design - Recruitment Rate|Feasibility of T1Doing Well App - Engagement With App At Least Twice A Week|Acceptability of T1Doing Well App (Survey)|Acceptability - Number of Participants That Felt The Intervention Was Well-Received|Adherence to Diabetes Regimen (Objective) - Blood Glucose Monitoring Frequency|Glycemic Control - HbA1c|Diabetes Family Impact - Diabetes Family Impact Scale (DFIS), Parent-report|Family Impact - Pediatric Quality of Life Impact Module (Peds QL-FI), Parent-report|Family Communication - Helping for Health Inventory (HHI), Parent-report|Family Communication - Helping for Health Inventory (HHI), Adolescent-report|Diabetes Family Conflict Scale-Revised (DFCS), Parent-report|Diabetes Family Conflict Scale-Revised (DFCS), Adolescent-report|Problem Areas in Diabetes-Teen (PAID-T), Parent-report|Problem Areas in Diabetes-Teen (PAID-T), Adolescent Self-report|Self-Management - Diabetes Self-Management Profile (DSMP), Parent-report|Self-Management - Diabetes Self-Management Profile (DSMP), Adolescent Self-report|Diabetes Strengths and Resilience Measure (DSTAR), Adolescent Self-report|Adolescent Quality of Life - The MIND-Youth Questionnaire, Adolescent Self-report|Parent-Adolescent Relationship Intervention Process Measure, Adolescent Report","Baylor College of Medicine|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Northwestern University Feinberg School of Medicine|United States Department of Agriculture (USDA)","All","12 Years to 17 Years (Child)","Not Applicable","82","Other|NIH|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-37311|1R21DK107951","July 31, 2017","May 30, 2019","May 30, 2019","August 24, 2016","June 9, 2020","September 24, 2020","Texas Children's Hospital, Houston, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT02877680/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02877680" | |
| 154,"NCT02883829","Effects of Web-Based Health Information on Risk Behavior for Youth With Type 1 Diabetes in College",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Behavioral: Peer-Based Web-Based Health Information|Behavioral: Provider-Based Web-Based Health Information","Changes in attitudes, beliefs, and intentions about alcohol","Boston Children's Hospital","All","17 Years to 25 Years (Child, Adult)","Not Applicable","138","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","IRB-P00023029","April 4, 2017","May 10, 2017","May 10, 2017","August 30, 2016",,"November 17, 2017","Boston Children's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02883829" | |
| 155,"NCT00525889","Proleukin and Rapamune in Type 1 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: IL-2|Drug: Rapamycin","Incidence and severity of adverse events and laboratory anomalies|AUC for C-peptide responses following MMTT|Frequency of severe hypoglycemia|Insulin dose in units per kilogram|HbA1c levels","National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN)","All","18 Years to 45 Years (Adult)","Phase 1","9","NIH|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DAIT ITN018AI","August 2007","September 2011","September 2013","September 6, 2007",,"February 8, 2017","Naomi Berrie Diabetes Center, Columbia University, New York, New York, United States|Oregon Health Sciences University, Portland, Oregon, United States|Benaroya Research Institute, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00525889" | |
| 156,"NCT00131755","Efficacy of Diazoxide in Type 1 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: diazoxide","Insulin secretion (measured by fasting and stimulated c-peptide)|Glycemic control (measured by blood glucose)|Autoimmune activity (measured by islet antibodies)|Side effects","Grill, Valdemar, M.D.","All","18 Years to 40 Years (Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","DIAZ 1|Eudract 2004-004103-38","February 2005","August 2008","August 2008","August 19, 2005",,"July 18, 2011","University Hospital of Trondheim, Trondheim, Norway",,"https://ClinicalTrials.gov/show/NCT00131755" | |
| 157,"NCT02619487","The Impact of Mobile Technology on Clinical Outcomes in Children and Adolescents With Type 1 Diabetes","Edu4U","Withdrawn","No Results Available","Diabetes Mellitus, Type 1","Other: text message to parent only|Other: text message to parent and adolescent","glycemic control assessed by HbA1C level.|number of episodes of Diabetic Ketoacidosis (DKA)|number of episodes of severe hypoglycemia|number of patient contacts to the diabetes educator|number of hospitalizations related to T1D","University of Louisville","All","8 Years to 18 Years (Child, Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care","01","March 2019","December 13, 2019","December 13, 2019","December 2, 2015",,"December 17, 2018","University of Louisville, Louisville, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT02619487" | |
| 158,"NCT02703350","A Study of LY900014 in Participants With Type 1 Diabetes on Insulin Injection Therapy",,"Completed","Has Results","Diabetes Mellitus, Type 1","Drug: LY900014|Drug: Insulin Lispro","Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve From Time Zero to 5 Hours (AUC[0-5h]) (Part A)|Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve From Time Zero to 5 Hours (AUC[0-5h]) (Part B)|Pharmacodynamics (PD): Area Under the Concentration Curve From Time Zero to 5 Hours (AUC[0-5h]) of Glucose Relative to a Mixed Meal Tolerance Test (MMTT) (Part A)|Pharmacodynamics (PD): Area Under the Concentration Curve From Time Zero to 5 Hours (AUC[0-5h]) of Glucose Relative to a Mixed Meal Tolerance Test (MMTT) (Part B)","Eli Lilly and Company","All","18 Years to 65 Years (Adult, Older Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","16068|I8B-FW-ITRG|2015-004737-27","March 2016","July 2016","July 2016","March 9, 2016","April 28, 2020","June 17, 2020","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Mainz, Germany",,"https://ClinicalTrials.gov/show/NCT02703350" | |
| 159,"NCT02703324","A Study of LY900014 Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps",,"Completed","Has Results","Diabetes Mellitus, Type 1","Drug: LY900014|Drug: Insulin Lispro","Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve From Time Zero to 5 Hours (AUC[0-5h])|Pharmacodynamics (PD): Area Under the Concentration Curve From Time Zero to 5 Hours (AUC[0-5h]) of Glucose Relative to a Mixed Meal Tolerance Test (MMTT)","Eli Lilly and Company","All","18 Years to 65 Years (Adult, Older Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","16070|I8B-FW-ITRF|2015-004705-16","March 2016","August 2016","August 2016","March 9, 2016","April 28, 2020","June 17, 2020","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Neuss, Germany",,"https://ClinicalTrials.gov/show/NCT02703324" | |
| 160,"NCT02232971","Treatment of Low Blood Sugar With Glucagon Among Patients With Type 1 Diabetes","GluST1","Unknown status","No Results Available","Diabetes Mellitus, Type 1","Drug: Glucagon|Other: Isotonic saline solution","Maximum plasma glucose response|Duration of hyperglycemic effect of glucagon","Hvidovre University Hospital|The Novo Nordic Foundation|University of Copenhagen","All","18 Years to 65 Years (Adult, Older Adult)","Phase 4","8","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","GluST1_2014|2014-002267-15|H-1-2014-041","September 2014","January 2015","July 2015","September 5, 2014",,"March 25, 2015","Hvidovre University Hospital, Hvidovre, Denmark",,"https://ClinicalTrials.gov/show/NCT02232971" | |
| 161,"NCT04509791","MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)","Meld-ATG","Recruiting","No Results Available","Diabetes Mellitus, Type 1","Drug: Anti-Human Thymocyte Immunoglobulin, Rabbit","the area under the stimulated C-peptide response curve|dry blood spot (DBS) C-peptide measurements|Cluster of differentiation 4 (CD4) positive T cells and Cluster of differentiation 8 (CD8) positive T cells|HbA1c|insulin requirements|T1D-associated autoantibodies (glutamic acid decarboxylase antibodies (GADA), insulin auto-antibodies (IAA), IA-2 antibodies (IA-2A) and Zinc transporter 8 antibodies (ZnT8A))|continuous glucose monitoring (CGM) measurements ( time in range, time above time below)","Universitaire Ziekenhuizen KU Leuven","All","5 Years to 25 Years (Child, Adult)","Phase 2","114","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","S63466|2019-003265-17","November 24, 2020","May 2023","May 2023","August 12, 2020",,"March 11, 2022","Medical University of Graz, Graz, Austria|Medical University of Vienna, Vienna, Austria|Universitair Ziekenhuis Antwerpen, Antwerp, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|Universitair ziekenhuis Brussel, Brussels, Belgium|Universite Libre de Bruxelles, Brussels, Belgium|Universitaire Ziekenhuizen Leuven, Leuven, Belgium|Herlev University Hospital, Herlev, Denmark|Helsinki University Hospital Children and Adolescents, Helsinki, Finland|Hannoversche Kinderheilanstalt Auf der Bult, Hannöver, Germany|IRCCS Ospedale San Raffaele, Milano, Italy|Ospedale Pediatrico Bambino Gesù, Roma, Italy|Slaski Uniwersytet Medyczny w Katowicach, Katowice, Poland|University Medical Centre Ljubljana, Ljubljana, Slovenia|Cambridge University Hospitals NHS Trust, Cambridge, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04509791" | |
| 162,"NCT02623452","A Study of a New Type of Insulin in Participants With Type 1 Diabetes on Insulin Injection Therapy",,"Withdrawn","No Results Available","Diabetes Mellitus, Type 1","Drug: Insulin Lispro","(Part A) Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) of Insulin Lispro|(Part B) PK: AUC of Insulin Lispro|(Part A) Pharmacodynamics (PD): AUC of Glucose Following a Meal|(Part B) PD: AUC of Glucose Following a Meal","Eli Lilly and Company","All","18 Years to 65 Years (Adult, Older Adult)","Phase 1","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","15627|F3Z-FW-ITCB|2015-003351-21","January 2018","April 2018","April 2018","December 7, 2015",,"July 13, 2017",,,"https://ClinicalTrials.gov/show/NCT02623452" | |
| 163,"NCT02702011","Empa Add on to Insulin in Japanese Patient With Type 1 Diabetes Mellitus",,"Completed","Has Results","Diabetes Mellitus, Type 1","Drug: empagliflozin medium dose|Drug: empagliflozin low dose|Drug: empagliflozin high dose|Drug: placebo","Change From Baseline in 24 Hour UGE on Day 7","Boehringer Ingelheim|Eli Lilly and Company","All","20 Years to 65 Years (Adult, Older Adult)","Phase 2","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","1245.113","March 20, 2016","September 5, 2016","October 3, 2016","March 8, 2016","April 2, 2018","April 2, 2018","Souseikai Hakata Clinic, Fukuoka, Fukuoka, Japan|Nishikumamoto Hospital, Kumamoto, Kumamoto, Japan|Shinjuku Research Park Clinic, Tokyo, Shinjyuku-ku, Japan|SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan",,"https://ClinicalTrials.gov/show/NCT02702011" | |
| 164,"NCT02623478","A Study of a Novel Insulin Lispro Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps",,"Withdrawn","No Results Available","Diabetes Mellitus, Type 1","Drug: Insulin Lispro","Pharmacokinetics (PK): Area under the Concentration Curve (AUC) of Insulin Lispro|Pharmacodynamics (PD): AUC of Glucose Following a Meal","Eli Lilly and Company","All","18 Years to 65 Years (Adult, Older Adult)","Phase 1","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","15639|F3Z-FW-ITCD|2015-003353-18","January 2018","April 2018","April 2018","December 7, 2015",,"July 13, 2017",,,"https://ClinicalTrials.gov/show/NCT02623478" | |
| 165,"NCT00148538","Type 1 Diabetes Aerobic and Resistance Exercise (T1-DARE)",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Behavioral: Resistance and/or Aerobic Exercise","HbA1c at the end of the 6-month exercise period|frequency of hypoglycemia|fructosamine|blood pressure|lipid concentrations|apolipoproteins A1 and B|C-reactive protein|FFA|body composition (CT & DEXA)|compliance with the exercise|quality of life","Ottawa Hospital Research Institute","All","16 Years and older (Child, Adult, Older Adult)","Phase 3","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","GA-3-05-1903-RS","July 2005","December 2010","April 2012","September 8, 2005",,"July 23, 2019","Ottawa Health Research Institute, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00148538" | |
| 166,"NCT04769037","Supplementation With B. Infantis for Mitigation of Type 1 Diabetes Autoimmunity","SINT1A","Recruiting","No Results Available","Diabetes Mellitus, Type 1","Dietary Supplement: B. infantis|Dietary Supplement: Placebo","Persistent confirmed multiple beta-cell autoantibodies|Persistent confirmed beta-cell autoantibodies|Diabetes|Transglutaminase antibodies|Respiratory infection rate|Measurement of Safety parameters","Helmholtz Zentrum München|Technical University of Munich|Kinderkrankenhaus auf der Bult|University Hospital Carl Gustav Carus|Skane University Hospital|Universitaire Ziekenhuizen KU Leuven|Medical University of Warsaw|Cambridge Biomedical Campus, Cambridge, UK|Royal Victoria Infirmary, Newcastle upon Tyne, UK","All","7 Days to 6 Weeks (Child)","Not Applicable","1144","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","GPPAD-04","April 22, 2021","October 2027","October 2027","February 24, 2021",,"November 9, 2022","University Hospitals Leuven Faculty of Medicine, Catholic University of Leuven, Leuven, Belgium|Universitätsklinikum Carl Gustav Carus Technische Universität Dresden, Dresden, Germany|AUF DER BULT, Kinder- und Jugendkrankenhaus, Hannover, Germany|Institute of Diabetes Research, Helmholtz Zentrum Munich, Germany, and Forschergruppe Diabetes, Technical University Munich (TUM), School of Medicine, Klinikum rechts der Isar, Munich, Germany|Department of Paediatrics Medical University of Warsaw, Warsaw, Poland|Lund University, Skane University Hospital SUS, Malmö, Sweden|University Department of Paediatrics, Cambridge Biomedical Campus, Cambridge, United Kingdom|Royal Victoria Infirmary, Newcastle upon Tyne, Newcastle, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04769037" | |
| 167,"NCT01879917","Liraglutide in Newly Onset Type 1 Diabetes.","NewLira","Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: Liraglutide|Drug: Placebo","Beta-cell function|Postprandial glucagon","Hvidovre University Hospital|Steno Diabetes Center Copenhagen|Hillerod Hospital, Denmark|Bispebjerg Hospital|Odense University Hospital|Aarhus University Hospital|Aalborg University Hospital|Hospital of South West Jutland","All","18 Years to 40 Years (Adult)","Phase 2|Phase 3","65","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2012-005317-39|U1111-1137-3221","February 2014","August 2018","August 2018","June 18, 2013",,"March 30, 2021","Dep. of Endocrinology, Hvidovre University Hospital, Hvidovre, Capital, Denmark",,"https://ClinicalTrials.gov/show/NCT01879917" | |
| 168,"NCT02443532","Effects of Structured Group Education on Quality of Life and Glycemic Control in Type 1 Diabetes",,"Terminated","No Results Available","Diabetes Mellitus, Type 1","Behavioral: Structured group education|Behavioral: Individual education","HbA1c (between-group difference in variation from baseline)|Quality of life (Well-being enquiry in Diabetics [WED] questionnaire)|Treatment satisfaction (Diabetes Treatment Satisfaction [DTS] questionnaire)|Fear of hypoglycemia (Fear of Hypoglycemia [FH-15] questionnaire)|Severe hypoglycemia (incidence of episodes of hypoglycemia requiring hospitalization and/or help from third parties, self-reported)","Azienda Ospedaliero-Universitaria Careggi","All","15 Years to 65 Years (Child, Adult, Older Adult)","Not Applicable","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DIAB120001","March 2012","January 8, 2018","January 8, 2018","May 14, 2015",,"June 4, 2018",,,"https://ClinicalTrials.gov/show/NCT02443532" | |
| 169,"NCT01997411","Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes",,"Completed","Has Results","Diabetes Mellitus, Type 1","Drug: Nasal Glucagon|Drug: Intramuscular Glucagon","Maximum Change From Baseline Concentration (Cmax) of Glucagon|Time to Maximum Concentration (Tmax) of Baseline Adjusted Glucagon|Area Under the Curve (AUC0-1.5) of Baseline Adjusted Glucagon|Maximum Concentration (Cmax) of Baseline-Adjusted Glucose|Time to Maximum Concentration (Tmax) of Baseline-Adjusted Glucose|Area Under the Effect Concentration Time Curve (AUEC0-1.5) of Baseline-Adjusted Glucose From Time Zero up to 90 Minutes|Nasal and Non-nasal Effects/Symptoms|Number of Participants Achieving at Least a 25 mg/dL Rise in Blood Glucose Above Nadir Level Within 30 Minutes|Time to Achieving ≥25 mg/dL Rise in Plasma Glucose Above Nadir Level Within 30 Minutes","Eli Lilly and Company|Jaeb Center for Health Research|Locemia Solutions ULC","All","4 Years to 16 Years (Child)","Phase 2|Phase 3","48","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","16418|I8R-MC-IGBB|INGluc002|AMG103","November 2013","January 2015","January 2015","November 28, 2013","March 6, 2017","August 29, 2018","Barbara Davis Center for Diabetes, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|University of Florida, Gainesville, Florida, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|Riley Hospital for Children Indiana University Health, Indianapolis, Indiana, United States|University of Minnesota, Minneapolis, Minnesota, United States|UPA Buffalo, Buffalo, New York, United States",,"https://ClinicalTrials.gov/show/NCT01997411" | |
| 170,"NCT02506647","PK/PD Study of Gan & Lee's Insulin Glargine Injection in Comparison to Lantus in Type 1 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: Gan & Lee insulin glargine followed by Lantus|Drug: Lantus followed by Gan & Lee insulin glargine","Pharmacodynamic effects|Pharmacokinetic effects|Safety assessment as measured by incidence and severity of adverse events","Gan and Lee Pharmaceuticals, USA","All","18 Years to 65 Years (Adult, Older Adult)","Phase 1","41","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","GL-GLA-001","December 2015","September 2016","September 2016","July 23, 2015",,"January 26, 2017","Profil Institute for Clinical Research, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT02506647" | |
| 171,"NCT02441504","Effects of Low Intensity Aerobic Exercise on the Microvascular Endothelial Function of Patients With Type 1 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Other: Low intensity Exercise","Change in Cutaneous Capillary Density in twelve weeks of aerobic physical activity","Instituto Nacional de Cardiologia de Laranjeiras|Rio de Janeiro State University","Male","25 Years to 50 Years (Adult)","Not Applicable","22","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","1988-CEP/HUPE","January 2014","September 2014","October 2014","May 12, 2015",,"May 13, 2015",,,"https://ClinicalTrials.gov/show/NCT02441504" | |
| 172,"NCT00592072","Effect of Medium Chain Fatty Acids on Cognitive Function During Acute Hypoglycemia in Patients With Type 1 Diabetes",,"Completed","Has Results","Diabetes Mellitus, Type 1","Dietary Supplement: Medium chain fatty acid (Octanoic and Decanoic acid)|Other: Splenda (Placebo Control)","Immediate Verbal Memory|Delayed Verbal Memory|Verbal Memory Recognition|Digit Span Backward|Letter/Number Sequencing|Digit Symbol Coding|Map Search (2min)|Map Search (1min)|Telephone Search","Yale University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Juvenile Diabetes Research Foundation","All","18 Years to 55 Years (Adult)","Not Applicable","12","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DK66108b_0505000079|R37DK020495|DK20495","July 2005","July 2008","July 2008","January 11, 2008","January 5, 2015","January 22, 2015","Yale University School of Medicine, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00592072" | |
| 173,"NCT01899274","Assessment of an iPhone Application on Glycemic Control in Type 1 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Device: bant iPhone application","Changes in Hemoglobin A1C levels|Hypoglycemic Events|Self-Efficacy|Self-Care Behaviour|Treatment Adherence|Quality of Life|bant Component Usage","The Hospital for Sick Children|Thrasher Research Fund|University Health Network, Toronto|York University","All","11 Years to 16 Years (Child)","Not Applicable","92","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1000036524|11054","July 2013","January 2016","January 2016","July 15, 2013",,"April 19, 2016","Trillium Health Partners, Mississauga, Ontario, Canada|The Hostpital for Sick Children, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01899274" | |
| 174,"NCT01630850","Islet Transplantation in Patients With ""Brittle"" Type I Diabetes",,"Recruiting","No Results Available","Diabetes Mellitus, Type 1","Biological: Allogenic islet cells (human, U. Chicago)|Procedure: Intraportal infusion of islet cells","HbAlc <7.0% and an absence of severe hypoglycemic events","University of Chicago","All","18 Years to 70 Years (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11-0684","May 2012","May 2025","June 2030","June 28, 2012",,"December 24, 2020","University of Chicago Medical Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01630850" | |
| 175,"NCT02414958","Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)",,"Completed","Has Results","Diabetes Mellitus, Type 1","Drug: Empagliflozin|Drug: Placebo","Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 26|Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 26 for Modified Intention-to-treat Population Set (mITT) (Observed Case (OC) - All Data (AD) (OC-AD) )|Rate Per Patient-year of Investigator-reported Symptomatic Hypoglycaemia Adverse Events (AEs) With Confirmed Plasma Glucose (PG)|Change From Baseline in Body Weight at Week 26|Change From Baseline in Percentage of Time Spent in Target Glucose Range From Weeks 23 to 26|Change From Baseline in Interstitial Glucose Variability Based on the Interquartile Range (IQR) as Determined by CGM in Weeks 23 to 26|Change From Baseline in Total Daily Insulin Dose (TDID) at Week 26|Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Week 26","Boehringer Ingelheim|Eli Lilly and Company","All","18 Years and older (Adult, Older Adult)","Phase 3","730","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","1245.69|2014-001922-14","June 30, 2015","April 20, 2017","October 23, 2017","April 13, 2015","November 20, 2018","January 3, 2019","AMCR Institute, Inc., Escondido, California, United States|Diabetes/Lipid Management and Research Center, Huntington Beach, California, United States|National Research Institute, Los Angeles, California, United States|Mills-Peninsula Health Services, San Mateo, California, United States|Metabolic Institute of America, Tarzana, California, United States|University Clinical Investigators, Inc., Tustin, California, United States|Creekside Endocrine Associates, PC, Denver, Colorado, United States|The Center for Diabetes and Endocrine Care, Fort Lauderdale, Florida, United States|East Coast Institute for Research, LLC, Jacksonville, Florida, United States|Baptist Diabetes Associates, PA, Miami, Florida, United States|Physicians Research Associates, LLC, Lawrenceville, Georgia, United States|Endocrine Research Solutions, Inc., Roswell, Georgia, United States|Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States|Northwest Endo Diabetes Research, LLC, Arlington Heights, Illinois, United States|Midwest Endocrinology, Crystal Lake, Illinois, United States|Iowa Diabetes and Endocrinology Research Center, West Des Moines, Iowa, United States|Diabetes anddocrine Associates, PC, Omaha, Nebraska, United States|Desert Endocrinology Clinical Research Center, Henderson, Nevada, United States|Palm Research Center, Las Vegas, Nevada, United States|Southern New Hampshire Diabetes and Endocrinology, Nashua, New Hampshire, United States|Albany Medical Center / Albany Medical College, Albany, New York, United States|University Physicians Group Research Division, Staten Island, New York, United States|Diabetes and Endocrinology Consultants, PC, Morehead City, North Carolina, United States|The Carl and Edyth Lindner Center for Research & Education at The Christ Hospital, Cincinnati, Ohio, United States|Diabetes and Obesity Clinical Trials Center, Nashville, Tennessee, United States|North Texas Endocrine Center, Dallas, Texas, United States|Office of Dr. Michelle Zaniewski-Singh, Houston, Texas, United States|Texas Diabetes and Endocrinology, Round Rock, Texas, United States|Bateman Horne Center, Salt Lake City, Utah, United States|Advanced Research Institute, South Ogden, Utah, United States|Larry D Stonesifer, MD Inc., PS, Federal Way, Washington, United States|Rainier Clinical Research Center, Inc, Renton, Washington, United States|The Polyclinic, Seattle, Washington, United States|MultiCare Institute for Research and Innovation, Tacoma, Washington, United States|Coffs Endocrine & Diabetes Services, Coffs Harbour, New South Wales, Australia|AIM Centre, Merewether, New South Wales, Australia|Royal Brisbane & Women's Hospital-Endocrinology, Herston, Queensland, Australia|VIVIT Instit.am LKH Feldkirch,Abt.f.Innere Med.u.Kardiologie, Feldkirch, Austria|LKH Steyr, Kardiologie, Steyr, Austria|KH Rudolfstiftung, 1. Med. Abt., Wien, Wien, Austria|Hospital Hietzing, Wien, Austria|Arlon - HOSP Sud Luxembourg - Vivalia, Arlon, Belgium|Bonheiden - HOSP Imelda, Bonheiden, Belgium|Brussels - UNIV UZ Brussel, Brussel, Belgium|ULB Hopital Erasme, Bruxelles, Belgium|Edegem - UNIV UZ Antwerpen, Edegem, Belgium|UNIV UZ Gent, Gent, Belgium|La Louvière - UNIV CHU Tivoli, La Louvière, Belgium|UZ Leuven, Leuven, Belgium|Centre Hospitalier Universitaire de Liège, Liège, Belgium|Liège - HOSP CHR de la Citadelle, Liège, Belgium|Merksem - HOSP ZNA Jan Palfijn, Merksem, Belgium|LMC Endocrinology Centres (Calgary) Ltd., Calgary, Alberta, Canada|The Bailey Clinic, Red Deer, Alberta, Canada|Royal Jubilee Hospital, Victoria, British Columbia, Canada|Health Sciences Centre Winnipeg, Winnipeg, Manitoba, Canada|CHUM - Pavillon R, Montreal, Migration Data, Canada|Capital District Health Auth., Halifax, Nova Scotia, Canada|Kingston General Hospital, Kingston, Ontario, Canada|LMC Thornhill/Vaughan, Thornhill, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Royal Victoria Hospital, Montreal, Quebec, Canada|General Univ.hosp.in Prague (VFN), Diabetes ambulance, Praha 2, Czechia|Diabetology and Internal Practice Dr. Vladimir Lelek, Slany, Czechia|Masaryk Hospital, Internal Department, Usti nad Labem, Czechia|Aalborg Sygehus Syd, Aalborg, Denmark|Aarhus Universitets Hospital, Aarhus C, Denmark|Steno Diabetes Center Copenhagen, Gentofte, Denmark|Nordsjællands Hospital - Hillerød, Hillerød, Denmark|Køge Sygehus, Køge, Denmark|IteLasaretti, Kuopio, Finland|Terveystalo Oulu, Diapolis, Oulu, Finland|TYKS, Turku, Finland|HOP Côte de Nacre, Caen, France|HOP Saint-Louis, La Rochelle Cedex 1, France|HOP de Narbonne, diabéto endo, Narbonne, Narbonne, France|HOP Robert Debré, Reims, France|HOP de Brabois, Vandoeuvre-lès-Nancy, France|HOP les Portes du Sud, Diabéto, Vénissieux, Vénissieux, France|Studienzentrum Aschaffenburg, Aschaffenburg, Germany|Gemeinschaftspraxis, Asslar, Asslar, Germany|ikfe - Institut für klinische Forschung und Entwicklung Berlin GmbH, Berlin, Germany|InnoDiab Forschung GmbH, Essen, Germany|Praxis Dr. Kosch, Pirna, Pirna, Germany|Allgemeinmedizinische und Diabetologische Schwerpunktpraxis, Rehlingen-Siersburg, Germany|Praxis Dr. Hirschhäuser, Saarbrücken, Germany|Praxis Dr. Segner, St. Ingbert, Saint Ingbert/Oberwürzbach, Germany|Ambulanzzentrum Schweinfurt, Schweinfurt, Germany|Noordwest Ziekenhuisgroep, Alkmaar, Netherlands|Academisch Medisch Centrum (AMC), Amsterdam, Netherlands|Rijnstate Hospital, Arnhem, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Bethesda Ziekenhuis Hoogeveen, Hoogeveen, Netherlands|Sint Franciscus Gasthuis, Rotterdam, Netherlands|Albert Schweitzer Ziekenhuis, Zwijndrecht, Zwijndrecht, Netherlands|Sykehuset Innlandet HF, Avd. Hamar, Hamar, Norway|Akershus Universitetssykehus HF, Lørenskog, Norway|Oslo Universitetssykehus HF, Aker Sykehus, Oslo, Norway|Helse Møre og Romsdal HF, Ålesund sjukehus, Ålesund, Norway|Med Univ Bialystok Clin Dep Endocrinol, Diabetol & Int Dis, Bialystok, Poland|NZOZ Specjalistyczny Osrodek Internistyczno-Diabetologiczny, Bialystok, Poland|Dobry Lekarz,Spec.Med.Clinics,Private Prac,Krakow, Krakow, Poland|NZOZ Specialized Ambulance ""MEDICA"", Lublin, Poland|Marcinkowski Poznan Univ of Med Sci, Clin Dept Diab, Poznan, Poznan, Poland|NZOZ Centrum Medyczne AESKULAP,Private Prac, Radom, Radom, Poland|Centrum Medyczne Medyk, Rzeszow, Poland|NBR Polska, Warsaw, Poland|C.A.P. Sardenya, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital de la Inmaculada Concepción, Granada, Spain|Hospital Virgen de la Victoria, Malaga, Spain|Hospital General de Segovia, Segovia, Spain|Hospital Nuestra Señora de Valme, Sevilla, Spain|Hospital Virgen Macarena, Sevilla, Spain|Ladulaas Kliniska Studier, Borås, Sweden|Centralsjukhuset, Karlstad, Karlstad, Sweden|Läkarhuset, Vällingby, Vällingby, Sweden|Chung Shan Medical University Hospital, Taichung, Taiwan|China Medical University Hospital, Taichung, Taiwan|Chi Mei Medical Center, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Milton Keynes Hospital, Buckinghamshire, United Kingdom|Addenbrooke's Hospital, Cambridge, United Kingdom|Wellcome Trust Clinical Research Facility, Edinburgh, United Kingdom|Leicester General Hospital, Leicester, United Kingdom|Royal London Hospital, London, United Kingdom|Queen's Medical Centre, Nottingham, United Kingdom|George Eliot Hospital, Nuneaton, United Kingdom|East Surrey Hospital, Surrey, United Kingdom|Queen Elizabeth II Hospital, Welwyn Garden City, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT02414958/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT02414958/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02414958" | |
| 176,"NCT01640834","Study of LY2409021 in Participants With Type 1 Diabetes",,"Completed","Has Results","Diabetes Mellitus, Type 1","Drug: LY2409021|Drug: Placebo|Drug: Glucagon","Pharmacodynamics: Change From Baseline to Day 2 in 24-hour Insulin Dose|Pharmacodynamics: Percentage Change From Baseline to Day 2 in 24-hour Insulin|Pharmacokinetics: Maximum Concentration (Cmax) of LY2409021|Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY2409021|Pharmacodynamics: Change From Baseline in 24 Hour Insulin Dose During Drug Washout Period|Pharmacodynamics: Change From Baseline in 24 Hour Insulin Dose Needed to Maintain Euglycemia|Pharmacodynamics: Maximum Concentration (Cmax) of Glucose Concentration After 1 Milligram (mg) Glucagon Injection on Day 3|Pharmacodynamics: Area Under the Glucose Concentration Curve After a Single Dose of Glucagon on Day 3","Eli Lilly and Company","All","18 Years to 65 Years (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","14576|I1R-MC-GLBR|2011-006178-19","July 2012","September 2012","September 2012","July 16, 2012","October 29, 2018","October 29, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Neuss, Germany",,"https://ClinicalTrials.gov/show/NCT01640834" | |
| 177,"NCT01791907","Effect of Structured Nutrition Education in Type 1 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Behavioral: Structured education in carbohydrate counting|Behavioral: Structured education in healthy food choices and low glycemic index","HbA1c|Quality of life|CVD risk factors|Hypoglycemia|Food choices|Health economics","Göteborg University","All","20 Years to 70 Years (Adult, Older Adult)","Not Applicable","181","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EPN 304-12","February 2013","December 2014","July 2017","February 15, 2013",,"November 5, 2018",,,"https://ClinicalTrials.gov/show/NCT01791907" | |
| 178,"NCT02660242","The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes",,"Completed","Has Results","Diabetes Mellitus, Type 1","Drug: G-Pen Mini™ (glucagon injection)|Other: Glucose Tabs|Other: Basal Insulin Reduction","Glycemic Response During Exercise and Early Recovery|Number of Participants With Hypoglycemia (<70 mg/dL) During Exercise and Early Recovery|Number of Participants With Hyperglycemia (≥250 mg/dL) During Exercise and Early Recovery|Continuous Glucose Monitor (CGM) Metrics During Late Recovery - Nadir Glucose|CGM Metrics During Late Recovery - Peak Glucose|CGM Metrics During Late Recovery - Mean Glucose|CGM Metrics During Late Recovery - Coefficient of Variation|CGM Metrics During Late Recovery - Time < 54 mg/dL|CGM Metrics During Late Recovery - Time < 70 mg/dL|CGM Metrics During Late Recovery - Time in Range (70-180 mg/dL)|CGM Metrics During Late Recovery - Time > 180 mg/dL|CGM Metrics During Late Recovery - Time > 250 mg/dL","Jaeb Center for Health Research|Xeris Pharmaceuticals","All","18 Years to 64 Years (Adult)","Phase 2","16","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","T1DX Mini-dose Exercise","January 2016","February 15, 2017","February 15, 2017","January 21, 2016","August 7, 2018","March 3, 2020","Joslin Diabetes Center, Boston, Massachusetts, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02660242/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02660242/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02660242" | |
| 179,"NCT01839370","Phase 2 Study of Adaptive Insulin Meal Supervisor (AIMS) in Adults With Type 1 Diabetes Mellitus",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Device: Closed Loop with Pramlintide","Percent of Glucose Measurements within Target Range","University of Virginia|DexCom, Inc.|Tandem Diabetes Care, Inc.","All","21 Years to 65 Years (Adult, Older Adult)","Not Applicable","9","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16666","July 2013","November 2013","November 2013","April 24, 2013",,"February 19, 2014","University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01839370" | |
| 180,"NCT00605592","UVA Islet Cell Transplantation in Patients With Type I Diabetes",,"Unknown status","No Results Available","Diabetes Mellitus, Type 1","Procedure: Pancreatic Islets of Langerhans Cell Transplant","A decrease in the average daily insulin requirement post-islet cell transplantation.","University of Virginia|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years to 65 Years (Adult, Older Adult)","Phase 1","20","Other|NIH|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12839","January 2007","January 2012","January 2012","January 31, 2008",,"February 18, 2009","University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00605592" | |
| 181,"NCT01483560","REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL)","REMOVAL","Completed","Has Results","Diabetes Mellitus, Type 1","Drug: Metformin|Drug: Placebo","Change in Averaged Mean Far Wall Common Carotid Artery Intima-media Thickness (cIMT)|Change in HbA1c|Change in LDL Cholesterol|Change in Estimated Glomerular Filtration Rate|Number of Participants With Retinopathy and at Least a 2 Stage Progression in Retinopathy From Baseline to 36 Months|Change in Weight|Change in Insulin Dose|Change in Endothelial Function","University of Glasgow|NHS Greater Glasgow and Clyde|Juvenile Diabetes Research Foundation|Imperial College London|University of Wisconsin, Madison|University of Dundee|Merck Serono S.A., Geneva|Itamar-Medical, Israel|University of Western Ontario, Canada|University of Melbourne|Steno Diabetes Center Copenhagen|Maastricht University Medical Center","All","40 Years and older (Adult, Older Adult)","Phase 3","493","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","GN10DI406|2011-000300-18","December 2011","March 19, 2017","April 18, 2017","December 1, 2011","June 3, 2019","June 19, 2019","Royal Melbourne Hospital, Melbourne, Australia|St Vincent's Hospital, Melbourne, Australia|Royal Prince Albert Hospital, Sydney, Australia|St Joseph's Health Care, London, Ontario, Canada|Ottawa Hospital Riverside Campus, Ottawa, Canada|Steno Diabetes Centre, Gentofte, Denmark|Maastricht University Medical Centre, Maastricht, Netherlands|Aberdeen Royal Infirmary, Aberdeen, United Kingdom|Ayr Hospital, Ayr, United Kingdom|University Hospitals Bristol, Bristol, United Kingdom|Diabetes Support Unit, Ninewells Hospital and Medical School, Dundee, United Kingdom|University Hospital North Durham, Durham, United Kingdom|Edinburgh Royal Infirmary, Edinburgh, United Kingdom|Edinburgh Western Infirmary, Edinburgh, United Kingdom|Peninsula NIHR Clinical Research Facility, Royal Devon and Exeter NHS Foundation Trust, Exeter, United Kingdom|Stobhill Hospital, Diabetes Clinic, Glasgow, United Kingdom|Gloucestershire Royal Hospital, Gloucester, United Kingdom|Michael White Diabetes Centre, Hull Royal Infirmary, Hull, United Kingdom|Clinical Sciences Centre, University Hospital, Liverpool, United Kingdom|Clinical Investigation Unit, International Centre for Circulatory Health, Imperial College Healthcare NHS Trust, London, United Kingdom|Wellcome Trust Clinical Research Facility, Manchester Royal Infirmary, Manchester, United Kingdom|Newcastle NIHR Clinical Research Facility, Royal Victoria Hospital, Newcastle, United Kingdom|Diabetes Clinical Research Centre, Plymouth, Plymouth, United Kingdom|Salford Royal NHS Foundation Trust, Salford, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT01483560/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT01483560/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01483560" | |
| 182,"NCT00419562","Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus","TN07","Completed","Has Results","Diabetes Mellitus, Type 1","Drug: Oral Insulin|Drug: Placebo","Rate of Type 1 Diabetes Per Year Among Individuals in the Primary Stratum When Treated With Oral Inulin Versus Placebo|Rate of Type 1 Diabetes Per Year in Secondary Stratum (Stratum 2) When Treated With Oral Insulin Versus Placebo|Rate of Type 1 Diabetes in Secondary Stratum (Stratum 3+4) When Treated With Oral Insulin Versus Placebo","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID)|National Center for Research Resources (NCRR)|American Diabetes Association|Juvenile Diabetes Research Foundation","All","3 Years to 45 Years (Child, Adult)","Phase 3","560","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","TN07 Oral Insulin|UC4DK106993|UC4DK117009","February 2007","December 2016","June 2017","January 8, 2007","February 18, 2020","May 7, 2020","University of California-San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|University of Florida, Gainesville, Florida, United States|University of Miami, Miami, Florida, United States|Indiana University-Riley Hospital for Children, Indianapolis, Indiana, United States|University of Minnesota, Minneapolis, Minnesota, United States|Columbia University, New York, New York, United States|Childrens Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Vanderbilt Eskind Diabetes Clinic, Nashville, Tennessee, United States|University of Texas, Dallas, Texas, United States|Benaroya Research Institute, Seattle, Washington, United States|Walter and Eliza Hall Institute, Parkville, Victoria, Australia|The Hospital for Sick Children, Toronto, Ontario, Canada|University of Turku, Turku, Finland|San Raffaele Hospital, Milan, Italy|University of Bristol, Bristol, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00419562" | |
| 183,"NCT01434030","Development of a Behavioral Observer for Type 1 Diabetes Mellitus","Phase1","Completed","Has Results","Diabetes Mellitus, Type 1","Behavioral: Focus Group","Desire to Receive Advice From Personal Glucose Advisory System (PGASystem)|Willingness to Follow PGASystem Advice","University of Virginia|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","21 Years to 65 Years (Adult, Older Adult)","Not Applicable","57","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)","14956|R01DK085623","April 2010","June 2011","June 2011","September 14, 2011","August 25, 2014","September 4, 2014","University of Virginia - Center for Diabetes Technology, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01434030" | |
| 184,"NCT01769404","A Study of LY2605541 and Glargine in Participants With Type 1 Diabetes",,"Completed","Has Results","Diabetes Mellitus, Type 1","Biological: LY2605541|Biological: Insulin Glargine","Concentration of Epinephrine|Amount of Glucose Required to Reach Blood Glucose (BG) of 72 mg/dL|Amount of Glucose Required to Maintain BG of 72 mg/dL|Concentration of Cortisol|Concentration of Glucagon|Concentration of Growth Hormone|Concentration of Norepinephrine","Eli Lilly and Company","All","18 Years to 65 Years (Adult, Older Adult)","Phase 1","25","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","14870|I2R-MC-BIDM","February 2013","December 2013","December 2013","January 16, 2013","June 24, 2019","June 24, 2019","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Neuss, Germany",,"https://ClinicalTrials.gov/show/NCT01769404" | |
| 185,"NCT01106157","Reversing Type 1 Diabetes After it is Established",,"Completed","Has Results","Diabetes Mellitus, Type 1","Drug: Anti-Thymocyte Globin (ATG)|Drug: Placebo|Drug: Pegylated GCSF","Change in Metabolic Function Baseline to 12 Months.|Percent Change in Regulatory T Cells (Treg) Baseline to 12 Months|A1c|Change in Insulin Requirements, Baseline to 12 Months|Change in Glutamic Acid Decarboxylase Antibodies (GADA) From Baseline to 12 Months|Change in Insulin Autoantibodies (IAA) From Baseline to 12 Months|Change in Insulinoma Associated 2 Autoantibodies (IA-2A) From Baseline to 12 Months|Change in Zinc Transporter 8 Autoantibodies (ZnT8A) From Baseline to 12 Months|Percentage of Neutrophils|Change in White Blood Count (WBC) From Baseline to 12 Months","University of Florida|The Leona M. and Harry B. Helmsley Charitable Trust|Genzyme, a Sanofi Company","All","12 Years to 45 Years (Child, Adult)","Phase 1|Phase 2","25","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","UF-ATG-GCSF001|IRB201702525|041-2010|OCR16038","April 2010","January 2015","July 16, 2019","April 19, 2010","January 20, 2016","August 5, 2019","University of California, San Francisco, San Francisco, California, United States|Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|University of Florida, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01106157" | |
| 186,"NCT01771250","A Study of Insulin Peglispro and Glargine on Fats in Participants With Type 1 Diabetes",,"Completed","Has Results","Diabetes Mellitus, Type 1","Biological: Insulin Peglispro|Biological: Insulin Glargine","Very Low Density Lipoprotein-Triglyceride (VLDL-TG) Concentrations|VLDL-TG Secretion Rate|VLDL-TG Oxidation Rate|VLDL-TG Clearance Rate","Eli Lilly and Company","All","18 Years to 65 Years (Adult, Older Adult)","Phase 1","15","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","14871|I2R-MC-BIDN","October 2013","December 2014","December 2014","January 18, 2013","March 11, 2019","March 11, 2019","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aarhus, Denmark",,"https://ClinicalTrials.gov/show/NCT01771250" | |
| 187,"NCT01969747","Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days",,"Completed","Has Results","Diabetes Mellitus, Type 1","Drug: Empagliflozin medium placebo|Drug: Empagliflozin low placebo|Drug: Empagliflozin high placebo|Drug: Empagliflozin medium|Drug: Empagliflozin low|Drug: Empagliflozin high","Change From Baseline in 24 h UGE (g/24 h) After Seven Days of Treatment With Empagliflozin 2.5 mg, 10 mg, or 25 mg, or Placebo","Boehringer Ingelheim|Eli Lilly and Company","All","18 Years to 65 Years (Adult, Older Adult)","Phase 2","75","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","1245.78|2011-004354-25","November 2013","April 2014","April 2014","October 25, 2013","April 8, 2015","April 8, 2015","1245.78.43001 Boehringer Ingelheim Investigational Site, Graz, Austria|1245.78.49001 Boehringer Ingelheim Investigational Site, Neuss, Germany",,"https://ClinicalTrials.gov/show/NCT01969747" | |
| 188,"NCT02000817","Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients",,"Completed","Has Results","Diabetes Mellitus, Type 1","Biological: Otelixizumab|Biological: Placebo","Number of Participants With Adverse Events (AEs) Related to Cytokine Release Syndrome (CRS)|Epstein-Barr Virus (EBV) Viral Load Detection|Number of Participants With Abnormal Laboratory Results|Number of Participants With Increase in QT Interval Corrected for Heart Rate (QTc)|Number of Participants With Abnormal Vital Sign Results|Free Serum Otelixizumab Concentrations by Treatment|Change From Baseline in C-Peptide Weighted Mean (Area Under Curve From 0 to 120 Minutes [AUC0-120 Minutes]) From Mixed Meal Tolerance Test|Change From Baseline in Glucose Weighted Mean (Area Under Curve From 0 to 120 Minutes, AUC0-120 Minutes) From Mixed Meal Tolerance Test|Change From Baseline in C-Peptide Weighted Mean (Area Under Curve From 60 to 140 Minutes, [AUC 60-140 Minutes]) From Hyperglycemic Clamp Test|Change From Baseline in Glucose Weighted Mean (Area Under Curve From 60 to 140 Minutes, AUC60-140 Minutes) From Hyperglycemic Clamp Test|Change From Baseline in Insulin Sensitivity (IS) Index From Hyperglycemic Clamp Test|Change From Baseline in Mean Daily Insulin Use|Change From Baseline in Hemoglobin A1c|Absolute Body Weight|Time-normalized Number of Hypoglycemic and Hyperglycemic Events|Relative Change From Baseline in Percentage (%) in CD4+ Cells|Relative Change From Baseline in Percentage (%) in CD8+ Cells|Change From Baseline in Free CD3 on CD8+ Cells|Change From Baseline in Free CD3 on CD4+ Cells|Change From Baseline in Bound CD3 Copies on CD4+ Cells|Change From Baseline in Bound CD3 Copies on CD8+ Cells|Number of Participants With Anti-drug Antibody Binding","GlaxoSmithKline|Parexel","All","16 Years to 27 Years (Child, Adult)","Phase 1|Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","116505|2013-003296-34","March 12, 2014","September 27, 2018","September 27, 2018","December 4, 2013","June 24, 2019","June 24, 2019","GSK Investigational Site, Brussels, Belgium|GSK Investigational Site, Bruxelles, Belgium|GSK Investigational Site, Edegem, Belgium|GSK Investigational Site, Gent, Belgium|GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Liège, Belgium","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT02000817/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT02000817/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02000817" | |
| 189,"NCT04732780","Avoidance of Hyperglycaemia in People With Type 1 Diabetes","HYPE","Completed","No Results Available","Diabetes Mellitus, Type 1","Other: No intervention","Hyperglycaemia Avoidance Scale|GAD-7|PHQ-9|State Trait Anxiety Inventory|Hypoglycaemia Fear Survey 2|Problem Areas in Diabetes 5","Imperial College London|Imperial College Healthcare NHS Trust|Imperial Health Charity","All","18 Years and older (Adult, Older Adult)",,"253","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","20SM6251","March 2, 2021","November 15, 2021","April 20, 2022","February 1, 2021",,"April 21, 2022","Imperial College Healthcare NHS Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04732780" | |
| 190,"NCT01784211","A Study of LY2605541 and Glargine and Exercise in Participants With Type 1 Diabetes",,"Completed","Has Results","Diabetes Mellitus, Type 1","Drug: LY2605541|Drug: Insulin Glargine","Part A: Pharmacokinetics: Area Under the Concentration Versus Time Curve Over the Dosing Interval (AUCτ) of LY2605541 and Insulin Glargine: Intra-Participant Variability|Part A: Pharmacokinetics: Maximum Drug Concentration (Cmax) of LY2605541 and Insulin Glargine: Intra-Participant Variability|Part A: Pharmacodynamics: Total Amount of Glucose Infused Over the Duration of the Clamp (Gtot): Intra-Participant Variability|Part B: Pharmacokinetics: AUCτ of LY2605541 and Insulin Glargine: Exercise Versus Non-Exercise|Part B: Pharmacokinetics: Cmax of LY2605541 and Insulin Glargine: Exercise Versus Non-Exercise","Eli Lilly and Company","All","18 Years to 65 Years (Adult, Older Adult)","Phase 1","76","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","14183|I2R-MC-BIAW","February 2013","November 2013","November 2013","February 5, 2013","March 15, 2019","March 15, 2019","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Neuss, Germany",,"https://ClinicalTrials.gov/show/NCT01784211" | |
| 191,"NCT01600950","A Study to Compare LY2963016 to Lantus After a Single Dose to Participants With Type 1 Diabetes Mellitus",,"Completed","Has Results","Diabetes Mellitus, Type 1","Drug: LY2963016|Drug: Lantus","Pharmacodynamics: Duration of Action of LY2963016 and Lantus|Maximum Glucose Infusion Rate (Rmax)|Total Glucose Infused (Gtot)|Time of Maximum Glucose Infusion Rate (tRmax)|Pharmacokinetics: Maximum Concentration (Cmax) of LY2963016 and Lantus|Pharmacokinetics: Area Under the Concentration-time Curve (AUC) of LY2963016 and Lantus","Eli Lilly and Company","All","18 Years to 60 Years (Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","13831|I4L-MC-ABEE","May 2012","July 2012","July 2012","May 17, 2012","October 7, 2014","October 7, 2014","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Neuss, Germany",,"https://ClinicalTrials.gov/show/NCT01600950" | |
| 192,"NCT05515939","Evaluating the InPen in Pediatric Type 1 Diabetes","EMPoWER","Enrolling by invitation","No Results Available","Type 1 Diabetes","Device: InPen Insulin Pen","Change in Hemoglobin A1c (HbA1c)|Change in Diabetes Numeracy Test (DNT-14)|Clinical Evaluation of Treatment","Wayne State University","All","13 Years to 21 Years (Child, Adult)",,"34","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","WSU-12-2021","September 9, 2022","August 2024","January 2025","August 25, 2022",,"October 3, 2022","Wayne State University, Detroit, Michigan, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT05515939/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT05515939" | |
| 193,"NCT01401790","Use of a Telehomecare Program for Young Patients With New Onset Type 1 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Device: Telehomecare (Intelligent Distance Patient Monitoring)|Other: Standard education and follow up at diabetes clinic","Patients' health (reported number of hypoglycemias and nocturnal hypoglycemias)|Patients and parents' health|Knowledge of diabetes|Organizational impacts|Family satisfaction with the software application","Huot, Celine, M.D.","All","6 Months to 18 Years (Child, Adult)","Not Applicable","86","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CHUSTEJUSTINE2644","February 2008","August 2009","August 2009","July 25, 2011",,"July 25, 2011","Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01401790" | |
| 194,"NCT00129259","Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes","AbATE","Completed","Has Results","Diabetes Mellitus, Type 1","Biological: Anti-CD3 mAb|Other: Diabetes Standard of Care Treatment|Dietary Supplement: Iron supplementation","Change in Mean C-peptide Area Under the Curve (AUC) Response to a Mixed Meal Tolerance Test (MMTT)|Change in HbA1c|Change in Average Total Insulin Dose Per Body Weight","National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN)","All","8 Years to 30 Years (Child, Adult)","Phase 2","83","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","DAIT ITN027AI","September 2005","March 2011","March 2011","August 11, 2005","September 16, 2013","May 22, 2017","The Diabetes Center at UCSF, San Francisco, California, United States|Barbara Davis Center for Childhood Diabetes, Denver, Colorado, United States|Yale University, New Haven, Connecticut, United States|Medical College of Georgia, Augusta, Georgia, United States|Dept. of Medicine, Division of Endocrinology and the Naomi Berrie Diabetes Center/Columbia University, New York, New York, United States|Benaroya Research Institute, Seattle, Washington, United States|Pacific Northwest Research Institute/University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00129259" | |
| 195,"NCT01440439","Comparing Long-acting Insulins During Exercise in Type 1 Diabetes",,"Unknown status","No Results Available","Diabetes Mellitus, Type 1","Drug: Insulin glargine|Drug: Insulin detemir","Glucose excursion (which, as defined below, is the change in blood glucose between the start and finish of one hour of exercise)|Lactate|NEFA (Non-esterified fatty acids)|B-OHB (beta-hydroxybutyrate)|Catecholamines|Glucagon|Human growth hormone (hGH)|Cortisol|IL-6 (interleukin 6)|High sensitivity CRP (Hs-CRP)|RQ (Respiratory Quotient)|Frequency of hypoglycaemic events|Time spent in hypoglycaemia|Blood glucose","Buckinghamshire Healthcare NHS Trust|Novo Nordisk A/S","All","18 Years to 65 Years (Adult, Older Adult)","Phase 4","30","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RXQ425|2011-001209-28|U1111-1119-8890","November 2011","June 2012","June 2012","September 26, 2011",,"November 8, 2011","Wycombe Hospital, High Wycombe, Buckinghamshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01440439" | |
| 196,"NCT01454284","A Study in Participants With Type I Diabetes Mellitus","IMAGINE 3","Completed","Has Results","Diabetes Mellitus, Type 1","Drug: Glargine|Drug: LY2605541|Drug: Insulin Lispro","Hemoglobin A1c (HbA1c)|Change From Baseline to 52 Weeks in HbA1c|Total Hypoglycemia Events|Percentage of Participants With Total Hypoglycemic Events|Percentage of Participants With HbA1c Equal to or Less Than 6.5% and Less Than 7.0%|Percentage of Participants With HbA1c Less Than 7.0% and Without Nocturnal Hypoglycemia|Nocturnal Hypoglycemia Rates|Percentage of Participants With Nocturnal Hypoglycemic Events|Change in Body Weight|9 Point Self-monitored Blood Glucose (SMBG)|Fasting Serum Glucose (by Laboratory Measurement)|Fasting Blood Glucose (by Participant Self Monitored Blood Glucose Readings)|Intra-participant Variability of Fasting Blood Glucose (FBG)|0300 Hours Blood Glucose (BG) to Fasting BG Excursion|Triglycerides, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C), and Total Cholesterol|Percentage of Participants With Change in Anti-LY2605541 Antibodies|Basal, Meal Time, and Total Insulin Dose Per Body Weight|Insulin Treatment Satisfaction Questionnaire|European Quality of Life -5 Dimension (EQ-5D-3L)|Adult Low Blood Sugar Survey|Rapid Assessment of Physical Activity (RAPA)","Eli Lilly and Company","All","18 Years and older (Adult, Older Adult)","Phase 3","1114","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12147|I2R-MC-BIAO|2011-001253-82","January 2012","February 2014","February 2014","October 18, 2011","April 17, 2018","April 17, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Concord, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fresno, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Mesa, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lancaster, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tustin, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aurora, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Longmont, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bradenton, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hollywood, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jacksonville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Port Richey, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Palm Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roswell, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Honolulu, Hawaii, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Idaho Falls, Idaho, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Springfield, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Des Moines, Iowa, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Topeka, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wichita, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lexington, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Metairie, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Eagan, Minnesota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Minneapolis, Minnesota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chesterfield, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Springfield, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Billings, Montana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Omaha, Nebraska, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Las Vegas, Nevada, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nashua, New Hampshire, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albany, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Durham, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Morehead City, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mentor, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Eugene, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Portland, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greer, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Myrtle Beach, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chattanooga, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Austin, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Round Rock, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ogden, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Federal Way, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Spokane, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tacoma, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Merewether, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Keswick, South Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Box Hill, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Parkville, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brussels, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edegem, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Huy, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sint-Niklaas, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fortaleza, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Porto Alegre, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., São Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edmonton, Alberta, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Red Deer, Alberta, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Winnipeg, Manitoba, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Halifax, Nova Scotia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oakville, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Laval, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montreal, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osijek, Croatia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kobenhavn, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Rochelle, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Le Creuzot, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rouen, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chalkida, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Thessaloniki, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dublin, Ireland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Haifa, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jerusalem, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Petah Tikva, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Petah Tiqva, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel Hashomer, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jonava, Lithuania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kaunas, Lithuania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dordrecht, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Groningen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Christchurch, New Zealand|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wellington, New Zealand|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gdansk, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Katowice, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Krakow, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lubin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lublin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Szczecin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warsaw, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sturovo, Slovakia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houghton, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pretoria, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Somerset West, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Alcala De Henares, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Alcira, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Málaga, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seville, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Alingsås, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Helsingborg, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Huddinge, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Karlstad, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bristol, Avon, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Portsmouth, Hampshire, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Blackburn, Lancashire, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leicester, Leicestershire, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Inverness, Scotland, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ipswich, Suffolk, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guildford, Surrey, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Swansea, Wales, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glasgow, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Northampton, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01454284" | |
| 197,"NCT00190502","Polyclonal Anti-T-Lymphocyte Globulin (ATG) in Type 1 Diabetes",,"Unknown status","No Results Available","Diabetes Mellitus, Type 1","Drug: Polyclonal anti-T-cell antibodies","C-peptide production|Diabetes remission rate|Insulin dose","Institute for Clinical and Experimental Medicine|Ministry of Health, Czech Republic","All","15 Years to 35 Years (Child, Adult)","Not Applicable","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Educational/Counseling/Training","KD CD IKEM 1|NB/6541-3 IGA MZCR","November 2000",,"December 2007","September 19, 2005",,"January 9, 2007","Institute for Clinical and Experimental Medicine, Department of Diabetes, Prague, Czech Republic",,"https://ClinicalTrials.gov/show/NCT00190502" | |
| 198,"NCT01481779","A Study in Participants With Type 1 Diabetes Mellitus","IMAGINE 1","Completed","Has Results","Diabetes Mellitus, Type 1","Drug: Glargine|Drug: LY2605541|Drug: Insulin Lispro","Hemoglobin A1c (HbA1c) at 26 Weeks|Hemoglobin A1c (HbA1c)|Change From Baseline in Hemoglobin A1c (HbA1c)|Percentage of Participants With Hemoglobin A1c (HbA1c) Less Than 7.0% or Less Than or Equal to 6.5% Using Last Observation Carried Forward (LOCF)|Proportion of Participants With Hemoglobin A1c (HbA1c) Less Than 7.0% Without Nocturnal Hypoglycemia|Total Hypoglycemia Rates (Adjusted by 30 Days)|Percentage of Participants With Total Hypoglycemia Events|Nocturnal Hypoglycemia Rates (Adjusted by 30 Days)|Percentage of Participants With Nocturnal Hypoglycemic Events|Fasting Serum Glucose (FSG) by Laboratory Measurement|Fasting Blood Glucose (FBG) Intra-participant Variability|0300-hour Blood Glucose (BG) to Fasting Blood (FBG) Glucose Excursion|9 Point Self-monitored Blood Glucose (SMBG)|Change From Baseline in Body Weight|Basal, Bolus, and Total Insulin Dose|Lipid Profile|Percentage of Participants With Change in Anti-LY2605541 Antibodies|Insulin Treatment Satisfaction Questionnaire (ITSQ)|Low Blood Sugar Survey (LBSS)|European Quality of Life-5 Dimension (EQ-5D)|Rapid Assessment of Physical Activity (RAPA)","Eli Lilly and Company","All","18 Years and older (Adult, Older Adult)","Phase 3","455","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12146|I2R-MC-BIAN|2011-001261-40","January 2012","May 2013","June 2014","November 30, 2011","April 17, 2018","April 17, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Concord, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Escondido, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fresno, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greenbrae, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Huntington Beach, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Mateo, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aurora, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Idaho Falls, Idaho, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Las Vegas, Nevada, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salt Lake City, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Renton, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Spokane, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Graz, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vienna, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bar Le Duc, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Corbeil-Essonnes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montpellier, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nantes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nice, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Mande, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Venissieux, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Eisenach, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Falkensee, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mainz, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mayen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Münster, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Neuwied, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pohlheim, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cagliari, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Catania, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lecce, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Padova, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Perugia, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ravenna, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hokkaido, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kumamoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guadalajara Jalisco, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guadalajara, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monterrey, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Katowice, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lodz, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poznan, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warsaw, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Arkhangelsk, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT01481779" | |
| 199,"NCT04387422","Recurrent Hypoglycemia in Type 1 Diabetes (Aim 2)",,"Recruiting","No Results Available","Diabetes Mellitus, Type 1","Other: Experimental hyperglycemia","Glucose kinetics during hyperglycemic clamps before and after induction of IAH|Antecedent glycemia concentration|Antecedent physical activity - moderate to vigorous physical activity|Antecedent physical activity - light physical activity|Antecedent physical activity - sedentary time|Antecedent physical activity - energy expenditure|Antecedent physical activity - sleep quality","University of Minnesota","All","18 Years to 65 Years (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","MED-2019-28365","August 12, 2020","December 2028","December 2028","May 13, 2020",,"September 30, 2022","University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04387422" | |
| 200,"NCT01049412","A Study for Patients With Type 1 Diabetes",,"Completed","Has Results","Diabetes Mellitus, Type 1","Drug: LY2605541|Drug: Insulin glargine","Daily Average Blood Glucose (Avg. BG) at Week 8 Endpoint as Measured by the 8-Point Self-Monitored Blood Glucose (SMBG) Profiles|Change From Baseline in Daily Average Blood Glucose (Avg. BG) at Week 8 Endpoint as Measured by the 8-Point Self-Monitored Blood Glucose (SMBG) Profiles|Change From Baseline in Hemoglobin (HbA1c) at Week 8 Endpoint of Period I|Percentage of Participants With HbA1c <7.0% and HbA1c ≤6.5% at Week 8 Endpoint of Period I|Percentage of Participants With HbA1c <7.0% and HbA1c ≤6.5% at Week 8 Endpoint Who Did Not Experience a Hypoglycemic Episode During Treatment (Period I)|8-Point Self-Monitored Blood Glucose (SMBG) Measures at Week 8 Endpoint|Daily Basal Insulin Dose at Week 2 and Week 8 Endpoint|Pharmacokinetics - Drug (LY2605541) Concentration at Steady State (Css) at Week 8 Endpoint|Percentage of Participants With Antibody Status Change From Baseline to Week 8, Week 16 and Week 20|Percentage of Participants With Hypoglycemia Baseline Through Week 8|Rate of Hypoglycemia Per 30 Days Baseline Through Week 8|Glycemic Variability in Fasting Blood Glucose (FBG) at Week 8 Endpoint","Eli Lilly and Company","All","18 Years to 65 Years (Adult, Older Adult)","Phase 2","138","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12151|I2R-MC-BIAD","January 2010","December 2010","January 2011","January 14, 2010","April 17, 2018","April 17, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chula Vista, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Idaho Falls, Idaho, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Topeka, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Metairie, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Minneapolis, Minnesota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Austin, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Renton, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Holon, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Petah Tiqva, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel Hashomer, Israel",,"https://ClinicalTrials.gov/show/NCT01049412" | |
| 201,"NCT00100178","New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical Trial","TN02","Completed","Has Results","Diabetes Mellitus, Type 1","Drug: Mycophenolate mofeteil (MMF)|Drug: Daclizumab (DZB)|Drug: Placebo control for Mycophenolate mofeteil (MMF)|Drug: Placebo control for Daclizumab (DZB)","Mean Stimulated C-peptide Area Under the Curve","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Juvenile Diabetes Research Foundation|National Center for Research Resources (NCRR)","All","8 Years to 45 Years (Child, Adult)","Phase 2","126","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","TN02 MMF/DZB|U01DK061055|UC4DK097835","May 2004","April 2008","April 2008","December 24, 2004","August 16, 2016","May 5, 2020","Childrens Hospital Los Angeles, Los Angeles, California, United States|University of California-San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|Barbara Davis Center for Childhood Diabetes, University of Colorado, Denver, Colorado, United States|University of Florida, Gainesville, Florida, United States|Indiana University, Indianapolis, Indiana, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Columbia University, New York, New York, United States|Benaroya Research Institute, Seattle, Washington, United States|Hospital for Sick Children, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00100178" | |
| 202,"NCT01285934","Hematopoietic Stem Cell Support Versus Insulin in T1D",,"Withdrawn","No Results Available","Diabetes Mellitus, Type 1","Biological: Autologous Hematopoietic Stem Cell Transplantation|Drug: intensive insulin therapy","C-peptide|Insulin dose|Serum levels of hemoglobin A1c|Stimulated C-peptide levels during mixed meal tolerance test","Northwestern University|University of Sao Paulo General Hospital","All","16 Years to 35 Years (Child, Adult)","Phase 1|Phase 2","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Diabetes2008","January 2009","August 2015","August 2015","January 28, 2011",,"August 21, 2015",,,"https://ClinicalTrials.gov/show/NCT01285934" | |
| 203,"NCT00146484","A Study of Two Versus Three Daily Injections in Children and Adolescents With Newly Diagnosed Type 1 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: Twice Daily versus Three Times Daily Insulin Injections","* Hemoglobin A1c over the first 24 months of diabetes|* Frequency of hypoglycemia (mild and severe) over the first 24 months of diabetes|* Frequency of morning hyperglycemia over the first 24 months of diabetes|* Residual c-peptide at two years post diagnosis (stimulated c-peptide post Sustacal challenge)|* Diabetes Quality of Life (DQOLY) over the first 24 months of diabetes|* Family Functioning (Family Environment Scale)over the first 24 months of diabetes","Children's Hospital of Eastern Ontario","All","up to 17 Years (Child)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHEO RI cc9993","April 1996",,"January 2001","September 7, 2005",,"September 7, 2005","Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00146484" | |
| 204,"NCT01483352","Evaluation of Accu-Chek DiaPort, a Port System for Continuous Intraperitoneal Insulin Infusion, in Patients With Type I Diabetes",,"Completed","Has Results","Diabetes Mellitus, Type 1","Device: Accu-Chek DiaPort","Suitability of the Device - Overall Suitability Score|Percentage of Participants With Problems Involving the Tight Connection Between Port and Skin|Percentage of Participants With Dislocation of Port|Percentage of Participants With Signs of Redness/Swelling in the Tissue Around the Port|Percentage of Participants With Signs of Infection in the Tissue Around the Port|Percentage of Participants With Signs of Pain in the Tissue Around the Port|Percentage of Participants With Persistent Dull Pain Due to Catheter|Percentage of Participants With Signs of Infection/Allergic Reaction at the Site of Implant|Percentage of Participants Categorized by Ability of the Port to Deliver Insulin Intraperitonally|Insulin Doses Dispensed From Insulin Pump|Hemoglobin A1c Levels|Self Monitored Blood Glucose Levels|Continuous Glucose Measurement (CGM) - Glucose Levels|Glycemic Variability: Percent Coefficient of Variation in Blood Glucose|Percentage of Participants Achieving Target Glucose Levels|Design Validation Participant Questionnaire - Percentage of Participants With a Positive Response","Hoffmann-La Roche","All","18 Years and older (Adult, Older Adult)","Not Applicable","12","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","RD001211","November 2011","March 2013","March 2013","December 1, 2011","March 3, 2016","April 15, 2016","Bad Heilbrunn, Germany",,"https://ClinicalTrials.gov/show/NCT01483352" | |
| 205,"NCT01397513","Effects of Aspirin Treatment on Fibrin Network Formation in Patients With Type 1 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: Aspirin","Fibrin network permeability|Platelet microparticles","Karolinska Institutet","All","30 Years to 70 Years (Adult, Older Adult)","Phase 4","48","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","151:2005/76316|2005/1403-31/2","March 2006","July 2010","February 2011","July 19, 2011",,"July 19, 2011","Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01397513" | |
| 206,"NCT01120119","Efficacy of Calcitriol in Recent Onset Type 1 Diabetes","IMDIABXIII","Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: Calcitriol","C peptide|Glycometabolic control","Campus Bio-Medico University","All","11 Years to 40 Years (Child, Adult)","Phase 2",,"Other","Interventional",,"CLF-1 2005-000751-15",,,,"May 10, 2010",,"May 10, 2010","University Campus Bio Medico, Rome, Italy|Bambino Gesù Children's Hospital, Rome, Italy|Catholic University,, Rome, Italy|Sandro Pertini Hospital, Rome, Italy|University Sapienza, Rome, Italy",,"https://ClinicalTrials.gov/show/NCT01120119" | |
| 207,"NCT01392560","Safety and Efficacy of Empagliflozin (BI 10773) in Type 1 Diabetes Mellitus Patients With or Without Renal Hyperfiltration",,"Completed","Has Results","Diabetes Mellitus, Type 1","Drug: BI 10773","Change in Glomerular Filtration Rate (GFR) After 8 Weeks of Treatment With Empagliflozin Under Controlled Conditions of Euglycaemia and Hyperglycaemia","Boehringer Ingelheim","All","18 Years and older (Adult, Older Adult)","Phase 2","52","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1245.46","June 2011","August 2012","August 2012","July 12, 2011","June 17, 2014","June 17, 2014","1245.46.10001 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01392560" | |
| 208,"NCT01520428","Interventions to Prevent Adolescents With Type 1 Diabetes From Long-term Complications",,"Unknown status","No Results Available","Diabetes Mellitus, Type 1","Behavioral: Motivational Interviewing, CBT and E-mail support","HbA1C|Predictors of positive effects on glycaemic control|Motivational changes|HbA1c","Medical University of Vienna|National Bank of Austria","All","13 Years to 20 Years (Child, Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","ÖNB13686","June 2010","January 2013","January 2014","January 30, 2012",,"September 27, 2012","Medical University of Vienna, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT01520428" | |
| 209,"NCT05315037","Resistance Training in Type 1 Diabetes Mellitus",,"Not yet recruiting","No Results Available","Type 1 Diabetes","Other: Resistance Training","Assess glucose response to different resistance training methods|To assess for correlation between lactate and glucose using different resistance training methods","University of Louisville|Norton Healthcare","All","13 Years to 17 Years (Child)","Not Applicable","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","21.0565","December 1, 2022","December 1, 2023","June 30, 2024","April 7, 2022",,"August 10, 2022","Norton Healthcare, Louisville, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT05315037" | |
| 210,"NCT02010541","The Influence of Technology, Education and Psychological Support on Metabolic Control in Children With T1D",,"Unknown status","No Results Available","Type 1 Diabetes",,"Glycaemic control|knowledge on diet and diabetes management","University Medical Centre Ljubljana|Slovenian Research Agency (ARRS)","All","up to 7 Years (Child)",,"40","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","TECH-EDU-KIDS-T1D-2013","December 2013","April 2014","May 2014","December 12, 2013",,"February 13, 2014","Dept. of Pediatric Endocrinology, Diabetes & Metabolism, University Children's Hospital, UMCL, Ljubljana, Slovenia",,"https://ClinicalTrials.gov/show/NCT02010541" | |
| 211,"NCT04772729","Does the Use of Fiasp vs. Asp Lead to the Prolonged TIR in Children With Type 1 Diabetes?",,"Not yet recruiting","No Results Available","Diabetes type1|Diabetes Mellitus, Type 1","Drug: Insulin faster aspart (Fiasp, Novo Nordisk)","Glycaemia difference in time in range (TIR) 70-180mg/dl|Glycaemia difference in time below range (TBR)|Glycaemia difference in time above range (TAR)|Glycaemia difference in the coefficient of variation (CV)|Difference in the average glycemia levels + standard deviation|Difference in Total Daily Dose (TDD) of insulin|Difference in the basal rate of insulin","Medical University of Warsaw","All","6 Years to 17 Years (Child)","Phase 4","77","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TIR: Fiasp vs. Asp","March 1, 2021","March 1, 2023","March 1, 2024","February 26, 2021",,"February 26, 2021",,,"https://ClinicalTrials.gov/show/NCT04772729" | |
| 212,"NCT00858897","Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study A",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Other: Cysteine isotope infusion at normoglycemia vs hyperglycemia|Drug: Regular Insulin","Increase in glutathione concentration under normoglycemia","Nemours Children's Clinic|Juvenile Diabetes Research Foundation","All","14 Years to 18 Years (Child, Adult)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","JDRF 1-2006-627-A","June 2007","February 2008","February 2009","March 10, 2009",,"July 15, 2009","Nemours Children's Clinic, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00858897" | |
| 213,"NCT00858273","Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study B",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Dietary Supplement: Antioxidant supplement|Other: Diabetes treatment|Drug: Regular Insulin","Restoration of glutathione homeostasis, measured by glutathione concentration while at near normoglycemia|Decrease in markers of oxidative stress (plasma protein bound 3-nitrotyrosine, urinary 8OH-2'-deoxyguanosine, urinary F2-isoprostane)","Nemours Children's Clinic|Juvenile Diabetes Research Foundation","All","12 Years to 21 Years (Child, Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","JDRF 1-2006-627-B","March 2008","March 2011","August 2011","March 9, 2009",,"May 4, 2012","Nemours Children's Clinic, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00858273" | |
| 214,"NCT04190693","IMCY-T1D-002: Long-term Follow-up Study of T1D Patients Previously Treated With IMCY-0098 or Placebo","IMCY-T1D-002","Completed","Has Results","Type 1 Diabetes Mellitus","Drug: IMCY-0098 or placebo","Adverse Events|Serious Adverse Events","Imcyse SA","All","18 Years to 31 Years (Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","2018-003728-35","February 14, 2019","October 8, 2019","November 18, 2019","December 9, 2019","January 21, 2022","May 2, 2022","Hôpital Erasme, Brussels, Belgium|UZ Brussel, Brussels, Belgium|UZ Gent, Gent, Belgium|Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark|Hôpital Cochin, Paris, France|GWT-TUD GmbH, Dresden, Germany|Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), München, Germany|Hospital of Lithuanian University of Health Sciences Kauno klinikos, Kaunas, Lithuania|Klaipeda University Hospital, Klaipėda, Lithuania|University Hospital Santaros Klinikos, Vilnius, Lithuania|Clinical Trial Center, CTC, Göteborg, Sweden|ProbarE Stockholm, Stockholm, Sweden|Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom|Cardiff University, Cardiff, United Kingdom|Royal Devon and Exeter NHS Trust, Exeter, United Kingdom|Guy's and St. Thomas NHS Trust, London, United Kingdom|St. Bartholomew's Hospital (Barts Health NHS Trust), London, United Kingdom|Newcastle University, Newcastle upon Tyne, United Kingdom|Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT04190693/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04190693" | |
| 215,"NCT00873925","Cord Blood Plus Vitamin D and Omega 3s in T1D",,"Completed","No Results Available","Type 1 Diabetes","Biological: Autologous UCB|Dietary Supplement: Omega 3 FA|Dietary Supplement: Vitamin D","C-Peptide following the 1 year mixed meal tolerance test|DHA Level|Vitamin D Level|HbA1c and Insulin Dose|Peripheral Blood T-cell assays","University of Florida|Juvenile Diabetes Research Foundation|National Institutes of Health (NIH)","All","1 Year to 18 Years (Child, Adult)","Phase 1","15","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UF IRB 696-2008","March 2009","March 2012","October 2012","April 2, 2009",,"April 4, 2013","University of Florida, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00873925" | |
| 216,"NCT03410277","Recurrent Hypoglycemia in Type 1 Diabetes (Aim 1)",,"Recruiting","No Results Available","Diabetes Mellitus, Type 1","Other: Experimental hypoglycemia","Neurochemical response to HG before and after induction of IAH|Antecedent glycemia concentration|Antecedent physical activity","University of Minnesota","All","18 Years to 65 Years (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","MED-2017-26317","May 24, 2018","December 2023","December 2023","January 25, 2018",,"September 21, 2022","University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03410277" | |
| 217,"NCT01148680","Trial Comparing Metabolic Efficiency of Islet Graft to Intensive Insulin Therapy for Type 1 Diabetes's Treatment","TRIMECO","Completed","No Results Available","Diabetes Mellitus, Type 1","Biological: Islet Graft","ß score evaluation 6 months after first infusion (group 1 'immediate registration on infusion waiting list') or 6 months after inclusion (group 2: 'delayed registration on infusion waiting list')|Evaluation of metabolism indicators : ß-score and individual analysis of the 4 components of the ß-score|Measure of quality of life (SF36, DQOL, DHP)|Cost evaluation of islet cell infusion|Evaluation of side effects and iatrogenic effects","University Hospital, Grenoble","All","18 Years to 64 Years (Adult)","Phase 3","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DCIC 08 31","June 2010","August 2018","September 2018","June 22, 2010",,"January 27, 2020","University Hospital, Department of Endocrinology, Strasbourg, Alsace, France|University Hospital Gabriel Montpied, Department of Endocrinology, Clermont Ferrand, Auvergne, France|University Hospital Besançon, Department of Endocrinology, Besançon, Franche-Comté, France|University Hospital, Department of Endocrinology, Montpellier, Languedoc-Roussillon, France|University Hospital, Department of Endocrinology, Nancy, Lorraine, France|University Hospital, Department of General Surgery and Endocrinology, Lille, Nord Pas De Calais, France|University Hospital, Department of Endocrinology, Grenoble, Rhône-Alpes, France|HCL Sud, Department of Endocrinology, Lyon, Rhône-Alpes, France|Hopitaux Universitaires de Genève, Department of Visceral Surgery and Transplant, Geneve, Switzerland",,"https://ClinicalTrials.gov/show/NCT01148680" | |
| 218,"NCT01194882","Benefit/Risk Evaluation of Insuman Implantable Versus Insuplant Using Medtronic MiniMed Implantable Pump System in Patients With Type 1 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: HUMAN INSULIN (BIOSYNTHETIC)|Drug: Insuplant","Refill accuracy between the 2 insulin groups|Change in glycosylated hemoglobin (HbA1c)|Occurrence of Hypoglycaemia (asymptomatic and symptomatic hypoglycaemia, severe and serious symptomatic hypoglycaemia|Occurrence of hyperglycaemia|Occurrence of diabetic ketoacidosis|Change in insulin dose|Antibody assessments (anti-Insulin antibodies)","Sanofi","All","18 Years and older (Adult, Older Adult)","Phase 3","479","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","HUBIN_L_05335|2010-021373-37|U1111-1116-7658","November 16, 2010","February 1, 2018","February 1, 2018","September 3, 2010",,"February 15, 2018","Investigational Site Number 056-001, Leuven, Belgium|Investigational Site Number 250-004, Corbeil Essonnes, France|Investigational Site Number 250-008, Dijon, France|Investigational Site Number 250-003, Dommartin Les Toul, France|Investigational Site Number 250-012, Le Mans Cedex 9, France|Investigational Site Number 250-009, LILLE Cedex, France|Investigational Site Number 250-007, Marseille, France|Investigational Site Number 250-001, MONTPELLIER Cedex 5, France|Investigational Site Number 250-005, Paris, France|Investigational Site Number 250-010, Pessac Cedex, France|Investigational Site Number 250-011, ST PRIEST EN JAREZ Cedex, France|Investigational Site Number 250-002, Strasbourg, France|Investigational Site Number 250-006, TOULOUSE Cedex 9, France|Investigational Site Number 528003, Den Haag, Netherlands|Investigational Site Number 528002, Roermond, Netherlands|Investigational Site Number 528001, Zwolle, Netherlands|Investigational Site Number 752-001, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01194882" | |
| 219,"NCT00943787","Counter-Regulatory Impairment and the Effect of Microvascular Insulin Transfer in Type 1 Diabetes Mellitus","BPK003","Completed","Has Results","Diabetes Mellitus, Type 1","Procedure: Hyperinsulinemic, euglycemic and hypoglycemic clamp","Maximum Epinephrine Response (LBGI Groups)|Maximum Epinephrine Response (ADRR Groups)","University of Virginia","All","18 Years and older (Adult, Older Adult)","Not Applicable","41","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)","12252","January 2006","May 2009","May 2009","July 22, 2009","September 8, 2014","September 8, 2014","University of Virginia Health System - Behavioral Medicine Center, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00943787" | |
| 220,"NCT03506022","Prevalence of Sleep Apnea Syndrome in Patients With Type 1 Diabetes","APT1","Completed","No Results Available","Diabetes Mellitus, Type 1","Other: standard polysomnography","Prevalence of obstructive sleep apnea syndrome confirmed by polysomnography an apnea hypopnea Index ≥ 15","Centre Hospitalier Universitaire, Amiens","All","18 Years and older (Adult, Older Adult)","Not Applicable","53","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","PI2017_843_0019","January 12, 2018","April 11, 2019","April 11, 2019","April 23, 2018",,"July 20, 2020","Chu Amiens Picardie, Amiens, Picardie, France",,"https://ClinicalTrials.gov/show/NCT03506022" | |
| 221,"NCT05560568","Effects of Optimizing Nocturnal Glycemic Control on Sleep Parameters in Type 1 Diabetes","DIABNIGHT","Recruiting","No Results Available","Type 1 Diabetes","Other: Sleep parameters data collection","Sleep efficiency","Hospices Civils de Lyon","All","18 Years to 50 Years (Adult)",,"20","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","69HCL22_0533","November 25, 2022","December 25, 2023","December 25, 2023","September 29, 2022",,"November 18, 2022","Centre du diabète Diab-eCare, Lyon, France",,"https://ClinicalTrials.gov/show/NCT05560568" | |
| 222,"NCT00824148","Use of Real-time Continuous Glucose Monitoring System in Patients With Type 1 Diabetes Mellitus",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Device: Guardian REAL-Time Continuous Glucose Monitoring System|Other: Conventional self-monitoring of plasma glucose","Level of HbA1c concentration|Quality of life assessed by SF-36, DTSQs and DTSQc|Number of hypoglycemic events","Norwegian University of Science and Technology|Norwegian Diabetes Association","All","18 Years to 50 Years (Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","4.2008.1607|19637","January 2009","September 2009","September 2009","January 16, 2009",,"February 27, 2017","Department of Endocrinology, St. Olavs Hospital, Trondheim, Norway",,"https://ClinicalTrials.gov/show/NCT00824148" | |
| 223,"NCT00397553","Insulin Glulisine, Diabetes Mellitus Type 1",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: Insulin glulisine","HbA1c|Fasting Blood Glucose|Post-prandial glycemia (2 hour after breakfast)","Sanofi","All","18 Years and older (Adult, Older Adult)","Phase 3","104","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HMR1964A_3517","January 2005","December 2007",,"November 9, 2006",,"September 18, 2009","Sanofi-Aventis, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00397553" | |
| 224,"NCT04432090","Study of the Pharmacologic Action of a GPR119 Agonist on Glucagon Counter-regulation During Insulin-induced Hypoglycemia in Type 1 Diabetes Mellitus","PHROG","Recruiting","No Results Available","Diabetes Mellitus, Type 1","Drug: Placebo|Drug: Study Medication (MBX-2982)|Other: No medication for this group","Maximal glucagon concentration during hypoglycemia|Total area under the curve (AUC) for glucagon during hypoglycemia.|Incremental AUC for glucagon during hypoglycemia (above baseline levels during euglycemia)","AdventHealth Translational Research Institute","All","20 Years and older (Adult, Older Adult)","Phase 2","29","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","1552172","April 21, 2021","June 2023","June 2023","June 16, 2020",,"November 17, 2022","AdventHealth Translational Research Institute, Orlando, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04432090" | |
| 225,"NCT00964574","Test of the Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus","PORTAL 1","Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: INSULIN GLULISINE (HMR1964)|Drug: INSULIN GLARGINE","Mean change in Glycosylated haemoglobin (HbA1c)|Mean Glycosylated haemoglobin (HbA1c)|Mean Fasting Blood Glucose and mean Post Prandial Glycemia|Number of documented symptomatic hypoglycaemic episodes|Mean dose and mean dose change of insulin glulisine, basal glulisine and total insulin from baseline|Mean change of Fasting Blood Glucose and Post Prandial Glycemia","Sanofi","All","18 Years and older (Adult, Older Adult)","Phase 4","68","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APIDR_L_02483","July 2009","July 2010","July 2010","August 25, 2009",,"July 17, 2012","Sanofi-Aventis Administrative Office, Minsk, Belarus",,"https://ClinicalTrials.gov/show/NCT00964574" | |
| 226,"NCT04074317","Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D",,"Completed","No Results Available","Diabetes Mellitus, Type 1|Insulin-dependent Diabetes Mellitus","Drug: PRAM9|Drug: Regular Insulin + Pramlintide|Drug: Regular Insulin","Area under the curve 0-180 minutes|Glucose time above 180 mg/dL|Glucose time in range|Plasma glucose maximum concentration (Cmax)|Plasma glucose time to maximum concentration (Tmax)","Xeris Pharmaceuticals","All","18 Years to 64 Years (Adult)","Phase 2","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DPI-201","August 22, 2019","April 2, 2020","April 2, 2020","August 30, 2019",,"May 28, 2020","World Wide Clinical Trials, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04074317" | |
| 227,"NCT00595569","Flexible, Intensive Insulin Therapy in Patients With Type 1 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Behavioral: Flexible insulin therapy (FIT)","Metabolic control (HbA1c, severe hypoglycemic events), psychological effects, diabetes knowledge|Changes in insulin doses, changes in weight","University of Lausanne Hospitals|Diabetes Association Basel|University Hospital, Basel, Switzerland","All","18 Years and older (Adult, Older Adult)",,"45","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","120/04","April 2002","December 2007","December 2007","January 16, 2008",,"January 16, 2008","University of Basel Hospital, Basel, Switzerland",,"https://ClinicalTrials.gov/show/NCT00595569" | |
| 228,"NCT00272090","Insulin Glargine in Type 1 Diabetes Mellitus",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: Insulin glargine","severe nocturnal hypoglycemias will be measured throughout the study period.|HbA1c will be measured at basal and 8/16 weeks after start of treatment|8 point glucose profile will be measured during last 2 weeks before each scheduled visit|severe hypoglycemias and nocturnal hypoglycemias will be measured throughout the study period.","Sanofi","All","18 Years to 60 Years (Adult)","Phase 3","489","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HOE901_3507","November 2002","December 2005","December 2005","January 4, 2006",,"June 8, 2011",,,"https://ClinicalTrials.gov/show/NCT00272090" | |
| 229,"NCT00434850","Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Biological: Allogeneic Pancreatic Islet Cells|Drug: Deoxyspergualin|Biological: Antithymocyte globulin|Biological: Daclizumab or basiliximab|Drug: Sirolimus|Drug: Tacrolimus|Biological: Etanercept","Proportion of Insulin-independent Subjects|Percent Reduction in Insulin Requirements|Hemoglobin A1c (HbA1c)|Mean Amplitude of Glycemic Excursions (MAGE)|Glycemic Lability Index (LI)|Ryan Hypoglycemia Severity Score (HYPO)|Basal (fasting) and 90-minute Glucose and C-peptide Results|Beta-score|C-peptide: Glucose Creatinine Ratio|Acute Insulin Response to Glucose, Insulin Sensitivity, and Disposition Index|Glucose Variability and Hypoglycemia Duration|Quality of Life (QOL) Measure|Incidence of Worsening Retinopathy|Clarke Score|HYPO Score|Basal (fasting) and 90-minute Glucose and C-peptide|Quality of life (QOL) Measure|Proportion of Subjects Receiving a Second Islet Cell Transplant|Proportion of Subjects Receiving a Third Islet Cell Transplant|Incidence and Severity of Adverse Events Related to the Islet Cell Transplant Procedure|Incidence and Severity of Adverse Events Related to the Immunosuppression Therapy|Incidence of a Change in the Immunosuppression Drug Regimen|Incidence of Immune Sensitization|Acute Insulin Response to Glucose, Insulin Sensitivity, and Disposition Index (DI)","National Institute of Allergy and Infectious Diseases (NIAID)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 65 Years (Adult, Older Adult)","Phase 2","14","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DAIT CIT-03","October 2006","September 2011","November 2013","February 13, 2007",,"March 16, 2016","University of Californinia, San Francisco, San Francisco, California, United States|Northwestern University, Chicago, Illinois, United States|University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00434850" | |
| 230,"NCT03882463","Interest of SmartGuard Technology (Predictive System for Stopping Insulin Before Hypoglycemia) in Children With Type 1 Diabetes Treated With Insulin Pump",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Device: Continuous glucose monitoring with the stop insulin pump function","Time spent hypoglycemia|Number of hypoglycemia","CHU de Reims","All","1 Year to 17 Years (Child)","Not Applicable","34","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PO19026*","April 30, 2019","April 18, 2021","December 31, 2021","March 20, 2019",,"May 23, 2022","Chu Reims, Reims, France",,"https://ClinicalTrials.gov/show/NCT03882463" | |
| 231,"NCT00883558","Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus",,"Completed","Has Results","Diabetes Mellitus, Type 1","Drug: Insulin Lispro|Drug: regular human insulin|Drug: recombinant human hyaluronidase PH20|Drug: Insulin glargine","Postprandial Glucose Excursion|Time Spent With Blood Glucose Value Outside a 71-139 Milligrams Per Deciliter (mg/dL) Range During Continuous Glucose Monitoring|Number of Participants With Hypoglycemic Events","Halozyme Therapeutics","All","18 Years to 65 Years (Adult, Older Adult)","Phase 2","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","HALO-117-203","May 2009","February 2010","April 2010","April 17, 2009","September 8, 2014","September 8, 2014","Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|Diabetes Research Institute, Miami, Florida, United States|Henry Ford Health System, Detroit, Michigan, United States|Mercury Street Medical, Butte, Montana, United States|UNC Diabetes Care Center/Highgate Specialty Center, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Texas Diabetes and Endocrinology, Austin, Texas, United States|West Olympia Internal Medicine, Olympia, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00883558" | |
| 232,"NCT01530178","Sitagliptin Dose Determination Study",,"Completed","Has Results","Diabetes Mellitus, Type 1","Drug: Sitagliptin|Drug: Placebo Oral Tablet","Better Targeted Blood Glucose Levels","Albert Einstein College of Medicine","All","13 Years to 30 Years (Child, Adult)","Phase 4","8","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2011-246","November 2011","March 2015","March 2015","February 9, 2012","July 16, 2018","July 16, 2018","Albert Einstein College of Medicine CRC, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT01530178" | |
| 233,"NCT05411952","Family-Based Behavioral Medical Nutrition Therapy Education in Children and Adolescents With Type 1 Diabetes",,"Completed","No Results Available","Type1diabetes","Other: Medical nutrition therapy and carbohydrate counting education|Other: No intervention","Change in mean of HbA1c from baseline to 6 months|Change in mean of Healthy Eating Index 2015 (HEI-2015) score from baseline to 6 Months|Change in mean of Mediterranean Diet Quality Index Scale (KIDMED) from baseline to 6 Months","Hasan Kalyoncu University","All","8 Years to 18 Years (Child, Adult)","Not Applicable","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hasan-Kalyoncu-UnivHulyaYilmaz","August 13, 2020","January 28, 2021","September 15, 2021","June 9, 2022",,"June 9, 2022","Gaziantep Cengiz Gokcek Gynecology and Pediatrics Hospital, Gaziantep, Turkey",,"https://ClinicalTrials.gov/show/NCT05411952" | |
| 234,"NCT00447213","A Study for Patients With Type 1 Diabetes Mellitus",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: Insulin glargine|Drug: Human Insulin Inhalation Powder|Drug: Injectable Insulin","Change in HbA1c from baseline|Proportion of patients who achieve an HbA1c < 7% and <= 6.5%|Insulin (regular human insulin, insulin lispro, human insulin inhalation powder or insulin glargine)doses|8-point self monitoring blood glucose profiles|Two hour glucose excursions for the morning, midday, and evening meals|Inhaler reliability|Patient-reported treatment satisfaction and insulin delivery satisfaction|Preference for the study therapies","Eli Lilly and Company|Alkermes, Inc.","All","20 Years and older (Adult, Older Adult)","Phase 2|Phase 3","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10299|H7U-JE-IDBB","April 2007","May 2008","May 2008","March 14, 2007",,"October 13, 2010","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Changhua, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tao-Yuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT00447213" | |
| 235,"NCT00487240","Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes","IOOZ","Completed","Has Results","Diabetes Mellitus, Type 1","Drug: Insulin Lispro Protamine Suspension|Drug: Insulin Levemir","Change in Hemoglobin A1c (HbA1c) From Baseline to Endpoint|Actual and Change From Baseline Hemoglobin A1c (HbA1c) Values|Percentage of Patients With Hemoglobin A1c (HbA1c) Less Than or Equal to 7.0% and HbA1c Less Than or Equal to 6.5%|7-Point Self-Monitored Blood Glucose (SMBG) at Endpoint|Glycemic Variability at Endpoint|Number of Self-Reported Hypoglycemic Episodes (Including Nocturnal, Non-Nocturnal, and Severe Hypoglycemia) Overall and at Endpoint|1-Year Adjusted Rates of Self-Reported Hypoglycemic Episodes (Including Nocturnal, Non-Nocturnal, and Severe) Overall and at Endpoint|30-Day Adjusted Rates of Self-Reported Hypoglycemic Episodes (Including Nocturnal, Non-Nocturnal, and Severe) Overall and at Endpoint|Change From Baseline in Absolute Body Weight at 32 Week Endpoint|Insulin Dose Per Body Weight (Total and By Component [Basal and Bolus])|Insulin Dose (Total and By Component [Basal and Bolus])","Eli Lilly and Company","All","18 Years and older (Adult, Older Adult)","Phase 3","387","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10937|F3Z-MC-IOOZ","June 2007","August 2008","August 2008","June 18, 2007","September 25, 2009","November 4, 2010","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Idaho Falls, Idaho, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Springfield, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Topeka, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Plata, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wollongong, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Box Hill, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fortaleza, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., São Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Thessaloniki, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Budapest, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mosonmagyarovar, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pecs, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Szentes, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zalaegerszeg, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guadalajara, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pachuca, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Puebla, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baia Mare, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brasov, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bucharest, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Iasi, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Arkhangelsk, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rostov-On-Don, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00487240" | |
| 236,"NCT03838900","The Loop Observational Study","LOS","Completed","No Results Available","Diabetes Mellitus, Type 1","Device: Loop","Measure of Loop Safety by Self-Report of Diabetic Ketoacidosis (DKA) Events|Measure of Loop Safety by Self-Report of Severe Hypoglycemic Events|Measure of Loop Safety by Self-Report of Hospitalization Events","Jaeb Center for Health Research|Stanford University|Tidepool Project|RileyLink","All","Child, Adult, Older Adult",,"1212","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","LOOP","January 17, 2019","March 31, 2020","April 25, 2020","February 12, 2019",,"August 14, 2020","Jaeb Center for Health Research, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03838900" | |
| 237,"NCT02641522","Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes",,"Completed","Has Results","Type 1 Diabetes","Drug: Siltuximab","Percent Change From Baseline in IL-6 Stimulated Intracellular p-STAT3 at Week 12","Carla Greenbaum, MD|Janssen Research & Development, LLC|Benaroya Research Institute","All","18 Years to 45 Years (Adult)","Early Phase 1","10","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","EMU-002","March 8, 2016","March 16, 2017","March 16, 2017","December 29, 2015","October 9, 2018","November 2, 2018","Benaroya Research Institute, Seattle, Washington, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT02641522/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02641522" | |
| 238,"NCT04022993","Efficacy and Safety of Insulin RinGlar® Compared to Lantus® SoloStar® in Type 1 Diabetes Mellitus Patients",,"Completed","No Results Available","Diabetes Mellitus, Type 1|Diabetes Mellitus","Drug: Lantus Solostar, 100 Units/mL Subcutaneous Solution|Drug: Insulin RinGlar, 100 Units/mL Subcutaneous Solution","Antibody Response|Adverse Events frequency and degree|Glycated hemoglobin|Fasting Plasma Glucose Level|Seven-Point Glucose Testing|Basal Insulin Dose|Total Insulin Dose|Body Mass Index|Treatment Satisfaction|Achievement of Glycated Hemoglobin Goals|Achievement of Glycated Hemoglobin < 7%","Geropharm","All","18 Years to 65 Years (Adult, Older Adult)","Phase 3","180","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GLARGIN-IM","July 4, 2018","February 25, 2019","May 15, 2019","July 17, 2019",,"July 17, 2019","Arkhangelsk Regional Clinical Hospital, Arkhangel'sk, Russian Federation|Kazan Endocrinology Dispensary, Kazan, Russian Federation|Krasnoyarsk State Medical University named after Professor V.F. Voino-Yasenetsky, Krasnoyarsk, Russian Federation|Endocrinology Research Centre (Moscow), Moscow, Russian Federation|V.A. Baranov Republic Hospital, Petrozavodsk, Russian Federation|Rostov State Medical University, Rostov-on-Don, Russian Federation|Polyclinic Сomplex, Saint Petersburg, Russian Federation|City Diagnostic Center № 1, Saint Petersburg, Russian Federation|City Hospital № 2, Saint Petersburg, Russian Federation|City Polyclinic № 117, Saint Petersburg, Russian Federation|EosMed, Saint Petersburg, Russian Federation|Almazov National Medical Research Centre, Saint Petersburg, Russian Federation|Pokrovskaya Municipal Hospital, Saint Petersburg, Russian Federation|Clinical City Hospital № 9, Saratov, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04022993" | |
| 239,"NCT03057470","Optimal Insulin Correction Factor in Post- High Intensity Exercise Hyperglycemia in Adults With Type 1 Diabetes (FIT)","FIT","Unknown status","No Results Available","Diabetes Mellitus, Type 1","Drug: 50% bolus insulin correction|Drug: 100% bolus insulin correction|Drug: 150% bolus insulin correction|Other: 0% bolus insulin correction","Reduction In Plasma Glucose (YSI)|Investigate Glycemic Response of a 0%, 50%, 100% and 150% Bolus Insulin Correction of Post-exercise Hyperglycemia Compared to no Bolus Insulin Correction","LMC Diabetes & Endocrinology Ltd.|Sanofi","All","18 Years to 55 Years (Adult)","Phase 4","18","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FIT","May 2016","March 2017","March 2017","February 20, 2017",,"February 20, 2017","LMC Bayview, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03057470" | |
| 240,"NCT00315588","Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation",,"Completed","Has Results","Diabetes Mellitus, Type 1","Drug: Islet Transplantation","Insulin Independence.|Stimulated C-peptide Greater Than 0.5 ng/ml|Reduction of Insulin Requirements|Reduction in Severe Hypoglycemia, Improvement in Hypoglycemia Awareness","Rodolfo Alejandro|National Institutes of Health (NIH)|Health Resources and Services Administration (HRSA)|Diabetes Research Institute Foundation|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Miami","All","18 Years to 60 Years (Adult)","Phase 2","7","Other|NIH|U.S. Fed","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2000/0329|5R01DK055347|5R01DK025802","December 2000","May 2014","May 2014","April 18, 2006","April 12, 2017","April 12, 2017","Diabetes Research Institute, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00315588" | |
| 241,"NCT00356109","Evaluate the Efficacy of Insulin Patients With Type 1 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: Human Insulin Inhalation Powder|Drug: Injectable insulin|Drug: Insulin Glargine","To test that preprandial AIR Insulin is non-inferior to preprandial injectable insulin (insulin lispro) with respect to mean change in HbA1c from baseline to endpoint.|Insulin dose requirements|Insulin antibody binding levels|To compare HbAlc change|To assess rate and incidence of hypoglycemia","Eli Lilly and Company|Alkermes, Inc.","All","18 Years and older (Adult, Older Adult)","Phase 3","494","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9627|H7U-MC-IDAV","August 2006","May 2008","May 2008","July 25, 2006",,"March 9, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aurora, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Idaho Falls, Idaho, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Springfield, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Grand Rapids, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., El Paso, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ogden, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aalst, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brussels, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edegem, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gent, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leuven, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Angers, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poitiers, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tours, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aschaffenburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Münster, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bangalore, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chennai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cochin, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mumbai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Delhi, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Perugia, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guadalajara, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toa Baja, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00356109" | |
| 242,"NCT00315939","Improving Control and Reducing the Risk of Hypoglycemic Episodes in Type 1 Diabetes","BPK002","Completed","Has Results","Diabetes Mellitus, Type 1","Device: Integrated Biobehavioral Monitoring & Feedback - 1 (IBMF-1)|Device: Integrated Biobehavioral Monitoring & Feedback - 2 (IBMF-2)","Hemoglobin A1c|Frequency of Severe Hypoglycemia","Boris Kovatchev, PhD|University of Virginia","All","18 Years and older (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","12126","January 2006","December 2009","December 2009","April 19, 2006","September 9, 2014","September 18, 2014","University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00315939" | |
| 243,"NCT00004984","The Diabetes Prevention Trial of Type 1 Diabetes (DPT-1)","DPT-1","Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: Parenteral Insulin|Other: Close Observation|Drug: Oral Insulin|Drug: Placebo","Rate of Type 1 Diabetes Per Year","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Center for Research Resources (NCRR)|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute on Minority Health and Health Disparities (NIMHD)|Office of Research on Women's Health (ORWH)","All","3 Years to 45 Years (Child, Adult)","Phase 3","711","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","DPT-1|U01DK060782|U01DK060916|U01DK060987|U01DK061010|U01DK061029|U01DK061030|U01DK061034|U01DK061035|U01DK061036|U01DK061037|U01DK061038|U01DK061040|U01DK061041|U01DK061042|U01DK061058|U01DK061055","February 1994","June 2003","June 2003","March 14, 2000",,"April 24, 2020","Childrens Hospital of Los Angeles, Division of Endocrinology, Los Angeles, California, United States|University of California-San Francisco, Milberry Union East RM 405, 500 Parnassus Ave Box 0136, San Francisco, California, United States|Stanford University, Stanford, California, United States|University of Colorado Barbara Davis Center for Childhood Diabetes, Denver, Colorado, United States|University of Florida Diabetes Research Center, Gainesville, Florida, United States|DPT-1 Operations Coordinating Center, Miami, Florida, United States|University of Miami School of Medicine, Jackson Medical Tower, Miami, Florida, United States|Indiana University, James Whitcomb Riley Hospital for Children, 702 Barnhill Dr, Ste 5960, Indianapolis, Indiana, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Naomi Berrie Diabetes Center, Columbia University, 1150 St. Nicholas Ave, New York, New York, United States|Children's Hospital of Pittsburgh, Dept/Pediatric Endocrinology, 3705 5th Ave, Pittsburgh, Pennsylvania, United States|University of Texas, Children's Medical Center, 6300 Harry Hines Ste 1200, Dallas, Texas, United States|Virginia Mason Research Center, 1201 Ninth Avenue, Seattle, Washington, United States|Hospital for Sick Children, Division of Endocrinology, 555 University Ave, Rm 5110, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00004984" | |
| 244,"NCT00424437","Six Month Clinical Trial Assessing Efficacy And Safety Of Inhaled Insulin In Type 1 Diabetes Mellitus.",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: Inhaled human insulin","Primary outcome is 24 week change in baseline in HbA1c|The secondary endpoints include the following efficacy assessments:|Incidence of hypoglycemia|Proportion of subjects with acceptable glycemic control (e.g., HbA1c<8%)|Change from baseline in fasting lipid profile|Change from baseline in fasting plasma glucose level|Change from baseline in meal glucose response (2-hour postprandial increment in plasma glucose)|Dose of insulin (total dose of injected sustained-duration insulin, and total dose of inhaled or injected Regular insulin during the study).|Change from baseline in body weight|Change from baseline in 24-hour home glucose profile (based on the area under the glucose profile curve calculated by the trapezoid rule with special weights assigned to the pre-breakfast and bedtime assessments).|Patient satisfaction and preference.","Pfizer","All","12 Years to 65 Years (Child, Adult, Older Adult)","Phase 3","320","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","217-106","September 1999",,"September 2000","January 19, 2007",,"February 13, 2007","Pfizer Investigational Site, Burlingame, California, United States|Pfizer Investigational Site, Irvine, California, United States|Pfizer Investigational Site, Newport Beach, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, San Francisco, California, United States|Pfizer Investigational Site, Tustin, California, United States|Pfizer Investigational Site, Hartford, Connecticut, United States|Pfizer Investigational Site, Washington, District of Columbia, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Stockbridge, Georgia, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Lexington, Kentucky, United States|Pfizer Investigational Site, Columbia, Missouri, United States|Pfizer Investigational Site, St Louis, Missouri, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, Omaha, Nebraska, United States|Pfizer Investigational Site, Albuquerque, New Mexico, United States|Pfizer Investigational Site, Buffalo, New York, United States|Pfizer Investigational Site, Manhasset, New York, United States|Pfizer Investigational Site, New Hyde Park, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Greenville, North Carolina, United States|Pfizer Investigational Site, Cleveland, Ohio, United States|Pfizer Investigational Site, Portland, Oregon, United States|Pfizer Investigational Site, Austin, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Irving, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, Charlottesville, Virginia, United States|Pfizer Investigational Site, Renton, Washington, United States|Pfizer Investigational Site, Calgary, Alberta, Canada|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, St John's, Newfoundland and Labrador, Canada|Pfizer Investigational Site, Halifax, Nova Scotia, Canada|Pfizer Investigational Site, London, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Laval, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00424437" | |
| 245,"NCT00424333","Six Month Clinical Trial Assessing Efficacy and Safety of Inhaled Insulin in Type 1 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: Inhaled human insulin","Primary outcome is 24 week change in baseline in HbA1c.|The secondary endpoints include the following efficacy assessments:|Incidence of hypoglycemia|Proportion of subjects with acceptable glycemic control (e.g., HbA1c<8%)|Change from baseline in fasting lipid profile|Change from baseline in fasting plasma glucose level|Change from baseline in meal glucose response (2-hour postprandial increment in plasma glucose)|Dose of insulin (total dose of injected sustained-duration insulin, and total dose of inhaled or injected Regular insulin during the study).|Change from baseline in body weight|Change from baseline in 24-hour home glucose profile (based on the area under the glucose profile curve calculated by the trapezoid rule with special weights assigned to the pre-breakfast and bedtime assessments).|Patient satisfaction and preference.","Pfizer","All","12 Years to 65 Years (Child, Adult, Older Adult)","Phase 3","320","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","217-107","May 1999",,"October 2000","January 19, 2007",,"February 13, 2007","Pfizer Investigational Site, Duarte, California, United States|Pfizer Investigational Site, Long Beach, California, United States|Pfizer Investigational Site, Los Angeles, California, United States|Pfizer Investigational Site, Stanford, California, United States|Pfizer Investigational Site, Denver, Colorado, United States|Pfizer Investigational Site, New Haven, Connecticut, United States|Pfizer Investigational Site, Gainesville, Florida, United States|Pfizer Investigational Site, Hollywood, Florida, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Tallahassee, Florida, United States|Pfizer Investigational Site, Peoria, Illinois, United States|Pfizer Investigational Site, Skokie, Illinois, United States|Pfizer Investigational Site, Lutherville, Maryland, United States|Pfizer Investigational Site, Waltham, Massachusetts, United States|Pfizer Investigational Site, Minneapolis, Minnesota, United States|Pfizer Investigational Site, Columbia, Missouri, United States|Pfizer Investigational Site, Bronx, New York, United States|Pfizer Investigational Site, New Hyde Park, New York, United States|Pfizer Investigational Site, Rochester, New York, United States|Pfizer Investigational Site, Syracuse, New York, United States|Pfizer Investigational Site, Durham, North Carolina, United States|Pfizer Investigational Site, Winston-salem, North Carolina, United States|Pfizer Investigational Site, Portland, Oregon, United States|Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Burlington, Vermont, United States|Pfizer Investigational Site, Charlottesville, Virginia, United States|Pfizer Investigational Site, Charlottsville, Virginia, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Edmonton, Alberta, Canada|Pfizer Investigational Site, Hamilton, Ontario, Canada|Pfizer Investigational Site, Mississauga, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00424333" | |
| 246,"NCT00297401","Renal and Peripheral Hemodynamic Function in Patients With Type 1 Diabetes Mellitus",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: ruboxistaurin|Drug: placebo","Primary outcomes will be the change in proteinuria, pre- and post-treatment with ruboxistaurin.|Change in the renal and peripheral pressor response to hyperglycemia pre and post treatment with ruboxistaurin|Change in the renal and peripheral pressor response to Angiotensin II pre and post-treatment with ruboxistaurin.|Secondary analyses will consist of the change in endothelial function and vascular compliance pre- and post-treatment with ruboxistaurin.","Chromaderm, Inc.|Heart and Stroke Foundation of Canada","All","18 Years and older (Adult, Older Adult)","Phase 3","20","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","8023|B7A-CA-S003","March 2006","November 2007","November 2007","February 28, 2006",,"August 29, 2016","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physcian., Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00297401" | |
| 247,"NCT00284232","Metabolic Effects of Accurate Blood Sugar Results and Education in Type 1 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Behavioral: Use and interpretation of blood glucose results|Drug: Insulin dosing based on SMBG chart and education","HbA1c %|Hypoclycemic events|Measurement quality of blood glucose instrument|Frequency of SMBG|Satisfaction|New learning points for patients|Confidence in new instrument quality","Helse Stavanger HF","All","18 Years to 70 Years (Adult, Older Adult)","Phase 4","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","Measure 2004","October 2004","August 2006","December 2006","January 31, 2006",,"July 28, 2015","Stavanger University Hospital, Stavanger, Norway",,"https://ClinicalTrials.gov/show/NCT00284232" | |
| 248,"NCT03022058","Evaluation of the EarEEG System for Detection of Hypoglycaemia-induced Changes in the EEG in Subjects With Type 1 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Device: Ear-EEG system","Presence of significant qEEG hypoglycaemia indicators when comparing normo- and hypoglycaemic EEG as measured by the EarEEG systems for subjects where hypoglycaemia-induced changes have been observed in the scalp EEG (visit 4)","Odense University Hospital|University of Aarhus|T&W Engineering A/S|UNEEG Medical A/S","All","18 Years to 70 Years (Adult, Older Adult)","Not Applicable","12","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","56205","June 22, 2017","November 16, 2017","November 16, 2017","January 16, 2017",,"April 11, 2018","Diabetes Research Center, Odense, Denmark",,"https://ClinicalTrials.gov/show/NCT03022058" | |
| 249,"NCT04308291","The MiniMed™ 780G Glycemic Control and Quality of Life Study for the Treatment of Pediatric and Adult Subjects With Type 1 Diabetes in France.",,"Completed","No Results Available","Type 1 Diabetes","Device: MiniMed™ 780G System","Time in range (TIR)|Satisfaction score|Quality of Life Change|Fear of hypoglycemic events Change|Treatment satisfaction score|Glycemic parameters changes","Medtronic Diabetes","All","7 Years and older (Child, Adult, Older Adult)",,"306","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CIP328","February 15, 2021","May 19, 2022","October 27, 2022","March 16, 2020",,"November 23, 2022","CHU Angers, Angers, France|CHU Besançon, Besançon, France|APHP Avicenne, Bobigny, France|CHU Bordeaux (Saint-André), Bordeaux, France|CH Boulogne-Sur-Mer, Boulogne-sur-Mer, France|CHU Brest, Brest, France|HCL Groupement Hospitalier Est, Bron, France|CHU Caen, Caen, France|Ch Sud Francilien, Corbeil-Essonnes, France|CHU Dijon, Dijon, France|CHRU La Rochelle, La Rochelle, France|CHU Grenoble, La Tronche, France|CHU Lille, Lille, France|CHU Limoges, Limoges, France|HCL DIAB-eCARE, Lyon, France|IDNC Chartres, Mainvilliers, France|APHM Marseille (Hôpital de la Conception), Marseille, France|APHM Marseille (La Timone), Marseille, France|GHEF (Centre Hospitalier de Meaux), Meaux, France|CHU Montpellier (Lapeyronie), Montpellier, France|CHU Nantes, Nantes, France|CHU Nice, Nice, France|CHU Nîmes, Nîmes, France|APHP Bichat, Paris, France|APHP Cochin, Paris, France|Ch Lariboisiere, Paris, France|CH Perpignan, Perpignan, France|CH Périgueux, Périgueux, France|CHU Rennes, Rennes, France|CHU Strasbourg, Strasbourg, France|CHU Toulouse (Rangueil), Toulouse, France|CHU Tours, Tours, France",,"https://ClinicalTrials.gov/show/NCT04308291" | |
| 250,"NCT05022875","Effectiveness of The Health Care CEO App for T1D",,"Recruiting","No Results Available","Type 1 Diabetes Mellitus","Device: Healthcare CEO app- for experimental app intervention|Device: Healthcare CEO app-for control app intervention","Change in HbA1c|Change in % with HbA1c <7.0%|Change in Hyperglycemic Events|Change in Hypoglycemic Events|Change in Perceived Diabetes Self-Management Scale score over time|Change in Self-care Behavior Assessment Scale score over time|Change in Diabetes Distress Scale score over time|Change in Diabetes Quality of Life Scale score over time|Change in Diabetes Knowledge Questionnaire score over time","Chang Gung University|Chang Gung Memorial Hospital","All","16 Years to 25 Years (Child, Adult)","Not Applicable","96","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Health Services Research","ChangGungUCEOApp","April 23, 2021","July 31, 2022","July 31, 2022","August 26, 2021",,"August 26, 2021","Chang-Gung University and Chang-Gung Memorial Hospital, Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT05022875" | |
| 251,"NCT00607087","Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus","PUMP","Completed","Has Results","Diabetes Mellitus, Type 1","Drug: Insulin glulisine|Drug: Insulin lispro|Drug: Insulin aspart","Percentage of Patients With at Least One Unexplained Hyperglycemia and/ or Confirmed Infusion Set Occlusion|Monthly Rate of Unexplained Hyperglycemia and/ or Confirmed Infusion Set Occlusion|Percentage of Patients With at Least One Unexplained Hyperglycemia|Monthly Rate of Unexplained Hyperglycemia|Percentage of Patients With at Least One Confirmed Infusion Set Occlusion|Monthly Rate of Confirmed Infusion Set Occlusion|Percentage of Patients With at Least One Episode of Significant Ketosis and/ or Risk Level for Impending Diabetic Ketoacidosis|Monthly Rate of Episode of Significant Ketosis and/ or Risk Level for Impending Diabetic Ketoacidosis|Rate of Symptomatic Hypoglycemia With a Plasma Glucose (PG) ≤ 70 mg/dL Per Patient-year|Rate of Severe Symptomatic Hypoglycemia Per Patient-year|Rate of Nocturnal Symptomatic Hypoglycemia With a Plasma Glucose (PG) ≤70 mg/dL Per Patient-year|Patients With at Least One Site Infection, Site Inflammation/Erythema, Pruritus or Isolated Pain at Injection Site|Time Interval Between Infusion Set Changes: All Changes|Time Interval Between Infusion Set Changes in Routine|Glycosylated Hemoglobin: HbA1c|Total Daily Basal Insulin Infusion|Total Daily Bolus Insulin Dose","Sanofi","All","18 Years to 75 Years (Adult, Older Adult)","Phase 4","289","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APIDR_C_02083|2007-003579-38","January 2008","June 2009","June 2009","February 5, 2008","July 30, 2010","August 31, 2010","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Macquarie Park, Australia|Sanofi-Aventis Administrative Office, Vienna, Austria|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Budapest, Hungary|Sanofi-Aventis Administrative Office, Natanya, Israel|Sanofi-Aventis Administrative Office, Milan, Italy|Sanofi-Aventis Administrative Office, Seoul, Korea, Republic of|Sanofi-Aventis Administrative Office, PE Gouda, Netherlands|Sanofi-Aventis Administrative Office, Barcelona, Spain|Sanofi-Aventis Administrative Office, Bromma, Sweden|Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00607087" | |
| 252,"NCT00127634","Study of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: Human Insulin Inhalation Powder|Drug: Injectable Insulin|Drug: Insulin Glargine","To assess change in baseline to endpoint in HbA1c in type 1 diabetic patients.|To compare preprandial Human Insulin Inhalation Powder with preprandial injectable insulin in patients with type 1 diabetes with respect to FEV1, FVC, and total lung capacity (TLC), and diffusing capacity of the lung for carbon monoxide (DLCO).|To compare preprandial Human Insulin Inhalation Powder with preprandial injectable insulin in patients with type 1 diabetes with respect to safety as assessed by insulin antibody binding levels, adverse events, and episodes of hypoglycemia|To compare preprandial Human Insulin Inhalation Powder with preprandial injectable insulin in patients with type 1 diabetes with respect to safety using serial HRCT scans of the chest|To compare preprandial Human Insulin Inhalation Powder with preprandial injectable insulin in patients with type 1 diabetes with respect to safety as assessed by Six-Minute Walk Test with the Borg CR10 scale to access perceived exertion.|To compare preprandial Human Insulin Inhalation Powder with preprandial injectable insulin in patients with type 1 diabetes with respect to proportion of patients who achieve or maintain an HbA1c < 7.0 %.|To compare preprandial Human Insulin Inhalation Powder with preprandial injectable insulin in patients with type 1 diabetes with respect to insulin dose requirements ( total, preprandial, and basal insulin)|To compare preprandial Human Insulin Inhalation Powder with preprandial injectable insulin in patients with type 1 diabetes with respect to Patient reported questionnaires.|To compare preprandial Human Insulin Inhalation Powder with preprandial injectable insulin in patients with type 1 diabetes with respect to resource utilization|To assess inhaler reliability in patients randomized to treatment with Human Insulin Inhalation Powder.|To explore differences in cough and other pulmonary symptoms in patients treated with Human Insulin Inhalation Powder or preprandial injectable insulin using the Pulmonary Symptom Questionnaire.|To compare preprandial Human Insulin Inhalation Powder with preprandial injectable insulin in patients with type 1 diabetes with respect to glycemic control as assessed by the 8-point self-monitored blood glucose profiles","Eli Lilly and Company|Alkermes, Inc.","All","18 Years and older (Adult, Older Adult)","Phase 3","385","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","6120|H7U-MC-IDAH","July 2005","May 2008","May 2008","August 8, 2005",,"March 9, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sacramento, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Walnut Creek, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aurora, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Denver, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Newark, Delaware, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hollywood, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jacksonville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Largo, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Port Richey, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Palm Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Idaho Falls, Idaho, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chicago, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Springfield, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Louisville, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Omaha, Nebraska, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., North Plainfield, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Flushing, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lake Success, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Hyde Park, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Staten Island, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Morehead City, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Raleigh, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Medford, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Downingtown, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sellersville, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sioux Falls, South Dakota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Renton, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milwaukee, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aalst, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Arlon, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brussels, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edegem, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leuven, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liege, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Winnipeg, Manitoba, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Corunna, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Niagara Falls, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Peterborough, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sarnia, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montreal, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zagreb, Croatia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Budapest, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hrs, EST), or speak with your personal physician., Debrecen, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Eger, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gyula, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kecskemet, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nyiregyhaza, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hrs, EST), or speak with your personal physician., Szeged, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Szolnok, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bangalore, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kochin, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mumbai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Dehli, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Noida, India",,"https://ClinicalTrials.gov/show/NCT00127634" | |
| 253,"NCT05147324","""MyPlan"" - Individualized Eating Patterns for Adolescents With Type 1 Diabetes",,"Recruiting","No Results Available","Type 1 Diabetes","Behavioral: ""MyPlan"" - Individualized Eating Pattern","Change in percent time in range|Mean adherence to each of the personalized eating behavior goals|Mean adherence to personalized eating behavior pattern|Percentage of time participant adhered to each personalized eating behavior goal|Mean number of personalized eating behavior goals adhered to by participants|Guardian composite acceptability score|Youth composite acceptability score|Change in hemoglobin A1c percentage","University of North Carolina, Chapel Hill|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Cincinnati","All","12 Years to 17 Years (Child)","Not Applicable","50","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","21-1337|1R21DK125033-01A1","December 13, 2021","March 2023","March 2023","December 7, 2021",,"January 14, 2022","University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT05147324" | |
| 254,"NCT00501072","Safety and Efficacy of RT-CGMS in Patients With Type 1 Diabetes Mellitus Treated With an Implantable Pump","IP_RT-CGMS","Completed","No Results Available","Diabetes Mellitus, Type 1","Device: Real-Time Continuous Glucose monitoring System (RT-CGMS)","Clinical effectiveness: percentage of time spent in euglycaemia|Clinical effectiveness: Percentage of time spent in hypoglycaemia and hyperglycaemia.|Safety: incidence of adverse effects|Incidence of hypoglycaemia; Number of SMBG performed, Number of adjustments of insulin therapy, Patient satisfaction, agreement of paired SMBG and RT-CGMS measurements.","Medical Research Foundation, The Netherlands","All","18 Years and older (Adult, Older Adult)","Not Applicable","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","07.0644|NL12530.075.06","November 2007","April 2008","April 2008","July 13, 2007",,"April 11, 2008","Diabetes Outpatient Clinic, Isala clinics, Zwolle, Netherlands",,"https://ClinicalTrials.gov/show/NCT00501072" | |
| 255,"NCT01461616","Effect of NPH Insulin, Insulin Detemir and Insulin Glargine on GH-IGF-IGFBP Axis",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: NPH|Drug: Detemir|Drug: Glargine","IGF-I(ng/ml)|IGFBP-1(ng/ml)|IGFBP-2(ng/ml)|IGFBP-3(ng/ml)|Growth Hormone(ng/ml)|plasma glucose concentration (mmol/L) after a single injection of either NPH insulin, insulin Detemir or insulin glargine|insulin concentration (mmol/L) after a single injection of either NPH insulin, insulin Detemir or insulin glargine","University of Aarhus","All","18 Years to 65 Years (Adult, Older Adult)","Phase 3","19","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NPH-Detemir-Glargine-2011","February 2012","November 2012","November 2012","October 28, 2011",,"December 4, 2012","Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark",,"https://ClinicalTrials.gov/show/NCT01461616" | |
| 256,"NCT00539396","A 3 Month, Randomized, Open Label, Multi-center Study of Technosphere/Insulin Compared to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Receiving Insulin Glargine",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: Technosphere Insulin","Change in blood glucose following a standard meal|Mean change from baseline HbA1c","Mannkind Corporation","All","18 Years to 80 Years (Adult, Older Adult)","Phase 2","110","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MKC-TI-101","March 2005",,"December 2005","October 4, 2007",,"October 14, 2009",,,"https://ClinicalTrials.gov/show/NCT00539396" | |
| 257,"NCT02923323","Neurocognitive Performance During Hyperglycemia , and Brain Tissue Integrity in Youth With Type 1 Diabetes and in Healthy","T1DM","Active, not recruiting","No Results Available","Diabetes Mellitus, Type 1","Device: MRI including DTI , EEG, CGMS|Behavioral: Neurocognitive tests","Association between interstitial glucose concentration and EEG power|Association between interstitial glucose concentration and neurocognitive functions","Assaf-Harofeh Medical Center|Bar-Ilan University, Israel|Hadassah Medical Organization","All","12 Years to 18 Years (Child, Adult)","Not Applicable","32","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","97/14","March 1, 2016","October 15, 2019","May 15, 2025","October 4, 2016",,"July 13, 2022","Assaf Haroffeh Medical center, Zerifin, Israel",,"https://ClinicalTrials.gov/show/NCT02923323" | |
| 258,"NCT00194558","Outcomes and Cost Consequences of Using an Internet Co-Management Module to Improve the Quality of Type 1 Diabetes Care",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Behavioral: Internet co-management module","Hemoglobin A1c|Utilization|Satisfaction with care","University of Washington|Aventis Pharmaceuticals","All","18 Years to 39 Years (Adult)","Not Applicable","82","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","04-3892-G-01","February 2005",,,"September 19, 2005",,"October 2, 2008","University of Washington, Diabetes Care Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00194558" | |
| 259,"NCT00107107","Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: pramlintide acetate","To investigate the long term safety profile of pramlintide treatment in subjects with type 1 diabetes completing protocol 137-150.|To examine the long-term effect of subcutaneously (SC) injected pramlintide on body weight|To examine the effects of long term pramlintide treatment on HbA1c in subjects with type 1 diabetes completing protocol 137-150.","AstraZeneca","All","18 Years and older (Adult, Older Adult)","Phase 3","190","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","137-150E","November 2002","June 2005","June 2005","April 6, 2005",,"September 23, 2015","Research Site, Tempe, Arizona, United States|Research Site, Concord, California, United States|Research Site, Fresno, California, United States|Research Site, San Diego, California, United States|Research Site, San Mateo, California, United States|Research Site, Santa Barbara, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Aventura, Florida, United States|Research Site, Fort Myers, Florida, United States|Research Site, New Port Richey, Florida, United States|Research Site, Tallahassee, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Detroit, Michigan, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, St. Peters, Missouri, United States|Research Site, Butte, Montana, United States|Research Site, Durham, North Carolina, United States|Research Site, Columbus, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Camp Hill, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Irving, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Renton, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00107107" | |
| 260,"NCT00073281","Islet Transplantation for Patients With Type 1 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Procedure: Islet transplantation",,"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 65 Years (Adult, Older Adult)","Phase 1","10","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9903 (completed)","August 2003",,"December 2004","November 20, 2003",,"January 15, 2010","Columbia Presbyterian Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00073281" | |
| 261,"NCT03963219","Clinical Assessment of a Novel Advanced Bolus Calculator for Type 1 Diabetes 5","ABC4D5","Unknown status","No Results Available","Type 1 Diabetes Mellitus","Device: ABC4D|Device: Standard Bolus Calculator","% Time blood glucose in target, day time assess by device","Imperial College London|DexCom, Inc.","All","18 Years and older (Adult, Older Adult)","Not Applicable","37","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15SM2847|DOCUMAS NUMBER","August 22, 2019","June 30, 2021","June 30, 2021","May 24, 2019",,"October 22, 2020","Imperial College Clinical Research Facility, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03963219" | |
| 262,"NCT00537251","32 Week, Open, Randomized, 2 Way Cross Over Multicentre Trial to Compare Safety & Efficacy of Combination of HOE901 Insulin Analogue Once Daily at Bedtime + Lispro Insulin Before Meals vs NPH Insulin (Twice a Day) + Regular in Type 1 Diabetes Mellitus",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: Insulin glargine","Compare efficacy of insulin glargine & short acting insulin (Lispro), NPH insulin regime as basal insulin and regular insulin for meal insulin for metabolic control, evaluated by means of HbA1c .","Sanofi","All","18 Years to 65 Years (Adult, Older Adult)","Phase 3","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HOE901_4023","November 2001",,"February 2004","October 1, 2007",,"October 1, 2007",,,"https://ClinicalTrials.gov/show/NCT00537251" | |
| 263,"NCT05649553","The Effect of Digital Game-Based Diabetes Education on Quality of Life of Children With Type 1 Diabetes Mellitus",,"Not yet recruiting","No Results Available","Type 1 Diabetes Mellitus","Behavioral: Digital Game Based Diabetes Education","Change in HbA1c|""Quality of Life Scale for Children with Diabetes Mellitus (PedsQL 3.0 Diabetes Scale)""","Pamukkale University","All","8 Years to 12 Years (Child)","Not Applicable","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","GPehlivan|Sebahat ALTUNDAĞ, Assoc. Prof.","December 19, 2022","February 6, 2023","June 15, 2023","December 14, 2022",,"December 20, 2022","Pamukkale University, Denizli, Turkey",,"https://ClinicalTrials.gov/show/NCT05649553" | |
| 264,"NCT03147274","Group Education Curriculum for Older Teens With Type 1 Diabetes","SMART T1D","Completed","No Results Available","Type 1 Diabetes Mellitus","Behavioral: Intervention","Change from baseline self-care adherence at 12 months|Change from baseline transition readiness at 12 months|Change from baseline hemoglobin A1c at 12 months","Boston Children's Hospital","All","15 Years to 18 Years (Child, Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","IRB-P00023671","May 3, 2017","February 21, 2019","February 21, 2019","May 10, 2017",,"April 17, 2019","Boston Children's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03147274" | |
| 265,"NCT00118937","Effect of Metformin in Patients With Type-1 Diabetes With Inadequate Glycaemic Control by Insulin and Diet",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: Metformin|Drug: Placebo.","HbA1c - difference between final visit and baseline.|Absolute HbA1c|Number of mild and severe hypoglycaemia with or without measurements of blood-glucose.|Insulin-dose|The following parameters are measured at baseline and at the final visit after 12 months of intervention:|Plasma-PAI-antigen and -activity, t-PA-antigen- and activity.|Plasma-fibrinogen|Serum-albumin|Markers of endothelial dysfunction: Von Willebrand Factor, ICAM, VCAM, Amadori-protein, selectin and endothelin.|Plasma-homocysteine|Asymmetric DiMethylArginine - ADMA|Urine-albumin-excretion in three 24 hour urine-collections|Blood-pressure in the sitting position after 10 minutes of rest.|Fasting lipid-profile (total-cholesterol, LDL-cholesterol, HDL-cholesterol, VLDL-cholesterol and triglycerides), small-dense-LDL, Lp(a) and Apo-B100.|Weight, BMI and Waist-hip-ratio|White blood-cell-count, hs-CRP, Interleukin-6 and TNF-alfa.|Serum-creatinine, sodium, potassium, ASAT, alkaline phosphatase, Factor 2, 7, 10, Cobalamin, Erythrocyte-folate and Haemoglobin-concentration.|Extra blood- and urine-samples will be stored at -80 degrees Celsius for potential extra analyses after closure of the study. DNA will be stored for later pharmaco-genetic analysis.","Steno Diabetes Center Copenhagen","All","18 Years and older (Adult, Older Adult)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Type-1-Metformin","December 2003","August 2006","August 2006","July 12, 2005",,"December 8, 2008",,,"https://ClinicalTrials.gov/show/NCT00118937" | |
| 266,"NCT03819335","¿Can mySugr App Improve Knowledge and Self-management of People With Type 1 Diabetes Mellitus?",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Device: mySugr app|Other: Standard care","Empowerment|Adherence to glycemic monitoring|Adherence to recommendations|Adherence to visits|Adherence to the app|Daily management of diabetes|Quality of life related to diabetes|Self-efficacy|Glycemic control|Satisfaction with the app","Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Roche Diagnostics","All","18 Years to 80 Years (Adult, Older Adult)","Not Applicable","28","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IIBSP-SUG-2018-01","April 9, 2019","February 26, 2021","April 13, 2021","January 28, 2019",,"September 21, 2021","Hospital de la Santa Creu i Sant Pau, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT03819335" | |
| 267,"NCT00137046","Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 1 Diabetes",,"Terminated","Has Results","Diabetes Mellitus, Type 1","Drug: Subcutaneous Insulin|Drug: Inhaled Insulin","Change From Baseline in Forced Expiratory Volume in One Second (FEV1)|Summary of ≥ 15% Decliners in Forced Expiratory Volume in One Second (FEV1)|Change From Baseline in Carbon Monoxide Diffusion Capacity (DLco)|Summary of ≥ 20% Decliners in Carbon Monoxide Diffusing Capacity (DLco).|Annual Rate of Change in Forced Expiratory Volume in 1 Second (FEV1)|Annual Rate of Change in Carbon Monoxide Diffusion Capacity (DLco)|Change From Baseline in Glycosylated Hemoglobin (HbA1c)|Hypoglycemic Event Rates|Severe Hypoglycemic Event Rates|Change From Baseline in Fasting Plasma Glucose|Change From Baseline Body Weight|Total Daily Long-Acting Insulin Dose (Unadjusted for Body Weight)|Total Daily Long-Acting Insulin Dose Adjusted for Body Weight|Total Daily Short-Acting Insulin Dose (Unadjusted for Body Weight)|Total Daily Short-Acting Insulin Dose Adjusted for Body Weight|Baseline Dyspnea Index (BDI)|Transition Dyspnea Index (TDI)|Lipids|Cough Questionnaire|Forced Vital Capacity (FVC)|Total Lung Capacity (TLC)|Insulin Antibodies","Pfizer","All","18 Years to 65 Years (Adult, Older Adult)","Phase 3","582","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A2171022","May 2002","December 2008","December 2008","August 29, 2005","January 26, 2010","February 18, 2010","Pfizer Investigational Site, Fullerton, California, United States|Pfizer Investigational Site, Long Beach, California, United States|Pfizer Investigational Site, Sacramento, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, Santa Barbara, California, United States|Pfizer Investigational Site, Santa Rosa, California, United States|Pfizer Investigational Site, Tustin, California, United States|Pfizer Investigational Site, Walnut Creek, California, United States|Pfizer Investigational Site, Denver, Colorado, United States|Pfizer Investigational Site, Longmont, Colorado, United States|Pfizer Investigational Site, Hamden, Connecticut, United States|Pfizer Investigational Site, Madison, Connecticut, United States|Pfizer Investigational Site, Newark, Delaware, United States|Pfizer Investigational Site, Coral Gables, Florida, United States|Pfizer Investigational Site, Hollywood, Florida, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Tallahassee, Florida, United States|Pfizer Investigational Site, West Palm Beach, Florida, United States|Pfizer Investigational Site, Winter Park, Florida, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Wilmette, Illinois, United States|Pfizer Investigational Site, Bethesda, Maryland, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, Butte, Montana, United States|Pfizer Investigational Site, New Hyde Park, New York, United States|Pfizer Investigational Site, Durham, North Carolina, United States|Pfizer Investigational Site, Portland, Oregon, United States|Pfizer Investigational Site, Lansdale, Pennsylvania, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, Burlington, Vermont, United States|Pfizer Investigational Site, Richmond, Virginia, United States|Pfizer Investigational Site, Renton, Washington, United States|Pfizer Investigational Site, Milwaukee, Wisconsin, United States|Pfizer Investigational Site, Capital Federal, Buenos Aires, Argentina|Pfizer Investigational Site, Capital Federal, Buenos Aires, Argentina|Pfizer Investigational Site, Capital Federal, Buenos Aires, Argentina|Pfizer Investigational Site, Capital Federal, Buenos Aires, Argentina|Pfizer Investigational Site, Belo Horizonte, MG, Brazil|Pfizer Investigational Site, Curitiba, PR, Brazil|Pfizer Investigational Site, Porto Alegre, RS, Brazil|Pfizer Investigational Site, Porto Alegre, RS, Brazil|Pfizer Investigational Site, Campinas, SP, Brazil|Pfizer Investigational Site, Sao Paulo, SP, Brazil|Pfizer Investigational Site, Sao Paulo, SP, Brazil|Pfizer Investigational Site, São Paulo, SP, Brazil|Pfizer Investigational Site, Calgary, Alberta, Canada|Pfizer Investigational Site, Calgary, Alberta, Canada|Pfizer Investigational Site, Edmonton, Alberta, Canada|Pfizer Investigational Site, Edmonton, Alberta, Canada|Pfizer Investigational Site, Victoria, British Columbia, Canada|Pfizer Investigational Site, Winnepeg, Manitoba, Canada|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, Halifax, Nova Scotia, Canada|Pfizer Investigational Site, Halifax, Nova Scotia, Canada|Pfizer Investigational Site, Kingston, Ontario, Canada|Pfizer Investigational Site, London, Ontario, Canada|Pfizer Investigational Site, Mississauga, Ontario, Canada|Pfizer Investigational Site, Oakville, Ontario, Canada|Pfizer Investigational Site, Ottawa, Ontario, Canada|Pfizer Investigational Site, Thornhill, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Laval, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Sherbrooke, Quebec, Canada|Pfizer Investigational Site, Saskatoon, Saskatchewan, Canada|Pfizer Investigational Site, Mexico Df, Col Las Americas, Mexico|Pfizer Investigational Site, Mexico, DF, Mexico|Pfizer Investigational Site, Mexico, DF, Mexico|Pfizer Investigational Site, Monterrey, Nuevo Leon, Mexico",,"https://ClinicalTrials.gov/show/NCT00137046" | |
| 268,"NCT05272059","Multiple Ascending Dose Study of MHS552 in Adults With Type 1 Diabetes Mellitus",,"Not yet recruiting","No Results Available","Type 1 Diabetes Mellitus","Drug: MHS552|Drug: Placebo","Number of participants with Adverse events (AEs) and Serious Adverse events (SAEs)|Area Under Plasma Concentration-time Curve calculated to the end of a dosing interval (AUCtau) for MHS552|Maximum ObservBlood Concentrations (Cmax) for MHS552|Time to Reach Maximum Blood Concentrations (Tmax) of MHS552","Novartis Pharmaceuticals|Novartis","All","18 Years to 45 Years (Adult)","Phase 1","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CMHS552B12101","February 13, 2023","April 14, 2025","April 14, 2025","March 9, 2022",,"September 29, 2022",,,"https://ClinicalTrials.gov/show/NCT05272059" | |
| 269,"NCT04614623","Defining the Role of Management Factors in Outcome Disparity in Pediatric T1D",,"Unknown status","No Results Available","Type1diabetes","Device: AHCL pump|Other: Video conferencing Application","Hemoglobin A1c (HbA1c) Change From Baseline to 6 months (End of study)|Mean blood glucose (MBG) Change From Baseline to 6 months (End of study)","Children's Hospital New Orleans, LA","All","10 Years to 17 Years (Child)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R21DK118643","November 1, 2020","July 30, 2022","December 31, 2022","November 4, 2020",,"November 4, 2020","Children's Hospital of New Orleans, New Orleans, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT04614623" | |
| 270,"NCT00063128","Safety and Efficacy of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes Mellitus.",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: insulin|Drug: human insulin inhalation powder (HIIP)","test the hypothesis that preprandial HIIP plus insulin glargine is noninferior to preprandial injectable insulin (regular human insulin or insulin lispro) plus insulin glargine with respect to HbA1c|compare the pharmacokinetics of test doses of preprandial HIIP and preprandial injectable insulin (regular human insulin or insulin lispro) administered to a subgroup of patients|compare 7-point self-monitored blood glucose profiles (blood glucose measurements before & 2 hours after start of morning, midday, evening meals, and blood glucose measurement at bedtime) for preprandial HIIP and preprandial inject|assess the safety of HIIP using pulmonary function tests, chest x rays, insulin antibody titers, adverse events (AEs), and episodes of hypoglycemia|assess symptoms of diabetes, patient vitality, and patient satisfaction with the diabetes treatments|compare insulin dose requirements (both preprandial and basal insulin [insulin glargine]) of patients administering preprandial HIIP and preprandial injectable insulin (regular human insulin or insulin lispro|assess insulin inhaler reliability|assess patient compliance with the HIIP delivery system Directions for Use (DFU)|assess the impact of practice inhalations on inspiratory flow parameters (peak inspiratory flow rate [IFR] and total inspired volume [TIV]) achieved by patients using the insulin inhaler following training with the DFU","Eli Lilly and Company|Alkermes, Inc.","All","18 Years and older (Adult, Older Adult)","Phase 2","119","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","6944|H7U-MC-IDAI","April 2003",,"April 2004","June 25, 2003",,"December 21, 2007","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Diego, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Denver, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hollywood, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Port Richey, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ocala, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pembroke Pines, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Idaho Falls, Idaho, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Springfield, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jackson, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chesterfield, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Omaha, Nebraska, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamptom, New Hampshire, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Flushing, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Hyde Park, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greenville, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salem, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Columbia, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Federal Way, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Renton, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tacoma, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charleston, West Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00063128" | |
| 271,"NCT04271228","Use of Insulin Adjustment Device DreaMed Advisor Pro During Routine Clinical Use for Subjects With Diabetes Type 1",,"Recruiting","No Results Available","Type 1 Diabetes","Device: DreaMed Advisor Pro","HbA1c|Percentage of glucose readings within target range of 70-180 mg/dl|Percentage of glucose sensor readings below 54 mg/dl|Percentage of glucose sensor readings above 250 mg/dl|Percentage of glucose sensor readings 70-54 mg/dl|Percentage of glucose sensor readings 180-250 mg/dl|Mean sensor glucose|Glucose variability|Total insulin dose|Total basal insulin dose|Total Bolus insulin dose|Total daily consumed carbohydrates","Rabin Medical Center","All","6 Years to 65 Years (Child, Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RMC0525-19ctil","February 15, 2020","August 26, 2023","August 26, 2023","February 17, 2020",,"August 9, 2022","Schnider Children's Medical Center, Petach-Tikva, Israel",,"https://ClinicalTrials.gov/show/NCT04271228" | |
| 272,"NCT02117765","Pilot Clinical Trial of Ustekinumab in Patients With New-onset T1D","UST1D","Unknown status","No Results Available","Type 1 Diabetes","Drug: Ustekinumab","Primary Safety Endpoints (composite outcome measure)|Immunological Endpoints (composite outcome measure)|Exploratory (composite outcome measure)","University of British Columbia|Juvenile Diabetes Research Foundation","All","18 Years to 35 Years (Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H14-00939","March 2015","February 2017","June 2017","April 21, 2014",,"May 25, 2016","BC Diabetes, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT02117765" | |
| 273,"NCT03911843","Omega-3 and Vitamin D Supplements in Childhood T1D",,"Completed","Has Results","Type 1 Diabetes Mellitus","Drug: omega-3 supplementation|Drug: Vitamin D supplementation","Daily Insulin Need (IU/Kg/Day) and Daily Insulin Pre-meal Demand (Pre-meal IU/Kg/Day) at 12 Months|HbA1c Percentage|Number of Participants With Insulin Demand Adjusted for HbA1c %(IDAA1c) <9","Azienda Ospedaliero Universitaria Maggiore della Carita|University of Eastern Piedmont","All","1 Year to 18 Years (Child, Adult)","Phase 2|Phase 3","64","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","AOU Novara","January 1, 2017","December 31, 2018","December 31, 2018","April 11, 2019","March 23, 2021","April 19, 2021",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT03911843/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT03911843/SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT03911843/ICF_002.pdf","https://ClinicalTrials.gov/show/NCT03911843" | |
| 274,"NCT05031429","Time Limited Eating in Type 1 Diabetes","TLET1D","Recruiting","No Results Available","Type 1 Diabetes","Other: Time Limited Eating","Acceptability and feasibility of intervention, as indicated by the ""Intervention Satisfaction Survey""|Change in β-cell function at 9 weeks, as indicated by mixed meal tolerance test with C-peptide levels|Change in glycemic control at 9 weeks, as indicated by continuous glucose monitoring (percent time in range), and HbA1c|Safety, as indicated by hypoglycemia|Dietary patterns, as indicated by the Automated Self-Administered 24-hour Dietary Assessment Tool (ASA24)|Quality of life, as indicated by Pediatric Quality of Life Inventory (PedsQL), Diabetes Module|Stress level, as indicated by Perceived Stress Scale|Binge Eating, as indicated by Binge Eating Disorder Screener|Anxiety, as indicated by Neuro-QOL-Anxiety-Short Form|Impact on activities of daily living, as indicated by Munich Chronotype Questionnaire (MCTQ)","Children's Hospital Los Angeles","All","12 Years to 25 Years (Child, Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHLA-21-00269","January 1, 2022","July 1, 2023","July 1, 2023","September 1, 2021",,"June 15, 2022","Children's Hospital Los Angeles, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT05031429" | |
| 275,"NCT02234947","Pancreas Volume in Preclinical Type 1 Diabetes",,"Active, not recruiting","No Results Available","Type 1 Diabetes","Procedure: MRI, US, and blood samples","MRI of Pancreatic volume|Ultrasound of Pancreatic volume|Blood Test will be done for pancreatic function and diabetes markers","University of Florida|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Diabetes Action Research and Education Foundation","All","8 Years to 45 Years (Child, Adult)",,"246","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB201600705 - N|89-2013|DP3DK101120","November 2013","December 2022","December 2022","September 9, 2014",,"February 12, 2021","University of Florida, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02234947" | |
| 276,"NCT05179954","Lipoprotein Kinetics in T1D",,"Recruiting","No Results Available","Type 1 Diabetes","Other: Metabolic testing","Apolipoprotein C turnover rate|Triglyceride turnover rate|Apolipoprotein B-100 turnover rate|Apolipoprotein C concentration|Triglyceride concentration|Apolipoprotein B-100 concentration","Washington University School of Medicine|University of Washington","All","18 Years to 45 Years (Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","LTD","May 9, 2022","December 31, 2025","December 31, 2027","January 6, 2022",,"November 2, 2022","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT05179954" | |
| 277,"NCT03520855","Serious Game in the Therapeutic Education of Type 1 Diabetes Paediatric Patients","eDIVE","Recruiting","No Results Available","Type 1 Diabetes","Other: Serious game|Behavioral: ETP","Diapason questionnaire (Aide aux Jeunes Diabètes)|HbA1c dosage|Number of hypo or hyperglycaemia|Evaluation of self-care skills|Evaluation of well-being with WHOFIVE|Evaluation of well-being with DQOLY","Assistance Publique - Hôpitaux de Paris","All","10 Years to 17 Years (Child)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","K150907J|2017-A02052-51","April 3, 2019","April 2023","July 2023","May 11, 2018",,"November 1, 2022","Necker Hospital, Paris, France",,"https://ClinicalTrials.gov/show/NCT03520855" | |
| 278,"NCT04598893","Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab",,"Enrolling by invitation","No Results Available","Type 1 Diabetes Mellitus","Biological: Teplizumab|Other: Placebo","Incidence of adverse events (AEs) and serious adverse events (SAEs) and adverse events of special interest (AESIs), including infections and malignancies.","Provention Bio, Inc.","All","9 Years to 18 Years (Child, Adult)",,"200","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","PRV-031-003","October 26, 2020","June 2026","June 2026","October 22, 2020",,"December 8, 2022","Rady Children's Hospital 3020 Children's Way (Site 840004), San Diego, California, United States|UCSF Medical Center Gateway Medical Building, 1825 Fourth Street (Site 840001), San Francisco, California, United States|Diablo Clinical Research2255 Ygnacio Valley Road, Ste. M (Site 840002), Walnut Creek, California, United States|Barbara Davis Center for Diabetes - Pediatrics 1775 Aurora Court (Site 840005), Aurora, Colorado, United States|University of Florida Health (UF Health) 1600 SW Archer Road, PO Box 100278 (Site 840015), Gainesville, Florida, United States|Johns Hopkins All Children's Hospital, 501 6th Avenue South (Site 840048), Saint Petersburg, Florida, United States|Atlanta Diabetes Associates 1800 Howell Mill Road. Suite 450 (Site 840009), Atlanta, Georgia, United States|Columbus Regional Research Institute 2425 Brookstone Parkway (Site 840006), Columbus, Georgia, United States|St. Luke's Children's Endocrinology, 305 E Jefferson St. (Site 840052), Boise, Idaho, United States|Rocky Mountain Clinical Research, LLC 3910 Washington Parkway, Suite E (Site 840007), Idaho Falls, Idaho, United States|Indiana University Hospital, Indiana Clinical Research Center, 550 North University Boulevard (Site 840014), Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics 200 Hawkins Drive (Site 840023), Iowa City, Iowa, United States|Capital Medical Research Associates (Site 840029), Camp Springs, Maryland, United States|Children's Mercy Hospitals and Clinics, 2401 Gillham Road (Site 840026), Kansas City, Missouri, United States|Washington University School of Medicine, Pediatric Clinical Research Unit, Suite 11W19 (Site 840018), Saint Louis, Missouri, United States|UBMD Pediatrics 1001 Main Street, 4th Floor (Site 840010), Buffalo, New York, United States|UNC Hospitals, The University of North Carolina at Chapel Hill, Children's Specialty Clinic, 101 Manning Drive (Site 840038), Chapel Hill, North Carolina, United States|Endocrinology Service Northwest, LLC 929 SW Simpson Ave. Suite 220 (Site 840034), Bend, Oregon, United States|Children's Hospital of Philadelphia, Division of Endocrinology 3500 Civic Center Blvd., Buerger Center 12th Floor (Site 840021), Philadelphia, Pennsylvania, United States|AM Diabetes & Endocrinology Center, 3025 Kate Bond Rd. (Site 840008), Bartlett, Tennessee, United States|Vanderbilt University Medical Center 1500 21st Avenue, Suite 1514, Village At Vanderbilt (Site 840024), Nashville, Tennessee, United States|UT Southwestern Children's Medical Center of Dallas 1935 Medical District Drive (Site 840033), Dallas, Texas, United States|Virginia Mason Medical Center, Benaroya Research Institute 1201 9th Ave, MS: D4-CRP (Site 840016), Seattle, Washington, United States|MultiCare Health System, Gateway Medical Building (Site 840003), Tacoma, Washington, United States|University Hospital Brussels (Site 056202), Jette, Brussels, Belgium|UCL Namur University Hospital Place Louise Godin 15 (Site 056205), Namur, Belgium|Alberta Diabetes Institute, 2-004 Li Ka Shing Centre for Health Research Innovation 8602 (Site 124103), Edmundston, Alberta, Canada|BCDiabetes - Medical Research Center, 210 West Broadway Suite 400 (Site 124102), Vancouver, British Columbia, Canada|University Hospital Motol V Uvalu 84, Praha 5 - Motol (Site 203301), Prague, Czechia|Lenval Hospital, 57 Avenue de la Californie (Site 250508), Nice, France|Hospital Center Regional D'Orleans Hospital La Source, Pediatric Department, 14 Hospital Ave Post box 86709 (Site 250513), Orleans, France|Necker Children's Hospital, 149 Rue de Sevres (Site 250502), Paris, France|Evangelic Clinic Bethel, Children's Clinic Grenzweg 14/Hs 2 (Site 276602), Bethel, Bielefeld, Germany|Hospital Augsburg, Stenglinstrasse 2 (Site 276606), Augsburg, Germany|University Hospital Carl Gustav Carus Fetscherstrasse 74 (Site 276601), Dresden, Germany|Pediatric Hospital on the Bult Janusz-Korczak-Allee 12 (Site 276604), Hannover, Germany|University Hospital Heidelberg, Im Neuenheimer Feld 430 (Site 276608), Heidelberg, Germany|University Teaching Centre, Department of Pediatrics, Diabetology and Endocrinology (Site 616803), Gdansk, Poland|University Teaching Centre of the Medical University of Warsaw, 63A, ul. Zwirki i Wigur (Site 616804), Warsaw, Poland|Institute of Diabetology ul. Raclawicka 129/2U, 02-117 (Site 616802), Warsaw, Poland|Children's Memorial Health Institute Al. Dzieci Polskich 20 (Site 616801), Warsaw, Poland|Sheffield Children's Hospital Western Bank, S10 2TH (Site 826903), Sheffield, Yorkshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04598893" | |
| 279,"NCT05368402","Clinical Trial on Ladarixin Adjunctive Therapy to Improve Glycemic Control in Type 1 Diabetes.","CONSERVA","Recruiting","No Results Available","Type 1 Diabetes","Drug: Ladarixin|Other: Placebo","The proportion of responders at week 27/28 (visit 4), with responders defined as ""patients with an HbA1c reduction from baseline of ≥0.50% (absolute difference) without episodes of severe hypoglycemia|The proportion of responders at week 11/12 (visit 3)|The mean difference from baseline in HbA1c [Timeframe: week 11/12 (visit 3) and 27/28 (visit 4)]|Average (previous 3 days) daily insulin requirements (IU/kg/day) assessed at week 11/12 (visit 3) and 27/28 (visit 4)|Glycemic Variability by CGM (previous 7 days): time in range (TIR), time above range (TAR) time below range (TBR), standard deviation and coefficient of variation assessed at week 11/12 (visit 3) and 27/28 (visit 4)|Incidence of Treatment Emergent Adverse Events (TEAEs) recorded from the beginning of study treatment to up to the end of study participation","Dompé Farmaceutici S.p.A","All","21 Years to 65 Years (Adult, Older Adult)","Phase 2","86","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LDX0122|2022-000743-68","July 27, 2022","July 15, 2023","July 30, 2023","May 10, 2022",,"November 22, 2022","Institute of Cellular Therapeutics, Pittsburgh, Pennsylvania, United States|Ospedale F. Spaziani Frosinone, Frosinone, Italy|Università Campus Bio-Medico di Roma (UCBM) Policlinico Universitario, Rome, Italy",,"https://ClinicalTrials.gov/show/NCT05368402" | |
| 280,"NCT04418869","Exercise in Adolescents With Type 1 Diabetes",,"Active, not recruiting","No Results Available","Type 1 Diabetes","Other: Exercise bouts","Change in plasma glucose during exercise and recovery|Sensor glucose|Changes in levels of hormones during exercise and recovery|Change in levels of messenger ribonucleic acid (mRNA) between baseline and exercise.|Comparisons of levels of messenger ribonucleic acid (mRNA) between different exercise bouts.|Change in heart rate during exercise.|Change in hemoglobin saturation during exercise.|Change in cardiac output.","Region Örebro County|Örebro University, Sweden","Male","16 Years to 18 Years (Child, Adult)","Not Applicable","8","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","251981","March 1, 2014","June 27, 2016","June 2024","June 5, 2020",,"October 31, 2022",,,"https://ClinicalTrials.gov/show/NCT04418869" | |
| 281,"NCT02284815","Can Gluten-free Diet Prevent the Destruction of Beta-cells During Remission?",,"Unknown status","No Results Available","Diabetes Mellitus, Type 1","Dietary Supplement: Glutenfree diet","C-peptide change from baseline to 12 months follow-up|Insulin Adjusted HbA1c change from baseline to 12 months follow-up|Insulin per kg from baseline to 12 months follow-up|Microbiota (feces samples) change from baseline to 6 months follow-up|Immune system (Th1 and Th2 cytokines) change from baseline to 12 months follow-up","Herlev Hospital","All","2 Years to 18 Years (Child, Adult)","Early Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DIRECT-2011-119","March 2012","June 2015","August 2015","November 6, 2014",,"November 6, 2014",,,"https://ClinicalTrials.gov/show/NCT02284815" | |
| 282,"NCT05233592","Glycemic Effects of the COVID-19 Booster Vaccine in Type 1 Diabetes",,"Recruiting","No Results Available","Type 1 Diabetes|Diabetes Mellitus, Type 1","Device: CGM","Total Daily Insulin Resistance (TDIR)|Change in TDIR|Change in Time in Range|Change in Daily Insulin Requirement|Change in Time in Hyperglycemia","Johns Hopkins University|DexCom, Inc.","All","18 Years and older (Adult, Older Adult)",,"40","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00305567","March 8, 2022","March 31, 2023","March 31, 2023","February 10, 2022",,"April 14, 2022","Cardiovascular Specialists of Central Maryland, Columbia, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT05233592" | |
| 283,"NCT03875729","Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab","PROTECT","Active, not recruiting","No Results Available","Type 1 Diabetes Mellitus","Biological: teplizumab|Biological: Placebo","The area under the time-concentration curve (AUC) of C-peptide after a mixed meal tolerance test (MMTT) at Week 78|Exogenous insulin use|HbA1c levels|Time in glycemic target range|Clinically important hypoglycemic episodes|Incidence of treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), and serious adverse events (SAEs)|Teplizumab serum concentrations|Incidence and titers of anti-teplizumab antibodies after treatment courses","Provention Bio, Inc.","All","8 Years to 17 Years (Child)","Phase 3","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PRV-031-001","April 5, 2019","May 2023","May 2023","March 15, 2019",,"December 12, 2022","Rady Children's Hospital-San Diego (Site 004), San Diego, California, United States|UCSF Medical Center (Site 001), San Francisco, California, United States|Diablo Clinical Research, Inc. (Site 002), Walnut Creek, California, United States|University of Colorado-Barbara Davis Center for Childhood Diabetes (Site 005), Aurora, Colorado, United States|Yale University of Medicine (Site 020), New Haven, Connecticut, United States|UF Clinical and Translation Research Building (Site 015), Gainesville, Florida, United States|Nemours Children's Specialty Care-Endocrinology (Site 047), Jacksonville, Florida, United States|University of Miami Health System (Site 028), Miami, Florida, United States|All Children's Hospital-Johns Hopkins Medicine (Site 048), Saint Petersburg, Florida, United States|University of South Florida Diabetes and Endocrinology Center (Site 011), Tampa, Florida, United States|Atlanta Diabetes Associates (Site 009), Atlanta, Georgia, United States|Columbus Regional Research Institute (Site 006), Columbus, Georgia, United States|St. Luke's Children's Endocrinology (Site 052), Boise, Idaho, United States|Rocky Mountain Diabetes and Osteoporosis Center (Site 007), Idaho Falls, Idaho, United States|University of Chicago Medical Center (Site 017), Chicago, Illinois, United States|Indiana University Hospital and Riley Hospital for Children (Site 014), Indianapolis, Indiana, United States|U. Iowa Children's Hospital (Site 023), Iowa City, Iowa, United States|Capital Diabetes & Endocrine Associates (Site 029), Camp Springs, Maryland, United States|Baystate Pediatric Endocrinology & Diabetes (Site 040), Springfield, Massachusetts, United States|U. Minnesota Health Clinical Research Unit (Site 031), Minneapolis, Minnesota, United States|Children's Mercy Hospitals & Clinics (Site 026), Kansas City, Missouri, United States|Washington University School of Medicine (Site 018), Saint Louis, Missouri, United States|Women and Children's Hospital of Buffalo (Site 010), Buffalo, New York, United States|UNC Hospitals Children's Specialty Clinic (Site 038), Chapel Hill, North Carolina, United States|Rainbow Babies & Children's Hospital (Site 049), Cleveland, Ohio, United States|Cleveland Clinic (Site 051), Cleveland, Ohio, United States|Endocrinology Service Northwest, LLC (Site 034), Bend, Oregon, United States|Childrens Hospital of Philadelphia - Endocrinology (Site 021), Philadelphia, Pennsylvania, United States|Sanford Diabetes and Thyroiid Clinical (Site 013), Sioux Falls, South Dakota, United States|AM Diabetes & Endocrinology Center (Site 008), Bartlett, Tennessee, United States|Vanderbilt University Medical Center (Site 024), Nashville, Tennessee, United States|Children's Medical Center Dallas (Site 033), Dallas, Texas, United States|Benaroya Research Institute at Virginia Mason (Site 016), Seattle, Washington, United States|MultiCare Institute for Research & Innovation (Site 003), Tacoma, Washington, United States|UZ Brussel - Campus Jette (Site 202), Bruxelles, Brussels Capital Region, Belgium|UZ Gent (Site 206), Gent, Oost-Vlaanderen, Belgium|CHU UCL Namur, site Clinique Sainte-Elisabeth (Site 205), Namur, Belgium|Alberta Diabetes Institute Clinical Research Unit Li Ka Shing Centre for Health Research Innovation (Site 103), Edmonton, Alberta, Canada|BC Diabetes (Site 102), Vancouver, British Columbia, Canada|Montreal Children's Hospital-McGill (Site 101), Montreal, Quebec, Canada|Fakultni nemocnice v Motole (Site 301), Praha 5, Czechia|Hopitaux Pediatriques de Nice CHU-Lenval service de diabetologie et d'endocrinologia (Site 508), Nice, Alpes-Maritimes, France|CHU Hopital de la Timone-Hopital d'Enfants (Site 512), Marseille, Bouces-du-Rhone, France|CHU DIJON hopital d'enfant (Site 504), Dijon Cedex, cote-d'Or, France|Groupe Hospitalier Necker Enfants Malades (site 502), Paris, Ile-de-France, France|Centre Hospitalier Regional (CHR) d'Orleans-Service de pediatrie (Site 513), Orleans, Loiret, France|Groupe hospitalier Est-Hopital Femme, Mere, Enfant (Site 509), Bron Cedex, Rhone, France|Centre hospitalier de Pau (Site 501), Pau cedex, France|Universitätsklinikum Freiburg (Site 603), Freiburg im Breisgau, Baden-Wurttemberg, Germany|Universitätsklinikum Heidelberg (Site 608), Heidelberg, Baden-Wurtternberg, Germany|Universitätsklinikum Augsburg (Site 606), Augsburg, Bayem, Germany|Evangelisches Klinikum Bethel Kinderklinik (Site 602), Bielefeld, Nordrhein-Westfalen, Germany|Universitatsklinikum Carl Gustav Carus (Site 601), Dresden, Sachson, Germany|Kinderkrankenhaus Auf Der Bult (Site 604), Hannover, Germany|Békés Megyei Központi Kórház Pándy Kálmán Tagkórház ( Site 705), Gyula, Hungary|Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu (Site 804), Warszawa, Mazowieckie, Poland|Instytut Diabetologii Sp. z o.o. (Site 802), Warszawa, Poland|Instytut ""Pomnik - Centrum Zdrowia Dziecka"" (Site 801), Warszawa, Poland|Uniwersyteckie Centrum Kliniczne (Site 803), Warszawa, Poland|Northwick Park Hospital - Paediatrics (site 904), London, City Of London, United Kingdom|Cardiff and Vale NHS Trust - University Hospital of Wales (Site 902), Cardiff, United Kingdom|Sheffield Children's NHS Foundation Trust Western Bank (Site 903), Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03875729" | |
| 284,"NCT02155855","Telemedicine for Adolescents With Insulin-dependent Diabetes",,"Completed","No Results Available","Type 1 Diabetes","Other: Telemedicine|Other: Control","hemoglobin A1c|Frequency of contact with diabetes care team","Texas Tech University Health Sciences Center","All","10 Years to 18 Years (Child, Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","L14-037","December 2014","October 2016","December 2016","June 4, 2014",,"December 10, 2019","TTUHSC Pediatric Clinic, Lubbock, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02155855" | |
| 285,"NCT03177096","Impact of the Continuous Measurement of Blood Glucose on Insulin Pump on Child Quality of Life With Type 1 Diabetes","IM-CAPT","Completed","No Results Available","Type1diabetes","Behavioral: Peds QL questionnaire and diabetes modulate|Behavioral: WHO-5 questionnaire|Behavioral: Felt questionnaire","Evolution of Peds QL questionnaire results|Evolution of WHO-5 and felt questionnaire","Groupe Hospitalier de la Region de Mulhouse et Sud Alsace","All","2 Years to 13 Years (Child)","Not Applicable","14","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","GHR 866|2016-A01264-47","September 20, 2016","July 12, 2017","July 12, 2017","June 6, 2017",,"August 21, 2019","GHRMSA, Mulhouse, France",,"https://ClinicalTrials.gov/show/NCT03177096" | |
| 286,"NCT05536232","Residual Insulin Secretion in Patients With Type 1 Diabetes Under a Low Carbohydrate Diet or a Ketogenic Diet","KetoDiab","Not yet recruiting","No Results Available","Type1 Diabetes","Behavioral: Low carbohydrate diet","Peptide C evolution|HbA1C measure|Insulin-dose adjusted A1c (IDAA1C) index calculation|Weight measure|Fat mass percentage measure|Lean mass percentage measure|Daily dose of insulin|Circulating rate of Tregs|Circulating rate of cytokines","Assistance Publique - Hôpitaux de Paris","All","18 Years and older (Adult, Older Adult)","Not Applicable","36","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","APHP211325|2022-A00523-40","October 2022","September 2024","September 2024","September 10, 2022",,"October 19, 2022","AP-HP - Pitié-Salpêtrière Hospital, Paris, France",,"https://ClinicalTrials.gov/show/NCT05536232" | |
| 287,"NCT04628481","A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function",,"Recruiting","No Results Available","New-onset type1 Diabetes","Drug: Ladarixin|Drug: Placebo","Change from baseline in 2-hour AUC of C-peptide response to the Mixed Model Tolerance Test (MMTT)|Change from baseline in HbA1c|Change from baseline in 2-hour AUC of C-peptide response to the MMTT|Change in HbA1c from baseline|Time in range (TIR) by Continuous Glucose Monitoring (CGM)|Proportion of patients with HbA1c <7% who did not experience severe hypoglycemic events during treatment|Average (previous 3 days) daily insulin requirement (IU/kg/day)|Proportion of patients with HbA1c <7% and daily insulin requirement <0.5 (IU/kg/day)|Number of self-reported episodes of severe hypoglycemia|Percentage of patients not requiring insulin therapy|Estimated Glucose Disposal Rate (eGDR)","Dompé Farmaceutici S.p.A","All","14 Years to 45 Years (Child, Adult)","Phase 3","327","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LDX0319|2020-001926-71","December 21, 2020","March 2024","March 2025","November 13, 2020",,"November 22, 2022","University of Alabama at Birmingham (UAB) - The Kirklin Clinic (TKC) - Multidisciplinary Comprehensive Diabetes Clinic (MCDC), Birmingham, Alabama, United States|Phoenician Centers for Research and Innovation, Phoenix, Arizona, United States|University of California San Diego, La Jolla, California, United States|Center of Excellence in Diabetes & Endocrinology (CEDE), Sacramento, California, United States|University of Colorado School of Medicine - Barbara Davis Center for Childhood Diabetes (BDC) - Specialty Clinic, Aurora, Colorado, United States|Christiana Care Endocrinology Specialists, Newark, Delaware, United States|Diabetes Care Center - Hudson, Hudson, Florida, United States|Global Life Research Network, Miami, Florida, United States|AdventHealth (Florida Hospital) - Diabetes Institute - Orlando, Orlando, Florida, United States|Atlanta Diabetes Associates (ADA), Atlanta, Georgia, United States|The University of Chicago, Chicago, Illinois, United States|Prairie Education and Research Cooperative d/b/a Central Illinois Diabetes and Clinical, Springfield, Illinois, United States|Indiana University - Riley Hospital for Children, Indianapolis, Indiana, United States|The Cotton-O'Neil Diabetes and Endocrinology Center, Topeka, Kansas, United States|University of Louisville, Louisville, Kentucky, United States|Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, United States|UBMD Physicians Group - Pediatrics - Conventus, Buffalo, New York, United States|""WakeMed Physician Practices - Pediatric Endocrinology - WakeMed Raleigh Medical Park Location"", Raleigh, North Carolina, United States|University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Pittsburgh - UPMC, Pittsburgh, Pennsylvania, United States|Cook Children's Endocrinology and Diabetes Program, Fort Worth, Texas, United States|Texas Children's Hospital, Houston, Texas, United States|Eastern Virginia Medical School (EVMS) - Strelitz Diabetes Center, Norfolk, Virginia, United States|Clinique du Sud Luxembourg - Vivialia-Arlon, Arlon, Belgium|Universitair Ziekenhuis Brussel (UZB), Jette, Belgium|General Hospital AZ Nikolaas, Sint-Niklaas, Belgium|Aleksandre Aladashvili Clinic LLC, Tbilisi, Georgia|National Center for Diabetes Research LTD, Tbilisi, Georgia|National Institute of Endocrinology LTD, Tbilisi, Georgia|Tbilisi Heart and Vascular Clinic LTD, Tbilisi, Georgia|Medical Center - University of Freiburg, Freiburg, Germany|Universitaetsklinikum Gessen und Marburg GmbH - Medizinische Klinik und Poliklinik III, Glessen, Germany|Diabestesinstitut Heidelberg, Heidelberg, Germany|Die Praxis am Ludwigsplatz, Ludwigshafen am Rhein, Germany|Institut fuer Diabetes forschung in Muenster (IDFM), Münster, Germany|Schwerpunktpraxis fuer Diabetes & Ernaehrungsmedizin, Münster, Germany|Soroka Medical Center, Be'er Sheva, Israel|Schneider Children's Medical Center, Petah Tikva, Petah Tikva, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv-Yafo, Israel|Ospedale Pediatrico G. Salesi - Centro Regionale di Diabetologia Clinica Pediatrica, Ancona, Italy|Azienda Ospedaliero-Universitaria Conzorziale Policlinico di Bari, Bari, Italy|Università degli Studi Magna Graecia di Catanzaro, Azienda Ospedaliero-Universitaria Mater Domini, Catanzaro, Italy|Universitá degli Studi di Milano - Ospedale Luigi Saco, Milan, Italy|Centro regionale di Diabetologia Pediatrica ""G. Stoppoloni"", Azienda Ospedaliera Universitaria ""Luigi Vanvitelli"", Napoli, Italy|Azienda Ospedaliera Universitaria Policlinico ""Paolo Giaccone"", Palermo, Italy|Università Campus Bio-Medico di Roma (UCBM) - Policlinico Universitario, Roma, Italy|Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale Pediatrico Bambino Gesu, Roma, Italy|Universita Cattolica del Sacro Cuore - Policlinico Universitario ""Agostino Gemelli"", Roma, Italy|""Sapienza"" Università di Roma- Azienda Ospedaliero Universitaria Policlinico Umberto I, Rome, Italy|Clinical Center of Serbia, Clinic for Endocrinology, Diabetes and Metabolic Diseases, Belgrade, Serbia|Clinical Center of Serbia, Clinic for Endocrinology, Diabetes and Metabolic Diseases, Belgrade, Serbia|University Children's Hospital, Belgrade, Serbia|Clinical center Kragujevac, Clinic for internal diseases, Center for endocrinology, diabetes and metabolic diseases, Kragujevac, Serbia|Clinical Center Nis, Clinic for endocrinology, Niš, Serbia|Clinical Center Nis, Clinic for endocrinology, Niš, Serbia|University Children's Hospital, University Medical Center Ljubljana, Lubiana, Slovenia",,"https://ClinicalTrials.gov/show/NCT04628481" | |
| 288,"NCT04899271","A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.",,"Active, not recruiting","No Results Available","New-onset Type 1 Diabetes","Drug: Ladarixin|Other: Placebo","Proportion of patients with HbA1c <7% and daily insulin requirement <0.50 IU/Kg/day|Proportion of patients with HbA1c < 7% and daily insulin requirement <0.50 IU/Kg/day|Proportion of patients with a reduction in HbA1c% > 0.5% from baseline and daily insulin requirement <0.50 IU/Kg|2-hour AUC of C-peptide response to the MMTT|Time in range (TIR) by Continuous Glucose Monitoring (CGM)|HbA1c levels|Proportion of patients with HbA1c < 7% who did not experience severe hypoglycemic events during treatment|Additional Glucose Variability Indices derived from CGM: PPG|Additional Glucose Variability Indices derived from CGM: MAGE|Additional Glucose Variability Indices derived from CGM: CONGA-n|Additional Glucose Variability Indices derived from CGM: MODD|Additional Glucose Variability Indices derived from CGM: mean daily blood glucose|Additional Glucose Variability Indices derived from CGM: Standard Deviation (SD)|Number of self-reported episodes of severe hypoglycemia|Average (previous 3 days) daily insulin requirements (IU/kg/day)|Estimated Glucose Disposal Rate (eGDR)|Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)","Dompé Farmaceutici S.p.A","All","18 Years to 45 Years (Adult)","Phase 2","25","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LDX0419|2020-002966-15","December 14, 2020","June 2023","December 2023","May 24, 2021",,"May 3, 2022","University of Alabama at Birmingham (UAB) - The Kirklin Clinic (TKC) - Multidisciplinary Comprehensive Diabetes Clinic (MCDC), Birmingham, Alabama, United States|University of Colorado School of Medicine - Barbara Davis Center for Childhood Diabetes (BDC) - Specialty Clinic, Aurora, Colorado, United States|Global Life Research Network, Miami, Florida, United States|Atlanta Diabetes Associates (ADA), Atlanta, Georgia, United States|Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, United States|Clinique du Sud Luxembourg - Vivialia-Arlon, Arlon, Belgium|Universitair Ziekenhuis Brussel (UZB), Jette, Belgium|General Hospital AZ Nikolaas, Sint-Niklaas, Belgium|Aleksandre Aladashvili Clinic LLC, Tbilisi, Georgia|National Center for Diabetes Research LTD, Tbilisi, Georgia|National Institute of Endocrinology LTD, Tbilisi, Georgia|Tbilisi Heart and Vascular Clinic LTD, Tbilisi, Georgia|Universitaetsklinikum Gessen und Marburg GmbH - Medizinische Klinik und Poliklinik III, Glessen, Germany|Diabestesinstitut Heidelberg, Heidelberg, Germany|Die Praxis am Ludwigsplatz, Ludwigshafen, Germany|Institut fuer Diabetes forschung in Muenster (IDFM), Muenster, Germany|Azienda Ospedaliero-Universitaria Conzorziale Policlinico di Bari, Bari, Italy|Università degli Studi Magna Graecia di Catanzaro, Azienda Ospedaliero-Universitaria Mater Domini, Catanzaro, Italy|Universitá degli Studi di Milano - Ospedale Luigi Sacco, Milan, Italy|Azienda Ospedaliera Universitaria Policlinico ""Paolo Giaccone"", Palermo, Italy|Università Campus Bio-Medico di Roma (UCBM), Roma, Italy|""Sapienza"" Università di Roma- Azienda Ospedaliero Universitaria Policlinico Umberto I, Rome, Italy|Clinical Center of Serbia, Clinic for Endocrinology, Diabetes and Metabolic Diseases, Belgrade, Serbia|Clinical center Kragujevac, Clinic for internal diseases, Center for endocrinology, diabetes and metabolic diseases, Kragujevac, Serbia|Clinical Center Nis, Clinic for endocrinology, Niš, Serbia",,"https://ClinicalTrials.gov/show/NCT04899271" | |
| 289,"NCT05044442","HIT on Hypoglycaemic Risk in T1D",,"Completed","No Results Available","Type1diabetes","Behavioral: moderate intensity continous training|Behavioral: high intensity interval training","Severe hypoglycaemia (using continuous glucose monitoring)|Mean glucose (using continuous glucose monitoring)|% of time in level 2 hypoglycaemia (<3.0mmol/L) (using continuous glucose monitoring)|% of time in level 1 hypoglycaemia (3.0-3.9mmol/L) (using continuous glucose monitoring)|% of time in target range (3.9-10.0mmol/L) (using continuous glucose monitoring)|% of time in level 1 hyperglycaemia (10.0-13.9mmol/L) (using continuous glucose monitoring)|% of time in level 2 hyperglycaemia (>13.9mmol/L) (using continuous glucose monitoring)|glycaemic variability (using continuous glucose monitoring)|area under the curve of episodes of hypoglycaemia and hyperglycaemia","Liverpool John Moores University|Society for Endocrinology|Royal Liverpool University Hospital|University of Birmingham|University of Exeter","All","18 Years to 55 Years (Adult)","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","SB_T1D_V1","October 1, 2018","August 1, 2019","August 1, 2019","September 14, 2021",,"September 14, 2021","Matthew Cocks, Liverpool, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05044442" | |
| 290,"NCT04123054","A Novel mHealth Application Guided by an Optimization Algorithm for T1D Sensor-Augmented Insulin Injection Users",,"Recruiting","No Results Available","Diabetes Mellitus|Diabetes Mellitus, Type 1","Device: Mobile App|Device: Mobile App + Basal-Bolus Optimization Algorithm","Change in HbA1c levels|The number of patients that achieve an HbA1c at the end-of-study visit of:|Percentage of time of sensor glucose levels spent:|Percentage of overnight time (23:00-7:00) of sensor glucose levels:|Percentage of daytime (7:00-23:00) of sensor glucose levels:|Standard deviation of glucose levels.|Total insulin delivery.|Mean sensor glucose level during:","McGill University","All","18 Years and older (Adult, Older Adult)","Not Applicable","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-5887","March 5, 2020","November 1, 2022","November 1, 2022","October 10, 2019",,"August 8, 2022","CIUSSS West-Central Montreal, Jewish General Hospital, Montreal, Quebec, Canada|McGill University Health Centre, Montréal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT04123054" | |
| 291,"NCT02184676","T1D Risk Assessment in Kids With Relatives","TRAKR","Completed","No Results Available","Type 1 Diabetes","Biological: Analysis of early immune modifications|Other: Collection of clinical and socio-demographic data","Autoreactive T lymphocytes|Metagenomic signatures|Metabolic signatures|Environmental factors|Incidence of autoantibodies","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé et de la Recherche Médicale (INSERM) U1016 - Institut Cochin, Immunology of Diabetes Team, Paris, France|INSERM U1153, Epidemiology Research Unit on Perinatal Health and Women and Children Health, Port-Royal Hospital, Paris, France|Institut National de la Recherche Agronomique|Commissariat A L'energie Atomique","All","1 Day and older (Child, Adult, Older Adult)","Not Applicable","512","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","P130405|ID RCB : 2014-A00453-44","May 28, 2015","May 17, 2019","May 17, 2019","July 9, 2014",,"April 5, 2021","Cochin Hospital, Paris, France",,"https://ClinicalTrials.gov/show/NCT02184676" | |
| 292,"NCT04118374","A Study to Determine Iatrogenic Hyperinsulinemia's Contribution to Insulin Resistance and Endothelial Dysfunction in Type 1 Diabetes",,"Recruiting","No Results Available","Diabetes Mellitus, Type 1","Other: Standard Carb Diet|Other: Low Carb Diet","Change in insulin sensitivity - diet 1|Change in insulin sensitivity - diet 2|Change in endothelial function - diet 1|Change in endothelial function - diet 2","Vanderbilt University Medical Center","All","18 Years to 60 Years (Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","190630","March 29, 2019","February 28, 2024","February 28, 2024","October 8, 2019",,"October 10, 2022","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04118374" | |
| 293,"NCT05413005","Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus","OPERA","Recruiting","No Results Available","Type 1 Diabetes","Combination Product: ECP regular-intensity arm|Combination Product: ECP accelerated-intensity arm|Biological: T1DM standard of care","Tolerability to ECP procedures|Incidence of adverse events (AEs)|Exogenous insulin use|HbA1c levels|C-peptide levels|Clinically important hypoglycemic episodes|Immune response profile (cellular)|Serum IgG levels|Serum IgA levels|Serum IgM levels","Abu Dhabi Stem Cells Center","All","18 Years to 50 Years (Adult)","Early Phase 1","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CT.004.1.1.OPERA","September 5, 2022","October 1, 2023","January 1, 2024","June 9, 2022",,"October 31, 2022","Abu Dhabi Stem Cells Center, Abu Dhabi, United Arab Emirates",,"https://ClinicalTrials.gov/show/NCT05413005" | |
| 294,"NCT05357534","Perception of Blood Sugar Variations During Physical Activity in Healthy Subjects and Type 1 Diabetes Patients","GLYSPORT","Not yet recruiting","No Results Available","Type 1 Diabetes","Other: Physical activity","blood sugar|Feeling lucidity|Feeling fatigue|feeling hungry|average speed per kilometer Sports performance|total running time|average running speed","Université de Reims Champagne-Ardenne","Male","18 Years to 65 Years (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2022-RIPH_002_GLYSPORT","June 1, 2022","November 1, 2022","February 1, 2023","May 3, 2022",,"May 18, 2022",,,"https://ClinicalTrials.gov/show/NCT05357534" | |
| 295,"NCT04798937","Motivational Interviewing to Improve Self Management in Youth With Type 1 Diabetes",,"Completed","No Results Available","type1diabetes","Other: Motivational interviewing","Transition Readiness Assessment Questionnaire (TRAQ) scores|Hemoglobin glycated values","Université de Sousse","All","13 Years to 18 Years (Child, Adult)","Not Applicable","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","140221","January 1, 2020","July 31, 2020","July 31, 2020","March 15, 2021",,"March 15, 2021","Farhat Hached University Hospital, Sousse, Tunisia",,"https://ClinicalTrials.gov/show/NCT04798937" | |
| 296,"NCT01268644","Effects of Metreleptin in Type 1 Diabetes Mellitus",,"Terminated","Has Results","Type 1 Diabetes","Drug: Leptin","HbA1c|Weight|Insulin Dose|Change in HbA1c From Baseline to Week 20 on Leptin Therapy","University of Texas Southwestern Medical Center|Juvenile Diabetes Research Foundation|Amylin Pharmaceuticals, LLC.","All","18 Years to 50 Years (Adult)","Phase 1","8","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FBA937|CTRC # 953","September 2010","January 2013","August 2014","December 31, 2010","August 28, 2019","August 28, 2019","UT Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01268644" | |
| 297,"NCT05095610","Clinical Effects of Intermitent Continuous Glucose Monitoring in Type 1 Diabetes",,"Completed","No Results Available","Type 1 Diabetes","Device: Flash","HbA1c difference|Frequency of SBGM|Adherence to Flash|TIR|TAR|TBR|%CV|Body weight|Insulin dose","Castilla-La Mancha Health Service","All","16 Years to 99 Years (Child, Adult, Older Adult)",,"1121","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","C-455","November 1, 2021","March 30, 2022","May 6, 2022","October 27, 2021",,"July 19, 2022","La Mancha- Centro Hospital, Alcázar De San Juan, Ciudad Real, Spain|Santa Barbara Hospital, Puertollano, Ciudad Real, Spain|Virgen de Altagracia Hospital, Valdepeñas, Ciudad Real, Spain|Virgen del Prado Hospital, Talavera De La Reina, Toledo, Spain|Albacete University Hospital, Albacete, Spain|Obispo Rafael Torija, St., Ciudad Real, Spain|Guadalajara University Hospital, Guadalajara, Spain|Toledo University Hospital, Toledo, Spain",,"https://ClinicalTrials.gov/show/NCT05095610" | |
| 298,"NCT04933851","ACT1VATE: Addressing Emotional Distress to Improve Outcomes Among Diverse Adults With Type 1 Diabetes",,"Recruiting","No Results Available","Type 1 Diabetes","Behavioral: ACT1VATE|Behavioral: DSME/S","Glycosylated Hemoglobin (HbA1c)|Diabetes Distress Scale|Summary of Diabetes Self-Care Activities Survey|Generalized Anxiety Disorder Assessment|Patient Health Questionnaire-8|Perceived Stress Scale|The WHO Well-Being Index|Hypoglycemic Attitudes and Behaviors Scale|Revised Diabetes Knowledge Test|Diabetes Support and Isolation Questionnaire","Scripps Whittier Diabetes Institute|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years and older (Adult, Older Adult)","Phase 2","484","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","1R01DK127491|R01DK127491","October 25, 2021","June 2026","June 2026","June 22, 2021",,"December 9, 2022","Scripps Whittier Diabetes Institute, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT04933851" | |
| 299,"NCT05281614","Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D","COBRA","Recruiting","No Results Available","Type 1 Diabetes","Drug: Etanercept|Drug: Vedolizumab","Impact on insulin secretion determined by 2-hour MMTT stimulated AUC C-peptide 10 weeks after first vedolizumab dose and 52 weeks after randomization.|Adverse events of etanercept treatment as a measure of safety and tolerability|Adverse events of vedolizumab treatment as a measure of safety and tolerability|Frequency of α4β7+ T cells|Frequency of myeloid DC1 cells|Frequency and surface marker phenotype of other immune cells such as antigen specific CD4 and CD8 cells, memory and naive T and B cells|Change in T1D antibody titers","Benaroya Research Institute|University of California, San Diego","All","18 Years to 45 Years (Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","BenaroyaRI","August 1, 2022","April 2024","April 2025","March 16, 2022",,"July 25, 2022","University of California San Diego, La Jolla, California, United States|Benaroya Research Institute, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT05281614" | |
| 300,"NCT05219409","Effects of Sitagliptin in Relatives of T1D Patients","SITA-one","Not yet recruiting","No Results Available","Type 1 Diabetes","Drug: Sitagliptin|Device: Professional CGM","Rate of new diagnoses of Type 1 Diabetes Mellitus per year|Number of participants with adverse effects on Sitagliptin","University of Milan","All","10 Years to 45 Years (Child, Adult)","Phase 2|Phase 3","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","01/2022","December 2022","December 2025","December 2027","February 2, 2022",,"June 21, 2022","ASST FBF Sacco, Milan, Italy",,"https://ClinicalTrials.gov/show/NCT05219409" | |
| 301,"NCT02053051","Advanced Bolus Calculator for Type 1 Diabetes (ABC4D)","ABC4D","Completed","No Results Available","Type 1 Diabetes","Device: ABC4D|Drug: Novorapid","HbA1c|Post-prandial hypoglycaemia|Post-meal glucose at 60 and 120 minutes|Post-prandial area under the curve (AUC) at 120 minutes|Hypoglycaemia at 4-hours post-prandially|Glycaemic risk: LBGI and HBGI|Glycaemic variability: MAGE and CONGA-2|Change in weight (kg)|Number achieving target HbA1c ( ≤ 53 mmol/mol )","Imperial College London","All","18 Years and older (Adult, Older Adult)","Not Applicable","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","13SM0091","November 12, 2013","September 30, 2021","December 31, 2021","February 3, 2014",,"March 31, 2022","Imperial College London, Imperial College Healthcare NHS Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02053051" | |
| 302,"NCT03699189","ANAIS, a Spanish Version of the DAFNE Programme","ANAIS","Completed","No Results Available","Diabetes Mellitus, Type 1","Behavioral: Immediate ANAIS","HbA1c|Lipids|Weight|Hypoglycemic events|Treatment satisfaction|Self-defined objectives|The quality of life","Rosa María Sánchez Hernández|Ana M. Wägner|Dácil Alvarado-Martel|Yaiza López-Plasencia|Armando Carrillo-Domínguez|Julia Rodríguez-Cordero|Francisco J Nóvoa-Mogollón|Angelines Jiménez-Rodríguez|Hospital Universitario Insular Gran Canaria","All","18 Years and older (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","ANAIS","November 2011","February 2015","February 2015","October 9, 2018",,"October 9, 2018",,,"https://ClinicalTrials.gov/show/NCT03699189" | |
| 303,"NCT04764786","Polyphenol Enriched Extra-virgin Olive Oil and Postprandial Glycemia in Type 1 Diabetes (DOP)","DOP","Completed","No Results Available","Type 1 Diabetes","Other: EVOO+POLY|Other: OO-POLY","the between-group difference in postprandial glycemia changes after the dietary interventions","Federico II University","All","18 Years to 65 Years (Adult, Older Adult)","Not Applicable","22","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","37/19","April 1, 2019","November 20, 2019","November 20, 2020","February 21, 2021",,"February 24, 2021","Federico II University, Napoli, Naples, Italy",,"https://ClinicalTrials.gov/show/NCT04764786" | |
| 304,"NCT04007809","Phenotypic and Genotypic Characterization of New-onset Type I Diabetes","DIATAG","Active, not recruiting","No Results Available","Type1diabetes","Other: Glucagon","Evaluation of T1D subgroups by using follow-up of clinical parameters : weight in kilograms|Evaluation of T1D subgroups by using follow-up of clinical parameters : Height in centimeter|Evaluation of T1D subgroups by using follow-up of clinical parameters : Body mass index (kg/m²)|Evaluation of T1D subgroups by using follow-up of clinical parameters : glycemic variability (%)|Follow-up of laboratory results - glycemia (mg/dL)|Follow-up of laboratory results - Insulin (mUI/L)|Follow-up of laboratory results - HbA1C (%)|Follow-up of laboratory results - C-peptide (mUI/L)|Evaluation and follow-up of diet, physical activity, quality of life using validated questionnaires.|Evaluation and follow-up of physical activity|Evaluation and follow-up of quality of life: DisabKids Questionnaires|Production of prediction model of β-cell mass evolution","Université Catholique de Louvain|Fonds National de la Recherche Scientifique|BESPEED","All","6 Months to 18 Years (Child, Adult)","Not Applicable","98","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","DIATAG","June 15, 2019","August 15, 2022","June 30, 2027","July 5, 2019",,"June 28, 2022","Cliniques universitaires Saint-Luc, Brussels, Belgium",,"https://ClinicalTrials.gov/show/NCT04007809" | |
| 305,"NCT01017965","Impact of Objective Sleep Duration on Blood Glucose Control in Type 1 Diabetes Adult Patients","DIAPASOM2","Terminated","No Results Available","Type 1 Diabetes","Device: Actimeter + blood pressure monitoring","HbA1c in %|Objective sleep duration in minutes|Blood pressure in cm Hg|Quality of life assessed through questionnaire","University Hospital, Grenoble","All","18 Years and older (Adult, Older Adult)",,"79","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","0917|2009-A00816-51","November 2009","April 2012","April 2012","November 23, 2009",,"October 5, 2012","Service de Diabétologie du Pr Halimi, CHU, Grenoble Cedex 9, France",,"https://ClinicalTrials.gov/show/NCT01017965" | |
| 306,"NCT04545411","Combination GRA and SGLT-2i Treatment in Type 1 Diabetes",,"Active, not recruiting","No Results Available","Type 1 Diabetes","Drug: Dapagliflozin 10 MG [Farxiga]|Drug: REMD-477|Drug: Placebo","Change in Beta-hydroxybutyrate (BHB) Level|Change in Glycemic Control|Change in Vascular Endothelial Function","University of California, San Diego|REMD Biotherapeutics, Inc.|Juvenile Diabetes Research Foundation|The Leona M. and Harry B. Helmsley Charitable Trust","All","18 Years to 65 Years (Adult, Older Adult)","Phase 1|Phase 2","12","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","UC-MEDJP-03","February 22, 2021","February 28, 2022","October 31, 2022","September 11, 2020",,"September 14, 2022","UC San Diego Altman Clinical & Translational Research Institute, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT04545411" | |
| 307,"NCT05403502","Safety Evaluation of an Advanced Hybrid Closed Loop System Using Lyumjev With the Tandem t:Slim X2 Insulin Pump With Control-IQ Technology in Adults, Adolescents and Children With Type 1 Diabetes",,"Recruiting","No Results Available","Type 1 Diabetes","Device: t:slim X2 insulin pump with Control-IQ technology 1.5","Severe hypoglycemia|Diabetic ketoacidosis|Unanticipated adverse device effects|Other serious adverse events|Adverse drug reactions|All reportable adverse events|CGM hypoglycemia outcomes: Overall % time <54 mg/dL|CGM hypoglycemia outcomes: Postprandial % time <54 mg/dL|CGM hypoglycemia outcomes: Overall % time <70 mg/dL|CGM hypoglycemia outcomes: Postprandial % time <70 mg/dL|CGM hypoglycemia outcomes: Rate of hypoglycemia events","Tandem Diabetes Care, Inc.|Eli Lilly and Company|Jaeb Center for Health Research","All","6 Years to 80 Years (Child, Adult, Older Adult)","Not Applicable","200","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TP-0009650","August 31, 2022","April 15, 2023","May 22, 2023","June 3, 2022",,"December 14, 2022","Children's Hospital Orange County, Orange, California, United States|Stanford University, Palo Alto, California, United States|University of California, San Francisco, San Francisco, California, United States|Barbara Davis Center, Aurora, Colorado, United States|Barbara Davis Center, Aurora, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of South Florida Diabetes Center, Tampa, Florida, United States|Northwestern University, Evanston, Illinois, United States|Indiana University / Riley Hospital for Children, Indianapolis, Indiana, United States|Iowa Diabetes and Endocrinology Research Center (IDERC), West Des Moines, Iowa, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Icahn School of Medicine at Mt. Sinai, New York, New York, United States|Diabetes & Glandular Disease (DGD), San Antonio, Texas, United States|University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT05403502" | |
| 308,"NCT04486547","Information Motivation Behavioral Skills Model's Effects on Adolescents With Type 1 Diabetes",,"Completed","No Results Available","Type 1 Diabetes","Behavioral: Information-Motivation-Behavioral Skills model-based intervention","Change from baseline knowledge level of adolescents at 6 months|Change from baseline personal motivation level of adolescents at 6 months|Change from baseline behavioral skills level of adolescents at 6 months|Change from baseline HbA1c levels of adolescents at 6 months|Change from baseline social motivation level of adolescents at 6 months","Elif Bakır|Hacettepe University","All","12 Years to 18 Years (Child, Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2018-059","October 15, 2018","August 15, 2019","December 15, 2019","July 24, 2020",,"July 24, 2020","Hacettepe University, Ankara, Altındağ, Turkey",,"https://ClinicalTrials.gov/show/NCT04486547" | |
| 309,"NCT02010528","Diabetes Distress, Psychological Well-being and Family Hardiness in Parents of Children and Adolescents With T1D",,"Completed","No Results Available","Type 1 Diabetes",,"parental diabetes-related distress|psychosocial characteristics","University Medical Centre Ljubljana|Slovenian Research Agency (ARRS)","All","2 Years to 18 Years (Child, Adult)",,"300","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","DIS-PSY-PAR-T1D-2013","December 2013","February 2014","February 2014","December 12, 2013",,"February 13, 2014","Dept. of Pediatric Endocrinology, Diabetes & Metabolism, University Children's Hospital, UMCL, Ljubljana, Slovenia",,"https://ClinicalTrials.gov/show/NCT02010528" | |
| 310,"NCT03886974","Transition to Adult Care in Type 1 Diabetes",,"Completed","No Results Available","Type1diabetes",,"Needs assessment for transition of care","Hoag Memorial Hospital Presbyterian","All","18 Years and older (Adult, Older Adult)",,"260","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","147-18-DI","September 7, 2018","October 1, 2019","October 1, 2019","March 22, 2019",,"November 12, 2019","Mary & Dick Allen Diabetes Center, Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States",,"https://ClinicalTrials.gov/show/NCT03886974" | |
| 311,"NCT03619031","Pizza Leavening and Postprandial Glycemia in Type 1 Diabetes (LEAVEN)","LEAVEN","Completed","No Results Available","Type 1 Diabetes","Other: LONG LEAVENING|Other: SHORT LEAVENING|Other: TRADITIONAL","Postprandial glucose response (AUC)|Blood glucose peak|Time to blood glucose peak","Federico II University","All","18 Years to 70 Years (Adult, Older Adult)","Not Applicable","16","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","107/18","May 3, 2018","August 30, 2018","September 15, 2018","August 7, 2018",,"July 30, 2019","Department of Clinical Medicine and Surgery, Naples, Italy",,"https://ClinicalTrials.gov/show/NCT03619031" | |
| 312,"NCT03758430","A Study of Technology to Improve Glucose Control in Participants With Type 1 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Other: Meal-Tagging App|Device: Fitness Tracker","Change from Baseline to Week 16 in Hemoglobin A1c (HbA1c)|Change from Baseline to Week 16 in Post-Prandial Glucose Concentrations Following Commonly Eaten Meals","Eli Lilly and Company|Joslin Diabetes Center","All","18 Years to 70 Years (Adult, Older Adult)",,"28","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","17111|F3Z-MC-IORA","February 6, 2019","August 7, 2020","August 7, 2020","November 29, 2018",,"August 21, 2020","Joslin Diabetes Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03758430" | |
| 313,"NCT02306005","Insulin Therapy and Lipoproteins' Profile in Type 1 Diabetes.","InLipoDiab1","Unknown status","No Results Available","Type 1 Diabetes Mellitus",,"Changes in lipoproteins' metabolism|Factors influencing relationship between insulin treatment and lipoproteins|Changes in apolipoproteins|Presence of insulin resistance|Development of Retinopathy|Development of Neuropathy|Development of Diabetic kidney disease","Poznan University of Medical Sciences","All","18 Years to 35 Years (Adult)",,"300","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","PoznanUMS","November 2014","December 2022","January 2023","December 3, 2014",,"May 5, 2020","Department of Internal Medicine and Diabetiology Poznan University of Medical Sciences, Poznan, Poland",,"https://ClinicalTrials.gov/show/NCT02306005" | |
| 314,"NCT01705899","Islet Allotransplantation in Type 1 Diabetes",,"Active, not recruiting","No Results Available","Type 1 Diabetes","Drug: Human Pancreatic Islets","Incidence of adverse events|Incidence of serious adverse events|Incidence of infectious complications|Incidence of procedural-related events|Incidence of elevated liver function tests|Incidence of hypoglycemia|Incidence of abnormalities in lipids|Incidence of donor-specific antibody development|Change in microalbumin level|Change in measured creatinine clearance|Amount of daily insulin units required|Measurement of C-peptide|Change in c-peptide level from fasting following administration of mixed meal|Change in acute insulin response to glucose|Incidence of blood glucose level <140mg/dl two hours after oral glucose tolerance tests|Change in Quality of Life|Change in hypoglycemia score|Change in glycemic lability score","Ohio State University","All","18 Years to 65 Years (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB 2006H0200","November 2006","October 2022","October 2022","October 12, 2012",,"November 3, 2021","The Ohio State University Medical Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01705899" | |
| 315,"NCT04336969","Teamwork, Targets, Technology, and Tight Control in Newly Diagnosed Pediatric T1D - 4T Study",,"Enrolling by invitation","No Results Available","Type1diabetes","Behavioral: 4T Education and Care","Change in rise of HbA1c|Change in CGM Benefits and Burden Scale|Change Diabetes Distress Scale|Change in Diabetes Technology Attitude Scale|Change in Parental Diabetes Distress Scale|Change in Promise Global Health Scale|Change in Physical Activity, Youth Physical Activity Questionnaire (Y-PAQ)|Change in Physical Activity, International Physical Activity Questionnaire (IPAQ)|Change in participant Hypoglycemic Fear Scale|Change in parent Hypoglycemic Fear Scale|Change in Self-Efficacy for Exercise Scale|Change in education exposure to safe exercise strategies","Stanford University|National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","6 Months to 21 Years (Child, Adult)","Not Applicable","500","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","52812|1R18DK122422-01A1","June 18, 2020","October 31, 2024","December 30, 2025","April 7, 2020",,"December 7, 2022","Franziska Katherine Bishop, Steamboat Springs, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT04336969" | |
| 316,"NCT02044848","Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus",,"Terminated","Has Results","Type 1 Diabetes Mellitus","Drug: Secukinumab|Drug: Placebo","Stimulated C-peptide in Response to a Standard Mixed Meal Tolerance Test","Novartis Pharmaceuticals|Novartis","All","18 Years to 35 Years (Adult)","Phase 2","5","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CAIN457A2227","February 2014","September 2014","September 2014","January 24, 2014","October 9, 2015","February 17, 2016","Novartis Investigative Site, New York City, New York, United States|Novartis Investigative Site, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02044848" | |
| 317,"NCT03046927","Vitamin D and Residual Beta-Cell Function in Type 1 Diabetes","PCR","Completed","No Results Available","Type 1 Diabetes","Drug: Ergocalciferol|Other: Placebo","Residual beta-cell function (RBCF)|Glycemic control (HbA1c)|Glucagon-like peptide-1 (GLP-1)|Differences in the duration of PCR in subjects with high-risk SNPs receiving vitamin D vs. placebo|Vitamin D Binding Protein (VDBP)|Duration of Partial Clinical Remission (PCR)","Benjamin U. Nwosu, MD|University of Massachusetts, Worcester|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","10 Years to 21 Years (Child, Adult)","Phase 2|Phase 3","48","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H00010550|1R21DK113353","October 19, 2017","April 12, 2021","April 20, 2021","February 8, 2017",,"January 11, 2022","University of Massachusetts Medical School, Worcester, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03046927" | |
| 318,"NCT00738907","Assessment of Beta Cell Mass by PET Scans With [11C] Dihydrotetrabenazine (DTBZ) in Longstanding Type 1 Diabetes.",,"Completed","No Results Available","Type 1 Diabetes",,"Pancreatic tracer binding as standardized uptake value (SUV) or binding potential (BPnd)","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 45 Years (Adult)",,"18","NIH","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","DK77493 (completed)","November 2006","January 2008","May 2008","August 21, 2008",,"September 25, 2014",,,"https://ClinicalTrials.gov/show/NCT00738907" | |
| 319,"NCT02500979","Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus",,"Completed","Has Results","Type 1 Diabetes Mellitus","Drug: Pramlintide acetate|Drug: Placebo|Drug: Lispro insulin U-100|Drug: Regular insulin U-100","Efficacy of Pramlintide by Measurement of 24-hour Tissue Mean Weighted Glucose (MWG) Obtained With Continuous Glucose Monitoring (CGM)|Efficacy of Pramlintide by Measurement of Absolute Plasma Glucose Area Under the Plasma Concentration-time Curve (AUC) Following Lunch|Efficacy of Pramlintide by Measurement of Absolute Plasma Glucose Area Under the Plasma Concentration-time Curve (AUC) Following Dinner|Efficacy of Pramlintide by Measurement of Absolute Plasma Glucose Area Under the Plasma Concentration-time Curve (AUC) Following Breakfast|Efficacy of Pramlintide by Measurement of Incremental 24-hour Tissue Glucose Area Under the Plasma Concentration-time Curve (AUC) Obtained With Continuous Glucose Monitoring (CGM)|Efficacy of Pramlintide by Measurement of Absolute 24-hour Plasma Glucose Area Under the Plasma Concentration-time Curve (AUC)|Efficacy of Pramlintide by Measurement of Incremental 24-hour Plasma Glucose Area Under the Plasma Concentration-time Curve (AUC)|Efficacy of Pramlintide Measured by Percent Time Spent in the Range of >70 mg/dL to <180 mg/dL Tissue Glucose Obtained With Continuous Glucose Monitoring (CGM)|Efficacy of Pramlintide by Measurement of Absolute 24-hour Plasma Glucagon Area Under the Plasma Concentration-time Curve (AUC)|Efficacy of Pramlintide by Measurement of Incremental 24-hour Plasma Glucagon Area Under the Plasma Concentration-time Curve (AUC)|Fasting Plasma Glucose Concentration|Pharmacokinetics of Insulin as Demonstrated by 24-hour Plasma Insulin Area Under the Plasma Concentration-time Curve (AUC)|Pharmacokinetics of Insulin as Demonstrated by 24-hour Average Plasma Insulin Concentration.|Pharmacokinetics of Insulin as Demonstrated by Maximum Plasma Insulin Concentration|Pharmacokinetics of Insulin as Demonstrated by the Time to the Maximum Plasma Insulin Concentration","AstraZeneca|Juvenile Diabetes Research Foundation","All","18 Years to 70 Years (Adult, Older Adult)","Phase 1","34","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","D5570C00002","August 17, 2015","August 5, 2016","August 5, 2016","July 17, 2015","November 2, 2018","November 2, 2018","Research Site, Chula Vista, California, United States|Research Site, Portland, Oregon, United States|Research Site, Chattanooga, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02500979" | |
| 320,"NCT00730392","Etanercept in New Onset Type 1 Diabetes",,"Completed","No Results Available","Type 1 Diabetes","Drug: Etanercept|Drug: Placebo","The primary end points of this study are percent change from baseline for HbA1c and C-peptide area under the curve (AUC).|Secondary end points are insulin dose and number of insulin injection discontinued, if any","University at Buffalo|Amgen","All","3 Years to 18 Years (Child, Adult)","Phase 1|Phase 2","18","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20020197","October 2002","October 2007","January 2008","August 8, 2008",,"August 8, 2008",,,"https://ClinicalTrials.gov/show/NCT00730392" | |
| 321,"NCT05268705","The Impact of Macronutrient Composition on Glucose Dynamics in Persons With Type 1 Diabetes","HiLo21","Recruiting","No Results Available","type1diabetes","Other: 7-day diet","The primary endpoint is the difference between study arms in difference from start to end plasma glucose concentration during 45 min fasted cycling (assessed by YSI (Yellow Spring Instruments 2900 STAT Plus)).|Mean CGM glucose level assessed by CGM during diet interventions|Time spent < 3.9 mmol/l assessed by CGM during diet interventions|Time spent < 3.0 mmol/l assessed by CGM during diet interventions|Time spent 3.9-10.0 mmol/l assessed by CGM during diet interventions|Time spent > 10.0 mmol/l assessed by CGM during diet interventions|Time spent > 13.9 mmol/l assessed by CGM during diet interventions|Plasma glucose coefficient of variation assessed by CGM during diet interventions|Standard deviation assessed by CGM during diet interventions|Number of hypoglycemia events (< 3.9 mmol/l) of at least 15 minutes duration assessed by CGM during diet interventions|Energy expenditure after each diet intervention assessed by indirect calorimetry|Respiratory exchange ratio after each diet intervention assessed by indirect calorimetry|Carbohydrate oxidation rate after each diet intervention assessed by indirect calorimetry|Fat oxidation rate after each diet intervention assessed by indirect calorimetry|Mean plasma glucose assessed by YSI during cycling and observation phase 2|Plasma glucose nadir assessed by YSI during cycling and observation phase 2|Plasma glucose variation assessed by YSI during cycling and observation phase 2|Plasma glucose standard deviation assessed by YSI during cycling and observation phase 2|Number of hypoglycemia events (< 3.9 mmol/l) assessed by YSI during cycling and observation phase 2|Mean insulin during cycling and observation phase 2|Peak insulin during cycling and observation phase 2|Areal under the curve for insulin during cycling and observation phase 2|Energy expenditure assessed by indirect calorimetry during cycling and observation phase 2|Respiratory exchange ratio assessed by indirect calorimetry during cycling and observation phase 2|Carbohydrate oxidation rate assessed by indirect calorimetry during cycling and observation phase 2|Fat oxidation rate assessed by indirect calorimetry during cycling and observation phase 2|Plasma glucose peak assessed by YSI during observation phase 3|Time to plasma glucose peak assessed by YSI during observation phase 3|Time from glucagon administration to 1.1 mmol/l increase in plasma glucose assessed by YSI during observation phase 3|Change in plasma glucose from injection of glucagon to peak plasma glucose assessed by YSI during observation phase 3","Steno Diabetes Center Copenhagen|Swansea University","All","18 Years and older (Adult, Older Adult)","Not Applicable","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","H-21042230","February 3, 2022","December 31, 2022","December 31, 2023","March 7, 2022",,"March 7, 2022","Steno Diabetes Center Copenhagen, Herlev, Denmark",,"https://ClinicalTrials.gov/show/NCT05268705" | |
| 322,"NCT04431947","Impact of Hybrid Closed-Loop Systems on Sleep and Psychosocial Outcomes in Youth With T1D and Their Parents",,"Completed","No Results Available","Type 1 Diabetes",,"Duration of Sleep|Impact on Diabetes Distress|Impact on Quality of Life|Impact on Fear of Hypoglycemia|Impact on Perceptions of Diabetes Technology|Impact on Hybrid Closed-Loop System Use Perceptions|Impact of Sleep on Glycemic Variability","University of Colorado, Denver|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","2 Years to 17 Years (Child)",,"46","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","20-0375|K12DK094712","March 13, 2020","April 1, 2022","April 1, 2022","June 16, 2020",,"April 25, 2022","University of Colorado, Barbara Davis Center, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT04431947" | |
| 323,"NCT04172077","Self Efficacy Levels, Attachment Style and Resiliency of Youth With Type 1 Diabetes",,"Completed","No Results Available","Type1diabetes",,"Examine the effects of patients' attachment styles (secure, mixed and fearful) on their type one diabetes management represented by A1C level|a) Effect of attachment style on self efficacy level in patients.|a) Effect of attachment style on self efficacy level in parents.|b)Compare diabetes management self-efficacy and attachment style in patients.|b)Compare diabetes management self-efficacy and attachment style in parents","The Hospital for Sick Children","All","12 Years to 18 Years (Child, Adult)",,"170","Other","Observational","Observational Model: Family-Based|Time Perspective: Prospective","1000059604","September 18, 2019","January 30, 2020","January 30, 2020","November 21, 2019",,"July 8, 2021","The Hospital for Sick Children, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04172077" | |
| 324,"NCT05377918","The Effect Of The Spiritual Diary In Children",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Other: Diary","Spritual well-being|Anxiety","Yeditepe University|Bahçeşehir University","All","9 Years to 12 Years (Child)","Not Applicable","89","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","B-TUGCEATAKMERİC-001","January 31, 2022","May 1, 2022","May 1, 2022","May 17, 2022",,"May 17, 2022","Bahçeşehir University, İstanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT05377918" | |
| 325,"NCT02634216","Effects of Capros in Patients With Type-1 Diabetes","CarposT1D","Completed","No Results Available","Type I Diabetes","Dietary Supplement: Capros","Effect of Capros on Blood Glycemic Index","Ohio State University|Natreon, Inc.","All","10 Years to 60 Years (Child, Adult)","Not Applicable","24","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2014H0206","January 2015","May 25, 2016","May 25, 2016","December 17, 2015",,"November 20, 2019","Carepoint East 543 Taylor Ave., Columbus, Ohio, United States|Martha Morehouse Medical Plaza 2050 Kenny Road, Columbus, Ohio, United States|Davis Heart and Lung Research Institute, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02634216" | |
| 326,"NCT04761094","Clinical Efficacy of Insulin Pumps in Type 1 Diabetes Mellitus Patients in Spain",,"Completed","No Results Available","Type 1 Diabetes","Device: Insulin pump","HbA1C|TIR|TAR|TUR|Clinical significant hypoglycemia|MIG|%CV|Adherence to CGM|Weight|Insulin dose|DKA|Severe hypoglycemia|Hospital admission","Castilla-La Mancha Health Service|Spanish Diabetes Association","All","Child, Adult, Older Adult",,"2977","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","C-386","September 1, 2021","December 31, 2021","December 31, 2021","February 18, 2021",,"February 9, 2022","Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital San Joan de Deu, Esplugues De Llobregat, Barcelona, Spain|Hospital Universitario Mutua de Tarrasa, Terrassa, Barcelona, Spain|Hospital Universitario de Jerez, Jerez De La Frontera, Cadiz, Spain|Hospital Universitario de Santiago de Compostela, Santiago De Compostela, La Coruña, Spain|Hospital Infanta Sofía, San Sebastián De Los Reyes, Madrid, Spain|Hospital Universitario Carlos Haya, Málaga, Malaga, Spain|Hospital Universitario Virgen de la Victoria, Málaga, Malaga, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Badajoz University Hospital, Badajoz, Spain|Hospital Clínic i Provincial, Barcelona, Spain|Hospital Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario de Basurto, Bilbao, Spain|Obispo Rafael Torija, St., Ciudad Real, Spain|Centro Medico D-Medical, Madrid, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario Clínico San Carlos, Madrid, Spain|Clinica DiaLibre, Madrid, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Universitario Joan XXIII, Tarragona, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Universitario y Politécnico La Fe, Valencia, Spain|Hospital Clínico Universitario de Valladolid, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT04761094" | |
| 327,"NCT02814838","A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study in Patients With New-onset Type 1 Diabetes",,"Completed","Has Results","Diabetes Mellitus, Insulin-Dependent","Drug: Ladarixin|Drug: Placebo","Area Under the Curve (AUC)(0-2 h) of C-peptide Response to the Mixed Meal Tolerance Test (MMTT) at Week 13|Area Under the Curve (AUC) (0-2 h) of C-peptide Response to the Mixed Meal Tolerance Test (MMTT) at Weeks 26 and 52|Percent Change From Baseline of 2-hour AUC of C-peptide Response to the MMTT|Change From Screening in Average (Previous 3 Days) Insulin Requirement|Change From Screening in Glycated Haemoglobin (HbA1c) Levels|Basal to 180 Minutes Time Course of C-peptide Concentration Derived From the MMTT|Basal to 180 Minutes Time Course of Glucose Concentration Derived From the MMTT|Cumulative Severe Hypoglycaemic Events Occurring From Randomisation by Visit|Proportion of Patients Maintaining a Residual β-cell Function|Proportion of Patients With HbA1c <7% and Absence of Episodes of Severe Hypoglycaemia From the Previous Visit|C-peptide AUC(15 to 120 Mins) Above Fasting Value|Area Under the Curve (AUC) (0-2 h) of C-peptide MMTT in Patients With Screening C-peptide < Median Value|Area Under the Curve (AUC) (15-120 Min) of C-peptide MMTT Above Fasting Value in Patients With Screening C-peptide < Median Value|Proportion of Patients With HbA1c <7% and Absence of Episodes of Severe Hypoglycaemia From the Previous Visit in Patients With Screening C-peptide < Median Value","Dompé Farmaceutici S.p.A","All","18 Years to 45 Years (Adult)","Phase 2","76","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MEX0114|2014-003968-20","August 2016","May 15, 2019","May 15, 2019","June 28, 2016","January 12, 2021","September 27, 2021","Universitair Ziekenhuis Brussel Diabetes Clinic, Brussels, Belgium|Universitair Ziekenhuis Leuven Campus Gasthuisberg Endocrinology, Leuven, Belgium|Med. Klinik und Poliklinik 3, Universitätsklinikum Giessen und Marburg GmbH, Giessen, Germany|Zentrum für Diabetes und Gefäßerkrankungen, Münster, Germany|Università Aldo Moro-Ospedale Policlinico, Bari, Italy|Presidio Policlinico di Monserrato, Cagliari, Italy|Internal Medicine - Diabetes & Endocrinology Unit, San Raffaele Hospital Milan, Milan, Italy|Unità Operativa Complessa di Endocrinologia e Dialettologia. Università Campus Bio-Medico di Roma, Rome, Italy","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT02814838/Prot_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT02814838/SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02814838" | |
| 328,"NCT00135915","Influence of Binge Drinking on Glucose Metabolism in Patients With Type 1 Diabetes - A Pilot Study",,"Completed","No Results Available","Diabetes Mellitus, Type 1",,,"The Royal Bournemouth Hospital","All","18 Years and older (Adult, Older Adult)",,"10","Other","Observational","Observational Model: Case-Crossover|Time Perspective: Prospective","BDEC ALC 1","August 2005",,"February 2007","August 26, 2005",,"November 1, 2009","Royal Bournemouth Hospital, Bournemouth, Dorset, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00135915" | |
| 329,"NCT02175732","Reducing Distress And Improving Glycemic Control In Adults With Type 1 Diabetes","T1REDEEM","Completed","No Results Available","Type 1 Diabetes Mellitus","Behavioral: 'KnowIt'|Behavioral: 'OnTrack'","Diabetes Distress|HbA1c|Self-efficacy|Hypoglycemia confidence|Depression","University of California, San Francisco|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","19 Years and older (Adult, Older Adult)","Not Applicable","301","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","5R01DK094863","September 2014","December 2018","December 2018","June 26, 2014",,"March 25, 2019","UC San Francisco, Family and Community Medicine Dept., San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT02175732" | |
| 330,"NCT05165615","Android Artificial Pancreas System (Android APS) Versus Control-IQ","CODIAC","Recruiting","No Results Available","Diabetes Mellitus, Type 1","Device: Insulin Pump t:slim X2 with Control-IQ technology","Percentage of time in target ranges|Percentage of time in hypoglycemic ranges|Percentage of time in hyperglycemic ranges|Changes in glycemic variability|Incidence of severe hypoglycaemia|Changes in glycated haemoglobin (HbA1c)|Hypoglycemia Attitudes and Behavior Scale (HABS)|Diabetes Distress Scale (DDS)|The 5-item World Health Organization well-being index (WHO-5 index)","Charles University, Czech Republic","All","18 Years and older (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CODIAC","December 1, 2020","June 30, 2022","December 31, 2022","December 21, 2021",,"December 21, 2021","3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University, Prague, Czechia",,"https://ClinicalTrials.gov/show/NCT05165615" | |
| 331,"NCT05346679","DEPS-R Turkish Version in Adults With Type 1Diabetes","DEPS-R","Completed","No Results Available","Type 1 Diabetes",,"DEPS-R Score|EDE-Q Score|Duration of diabetes (years)|HbA1c|BMI","Ege University|Istanbul University","All","18 Years to 50 Years (Adult)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","DEPS-R Adult","March 1, 2021","October 30, 2021","February 28, 2022","April 26, 2022",,"April 26, 2022","Istanbul University, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT05346679" | |
| 332,"NCT04162067","The Current Health Status of Patients Living With Type 1 Diabetes From the LMC Diabetes Patient Registry",,"Completed","No Results Available","Type1diabetes",,"HbA1c|Fasting plasma glucose|Proportion of patients with HbA1c ≤7.0%, 7.1 to 8.0%, 8.1 to 9.0% and >9.0%|Lipid parameters|Proportion of patients below and above target LDL cholesterol|Blood pressure|estimated glomerular filtration rate (eGFR)|Albuminuria|Weight|Body mass index (BMI)|Waist circumference|Thyroid stimulating hormone (TSH)|Alanine aminotransferase (ALT)|Microvascular comorbidity|Macrovascular comorbidity|Weekly incidence of any hypoglycemia|Yearly incidence of severe hypoglycemia|Mental health comorbidity|Erectile dysfunction|Insulin type|Insulin therapy regimen|Pump model|Adjunct diabetes therapies|Lipid lowering therapies|Antihypertensive therapies|Mental health therapies|Glucose meter use|Continuous glucose monitor (CGM) use|Glucagon availability|Clinical outcomes stratified by age group","LMC Diabetes & Endocrinology Ltd.","All","18 Years and older (Adult, Older Adult)",,"3600","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","T1D Registry","January 6, 2020","January 20, 2020","January 20, 2020","November 14, 2019",,"January 28, 2020","LMC Healthcare, Toronto, Canada",,"https://ClinicalTrials.gov/show/NCT04162067" | |
| 333,"NCT03020069","Use of Continuous Glucose Monitoring System With Intensive Feedback in Adolescents With Poorly Controlled Type 1 Diabetes",,"Completed","Has Results","Type 1 Diabetes","Device: CGMS Device|Other: No Device","Change in Score of Pediatric Quality of Life Inventory 3.2 Diabetes Module (Peds QL 3.2) From Baseline to 3 Months|Change in Glycated Hemoglobin (HbA1c) Levels From Baseline to 3 Months|Change in Level of Blood Sugar (Glucose) From Baseline to 3 Months|Change in Score of Diabetes Empowerment Scale Short Form (DES-SF) From Baseline to 3 Months","NYU Langone Health","All","13 Years to 19 Years (Child, Adult)","Not Applicable","13","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","16-01011","November 2015","July 13, 2018","July 13, 2018","January 13, 2017","March 16, 2020","March 16, 2020","New York University Medical Center, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT03020069/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03020069" | |
| 334,"NCT03764280","The Efficacy of MDI Treatment With an Optimization Algorithm Adjusting Basal-Bolus Parameters in Children and Adolescents With Type 1 Diabetes at a Diabetes Camp",,"Completed","No Results Available","Diabete Mellitus|Diabetes Mellitus, Type 1","Other: Multiple Daily Injections: Slow acting insulin and Rapid acting insulin","Percentage of time of sensor glucose levels spent in target range (defined to be between 3.9 mmol/L and 10.0 mmol/L).|Percentage of time of sensor glucose levels spent:|Percentage of overnight time (23:00-7:00) of sensor glucose levels|Percentage of daytime (7:00-23:00) of sensor glucose levels|Standard deviation of glucose levels as a measure of glucose variability|Total insulin delivery.|Mean sensor glucose level during|Number of participants experiencing hypoglycemia requiring oral treatment during","McGill University","All","8 Years to 21 Years (Child, Adult)","Not Applicable","21","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","MDI Optimization Algorithm","July 2, 2018","August 10, 2018","August 10, 2018","December 5, 2018",,"August 15, 2019","Camp Carowanis, Sainte-Agathe-des-Monts, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03764280" | |
| 335,"NCT03101865","The Artificial Pancreas in Very Young Children With T1D - Pilot (KidsAP01)",,"Completed","No Results Available","Type 1 Diabetes Mellitus","Device: FlorenceM","Time in target (3.9 to 10.0mmol/l) (70 to 180 mg/dl)|Time spent below target glucose (3.9mmol/l)(70mg/dl)|Time spent above target glucose (10.0mmol/l) (180mg/dl)|Average glucose|Standard deviation of glucose levels|Coefficient of variation of glucose levels|Time with glucose levels < 3.5mmol/l (63 mg/dl)|Time with glucose levels <2.8mmol/l (50mg/dl)|Time with glucose levels in significant hyperglycaemia|Total daily insulin dose|Daily basal insulin dose|Daily bolus insulin dose|AUC of glucose below 3.5mmol/l (63mg/dl)","University of Cambridge|European Commission|Medtronic|Cambridge University Hospitals NHS Foundation Trust|The Leeds Teaching Hospitals NHS Trust|University of Luxembourg|University of Leipzig|Medical University of Graz|Medical University Innsbruck|Medical University of Vienna|Jaeb Center for Health Research","All","1 Year to 7 Years (Child)","Not Applicable","24","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","KidsAP01","August 8, 2017","May 11, 2018","May 11, 2018","April 5, 2017",,"June 6, 2018","Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria|Department of Pediatrics I, Medical University of Innsbruck, Innsbruck, Austria|Deptartment of Pediatrics, Medical University of Vienna, Vienna, Austria|Division for Paediatric Diabetology, University of Leipzig, Leipzig, Germany|Clinique Pédiatrique de Luxembourg, Luxembourg, Luxembourg|University of Cambridge, Cambridge, United Kingdom|St James's University Hospital, Leeds, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03101865" | |
| 336,"NCT02892604","Study the Feasibility of Permanent Use of inControl for the Treatment of Type 1 Diabetes","IDCLTraining","Terminated","No Results Available","Type 1 Diabetes","Device: insulin pump to inControl AP platform","Percent time of active insulin closed-loop delivery|Percent time with blood glucose in target range","University Hospital, Montpellier|MEDBIOMED, Montpellier, France|Jaeb Center for Health Research|University of Virginia","All","18 Years to 75 Years (Adult, Older Adult)","Not Applicable","3","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9722","November 24, 2015","June 24, 2017","June 24, 2017","September 8, 2016",,"December 9, 2021","UHMontpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT02892604" | |
| 337,"NCT00336674","Trial of Intranasal Insulin in Children and Young Adults at Risk of Type 1 Diabetes","INITII","Completed","No Results Available","Type 1 Diabetes","Biological: Intranasal insulin|Other: Placebo","Diagnosis of Diabetes AT 5 years according to American Diabetes Association / World Health Organization (ADA/WHO) criteria.|B cell function|Insulin Action|Immune function","Melbourne Health","All","4 Years to 30 Years (Child, Adult)","Phase 2","110","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","INIT II","December 2006","November 13, 2019","November 13, 2019","June 14, 2006",,"October 8, 2020","The Children's Hospital at Westmead, Westmead, New South Wales, Australia|Mater Children's Hospital, Brisbane, Queensland, Australia|Womens and Childrens Hospital, North Adelaide, South Australia, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|Princess Margaret Hospital, Subiaco, Western Australia, Australia|University of Auckland, Auckland, New Zealand",,"https://ClinicalTrials.gov/show/NCT00336674" | |
| 338,"NCT01296438","A Trial Investigating the Pharmacokinetic Properties of NN1218 in Subjects With Diabetes Mellitus, Type 1",,"Completed","No Results Available","Diabetes|Diabetes Mellitus, Type 1","Drug: Faster-acting insulin aspart|Drug: insulin aspart","Area under the serum insulin aspart concentration-time curve","Novo Nordisk A/S","All","18 Years to 65 Years (Adult, Older Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NN1218-3872|2010-022222-33|U1111-1118-6955","February 2011","March 2011","March 2011","February 15, 2011",,"February 23, 2015","Neuss, Germany",,"https://ClinicalTrials.gov/show/NCT01296438" | |
| 339,"NCT00989898","Automated Overnight Closed-loop Glucose Control in Young People With Type 1 Diabetes","APCam05","Completed","No Results Available","Type 1 Diabetes","Other: Automated closed-loop insulin delivery","The primary outcome measure is overnight glucose control as measured by plasma glucose concentration between midnight and 8:00 a.m. in the two Time Schedules (closed-loop control starting at 1800 or 2100).","University of Cambridge|Cambridge University Hospitals NHS Foundation Trust","All","6 Years to 18 Years (Child, Adult)","Not Applicable","16","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CI/2008/0036","February 2009","May 2011","December 2011","October 6, 2009",,"June 25, 2012","Wellcome Trust Clinical Research Facility, Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00989898" | |
| 340,"NCT04343131","Different Dietary Interventions and Glycemia in T1DM",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Behavioral: Dietary intervention","Percentage of time spent with glucose levels between 70-140 mg/dl","National and Kapodistrian University of Athens","All","Child, Adult, Older Adult","Not Applicable","15","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Diet in T1DM","November 2014","November 2017","November 2017","April 13, 2020",,"April 13, 2020",,,"https://ClinicalTrials.gov/show/NCT04343131" | |
| 341,"NCT04540536","Feasibility and Effectiveness of Real-time, Remote Continuous Glucose Monitoring in Adolescents With Poorly Controlled Type 1 Diabetes",,"Recruiting","No Results Available","Diabetes Mellitus, Type 1|Noncompliance, Patient","Other: Continuous Glucose Monitoring|Other: Secure texting","Change in hemoglobin A1c after three-month follow-up visit after remote continuous glucose monitoring monitoring and secure text messaging.","University of Texas Southwestern Medical Center|DexCom, Inc.","All","13 Years to 18 Years (Child, Adult)","Not Applicable","20","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","STU-2020-0699","November 1, 2021","August 2023","October 2023","September 7, 2020",,"September 28, 2022","UT Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04540536" | |
| 342,"NCT00133809","Islet Transplantation in Type 1 Diabetics Using the Edmonton Protocol of Steroid Free Immunosuppression",,"Completed","Has Results","Diabetes Mellitus, Type 1","Drug: Transplantation of Human Islets","The Number of Insulin-Independent Subjects at One Year Following Islet Cell Transplantation|Number of Insulin-independent Subjects Following Islet Transplantation|Number of Subjects With HbA1C ≤ 6.5%|The Number of Subjects Exhibiting Fasting C-peptide Levels ≥ 0.5 ng/mL","Emory University|Juvenile Diabetes Research Foundation","All","18 Years to 65 Years (Adult, Older Adult)","Phase 2","8","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00041120|10402","July 2002","December 2014","December 2014","August 24, 2005","June 1, 2016","July 18, 2016","The Emory Transplant Center, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT00133809" | |
| 343,"NCT03528226","Exercise Training and Endothelial Function in Type 1 Diabetes","EVaDia","Recruiting","No Results Available","Type1diabetes","Behavioral: Exercise Training Procedure|Behavioral: Normal life procedure","Change in percent flow-mediated dilation (FMD) values|Change the vascular responses|change the maximum oxygen consumption ( VO2max)|Change Blood marker concentrations of nitric oxide (NO)|change Blood concentration of neurotrophic factors|Body composition (DEXA)","University Hospital, Lille","All","18 Years to 50 Years (Adult)","Not Applicable","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","2016_45.1|2017-A02873-50","November 12, 2019","March 2025","March 2025","May 17, 2018",,"September 11, 2020","Hop Claude Huriez Chu Lille, Lille, France",,"https://ClinicalTrials.gov/show/NCT03528226" | |
| 344,"NCT03920397","Mesenchymal Stem Cells in Patients With Type 1 Diabetes Mellitus",,"Completed","No Results Available","Type 1 Diabetes Mellitus","Biological: Infusion of adipose tissue-derived stem/stromal cells and oral Cholecalciferol supplementation","Pancreatic β-cell function after an adipose tissue-derived stem/stromal cells infusion|Glycemic control after an adipose tissue-derived stem/stromal cells|Oral cholecalciferol 2000UI/day supplementation","Universidade Federal do Rio de Janeiro","All","16 Years to 35 Years (Child, Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Nutro_MesenchymalStemCells_DM1","March 1, 2015","March 1, 2021","May 1, 2021","April 18, 2019",,"May 26, 2021","Clementino Fraga Filho University Hospital of Rio de Janeiro, Rio de Janeiro, Brazil",,"https://ClinicalTrials.gov/show/NCT03920397" | |
| 345,"NCT04759495","Is Real-time CGM Superior to Flash Glucose Monitoring in Real Life Study (CORRIDA LIFE)",,"Active, not recruiting","No Results Available","Diabetes Mellitus, Type 1","Device: Continuous Glucose Monitoring Dexcom G5 and G6 system (real-time continuous glucose monitoring)|Device: Continuous Glucose Monitoring FreeStyle Libre Flash system (flash glucose monitoring)","Changes in glycated haemoglobin (HbA1c)|Percentage of time in hypoglycemic ranges|Percentage of time in target ranges|Percentage of time in hyperglycemic ranges|Changes in glycemic variability|Mean sensor glucose concentration|Incidence of severe hypoglycaemia|Incidence of severe ketoacidosis|Incidence of skin reaction, infection or hematoma at the site of insertion of the sensor","Charles University, Czech Republic","All","18 Years and older (Adult, Older Adult)","Not Applicable","187","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CORRIDA LIFE","June 1, 2019","November 30, 2020","September 30, 2021","February 18, 2021",,"February 18, 2021","3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University, Prague, Czechia",,"https://ClinicalTrials.gov/show/NCT04759495" | |
| 346,"NCT02131675","Detection of C-peptide in Youth With Longstanding Type 1 Diabetes Mellitus",,"Completed","No Results Available","Type 1 Diabetes Mellitus","Dietary Supplement: Boost shake","C-peptide level|Hemoglobin A1c|Total daily dose of insulin|Age at diabetes diagnosis|Duration of diabetes","Icahn School of Medicine at Mount Sinai","All","1 Year to 21 Years (Child, Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","GCO 12-1425","October 2012","December 2013","December 2013","May 6, 2014",,"May 6, 2014","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02131675" | |
| 347,"NCT01726829","Overnight Type 1 Diabetes Control Under MD-Logic Closed Loop System at the Patient's Home",,"Completed","No Results Available","Type 1 Diabetes","Device: MD-Logic Artificial Pancreas (MDLAP) system|Procedure: sensor augmented pump therapy","time sensor glucose level spent below 70mg/dl|The percentage of nights mean overnight sensor glucose levels was within90-140 mg/dl|The time sensor glucose level spent within 70-140 mg/dl|The number and frequency of hypoglycemic events below 63, 79 mg/dl|The time sensor glucose level spent above 140, 180 mg/dl|The area under the curve <63, <70, >140, >180 mg/dl|Glucose variability|The total insulin dose during the overnight period|Artificial pancreas technical performance defined as total frequency of technical failures|Artificial pancreas technical performance defined as total frequency of lost or inaccurate sensor records|Percentage of time of active closed loop control|Fear of Hypoglycemia questionnaire|Acceptance questionnaire|Artificial Pancreas Satisfaction Questionnaire","Rabin Medical Center","All","10 Years to 65 Years (Child, Adult, Older Adult)","Not Applicable","75","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","rmc007053ctil","November 2012","November 2015","December 2015","November 15, 2012",,"April 8, 2016","Diabetes -Zentrum fuer kinder und jugendliche, Hannover, Germany|Schneider Children's Medical Center, Petah-Tikva, Israel|University Children's Hospital, Slovenia, Slovenia",,"https://ClinicalTrials.gov/show/NCT01726829" | |
| 348,"NCT03895437","Diabetes Autoimmunity Withdrawn In New Onset and In Established Patients","SUNRISE","Active, not recruiting","No Results Available","Diabetes Mellitus, Type 1","Biological: TOL-3021|Other: TOL-3021 Placebo","Treatment effect on log-transformed MMTT C-peptide area under the curve (AUC)|Treatment effect on rates of clinically important hypoglycemia|Treatment effect on daily Insulin requirements|Treatment effect on HbA1c|Treatment effect on GCM measurement of glucose levels l< 70 and <55 mg/dL|Treatment effect on a Clinical responder analysis|Treatment effect on non-fasting or fasting C-peptide single test|Treatment effect on CGM parameters|Treatment effect on other measures of hypoglycemia|Immunologic - Quantum dot (Q-dot) responses|Immunologic - determine effect of treatment and predictive values of antibody response|Safety Variables|Events of Special Interest","Tolerion, Inc.","All","12 Years to 40 Years (Child, Adult)","Phase 2","78","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","TOL-3021-231","June 17, 2019","March 15, 2021","September 30, 2023","March 29, 2019",,"November 9, 2020","Altman Clinical and Translational Research Institute UCSD, San Diego, California, United States|University of California San Francisco, San Francisco, California, United States|Mills-Peninsula Medical Center, San Mateo, California, United States|Stanford University, Stanford, California, United States|Barbara Davis Center - University of Colorado Denver, Denver, Colorado, United States|Yale University, New Haven, Connecticut, United States|University of Florida, Gainesville, Florida, United States|Baptist Health Research Institute, Jacksonville, Florida, United States|University of Miami Diabetes Research Institute, Miami, Florida, United States|University of South Florida Diabetes Center, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Rocky Mountain Clinical Research, Idaho Falls, Idaho, United States|University of Iowa, Iowa City, Iowa, United States|MedStar Health Research Institute, Baltimore, Maryland, United States|MedStar Health Research Institute, Hyattsville, Maryland, United States|Joslin Diabetes Center- Adult & Pediatric, Boston, Massachusetts, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Naomi Berrie Diabetes Center, Columbia University, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Mountain Diabetes and Endocrine Center, Asheville, North Carolina, United States|University of North Carolina Diabetes Care Center, Chapel Hill, North Carolina, United States|Diabetes and Glandular Disease Clinic, P.A., San Antonio, Texas, United States|University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03895437" | |
| 349,"NCT05628532","DBLG1 System With TERUMO MEDISAFE WITH Insulin Pump Trial","BETTER","Not yet recruiting","No Results Available","Diabetes Mellitus, Type 1","Device: Use of the DBLG1 system","Percentage of time spent in 70 - 180 mg/dL glycemic range|Percentage of time spent in specific glycemic ranges|Incidence of severe hypoglycemia|Incidence of severe hyperglycemia|Number of adverse events, adverse device effects, serious adverse events, serious adverse device effects, unanticipated serious adverse device effects|Evolution of HbA1c measured by blood sampling for patients participating in extension study phase|Glucose management indicator (GMI)|Average sensor glucose level|Variability of the glucose level|Average dose of insulin used during the entire study|Percentage of time spent in closed loop mode|Percentage of days with >75% closed loop records|Diabetes Treatment Satisfaction (DTSQs) Questionnaire items|Scoring of Diabetes Treatment Satisfaction (DTSQs) Questionnaire|Scoring of Hypoglycemia Fear Survey (HFS II) questionnaire total score|Scoring of Hypoglycemia Fear Survey (HFS II) questionnaire - Behaviour scale|Scoring of Hypoglycemia Fear Survey (HFS II) questionnaire - Worrieness scale|Scoring of Diabetes Distress Scale (DDS)","Diabeloop|Icadom","All","18 Years and older (Adult, Older Adult)","Not Applicable","90","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RCB 2022-A01901-42","January 2023","June 2023","June 2023","November 28, 2022",,"November 28, 2022","CH Sud Francilien, Corbeil-Essonnes, France|CHU Grenoble, Grenoble, France|Groupe Hospitalier La Rochelle - Ré - Aunis, La Rochelle, France|CHU Lille - Hôpital Huriez, Lille, France|Centre du diabète DIAB-eCARE - HCL, Lyon, France|Hôpital la Conception - APHM, Marseille, France|Hôpital Nord Laennec, Nantes, France|CHU Rennes Pontchaillou, Rennes, France|CHRU de Strasbourg - Hôpital Civil, Strasbourg, France|CHU Toulouse - Hôpital de Rangueil, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT05628532" | |
| 350,"NCT01351857","Diabetes Care Management Compared to Standard Diabetes Care in Adolescents and Young Adults With Type 1 Diabetes","TransClin","Completed","No Results Available","Type 1 Diabetes","Other: Transition Coordinator","The proportion of subjects who fail to attend at least one outpatient adult endocrinology visit during the second year after transition to adult diabetes care.|In the 2 year transfer to adult care-Frequency of A1C (glycated hemoglobin test)","University of Western Ontario, Canada|Juvenile Diabetes Research Foundation|Western University, Canada","All","17 Years to 20 Years (Child, Adult)","Phase 4","188","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CCTN1102","April 2012","June 28, 2017","June 30, 2017","May 11, 2011",,"November 9, 2018","St. Joseph's Health Care, London, Ontario, Canada|London Health Sciences Centre - Children's Hospital, London, Ontario, Canada|Trillium Pediatric Diabetes Clinic, Mississauga, Ontario, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01351857" | |
| 351,"NCT03794973","Diabetes Autoimmunity Withdrawn in New Onset Patients (DAWN)","DAWN","Withdrawn","No Results Available","Diabetes Mellitus, Type 1","Biological: TOL-3021|Other: TOL-3021 Placebo","Treatment effect on log-transformed MMTT C-peptide area under the curve (AUC)|Rate of clinically important hypoglycemia|Daily Insulin requirements|Clinical Responder|Exogenous insulin-free|Persistent Reduction|GCM Measurement|Other measures of hypoglycemia|Immunologic","Tolerion, Inc.","All","12 Years to 35 Years (Child, Adult)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","TOL-3021-220","December 14, 2019","December 14, 2021","December 14, 2023","January 7, 2019",,"December 8, 2020","University of Miami Diabetes Research Institute, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03794973" | |
| 352,"NCT02804165","Gene-virus Interactions Implicated in Type 1 Diabetes","GENEVIR","Withdrawn","No Results Available","Type 1 Diabetes","Genetic: Enterovirus vaccination","Identification of gene-enterovirus interaction effect on T1D onset|""Precipitating"" effect of enterovirus infection on T1D.","Hospices Civils de Lyon","All","1 Year to 60 Years (Child, Adult)","Not Applicable","0","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2013-836","January 2017","July 2022","July 2022","June 17, 2016",,"May 11, 2018","Hospices Civils de Lyon, Lyon, France",,"https://ClinicalTrials.gov/show/NCT02804165" | |
| 353,"NCT00946257","Subcutaneous Administration of Otelixizumab to T1DM Patients","RAO112438","Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: Otelixizumab","Safety and tolerability after a single dose of otelixizumab in T1DM patients","GlaxoSmithKline","All","18 Years to 65 Years (Adult, Older Adult)","Phase 1","33","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","112438","July 8, 2009","August 1, 2011","June 25, 2013","July 24, 2009",,"June 1, 2017","GSK Investigational Site, Brussels, Belgium|GSK Investigational Site, Bruxelles, Belgium|GSK Investigational Site, Gent, Belgium|GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Liège, Belgium|GSK Investigational Site, Merksem, Belgium",,"https://ClinicalTrials.gov/show/NCT00946257" | |
| 354,"NCT03794960","Diabetes AutoimmunitY Withdrawn in Established Patients (DAY)","DAY","Withdrawn","No Results Available","Diabetes Mellitus, Type 1","Biological: TOL-3021|Other: TOL-3021 Placebo","Treatment Effect|Rate of Clinically important hypoglycemia as defined by measured glucose value of <54 mg/dL (3.0 mM/L)|Clinical responder analysis|Other measures of hypoglycemia|Immunologic","Tolerion, Inc.","All","12 Years to 36 Years (Child, Adult)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","TOL-3021-230","December 14, 2019","December 14, 2021","December 14, 2023","January 7, 2019",,"December 8, 2020",,,"https://ClinicalTrials.gov/show/NCT03794960" | |
| 355,"NCT03014908","Metabolic Profiling of Type 1 Diabetes Mellitus in Children and Adolescents","T1DM","Completed","No Results Available","Type1diabetes","Other: Blood sampling","Metabolic phenotype of type 1 diabetes mellitus","Hasselt University|Jessa Hospital","All","8 Years to 18 Years (Child, Adult)",,"14","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","LCRP-obesitas","January 2014","September 2014","December 2014","January 9, 2017",,"January 9, 2017","Hasselt University, Hasselt, Limburg, Belgium",,"https://ClinicalTrials.gov/show/NCT03014908" | |
| 356,"NCT05163054","Cohort Study of Patients With Type 1 Diabetes Registered With Mobile Application in China","COOPERATIONS","Not yet recruiting","No Results Available","Type 1 Diabetes",,"HbA1c|Time in range (TIR)|Incidence of hypoglycemia|Comprehensive metabolic control|Occurrence of Diabetes-related complications.|Progression of Diabetes-related complications.|Anxiety condition.|Depression condition.|Life quality.","Peking University Third Hospital","All","12 Years and older (Child, Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","M2021380","June 2022","January 2032","January 2032","December 20, 2021",,"June 1, 2022","Peking University Third Hospital, Beijing, China",,"https://ClinicalTrials.gov/show/NCT05163054" | |
| 357,"NCT00564018","Duration of The Honeymoon Phase of Type 1 Diabetes: A Comparison of Insulins Detemir, Glargine and NPH",,"Terminated","Has Results","Type 1 Diabetes","Drug: Insulin detemir|Drug: Glargine|Drug: NPH","C-peptide Area Under the Curve|Glycemic Control as Determined by HgbA1c Values at 6 Months After Diagnosis","University of Texas Southwestern Medical Center|Novo Nordisk A/S","All","6 Years to 18 Years (Child, Adult)","Not Applicable","33","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UTSW-052006-056|816","September 2006","February 2009","April 2011","November 27, 2007","October 11, 2019","October 11, 2019","Children's Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00564018" | |
| 358,"NCT02159638","Accuracy of Two CGM Systems Tested Simultaneously in Ambulatory Patients With Type 1 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 1|Blood Glucose","Device: Guardian Enlite sensor|Device: Dexcom G4 platinum sensor","Difference between the two CGM systems compared to capillary glucose value|the accuracy of the 2 CGM systems during each studied time interval (day 1-3 and day 4-6)|the accuracy of the 2 CGM systems for hypoglycaemia|the accuracy of the 2 CGM systems for normoglycaemia|the accuracy of the 2 CGM systems for hyperglycaemia|Evaluation of two CGM systems from questionnaire","Vastra Gotaland Region","All","18 Years and older (Adult, Older Adult)","Not Applicable","38","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VGFOUREG-387191","May 2013","July 1, 2014","September 1, 2014","June 10, 2014",,"December 19, 2017","NU-hospital Organisation, Trollhattan, Sweden|Uddevalla hospital, Uddevalla, Sweden",,"https://ClinicalTrials.gov/show/NCT02159638" | |
| 359,"NCT04358263","Is Real-time CGM Superior to Flash Glucose Monitoring","CORRIDA","Unknown status","No Results Available","Diabetes Mellitus, Type 1","Device: Continuous Glucose Monitoring Guardian Connect Mobile system (real-time continuous glucose monitoring)|Device: Continuous Glucose Monitoring FreeStyle Libre Flash system (intermittently-scanned continuous glucose monitoring)","Percentage of time in hypoglycemic ranges|Percentage of time in target ranges|Percentage of time in hyperglycemic ranges|Changes in glycemic variability|Mean sensor glucose concentration|Changes in quality of life as assessed by validated questionnaire|Incidence of severe hypoglycaemia|Changes in glycated haemoglobin (HbA1c)","Charles University, Czech Republic","All","18 Years and older (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CORRIDA","September 1, 2018","April 30, 2019","November 30, 2020","April 24, 2020",,"April 28, 2020","3rd Department of Internal Medicine, 1st Faculty of Medicine Charles University, Prague, Czech Republic, Czechia",,"https://ClinicalTrials.gov/show/NCT04358263" | |
| 360,"NCT04936633","Efficacy of FSGM Cloud-based Remote Intervention for Insulin-dEpendent Diabetic Patients (FRIEND)",,"Completed","No Results Available","Type 1 Diabetes Mellitus","Other: Intervention by medical staff based on a cloud system","Changes in glycemic control measured by HbA1c|Changes in the time in range|Changes in the duration of hyperglycemic episodes|Changes in the duration of hypoglycemic episodes|Changes in hypoglycemic episodes|Changes in the mean glucose values|Changes in the frequency of use of trend arrows|Changes in the mean number of scans|Changes in the insulin dose|Changes in the lipid parameter|Changes in blood pressure|Changes in body weight|Lifestyle changes in diet|Lifestyle changes in the number of exercises|Lifestyle changes in the duration of exercises|Changes in the patient absolute satisfaction with treatment assessed by questionnaires|Changes in the patient relative satisfaction with treatment assessed by questionnaires|Changes in depression assessed by questionnaires|Changes in anxiety assessed by questionnaires","Young Shin Song|CHA University","All","19 Years to 75 Years (Adult, Older Adult)","Not Applicable","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2021-03-032-001","June 30, 2021","April 30, 2022","April 30, 2022","June 23, 2021",,"October 25, 2022","CHA Bundang Medical Center, Seongnam, Gyeonggi-do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04936633" | |
| 361,"NCT01868594","Clinical Trial of Efficacy and Safety of Subetta in the Combined Treatment of Patients With Type I Diabetes Mellitus",,"Completed","Has Results","Type I Diabetes Mellitus","Drug: Subetta|Drug: Placebo","Changes in the Mean Value of HbA1c|Change in Fasting Plasma Glucose (Based on the Data of Biochemical Analysis)|Change in Average Daily Blood Glucose From a 7-point Patient Self-monitoring of Blood Glucose (SMBG)|Changes in Lipids (Concentrations of Plasma Total Cholesterol, HDL Cholesterol, LDL Cholesterol and Triglycerides)|Changes in Dosage of Insulin (Basal, Prandial and Total Daily Dose Insulin Measured in IU)|Changes in Dosage of Total Insulin Measured in IU/kg of Body Weight|Satisfaction of Diabetes Treatment Based on Diabetes Treatment Satisfaction Questionnaire Data","Materia Medica Holding","All","18 Years to 65 Years (Adult, Older Adult)","Phase 4","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","MMH-SU-003","May 7, 2013","July 2016","July 10, 2016","June 4, 2013","March 4, 2019","May 30, 2019","Municipal budgetary authority ""Khimki Central Clinical Hospital"", Moscow region, Russian Federation|State Healthcare Institution of Moscow ""Central research institute of gastroenterology"" of Department of health care of Moscow, Moscow, Russian Federation|State Educational Institution of Higher Professional Education ""Moscow State Medical Academy named after I.M. Sechenov"", Moscow, Russian Federation|Nonstate Health Care Institution ""Central Clinical Hospital №2 named after N.A. Semashko of Public Limited Company ""Russian Railways"", Moscow, Russian Federation|The State Budgetary Institution of Health Care of the Nizhny Novgorod Region ""City clinical hospital No. 10 "", Nizhny Novgorod, Russian Federation|Nizhny Novgorod regional State Budgetary Health Institution "" Nizhny Novgorod regional Clinical Hospital named after N.A. Semashko "", Nizhny Novgorod, Russian Federation|State Budgetary Educational Institution of High Professional Training ""Rostov State Medical University"" of Ministry of Health of Russian Federation, Department of Endocrinology, Rostov-on-Don, Russian Federation|Co.Ltd "" Diabet Center"", Samara, Russian Federation|Private company ""Polyclinic Complex"", St. Petersburg, Russian Federation|St. Petersburg State Budgetary Health Care Institution ""City Polyclinic №6"", St. Petersburg, Russian Federation|St. Petersburg State Budgetary Health Care Institution ""Saint Venerable Martyr Elizaveta Municipal Hospital"", St. Petersburg, Russian Federation|State Budgetary Educational Institution of High Professional Training ""St. Petersburg State Medical University named after academician I.P. Pavlov"" of Ministry of Health of Russian Federation, Therapy Faculty Board, St. Petersburg, Russian Federation|St. Petersburg Sate Budgetary Institution ""Consultative-Diagnostic Polyclinic №1 of Coastal Area"", St. Petersburg, Russian Federation|Independent Health Care Institution of Voronezh Region ""Voronezh Regional Clinical Consultative-Diagnostic Center"", Voronezh, Russian Federation|State Budgetary Health Care Institution of Yaroslavl Region ""Regional Сlinical Hospital"", Yaroslavl, Russian Federation",,"https://ClinicalTrials.gov/show/NCT01868594" | |
| 362,"NCT02773875","Fault Detection, Zone MPC and DiAs System in T1D","ZoneMPC","Unknown status","No Results Available","Type 1 Diabetes","Device: Artificial pancreas system (Algorithm + CGM + pump)","Amount of time sensor glucose levels are >250 mg/dl|Effectiveness of sensor fault detection algorithm as defined by % of sensor failures caught by the system|Mean sensor glucose values|Percent of time in range between 70-180 mg/dl","Rensselaer Polytechnic Institute|Stanford University|University of Colorado, Denver|Harvard University|University of California, San Diego|University of California, Santa Barbara","All","18 Years to 55 Years (Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IDE G150122","May 2016","November 2016","December 2016","May 16, 2016",,"May 16, 2016",,,"https://ClinicalTrials.gov/show/NCT02773875" | |
| 363,"NCT03785275","Beta Cell Imaging in T1D Patients With a Different Glycemic Control","GLP1-reg","Terminated","No Results Available","Type 1 Diabetes Mellitus","Radiation: gallium-68-exendin PET/CT","Beta cell mass|Beta cell mass vs. beta cell function","Radboud University Medical Center","All","18 Years and older (Adult, Older Adult)",,"16","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","NL59582.091.17","December 6, 2017","November 9, 2020","November 9, 2020","December 24, 2018",,"February 14, 2022","Radboudumc, Nijmegen, Gelderland, Netherlands",,"https://ClinicalTrials.gov/show/NCT03785275" | |
| 364,"NCT01901913","MD-Logic Artificial Pancreas for Automatic Type 1 Diabetes Meals Management",,"Completed","No Results Available","Type 1 Diabetes","Device: MD-bolus calculator for pre-meal bolus|Device: No MD-bolus calculator for pre-meal bolus","Area under the curve above 180 mg/dl (10 mmol/l)|Time within range of 70-180 mg/dl over 4 hours from the beginning of the meal|The incremental glucose rise from premeal to peak postprandial level|Number of hypoglycemic events below 70 mg/dl (3.9 mmol/l)|The percentage of subjects who reached the desired glucose target (70-180 mg/dl) 4 hours postprandial.|Percentage of time spent below 70 mg/dl (3.9mmol/l)|Percentage of time spent above 180, 250, (10, 13.9 mmol/l)","Rabin Medical Center","All","14 Years to 25 Years (Child, Adult)","Not Applicable","26","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","rmc007418ctil","October 2013","April 2015","April 2015","July 17, 2013",,"April 16, 2015","Schneider Children's Medical Center, Petah-Tikva, Israel",,"https://ClinicalTrials.gov/show/NCT01901913" | |
| 365,"NCT00973492","Impact of Functional Insulinotherapy on Blood Glucose Variability Indicators in Patients With Type 1 Diabetes","VARIAFIT","Unknown status","No Results Available","Type 1 Diabetes","Other: functional insulinotherapy class","MAGE, ADRR, Lability Index and LBGI computed with the blood glucose measurement or CGMS|anti-transglutaminase and anti-endomysium antibodies|dosage of urinary leucotriene E4 and 11-dehydro-thromboxane B2, 8-iso-PGF2alpha|anti-insulin antibodies by ELISA","Association Grenobloise pour le Developpement D'etudes et de Recherches en Physiopathologie Endocrinienne, Diabetologie et Maladies de la Nutrition","All","18 Years and older (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2007-A00903-50","September 2007","December 2009","December 2009","September 9, 2009",,"September 9, 2009","Service de Diabétologie du Pr Halimi, CHU, Grenoble Cedex 9, France",,"https://ClinicalTrials.gov/show/NCT00973492" | |
| 366,"NCT03632759","Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1D",,"Completed","No Results Available","Type 1 Diabetes Mellitus","Drug: Liraglutide|Drug: Golimumab","Proportion of individuals with peak MMTT stimulated C-peptide >0.017 pmol/mL.","Carla Greenbaum, MD|Juvenile Diabetes Research Foundation|Benaroya Research Institute","All","18 Years to 50 Years (Adult)","Early Phase 1","16","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IRB18-044","August 15, 2018","November 9, 2021","November 9, 2021","August 15, 2018",,"January 24, 2022","Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States|Benaroya Research Institute, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03632759" | |
| 367,"NCT01173991","Carbohydrate Counting in Adults With Type 1 Diabetes Treated With Continuous Subcutaneous Insulin Infusion","GIOCAR","Completed","No Results Available","Diabetes Mellitus, Type 1|Insulin Pump, Programmable","Behavioral: Carbohydrate counting training","Glycated haemoglobin (HbA1c)|Fasting glucose|Glycemic variability (mean, sd, min, max, variability range, BG in target range, LBGI, HBGI) based on capillary glucose data|Daily insulin requirement (basal daily requirement, bolus daily requirement, total daily requirement)|Body Mass Index (BMI)|Waist circumference|Quality of life by Diabetes Specific Quality of Life Scale (DSQOLS) questionnaire|Hypoglycemia (capillary glucose<50 mg/dl)","IRCCS San Raffaele","All","18 Years to 65 Years (Adult, Older Adult)","Phase 3","61","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GIOCAR","October 2008","September 2009","January 2010","August 3, 2010",,"August 3, 2010","San Raffaele Scientific Institute, Milano, Italy",,"https://ClinicalTrials.gov/show/NCT01173991" | |
| 368,"NCT00491465","The Role of Physical Activity in the Treatment of Children With Type 1 Diabetes.","4301","Unknown status","No Results Available","Type 1 Diabetes","Behavioral: Intensive Physical activity|Behavioral: Control- regular physical activity","HbA1C|fructosamine|Body composition & BMR|Self esteem & QOL questionnaires|3 days CGMS & SBGM profile","Rabin Medical Center","All","8 Years to 16 Years (Child)","Not Applicable","2007","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","rmc074301ctil","July 2007",,"July 2009","June 26, 2007",,"June 26, 2007","Schnider children's medical center, Petach-Tikva, Israel",,"https://ClinicalTrials.gov/show/NCT00491465" | |
| 369,"NCT03818711","Communication and Coping for Mothers of Adolescents With Type 1 Diabetes","T1D","Active, not recruiting","No Results Available","Type 1 Diabetes Mellitus","Behavioral: Communication & Coping Intervention|Behavioral: Education & Check Ins","Glycemic control (A1C)|Maternal depressive symptoms|Mothers' Diabetes Distress|Adolescent psychosocial functioning - parent report|Adolescent psychosocial functioning - self report|Adolescent quality of life|Diabetes-related family conflict - parent report|Diabetes-related family conflict - adolescent report|Maternal coping|Mothers' Social Support|Maternal Symptoms of Anxiety|Adolescent Diabetes Distress|Diabetes Knowledge|Parental Involvement|Adolescent Adherence|Quality of Parental Involvement","Vanderbilt University Medical Center|University of Connecticut","All","Child, Adult, Older Adult","Not Applicable","154","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","171940","April 1, 2019","June 30, 2023","September 30, 2023","January 28, 2019",,"September 7, 2022","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03818711" | |
| 370,"NCT05478707","Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes","KML002","Not yet recruiting","No Results Available","Diabetes Mellitus, Type 1|Endothelial Dysfunction","Drug: Dulaglutide|Drug: Placebo|Behavioral: exercise training","Microvascular blood volume (MBV)|Brachial artery flow mediated dilation (FMD)|Glucose infusion rate (GIR)|Cardiorespiratory fitness, maximum consumption of oxygen (VO2max)|Skeletal muscle oxygenation, deoxyhemoglobin (HHb)","University of Virginia","All","18 Years to 40 Years (Adult)","Phase 2","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Basic Science","210198","November 2022","June 2027","June 2027","July 28, 2022",,"November 3, 2022","University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT05478707" | |
| 371,"NCT03583268","Determining the Appropriate Intensity of Exercise to Prevent Post-exercise Hypoglycemia in Persons Living With T1D",,"Completed","No Results Available","Type 1 Diabetes","Other: Exercise","Percent time spent </= 3.9 mmol/L as measured by continuous glucose monitor|Mean absolute glucose change (MAG-mmol/L/h) as measured by continuous glucose monitor|Continuous overall net glycemic action (CONGA-mmol/L) as measured by continuous glucose monitor","University of Manitoba|The Lawson Foundation","All","15 Years to 35 Years (Child, Adult)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","B2014:095","May 2013","March 2016","March 2016","July 11, 2018",,"July 11, 2018","Children's Hospital Research Institute of Manitoba, Winnipeg, Manitoba, Canada",,"https://ClinicalTrials.gov/show/NCT03583268" | |
| 372,"NCT05282264","Acceptability of Hybrid Closed-loop Systems in Patients Living With Highly Unbalanced Type 1 Diabetes","HCL-VHP","Recruiting","No Results Available","Type 1 Diabetes","Other: device","Acceptability of hybrid closed-loop systems|Demographic characteristics : age|Demographic characteristics : gender|Demographic characteristics : level of education|Demographic characteristics : currrent activity|Demographic characteristics : duration of diabete|HbA1c|Efficiency|Quality|Patient satisfaction|Hypoglycemia Fear","Centre Hospitalier Sud Francilien","All","18 Years and older (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IDRCB 2022-A00144-39","April 1, 2022","March 31, 2023","March 31, 2023","March 16, 2022",,"September 29, 2022","Penfornis, Corbeil-essonnes Cedex, Centre Hospitalier Sud Francilien, France|Centre Hospitalier Sud Francilien, Corbeil-essonnes Cedex, France",,"https://ClinicalTrials.gov/show/NCT05282264" | |
| 373,"NCT00800085","Beta Cell Function in (Pre) Type 1 Diabetes",,"Unknown status","No Results Available","Type 1 Diabetes","Drug: glucose 20%","The systematic and simultaneous determination of markers of functional beta cell mass and immune status allows stratification according to the stage of the pathogenic process rather than according to a late metabolic consequence of this process","AZ-VUB","All","5 Years to 40 Years (Child, Adult)","Phase 1|Phase 2","200","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)","KD_BF_01","October 2006","October 2014","October 2015","December 1, 2008",,"December 30, 2013","Universitair Ziekenhuis Antwerpen, Antwerpen, Belgium|UZ Brussels, Brussels, Belgium|UZ Gent, Gent, Belgium|UZ Leuven, Leuven, Belgium",,"https://ClinicalTrials.gov/show/NCT00800085" | |
| 374,"NCT03917238","Beta Cell Imaging During and Shortly After the Honeymoon Phase of T1D","Honeymoon","Unknown status","No Results Available","Type 1 Diabetes Mellitus","Radiation: gallium-68-exendin injection followed by PET/CT scan","Pancreatic uptake of gallium-68-NODAGA-exendin-4","Radboud University Medical Center","All","16 Years and older (Child, Adult, Older Adult)","Not Applicable","14","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","NL61915.091.17","October 11, 2019","November 25, 2021","December 25, 2021","April 17, 2019",,"October 9, 2020","Radboud university medical center, Nijmegen, Gelderland, Netherlands|Diabeter, Rotterdam, Zuid-Holland, Netherlands",,"https://ClinicalTrials.gov/show/NCT03917238" | |
| 375,"NCT00806572","Treatment With hOKT3gamma1(Ala-Ala) in T1DM",,"Terminated","No Results Available","Diabetes Mellitus, Type 1","Drug: hOKT3gamma1(Ala-Ala)","4-hour C-peptide AUC|Insulin usage","National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN)","All","7 Years to 30 Years (Child, Adult)","Phase 2","10","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DAIT ITN007AI|NDB01","May 2002","July 2004","August 2007","December 11, 2008",,"February 8, 2017","University of California San Francisco, San Francisco, California, United States|Naomie Berrie Diabetes Center, Columbia University, New York, New York, United States|Benaroya Research Institute, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00806572" | |
| 376,"NCT05481034","Simplified Meal Approach Using Hybrid Closed-loop Insulin Delivery in Youth and Young Adults With Type 1 Diabetes","SMASH","Not yet recruiting","No Results Available","Type 1 Diabetes","Device: SMA bolus option|Device: Exactly estimated carbohydrate content bolus option","Percentage of sensor glucose measurements between 3.9 and 10.0 mmol/L|Sensor glucose measurements >10.0 mmol/L|Sensor glucose measurements < 3.9 mmol/L|Sensor glucose measurements < 3.0 mmol/L|Sensor glucose measurements > 20.0 mmol/L|Mean sensor glucose measurements|Glycated hemoglobin A1c|Total daily insulin dose|Total daily basal insulin dose|Total daily bolus insulin dose","University Hospital Inselspital, Berne|University of Zurich","All","12 Years to 20 Years (Child, Adult)","Not Applicable","45","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SMASH","September 1, 2022","September 30, 2023","November 30, 2023","July 29, 2022",,"August 15, 2022","Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT05481034" | |
| 377,"NCT05498974","China Diabetes Type 1 Study (CD1S) by China Alliance for Type 1 Diabetes",,"Recruiting","No Results Available","Type1diabetes|Diabetes","Other: Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center","Change in serum hemoglobin A1c level|Albumin-to-creatinine ratio in urine sample|Arteriosclerotic cardiovascular diseases|Electromyography|PHQ-9|GAD-7|WHO-5|PAID|Change in C-peptide|Change in titer of autoantibodies|Fasting blood glucose|Systolic blood pressure|Diastolic blood pressure|Change in lipid profiles|Metabolomics","Second Xiangya Hospital of Central South University","All","Child, Adult, Older Adult",,"20000","Other","Observational","Observational Model: Other|Time Perspective: Other","CD1S","January 1, 2022","December 31, 2035","December 31, 2035","August 12, 2022",,"August 12, 2022","Gansu Provincial People's Hospital, Lanzhou, Gansu, China|Shenzhen Second People's Hospital, Shenzhen, Guangdong, China|Hainan General Hospital, Haikou, Hainan, China|the First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China|The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China|The Second Xiangya Hospital, Central South University, Changsha, Hunan, China|The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China|Heji Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi, China|The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China|The First People's Hospital of Yunnan, Kunming, Yunnan, China|Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT05498974" | |
| 378,"NCT00848705","Adolescent Self-Management of Type 1 Diabetes: an Intervention (Completed)","YourWay","Completed","No Results Available","Adolescent Type 1 Diabetes","Behavioral: YourWay Internet Intervention","Self-management behaviors|Self-management Problem solving","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","13 Years to 17 Years (Child)","Early Phase 1","72","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","DK70026-01A2","October 2007","January 2009","May 2009","February 20, 2009",,"February 2, 2011","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00848705" | |
| 379,"NCT02730949","D-chiro-Inositol in Overweight Type 1 Diabetes Patients",,"Completed","No Results Available","Type 1 Diabetes","Dietary Supplement: D-chiro-inositol|Dietary Supplement: Folic Acid","efficacy of DCI oral supplementation on metabolic control|BMI kg/m2|Insulin Requirement (I.R.) IU/kg","Campus Bio-Medico University","All","17 Years to 50 Years (Child, Adult)","Phase 3","26","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16/14PARComETCBM","March 2014","May 2015","December 2015","April 7, 2016",,"April 7, 2016","University Campus Bio Medico, Rome, Italy",,"https://ClinicalTrials.gov/show/NCT02730949" | |
| 380,"NCT05620251","Response to BNT162b2 Vaccine in Adolescents With Type 1 Diabetes",,"Completed","No Results Available","type1diabetes","Diagnostic Test: Blood test","humoral immune response after first vaccine dose|humoral immune response after second vaccine dose|Adverse events","Istanbul Medeniyet University","All","12 Years to 18 Years (Child, Adult)",,"121","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2022/0190","September 3, 2021","February 28, 2022","June 12, 2022","November 17, 2022",,"November 17, 2022","Istanbul Medeniyet University, Professor Doctor Suleyman Yalcin city Hospital, Istanbul, Eğitim Mah. Fahrettin Kerim Gökay Caddesi, Kadıköy, Turkey",,"https://ClinicalTrials.gov/show/NCT05620251" | |
| 381,"NCT02611232","Incretin-based Therapy in Preclinical Type 1 Diabetes in Adults",,"Enrolling by invitation","No Results Available","Type 1 Diabetes","Drug: Victoza®|Drug: Placebo","FPIR (first phase insulin response)|Safety: serum and urine amylase, serum lipase, serum calcitonin, hypoglycemia|Tolerability|Serum C-peptide AUC","University of Oulu|Oulu University Hospital|Tampere University Hospital|Turku University Hospital","All","18 Years to 30 Years (Adult)","Phase 2","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","LiraAAB18-30|2014-003667-37|3-SRA-2014-301-M-R|U1111-1176-6062","December 2015","June 2024","June 2024","November 20, 2015",,"January 25, 2022","University of Oulu and Oulu University Hospital, Oulu, Finland|University of Tampere and Tampere University Hospital, Tampere, Finland|University of Turku and Turku University Hospital, Turku, Finland",,"https://ClinicalTrials.gov/show/NCT02611232" | |
| 382,"NCT00449891","Neuropsychological and Neuroanatomical Studies of Young Children With and Without Type 1 Diabetes Mellitus",,"Completed","No Results Available","Type 1 Diabetes Mellitus",,,"Stanford University|William E And Aenid R Weisgerber Foundation","All","3 Years to 10 Years (Child)",,"30","Other","Observational","Time Perspective: Cross-Sectional","IRB 97517|1102002-100-GHATW","January 2007","March 2016","March 2016","March 21, 2007",,"April 14, 2016","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT00449891" | |
| 383,"NCT03478969","Participant-Reported Outcomes With the Accu-Chek® Solo Micropump System","PRO Solo","Completed","Has Results","Diabetes Mellitus, Type 1","Device: Accu-Chek® Solo micropump system|Device: mylife™ OmniPod® Insulin Management System|Other: Multiple Daily Injections (MDI) therapy","Treatment Satisfaction: Accu-Chek® Micropump System vs. MDI, Measured by the Difference in the Diabetes Technology Questionnaire (DTQ) Total Change Score|Treatment Satisfaction: Accu-Chek® Micropump System vs. Mylife™ OmniPod®, Measured by the Difference in the Diabetes Technology Questionnaire (DTQ) Total Change Score|Diabetes-Related Emotional Distress Assessed by Problem Areas in Diabetes Scale (PAID)-5|Device Satisfaction and Treatment Preference|Therapy Success Confirmed by Glycated Hemoglobin (Hb1Ac) Levels|Therapy Success Indicated by Change in Body Mass Index (BMI)|Therapy Success Indicated by Change in Weight|Change in Glycemic Index|Number of Participants With Therapy Parameters Indicated by Commencement of Continuous Subcutaneous Insulin Infusion (CSII)|Change in Therapy Parameters Based on Type of Insulin Used|Change in Therapy Parameters Indicated by Total Daily Insulin Dose (TDD)|Change in Therapy Parameters Indicated by Total Daily Basal Insulin Dose (TBD)|Change in Therapy Parameters Based on Average Number of Self Monitoring of Blood Glucose (SMBGs) Per Day|Percentage of Time Spent in Hypoglycaemic Blood Glucose (BG) Ranges|Percentage of Time Spent in Hyperglycaemic Blood Glucose (BG) Ranges|Number of Consultations|Number of Pods/Infusion Assemblies Falling Off Prematurely|Average Time Spent on Infusion Assembly|Number of Participants With Skin Reactions (Including Type and Intensity)|Socio-economic Acceptance: Amount of Insulin Left in Device at Reservoir Change/Device Discard|Amount of Waste, Inferred by Total Material Consumption","Hoffmann-La Roche","All","18 Years to 65 Years (Adult, Older Adult)","Not Applicable","181","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","RD002718","May 17, 2018","May 18, 2020","May 18, 2020","March 27, 2018","August 16, 2021","August 20, 2021","VIVIT Institut am LKH Felkirch, Feldkirch, Austria|LKH Graz, Medizinische Universität Graz, Graz, Austria|Medizinische Universität Innsbruck, Innsbruck, Austria|Salzburger Landeskliniken - Universitätsklinikum Salzburg (SALK), Salzburg, Austria|Diakonissen & Wehrle Privatklinik GmbH, Standort Andräviertel, Salzburg, Austria|Hietzing Hospital, Vienna, Austria|Diabetes Klinik Bad Mergentheim GmbH, Bad Mergentheim, Germany|InnoDiab Forschung GmbH, Essen, Germany|Gemeinschaftspraxis im Altstadt-Carree, Fulda, Germany|Gemeinschaftspraxis Drs Bieber Kraus Nolte Vortherms, Lage, Germany|Diabeteszentrum am CKQ, Quakenbrueck, Germany|Diabendo Praxiszentrum, Rostock, Germany|Regionalne Centrum Diabetologii - Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Jagiellonian University, Krakow, Poland|Central Clinical Hospital of the MSWiA in Warsaw, Warsaw, Poland|Bournemouth Diabetes and Endocrine Centre, Bournemouth, United Kingdom|Wolfson Diabetes & Endocrine Clinic, Cambridge, United Kingdom|Centre for Clinical Research and Innovation, Darlington, United Kingdom|King's College London, Diabetes Research Group, London, United Kingdom|Imperial College London, Diabetes, Endocrinology and Metabolism Division, London, United Kingdom|Manchester Royal Infirmary, University Hospital, Manchester, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT03478969/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT03478969/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03478969" | |
| 384,"NCT01724190","Effect of Vitamin D on the Honeymoon Period in Children and Adolescents With Type 1 Diabetes",,"Completed","No Results Available","Type 1 Diabetes","Drug: Vitamin D|Drug: Placebo","IDAA1c|fasting c-peptide|high sensitivity c-reactive protein (hsCRP)|interleukin-6 (IL-6)|tumor necrosis factor-alpha (TNF-alpha)|25-(OD)D","Nationwide Children's Hospital","All","4 Years to 18 Years (Child, Adult)","Not Applicable","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)","285412","November 2012","June 2014","June 2014","November 9, 2012",,"June 22, 2015","Nationwide Children's Hospital, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01724190" | |
| 385,"NCT03941132","Clinical Phase II/III Trial of Ustekinumab to Treat Type 1 Diabetes (UST1D2)","UST1D2","Recruiting","No Results Available","Type 1 Diabetes Mellitus","Drug: Ustekinumab|Drug: Placebo","Baseline change in 2-hour mixed meal-stimulated C-peptide AUC at week 52.|Rate, frequency and severity of all adverse events including; hypoglycemic episodes; injection reactions; hypersensitivity reactions; evidence of infection and posterior leukoencephalopathy syndrome.|2-hour MMTT-stimulated C-peptide AUC at weeks 28 and 78)|HbA1C and insulin use in units per kg body weight per day at weeks 0, 8, 16, 24, 28, 32, 40, 48, 52, 78.|Immune phenotyping via flow cytometry of all IL-12, IL-23, IL-17, IFN-γ secreting immune subsets at weeks 0, 32, 52, 78).|Basic immune phenotyping of WBC subsets|HLA- A, B, C, DR, DP, DQ typing at weeks 0, 8 ,16, 32, 52, 78)|Fluorospot (ELISpot) analysis for IL-17 and IFN-γ secretion in response to whole insulin and antigens for CD8+ and CD4+ T cells.|Luminex/Mesoscale assessment of serum cytokines IL-17, IFN-γ, IL-12p40, IL-12p70 and IL-23.|Regulatory T cell (CD4+ FOXP3+): Effector T cell (CD4+ FOXP3-CD25+) ratio.|CD154 and CD134 (OX40) based assays to determine diabetogenic antigen specific responses of T helper cells.|Nanostring assessment of whole blood and PBMC RNA gene expression of IL-17 and IFN-γ family genes.|Epigenetic assessment of Treg phenotype and function.|Sequencing and profiling of microbiome.|Glycaemic variability in continuous glucose monitoring and hypoglycaemia rates.","University of British Columbia|Juvenile Diabetes Research Foundation|Janssen, LP","All","18 Years to 35 Years (Adult)","Phase 2|Phase 3","66","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H19-00411","January 4, 2021","January 2024","August 2025","May 7, 2019",,"June 8, 2022","Mount Sinai Hospital/UHN, Toronto, British Columbia, Canada|BCDiabetes, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT03941132" | |
| 386,"NCT00821899","Bone Marrow Autotransplantation in Type 1 Diabetes",,"Completed","No Results Available","Type 1 Diabetes Mellitus","Biological: administration of autologous bone marrow blood","Evaluate glycosylated hemoglobin 1,3,6, and 12 months after autologous bone marrow blood administration.|Evaluate number of hypoglycemias 1,3,6, and 12 months after autologous bone marrow blood administration.|Evaluate insulin dose 1,3,6, and 12 months after autologous bone marrow blood administration.|Evaluate GADab titers and treatment tolerance 1,3,6, and 12 months after autologous bone marrow blood administration.","Hospital Clinic of Barcelona","All","18 Years to 50 Years (Adult)","Not Applicable","3","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BMATxDM1","January 2009","May 2010","May 2010","January 14, 2009",,"March 20, 2012","Enric Esmatjes, Barcelona, Spain|Hospital Clinic, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT00821899" | |
| 387,"NCT04877730","Diabetes Closed-Loop Project 6 (DCLP6): Fully Automated Closed-Loop Control in Type 1 Diabetes Using Meal Anticipation",,"Completed","No Results Available","Type 1 Diabetes","Device: Fully Closed Loop (FCL)|Device: Fully Closed Loop with meal anticipation module (FCL+)|Device: Hybrid Closed Loop (HCL)","Time in range (TIR) 70-180 mg/dL from breakfast time + 5 hours|Time in range (TIR) 70-180 mg/dL overall|Time in range (TIR) 70-180 mg/dL from dinner time + 5 hours|Time in range (TIR) 70-180 mg/dL from lunch time + 5 hours|Time below range (TBR) from breakfast time + 5 hours|Time below range (TBR) overall|Time below range (TBR) from dinner time + 5 hours|Time below range (TBR) from lunch time + 5 hours|Time above range (TAR) from breakfast time + 5 hours|Time above range (TAR) overall|Time above range (TAR) from dinner time + 5 hours|Time above range (TAR) from lunch time + 5 hours|Time in significant hyperglycemia from breakfast time + 5 hours|Time in significant hyperglycemia overall|Time in significant hyperglycemia from dinner time + 5 hours|Time in significant hyperglycemia from lunch time + 5 hours|Time in significant hypoglycemia from breakfast time +5 hours|Time in significant hypoglycemia overall|Time in significant hypoglycemia dinner time + 5 hours|Time in significant hypoglycemia lunch time + 5 hours|Number of hypoglycemia events from breakfast time + 5 hours|Number of hypoglycemia events overall|Number of hypoglycemia events dinner time + 5 hours|Number of hypoglycemia events lunch time + 5 hours|Units of insulin injected between 2 hours before and 5 hours after breakfast|Units of insulin injected during test period|Units of insulin injected between 4 hours before and 5 hours after dinner|Units of insulin injected between 2 hours before and 5 hours after lunch","University of Virginia|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 70 Years (Adult, Older Adult)","Not Applicable","50","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","210035|UC4DK108483","May 21, 2021","March 4, 2022","March 6, 2022","May 7, 2021",,"June 10, 2022","University of Virginia Center for Diabetes Technology, Charlottesville, Virginia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT04877730/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT04877730/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT04877730" | |
| 388,"NCT01521520","Imaging of Type 1 Diabetes Progression",,"Unknown status","No Results Available","Type 1 Diabetes","Drug: ferumoxytol",,"Jason Gaglia|National Institute of Allergy and Infectious Diseases (NIAID)|Harvard Medical School (HMS and HSDM)|Massachusetts General Hospital","All","18 Years and older (Adult, Older Adult)",,"65","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2011P001957|P01AI054904","January 2012",,,"January 30, 2012",,"April 10, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01521520" | |
| 389,"NCT04089462","Effects of Frequency and Duration of Exercise in People With Type 1 Diabetes A Randomized Crossover Study",,"Completed","No Results Available","Diabetes Mellitus, Type 1|Insulin Hypoglycemia","Behavioral: ""Five sessions per period"" - ""Two sessions per period""|Behavioral: ""Two sessions per period"" - ""Five sessions per period""","Percentage of time spent in the hypoglycemic range (CGM <3.9 mmol/l)|Percentage of time spent in the alert and clinical hypoglycemic range|Number of alert and clinical hypoglycemia events|Number of severe hypoglycemia events during|Number of severe hypoglycemia events|Percentage of time in range (3.9-10 mmol/l)|Percentage of time in good range (3.9-7.8 mmol/l)|Percentage of time in hyperglycemia (>10 mmol/l)|Percentage of time in hyperglycemia (>10 mmol/l) during all the predefined time blocks. Per protocol analysis and intention-to-treat analysis|Glycemic variability measured as standard deviation (SD), coefficient of variation (CV) and low and high blood glucose index (LBGI/HBGI) during all the predefined time blocks in the intervention period|Mean CGM glucose level du during all the predefined time blocks in the intervention period|CGM estimated eA1c during the primary intervention period|Total carbohydrate intake registered from the insulin pumps during all the predefined time blocks in the intervention period|Carbohydrate interventions for prevention and treatment of hypoglycemia registered by the participants in the booklet for the primary and total intervention period|Change in total daily insulin dose (basal and bolus insulin) of 7 days prior to screening day and during the primary and total intervention period|Actigraph wrist wear time during all predefined time blocks|Physical activity energy expenditure (accelerometer and heart rate based) measured as kcal during all predefined time blocks|Metabolic expenditure rate for the primary intervention periods|Number of exercise (light to vigorous) and sedentary bouts in the primary intervention period|Time in sedentary during predefined time blocks|Time in light physical activity during predefined time blocks|Time in moderate physical activity during predefined time blocks|Time in vigorous physical activity during predefined time blocks|Number of steps during predefined time blocks|Heart rate during exercise sessions|R-R intervals during exercise sessions (f)|Sleep latency (min) during the primary and total intervention period|Total sleep time (min) during the primary and total intervention period|Sleep efficiency (%) during the primary and total intervention period|Number of awakening during sleep in the primary and total intervention period|Time of awakening during sleep in the primary and total intervention period|Question about patient preference regarding the two study arms","Steno Diabetes Center Copenhagen","All","18 Years to 64 Years (Adult)","Not Applicable","26","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-19035830","September 30, 2019","October 15, 2020","January 1, 2021","September 13, 2019",,"September 28, 2021","Steno Diabetes Center Copenhagen, Gentofte, Denmark",,"https://ClinicalTrials.gov/show/NCT04089462" | |
| 390,"NCT04450563","Low Dose Empagliflozin in Adults With Type 1 Diabetes on Closed Loop Insulin System","CL-LoDE","Completed","No Results Available","Type 1 Diabetes","Drug: 14-day outpatient intervention","Percentage of time of plasma glucose levels spent in target range (placebo vs empagliflozin 2.5 mg)|Percentage of time of plasma glucose levels spent in target range (placebo vs empagliflozin 5 mg)|Percentage of time spent in the following ranges of glucose levels between 3.9 and 7.8 mmol/L|Percentage of time spent in the following ranges of glucose levels: below 3.9, 3.3 and 2.8 mmol/L|Percentage of time spent in the following ranges of glucose levels: above 7.8, 10, 13.9, and 16.7 mmol/L|Average glucose level|Percentage coefficient of variation of glucose levels|Quality of life measure by Type 1 Diabetes Distress Scale: score is the average of 28 items from 1 to 6 (higher score indicates more emotional distress)|Quality of life measure by Hypoglycemic Fear Survey - II: score is the average of 33 items from 1 to 5 (average of higher scorer equates to more distress)|Quality of life measure by INSPIRE (Insulin delivery Systems: Perceptions, Ideas, Reflections and Expectations) questionnaire for adults: score is the average of 22 items from 1 to 5 (average of higher scorer equates to more distress)|Total daily insulin dose|Average point-of-care ketone level per intervention|Rise in ketone level between interventions","McGill University","All","18 Years and older (Adult, Older Adult)","Phase 1","25","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2021 - 6542","November 2, 2020","January 5, 2022","January 13, 2022","June 29, 2020",,"October 12, 2022","Clinique Médicale Hygea, Montreal, Quebec, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT04450563/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04450563" | |
| 391,"NCT02636491","Use of an Automated Insulin Delivery System Compared to Sensor Augmented Pump at Patients With Type 1 Diabetes (T1D)","DREAM5","Completed","No Results Available","Type 1 Diabetes","Device: MD-Logic-Automated Insulin Delivery System|Device: MiniMed Paradigm® Veo™ System","normal glucose level|Hypoglycemia|increased glucose level|glucose sensor readings","Kinderkrankenhaus auf der Bult","All","10 Years to 65 Years (Child, Adult, Older Adult)","Not Applicable","45","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MC-01","December 2015","June 2016","June 2016","December 21, 2015",,"February 28, 2018","Kinder - und Jugendkrankenhaus AUF DER BULT, Hannover, Germany",,"https://ClinicalTrials.gov/show/NCT02636491" | |
| 392,"NCT01402037","Beta Cell Function in (Pre)Type 1 Diabetes",,"Unknown status","No Results Available","Type 1 Diabetes","Drug: Glucose|Device: Continuous glucose monitoring","evaluate the hyperglycemic clamp to measure the functional beta cell mass test|Follow up of OGTT's and HbA1c levels in high risk first degree relatives and patients|evaluate the continuous glucose monitoring to measure within- and between-day glycemic variability","AZ-VUB|Vrije Universiteit Brussel|University Hospital, Ghent|University Hospital, Antwerp","All","5 Years to 39 Years (Child, Adult)","Not Applicable","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","KD_BF_02","July 2011","July 2015","July 2016","July 26, 2011",,"December 30, 2013","UZ Brussels, Brussels, Belgium|UZ Antwerpen, Edegem, Belgium|UZ Gent, Gent, Belgium",,"https://ClinicalTrials.gov/show/NCT01402037" | |
| 393,"NCT00390728","Insulin Glargine in Type I Diabetes Mellitus> Main Study ""AT.LANTUS"": A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar. Sub-study: ""HALT""(Hypoglycaemia Avoidance With Lantus Trial)","AT-LANTUS","Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: Insulin Glargine","Main study: Frequency of severe hypoglycaemia|Sub-study: The fear of hypoglycaemia as measured by the Hypoglycaemia Fear Survey questionnaire (HFS-98) assessed at baseline, 3 months and study end point or upon withdrawal of the subject from the study.|Main study: HbA1c|Incidence of nocturnal, symptomatic and asymptomatic hypoglycaemia|Self monitored blood glucose|Change in subject weight|Changes in doses of insulin|Changes in treatment satisfaction|Safety assessment|Quality of Life (QoL)using the Diabetes Treatment Satisfaction Questionnaire (DTSQ)|Sub-study:Quality of Life tools assessed at baseline, 3 months and at study end point or upon withdrawal of the subject|Quality of Life - EQ-5D|Hospital Anxiety and Depression Scale (HADS)|Adverse events correlating with Quality of Life tools and hypoglycaemic events|Medications for diabetes|HbA1c|Weight and height (BMI)|Proportion of patients reaching HbA1c target as per participation with the Prescription Plan","Sanofi","All","18 Years and older (Adult, Older Adult)","Phase 4","2346","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HOE901_3505","April 2002","August 2003","August 2003","October 20, 2006",,"August 31, 2010",,,"https://ClinicalTrials.gov/show/NCT00390728" | |
| 394,"NCT02389335","Roles of T Helper 1 Cytokines in Type 1 Diabetes",,"Completed","No Results Available","Type 1 Diabetes",,"Roles of interferon gamma, interleukin-2, tumor necrotizan factor alpha in the pathogenesis of type 1 diabetes","Istanbul Medeniyet University","All","Child, Adult, Older Adult",,"128","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MUGEAH-2|Interleukins in type 1diabetes","April 2013","July 2014","November 2014","March 17, 2015",,"March 17, 2015","Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT02389335" | |
| 395,"NCT00842075","Pramlintide in Adolescents With Type 1 Diabetes",,"Completed","Has Results","Type 1 Diabetes","Drug: pramlintide","HbA1c Value After 28 Days|Weight Change After 28 Days Intervention Period","University of Colorado, Denver|Amylin Pharmaceuticals, LLC.","All","13 Years to 17 Years (Child)","Not Applicable","10","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","05-0724(2)","December 2006","December 2009","December 2009","February 12, 2009","October 19, 2012","June 23, 2015","Barbara Davis Center, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT00842075" | |
| 396,"NCT04819815","Investigation of Chronotropic Index, Exercise Capacity in Type 1 Diabetes Mellitus",,"Completed","No Results Available","Type 1 Diabetes Mellitus",,"Exercise Capacity|Chronotropic index|Pulmonary function (Forced vital capacity (FVC))|Pulmonary function (Forced expiratory volume in the first second (FEV1))|Pulmonary function (FEV1 / FVC)|Pulmonary function (Flow rate 25-75% of forced expiratory volume (FEF 25-75%))|Pulmonary function (Peak flow rate (PEF))|Respiratory Muscle Strength|Respiratory Muscle Endurance|Peripheral Muscle Strength|Physical Activity Level|Shortness of breath|Fatigue|Life Quality","Gazi University","All","18 Years to 65 Years (Adult, Older Adult)",,"54","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","Gazi University 26","January 20, 2020","July 30, 2021","September 30, 2021","March 29, 2021",,"March 22, 2022","Gazi University Faculty of Health Sciences Department of Physiotherapy and Rehabilitation, Cardiopulmonary Rehabilitation Unit, Ankara, Çankaya, Turkey",,"https://ClinicalTrials.gov/show/NCT04819815" | |
| 397,"NCT02760303","Reducing Stress in Adolescents and Young Adults With Type 1 Diabetes to Improve Diabetes Care","T1D","Completed","No Results Available","Type 1 Diabetes","Behavioral: Cognitive Behavioral Therapy|Behavioral: Mindfulness Based Stress Reduction|Behavioral: Diabetes Support and Education","Metabolic Control|Regimen Adherence (objective)|Regimen Adherence (daily diary)|Regimen Adherence (self-reported)|Psychological Stress (general)|Psychological Stress (diabetes-related)|Psychological Stress (attitudes)|Diabetes Quality of Life","Wayne State University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","16 Years to 20 Years (Child, Adult)","Not Applicable","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","066115B3E|R01DK059067","September 2015","October 2016","May 2017","May 3, 2016",,"June 2, 2017","Wayne State University School of Medicine, Detroit, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT02760303" | |
| 398,"NCT02727231","Closing the Loop in Adults With Type 1 Diabetes and HbA1C<7.5% Under Free Living Conditions",,"Completed","No Results Available","Type 1 Diabetes","Device: Florence D2A or similar closed loop glucose control system|Device: CSII with CGM","Time spent in the target glucose range (3.9 to 10.0 mmol/l) based on subcutaneous glucose monitoring|Continuous subcutaneous glucose monitoring (CGM) based outcome|Continuous subcutaneous glucose monitoring (CGM) based outcome during overnight period between 24:00 and 06:00|Continuous subcutaneous glucose monitoring (CGM) based outcome during day period between 06:00 to 24:00|Insulin dose|Adverse Events|Utility Evaluation","University of Cambridge|Medical University of Graz","All","18 Years and older (Adult, Older Adult)","Not Applicable","29","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AP@home04 phase2","March 2016","October 2016","October 2016","April 4, 2016",,"October 11, 2016","Medical University of Graz, Graz, Austria|Cambridge University Hospitals NHS Foundation Trust, Addenbrookes Hospital, Cambridge, Cambridgeshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02727231" | |
| 399,"NCT03579615","Comparison of Day and Night Closed-loop With Faster-acting Insulin Aspart With Insulin Aspart","AP-MFT-01","Completed","No Results Available","Diabetes Mellitus, Type 1","Device: FIASP + closed loop device|Device: Insulin aspart (standard of care insulin) + closed loop device","Time spent in the target glucose range|Time spent in the target glucose range within 4 hours of each meal|Incremental area under the curve of sensor glucose level within 4 hours of each meal|Time spent below target glucose|Time spent above target glucose|Average, coefficient of variation and standard deviation glucose levels|The time with sensor glucose levels < 3.5 mmol/l (63 mg/dl)|The time with sensor glucose levels <3.0 (54mg/dl)|The time with sensor glucose levels <2.8 mmol/l (50 mg/dl)|The time with sensor glucose levels in the significant hyperglycaemia|Total, basal and bolus insulin dose|AUC of glucose below 3.0mmol/l (54mg/dl)","Manchester University NHS Foundation Trust|Novo Nordisk A/S","All","18 Years and older (Adult, Older Adult)","Not Applicable","18","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","R04695","December 23, 2020","February 24, 2022","August 1, 2022","July 6, 2018",,"August 22, 2022","Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03579615" | |
| 400,"NCT03784027","The Artificial Pancreas in Very Young Children With T1D","KidsAP02","Completed","No Results Available","Type 1 Diabetes Mellitus","Device: CamAPS FX|Other: Sensor augmented therapy","Time in target (3.9 to 10.0 mmol/l) (70 to 180 mg/dl)|Time spent above target glucose (10.0 mmol/l) (180 mg/dl)|HbA1c|Average glucose|Time spent below target glucose (3.0 mmol/l) (70 mg/dl)|Standard deviation|Coefficient of variation of glucose levels|Time with glucose levels <3.0 mmol/l (54 mg/dl)|Time with glucose levels in significant hyperglycaemia (glucose levels > 16.7 mmol/l) (300 mg/dl)|AUC of glucose below 3.5 mmol/l (63 mg/dl)|BMI SDS|Total, basal, and bolus insulin dose|Number of episodes of severe hypoglycaemia|Number of subjects experiencing severe hypoglycaemia|Frequency of diabetic ketoacidosis|Frequency and nature of other adverse events or serious adverse events|Percentage of time of closed-loop operation|Percentage of time of CGM availability","University of Cambridge|European Commission|Cambridge University Hospitals NHS Foundation Trust|The Leeds Teaching Hospitals NHS Trust|University of Luxembourg|University of Leipzig|Medical University of Graz|Medical University Innsbruck|Medical University of Vienna|Jaeb Center for Health Research|University of Edinburgh|Stanford University|Glooko","All","1 Year to 7 Years (Child)","Not Applicable","81","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KidsAP02","May 1, 2019","February 22, 2021","October 3, 2022","December 21, 2018",,"November 2, 2022","Medical University of Graz Department of Pediatrics and Adolescent Medicine, Graz, Austria|Medical University of Innsbruck Department of Pediatrics I, Innsbruck, Austria|Medical University of Vienna Department of Pediatrics, Wien, Austria|University of Leipzig Division for Paediatric Diabetology, Leipzig, Germany|Clinique Pédiatrique de Luxembourg Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg|University Department of Paediatrics, Cambridge, Cambridgeshire, United Kingdom|Wellcome Trust-MRC Institute of Metabolic Science University of Cambridge, Cambridge, Cambridgeshire, United Kingdom|St James's University Hospital, Leeds, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03784027" | |
| 401,"NCT01398826","Glycemic Response to Road Cycling in Type 1 Diabetes",,"Unknown status","No Results Available","Type 1 Diabetes",,,"Team Type 1, Inc.","Male","18 Years and older (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","TT1-001","May 2011","August 2011","August 2011","July 21, 2011",,"July 21, 2011",,,"https://ClinicalTrials.gov/show/NCT01398826" | |
| 402,"NCT02897219","A Study of ASP1941 in Combination With Insulin in Patients With Type 1 Diabetes Mellitus",,"Completed","No Results Available","Type 1 Diabetes Mellitus","Drug: ipragliflozin|Drug: Placebo|Other: Insulin Therapy","Change from baseline in HbA1c|Change from baseline in Fasting plasma glucose|Change from baseline in self-monitored blood glucose level|Change from baseline in leptin|Change from baseline in glycoalbumin|Change from baseline in adiponectin|Change from baseline in glucagon|Change from baseline in number of units of insulin administered concomitantly|Change from baseline in body weight|Change from baseline in waist circumference|Safety assessed by incidence of adverse events|Safety assessed by sitting blood pressure|Safety assessed by sitting pulse rate|Safety assessed by standard 12-lead electrocardiogram|Safety assessed by laboratory tests: Hematology|Safety assessed by laboratory tests: Biochemistry|Safety assessed by laboratory tests: Urinalysis","Astellas Pharma Inc","All","20 Years and older (Adult, Older Adult)","Phase 3","175","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1941-CL-6002","August 29, 2016","July 22, 2017","March 15, 2018","September 13, 2016",,"March 6, 2019","Site JP00005, Aichi, Japan|Site JP00028, Aichi, Japan|Site JP00003, Chiba, Japan|Site JP00013, Chiba, Japan|Site JP00035, Chiba, Japan|Site JP00022, Fukuoka, Japan|Site JP00023, Fukuoka, Japan|Site JP00031, Fukuoka, Japan|Site JP00002, Gunma, Japan|Site JP00011, Gunma, Japan|Site JP00006, Hiroshima, Japan|Site JP00033, Hokkaido, Japan|Site JP00034, Hokkaido, Japan|Site JP00021, Hyogo, Japan|Site JP00009, Ibaraki, Japan|Site JP00010, Ibaraki, Japan|Site JP00004, Kanagawa, Japan|Site JP00015, Kanagawa, Japan|Site JP00016, Kanagawa, Japan|Site JP00019, Mie, Japan|Site JP00008, Nagasaki, Japan|Site JP00024, Nagasaki, Japan|Site JP00025, Nagasaki, Japan|Site JP00032, Nagasaki, Japan|Site JP00026, Niigata, Japan|Site JP00020, Osaka, Japan|Site JP00029, Osaka, Japan|Site JP00036, Osaka, Japan|Site JP00012, Saitama, Japan|Site JP00017, Shizuoka, Japan|Site JP00018, Shizuoka, Japan|Site JP00001, Tochigi, Japan|Site JP00030, Tokushima, Japan|Site JP00014, Tokyo, Japan|Site JP00027, Toyama, Japan|Site JP00007, Yamaguchi, Japan",,"https://ClinicalTrials.gov/show/NCT02897219" | |
| 403,"NCT04039945","Fr1da-/Fr1da-Plus-Study in Bavaria: Early Detection for Early Care of Type 1 Diabetes","Fr1da-Plus","Recruiting","No Results Available","Type 1 Diabetes Mellitus",,"presence of multiple islet autoantibodies","Helmholtz Zentrum München","All","2 Years to 5 Years (Child)",,"180000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","808040014","February 2015","April 2023","April 2023","July 31, 2019",,"March 16, 2022","Institut für Diabetesforschung, Helmholtz Zentrum München, Munich, Germany",,"https://ClinicalTrials.gov/show/NCT04039945" | |
| 404,"NCT02916251","ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed Glucagon",,"Completed","No Results Available","Diabetes Mellitus Type 1","Drug: ZP4207(dasiglucagon) glucagon analogue|Drug: Glucagon (Native glucagon)","PK endpoint for ZP4207(dasiglucagon) and baseline adjusted glucagon: AUC 0-240 min|PK endpoint for ZP4207(dasiglucagon) and baseline adjusted glucagon: Cmax|PK endpoint for ZP4207(dasiglucagon) and baseline adjusted glucagon: tmax|PD endpoint: Plasma glucose profiles above baseline: AUE 0-240 min|PD endpoint: Plasma glucose profiles above baseline: CEmax|PD endpoint: Plasma glucose profiles above baseline: tmax|PK endpoints for ZP4207(dasiglucagon) and baseline adjusted glucagon: MRT|PK endpoints for ZP4207(dasiglucagon) and baseline adjusted glucagon: Vz/f,|PK endpoints for ZP4207(dasiglucagon) and baseline adjusted glucagon: λz|PK endpoints for ZP4207(dasiglucagon) and baseline adjusted glucagon: t½,|PK endpoints for ZP4207(dasiglucagon) and baseline adjusted glucagon: CL/f|PK endpoints for ZP4207(dasiglucagon) and baseline adjusted glucagon: AUC 0-30min|PK endpoints for ZP4207(dasiglucagon) and baseline adjusted glucagon: AUC 0-inf|Insulin concentrations before and after dosing with ZP4207(dasiglucagon) or glucagon:|PD endpoints for ZP4207(dasiglucagon) and baseline adjusted glucagon: AUE 0-30min|PD endpoints for ZP4207(dasiglucagon) and baseline adjusted glucagon: CE 30min|PD endpoints for ZP4207(dasiglucagon) and baseline adjusted glucagon: t50%CE, early|PD endpoints for ZP4207(dasiglucagon) and baseline adjusted glucagon: t10%CE, late|PD endpoints: Percentage of patients achieving a plasma glucose increase of ≥20 mg/dL within 30 minutes after treatment|PD endpoints: Time to plasma glucose increase of ≥20 mg/dL|PD endpoints: Percentage of patients achieving a plasma glucose concentration ≥70 mg/dL within 30 minutes after treatment (insulin-induced hypoglycemia)|PD endpoints: Time to plasma glucose concentration of ≥70 mg/dL (insulin-induced hypoglycemia)|Safety endpoints: Number of participants with adverse events|Safety endpoints: Local tolerability of injection site|Safety endpoints: Laboratory safety parameters|Safety endpoints: Physical examination|Safety endpoints: Vital signs|Safety endpoints: ECGs|Safety endpoints: Antidrug antibodies incidences","Zealand Pharma","All","18 Years to 64 Years (Adult)","Phase 2","38","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ZP4207-16098","December 1, 2016","April 5, 2017","April 5, 2017","September 27, 2016",,"April 21, 2017","Profil Institut für Stoffwechselforschung GmbH, Neuss, North Rhine-Westphalia, Germany",,"https://ClinicalTrials.gov/show/NCT02916251" | |
| 405,"NCT02854696","Health Economic Analysis of Islet Cell Transplantation for the Stabilization of the Severe Forms of Type 1 Diabetes","STABILOT","Active, not recruiting","No Results Available","Type 1 Diabetes","Procedure: Islet graft|Drug: best medical care","Incremental cost- utility ratio at 1 year|Cost-effectiveness ratio at 1 year|Assessment of individual medical benefit of quality of life|Assessment of individual medical benefit in terms of metabolic efficacy|Assessment and comparison of individual medical benefit in terms of complications of islet cell transplantation between the two groups|Assessment and comparison of clinical benefit for patients with brittle type 1 diabetes with impairment of vital prognosis before and after islet cell transplantation|Assessment and comparison of costs for patients with brittle type 1 diabetes with impairment of vital prognosis before and after islet cell transplantation|Assessment of total cost of islet cell transplantation","University Hospital, Grenoble","All","18 Years to 65 Years (Adult, Older Adult)","Phase 3","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","38RC14.453","July 7, 2016","May 2023","December 2023","August 3, 2016",,"June 24, 2022","University Hospital of Besançon, Besancon, France|university hospital of Clermont Ferrand, Clermont Ferrand, France|Grenoble University Hospital, Grenoble, France|University hospital of Lille, Lille, France|University Hospital of Lyon, Lyon, France|University Hospital of Montpellier, Montpellier, France|University hospital of Nancy, Nancy, France|university hospital of Nantes, Nantes, France|APHP, Paris, France|University hospital of Strasbourg, Strasbourg, France|University Hospital of Geneva, Geneva, Switzerland",,"https://ClinicalTrials.gov/show/NCT02854696" | |
| 406,"NCT02527525","First STEPS- Study of Type 1 in Early Childhood and Parenting Support",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Behavioral: Stepped Care","glycemic control|parental mood|glycemic variability","Children's National Research Institute|Baylor College of Medicine|National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","21 Years and older (Adult, Older Adult)","Not Applicable","158","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","6270|1R01DK102561-01A1","April 2016","July 2021","July 2021","August 19, 2015",,"August 6, 2021",,,"https://ClinicalTrials.gov/show/NCT02527525" | |
| 407,"NCT02908087","Incretin-based Therapy in Early Diagnosed Type 1 Diabetes",,"Completed","No Results Available","Type 1 Diabetes","Drug: Victoza® (liraglutide)|Drug: Placebo","Serum C-peptide AUC|Safety: Serum and urine amylase, serum lipase, serum calcitonin levels will be monitored|Number of hypoglycemia episodes|Frequency of gastrointestinal side effects|Insulin dose","University of Oulu|Oulu University Hospital|Tampere University Hospital|Turku University Hospital|Skane University Hospital","All","10 Years to 30 Years (Child, Adult)","Phase 2","13","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LiraT1D10-30|2014-004760-37|3-SRA-2014-301-M-R|U1111-1177-0661","March 2016","May 2021","May 2021","September 20, 2016",,"January 11, 2022","University of Oulu and Oulu University Hospital, Dept of Children and Adolescents, Oulu, Finland|University of Tampere and Tampere University Hospital, Tampere, Finland|University of Turku and Turku University Hospital, Turku, Finland|Lund University and Skåne University Hospital, Malmö, Sweden",,"https://ClinicalTrials.gov/show/NCT02908087" | |
| 408,"NCT05666791","The Association Between Diabetes Stress, Self-efficacy, Self-management, and Glycemic Control in Children and Adolescents With Type 1 Diabetes Mellitus",,"Not yet recruiting","No Results Available","Children and Adolescents With Type 1 Diabetes Mellitus",,"Demographic characteristics|Diabetes specific-stress|Self-management|Self-efficacy","National Taiwan University Hospital","All","8 Years to 25 Years (Child, Adult)",,"200","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","202210117RINC","December 21, 2022","December 2023","December 2023","December 28, 2022",,"January 2, 2023",,,"https://ClinicalTrials.gov/show/NCT05666791" | |
| 409,"NCT01235819","Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus",,"Completed","No Results Available","Type 1 Diabetes","Drug: Insulin|Drug: Sitagliptin|Drug: Exenatide","change in insulin requirement|C peptide response","Command Hospital, India","All","12 Years to 30 Years (Child, Adult)","Phase 4","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DM/CHCC/03/2010","November 2010","September 2011","September 2011","November 8, 2010",,"July 27, 2016","Command Hospital, Lucknow, UP, India",,"https://ClinicalTrials.gov/show/NCT01235819" | |
| 410,"NCT03236558","The Role of the Thymus in Type I Diabetes.","TregDiab","Withdrawn","No Results Available","Type1 Diabetes","Procedure: Blood collection","Variability of the diversity of antigen-receptors' repertoires, expressed by regulatory T cells from type I diabetes patients and healthy controls.|Ratio between TCR diversities expressed by Treg cells vs. conventional T cells.","University Hospital, Toulouse|Institut National de la Santé Et de la Recherche Médicale, France|Centre National de la Recherche Scientifique, France","All","6 Years to 12 Years (Child)","Not Applicable","0","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","RC31/16/8254","March 2018","March 2019","March 2019","August 2, 2017",,"April 1, 2020","CHU de Toulouse, Toulouse, Midi-Pyrénées, France",,"https://ClinicalTrials.gov/show/NCT03236558" | |
| 411,"NCT01736228","Open-label Investigation of the Safety and Efficacy of DIABECELL in Patients With Type 1 Diabetes Mellitus",,"Completed","No Results Available","Type 1 Diabetes","Device: DIABECELL","to establish the efficacy and safety of DIABECELL|Porcine β-cell function as demonstrated by measurement of porcine pro-insulin in xenotransplant recipients|Improvement in the quality-of-life of xenotransplant recipients","Living Cell Technologies","All","18 Years to 65 Years (Adult, Older Adult)","Phase 2","14","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCT/DIA-12","November 2012","December 2014","December 2014","November 29, 2012",,"March 17, 2015","Hospital Interzonal General de Agudos Eva Perón, San Martin, Buenos Aires, Argentina",,"https://ClinicalTrials.gov/show/NCT01736228" | |
| 412,"NCT02208115","Post-exercise Appetite Responses in Type 1 Diabetes",,"Completed","No Results Available","Type 1 Diabetes Mellitus","Dietary Supplement: Meal composition - Low versus high GI.","Acute subjective appetite responses","Northumbria University|Newcastle University","Male","18 Years to 50 Years (Adult)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","West-Walker3.1","November 2013","November 2013","November 2013","August 4, 2014",,"August 4, 2014","Clinical Research Facility, Royal Victoria Infirmary, Newcastle upon Tyne, Tyne and Wear, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02208115" | |
| 413,"NCT01709851","Performance Study to Test the GlucoMen®Day System Using Intravascular and Subcutaneous Microdialysis in Subjects With Type 1 Diabetes",,"Completed","No Results Available","Type 1 Diabetes","Device: Vascular microdialysis using the GMD-system|Device: Vascular and subcutaneous microdialysis using the GMD-system","Point Accuracy of the microdialysis signal|Rate accuracy of the microdialysis signal","Medical University of Graz|Menarini Group","All","18 Years to 75 Years (Adult, Older Adult)",,"12","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","GMD_05","November 2012","December 2012","April 2013","October 18, 2012",,"April 16, 2013","Medical University of Graz, Dept. of Internal Medicine, Endocrinology and Metabolism, Graz, Austria",,"https://ClinicalTrials.gov/show/NCT01709851" | |
| 414,"NCT01739829","Open-label Investigation of the Safety and Effectiveness of DIABECELL® in Patients With Type 1 Diabetes Mellitus",,"Completed","No Results Available","Type 1 Diabetes","Device: DIABECELL (R)","To establish the safety and efficacy of xenotransplantation of DIABECELL","Diatranz Otsuka Limited","All","18 Years to 65 Years (Adult, Older Adult)","Phase 1|Phase 2","8","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCT/DIA-09","August 2011","June 2014","June 2014","December 4, 2012",,"October 20, 2017","Hospital Interzonal General de Agudos Eva Perón, Buenos Aires, Argentina",,"https://ClinicalTrials.gov/show/NCT01739829" | |
| 415,"NCT02632032","Impact of a Diabetes Camp on Glycemic Control Among Children and Adolescents Living With Type 1 Diabetes in Cameroon",,"Completed","No Results Available","Type 1 Diabetes","Drug: Insulin","Changes in HbA1c|Changes in insulin doses|Hypoglycemic episode per camper per day|Changes in weight","Yaounde Central Hospital","All","6 Years to 23 Years (Child, Adult)","Not Applicable","46","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)","CDiC-01","July 2013","August 2013","August 2014","December 16, 2015",,"December 17, 2015",,,"https://ClinicalTrials.gov/show/NCT02632032" | |
| 416,"NCT03588234","Food Literacy and Type 1 Diabetes",,"Completed","No Results Available","Type1diabetes",,"Food literacy level|Fruit and vegetable consumption|Hypoglycaemia frequency|Self-reported A1c|Fast food consumption","McGill University|Diabetes Québec","All","18 Years to 29 Years (Adult)",,"427","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","43-0618","June 28, 2018","March 1, 2020","August 31, 2020","July 17, 2018",,"September 16, 2020","McGill University, Montréal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03588234" | |
| 417,"NCT01887431","Telecare in Type 1 Diabetes (T1D) Patients Treated by Insulin Pump",,"Completed","No Results Available","Type 1 Diabetes Mellitus","Other: Telecare|Other: Conventional therapy","Change in Glycosylated Hemoglobin (Hba1c)|Time spent on data analysis and telephone calls by team|Number of severe hypoglycemic and diabetic ketoacidosis (DKA) events and hospitalizations|Patients' quality of life|Patients' satisfaction","Assuta Hospital Systems|Maccabi Healthcare Services, Israel","All","22 Years and older (Adult, Older Adult)","Not Applicable","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","71156","October 2013","November 2016","November 2016","June 26, 2013",,"January 31, 2017","Maccabi Healthcare Services, Ra'anana, Israel",,"https://ClinicalTrials.gov/show/NCT01887431" | |
| 418,"NCT02529449","Pharmacodynamics, Pharmacokinetics, and Safety of ASP1941 in Patients With Type 1 Diabetes Mellitus",,"Completed","No Results Available","Type 1 Diabetes Mellitus","Drug: Placebo|Drug: ASP1941","Daily profile of plasma glucose levels|Area under the concentration-time curve (AUC) 0-24hr (AUC0-24h) of plasma glucose levels|AUC0-3h of plasma glucose levels|AUC0-4h of plasma glucose levels|AUC0-10h of plasma glucose levels|Fasting plasma glucose levels|Glycoalbumin|Urinary glucose excretion|Urinary glucose excretion rate|Urine volume|Urinary glucose concentration|Body weight|Renal glucose clearance|Plasma concentration of unchanged ASP1941|Urinary concentration of unchanged ASP1941|Pharmacokinetics (PK) parameter of ASP1941 in plasma: AUC from time 0 extrapolated to infinity (AUCinf)|PK parameter of ASP1941 in plasma: AUC from the time of dosing to the last measurable concentration (AUClast)|PK parameter of ASP1941 in plasma: AUC from the time of dosing to 24 hr (AUC0-24h)|PK parameter of ASP1941 in plasma: Oral Clearance (CL/F)|PK parameter of ASP1941 in plasma: Maximum concentration (Cmax)|PK parameter of ASP1941 in plasma: Terminal Elimination Half-life (t1/2)|PK parameter of ASP1941 in plasma: Time of the Maximum Concentration (tmax)|PK parameter of ASP1941 in urine: Amount excreted in urine between time (Ae)|PK parameter of ASP1941 in urine: % of the dose of excreted in urine (Ae%)|PK parameter of ASP1941 in plasma and urine: Renal Clearance (CLr)|Safety assessed by vital signs|Safety assessed by 12-lead electrocardiogram|Safety assessed by laboratory tests|Safety assessed by self-monitored blood glucose levels|Safety assessed by Adverse events","Astellas Pharma Inc","All","20 Years to 74 Years (Adult, Older Adult)","Phase 2","43","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1941-CL-6001","September 1, 2015","March 19, 2016","March 19, 2016","August 20, 2015",,"March 18, 2019","Site JP00006, Aichi, Japan|Site JP00002, Fukuoka, Japan|Site JP00009, Gunma, Japan|Site JP00001, Ibaraki, Japan|Site JP00005, Kanagawa, Japan|Site JP00008, Kanagawa, Japan|Site JP00003, Okayama, Japan|Site JP00004, Osaka, Japan|Site JP00010, Osaka, Japan|Site JP00011, Osaka, Japan|Site JP00007, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT02529449" | |
| 419,"NCT02265809","Adaptive Study of IL-2 Dose Frequency on Regulatory T Cells in Type 1 Diabetes","DILfrequency","Completed","No Results Available","Type 1 Diabetes","Drug: Aldesleukin","Change from baseline of CD4 T regulatory cells, CD4 T effector cells and CD25 expression on T regulatory cells during treatment with ultra low dose IL-2|T regulatory cell number, phenotype and proliferation|T effector cell number, phenotype and proliferation|Natural Killer cell number, phenotype and proliferation|B lymphocyte cell number, phenotype and proliferation|T cell and Natural killer cell intracellular signalling|Full blood count|Blood levels of IL-2, IL-6, IL-10, TNF-alpha, soluble CD25, IP-10, soluble rIL-6, and CRP|Change in metabolic control|Safety and tolerability","Cambridge University Hospitals NHS Foundation Trust|University of Cambridge|Sir Jules Thorn Charitable Trust|Juvenile Diabetes Research Foundation|Wellcome Trust|National Institute for Health Research, United Kingdom","All","18 Years to 70 Years (Adult, Older Adult)","Phase 1|Phase 2","41","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","DILfrequency","October 3, 2014","May 26, 2016","May 26, 2016","October 16, 2014",,"August 21, 2018","Wellcome Trust Clinical Research Facility, Addenbrookes Hospital, Cambridge, Cambridgeshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02265809" | |
| 420,"NCT04682457","Defining the Decline in Endogenous Insulin Secretion in Type 1 Diabetes Diagnosed After 30 Years of Age.","DROPLeT","Recruiting","No Results Available","Diabetes Mellitus, Type 1|Progression",,"C-peptide value at a year|Change in C-peptide over a year|C-peptide value at 12 months|Glucose variability & hypoglycemia|Change in dried blood spot C-peptide","Royal Devon and Exeter NHS Foundation Trust","All","18 Years and older (Adult, Older Adult)",,"196","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2003962","November 1, 2019","June 2022","December 2023","December 23, 2020",,"March 11, 2022","Royal Devon & Exeter NHS Foundation Trust, Exeter, Devon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04682457" | |
| 421,"NCT04646473","Sweetgoals for Type 1 Diabetes",,"Recruiting","No Results Available","Type 1 Diabetes","Behavioral: SweetGoals app|Behavioral: Coaching|Behavioral: Incentives","HbA1c|Glucose checking adherence|Problem solving","Trustees of Dartmouth College|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","19 Years to 29 Years (Adult)","Not Applicable","300","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","23559|R01DK124428","April 29, 2021","April 30, 2025","April 30, 2025","November 30, 2020",,"March 3, 2022","Dartmouth College, Hanover, New Hampshire, United States",,"https://ClinicalTrials.gov/show/NCT04646473" | |
| 422,"NCT03003806","Evaluation of the Dreamed Advisor Pro for Automated Insulin Pump Setting Adjustments in Children and Adolescents With Type 1 Diabetes- The Advice4U Pro Study","Advice4U","Completed","No Results Available","Type1 Diabetes Mellitus","Device: DreaMed Advisor Pro|Other: Medical guided recommendation","Percentage of glucose readings within range of 70-180 mg/dl (3.9 to 10 mmol/l).|Percentage of glucose readings below 54 mg/dl (3.3 mmol/l)|HbA1c|Percentage of glucose readings below 70 mg/dl (3.9 mmol/L)|Percentage of readings below 50 mg/dl (2.8 mmol/L)|Percentage of readings above 180 mg/dl (10.0 mmol/L)|Percentage of readings above 240 mg/dl (13.3 mmol/L)|Area above the curve of glucose glucose level of 180 mg/dl|Area under the curve of glucose level of 70 mg/dl|Mean sensor blood glucose|Glucose variability measured by Standard Deviation|Number of recommendations for changes in settings per patient|Number of recommendations for changes in settings per iteration|Number of physician override Advisor recommendations|Number of patients overrides of recommendation|Estimated time duration needed for the physician to give its recommendations|Device satisfaction questionaire|Diabetes treatment satisfaction questionnaire","Rabin Medical Center|DreaMed|The Leona M. and Harry B. Helmsley Charitable Trust","All","10 Years to 21 Years (Child, Adult)","Not Applicable","122","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RMC072016ctil","October 2, 2017","November 10, 2019","November 10, 2019","December 28, 2016",,"December 27, 2019","Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|University of Florida College of Medicine, Gainesville, Florida, United States|Joslin Diabetes Center, One Joslin Place, Boston, Massachusetts, United States|Diabetes -Zentrum fuer kinder und jugendliche, Hannover, Germany|Schnider children's medical center, Petach-Tikva, Israel|University Children's Hospital, Ljubljana, Slovenia",,"https://ClinicalTrials.gov/show/NCT03003806" | |
| 423,"NCT01600664","The Effect of the Use of Computer Game- ""My Diabetic Friend"" in Children With Type 1 Diabetes",,"Completed","No Results Available","Type 1 Diabetes","Behavioral: Interactive computer game|Behavioral: Convertible PC","Quality of life|Metabolic control|Diabetes knowledge|Patient's gaming duration|Compliance to diabetes treatment|Average glucose levels|Average number of blood glucose measurements|Measurements within normal range|Hypoglycemia events|Hyperglycemia events","Rabin Medical Center|Intel Corporation","All","7 Years to 11 Years (Child)","Not Applicable","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","rmc006814ctil","June 2012","August 2013","August 2013","May 17, 2012",,"May 6, 2014","Schneider Medical Center, Petach- Tikva, Israel",,"https://ClinicalTrials.gov/show/NCT01600664" | |
| 424,"NCT01691287","MICHAEL Method- Fulfilling Individual Potential to Attain Excellence - as a Tool for Improving Metabolic Control and Quality of Life Among Adolescence With Type 1 Diabetes",,"Completed","No Results Available","Type 1 Diabetes","Behavioral: Michael Method","Metabolic Control measured as HbA1c level|Diabetes Quality of Life questionnaire (DQOLY)|Self assessment questionnaire|Number of severe hypoglycemic events|Number of Diabetic Keto Acidosis events","Rabin Medical Center","All","12 Years to 17 Years (Child)","Not Applicable","23","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","rmc006444ctil","October 2012","December 2013","December 2013","September 24, 2012",,"May 1, 2014","Schneider Medical Center, Petah-TTikva, Israel",,"https://ClinicalTrials.gov/show/NCT01691287" | |
| 425,"NCT01189422","Subcutaneous Administration of Teplizumab in Adults With Type 1 Diabetes","SUBCUE","Terminated","No Results Available","Type 1 Diabetes Mellitus","Drug: teplizumab or placebo","Dose regimen","MacroGenics|Eli Lilly and Company","All","18 Years to 35 Years (Adult)","Phase 1","1","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","CP-MGA031-06","August 2010","February 2011","February 2011","August 26, 2010",,"February 8, 2022",,,"https://ClinicalTrials.gov/show/NCT01189422" | |
| 426,"NCT01787916","52 Week Trial of Liraglutide in Type 1 Diabetes","LIDO","Completed","Has Results","Type 1 Diabetes","Drug: Liraglutide|Drug: Placebos","Assessment of Changes in Glycemic Control by HbA1c.|Assessment of Changes on Adipose Tissue","CHU de Quebec-Universite Laval|Novo Nordisk A/S","All","18 Years to 50 Years (Adult)","Phase 4","15","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2013LIDO","April 2013","April 2015","April 2015","February 11, 2013","January 5, 2018","January 5, 2018","CHU de Québec, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01787916" | |
| 427,"NCT02005848","Phase II Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 Diabetes",,"Completed","No Results Available","New Onset Type-1 Diabetes","Biological: Alpha-1 Antitrypsin|Other: Placebo","Beta cell function|Glycemic control|Insulin dose|Hypoglycemic episodes|Safety parameters","Kamada, Ltd.","All","8 Years to 25 Years (Child, Adult)","Phase 2","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Kamada-AAT(IV)-011","April 2014","February 2017","February 2017","December 9, 2013",,"October 11, 2018","Soroka Medical Center, Beer Sheva, Israel|Rambam Medical Center, Haifa, Israel|Schneider Children's Medical Center, Pethach Tikva, Israel|Assaf Harofe Medical Center, Zerifin, Israel",,"https://ClinicalTrials.gov/show/NCT02005848" | |
| 428,"NCT01827735","Regulatory T Cells in Type 1 Diabetes Patients Treated With IL-2","DILT1D","Completed","No Results Available","Type 1 Diabetes","Drug: Aldesleukin (Proleukin)","The primary endpoint is based upon the percentage of CD4+T regulatory (defined as CD3+CD4+CD25highCD127low) cells within the CD3+CD4+T cell gate following treatment with IL-2.|T regulatory cell phenotype and stability|T effector cell number and phenotype|T cell subset proliferation and populations|Intracellular T cell and natural killer(NK) cell signalling|T regulatory cell function|IL-2 pathway genotype|Lymphocyte Subsets|Serum Cytokines|Glycaemic control|Number of Participants with Adverse Events as a Measure of Safety and Tolerability","Cambridge University Hospitals NHS Foundation Trust|University of Cambridge|Juvenile Diabetes Research Foundation|National Institute for Health Research, United Kingdom|Wellcome Trust","All","18 Years to 50 Years (Adult)","Phase 1|Phase 2","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","A092737|ISRCTN27852285","March 2013","May 2014","May 2014","April 10, 2013",,"June 23, 2015","Wellcome Trust Clinical Research Facility, Addenbrooke's Hospital, Cambridge, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01827735" | |
| 429,"NCT02307695","The Effect of Saxagliptin on Glucose Fluctuation and Immune Regulation in Patients With Type 1 Diabetes",,"Unknown status","No Results Available","Type 1 Diabetes","Drug: Saxagliptin|Drug: Insulin","Change of Mean amplitude of glycemic excursions (MAGE) from baseline in patients with type 1 diabetes treated with saxagliptin plus insulin or insulin alone by continuous glucose monitoring system (CGMS)|Change of C-peptide area under the curve (AUC C-peptide) or fasting C-peptide from baseline in patients with type 1 diabetes treated with saxagliptin plus insulin or insulin alone by 3-hour mixed meal tolerance test(MMTT)|Change of Haemoglobin A1c (HbA1c) from baseline in patients with type 1 diabetes treated with saxagliptin plus insulin or insulin alone|Change of insulin dosage (U/kg/d) from baseline in patients with type 1 diabetes treated with saxagliptin plus insulin or insulin alone","Nanjing Medical University","All","12 Years to 65 Years (Child, Adult, Older Adult)","Phase 4","184","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014-SR-123","November 2014","March 2017","March 2017","December 4, 2014",,"July 6, 2016","First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT02307695" | |
| 430,"NCT00071409","Safety and Efficacy of INGAP-Peptide in Patients With Type 1 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Insulin-Dependent","Drug: INGAP-Peptide|Drug: placebo","assess efficacy and safety based on arginine stimulated C peptide, fasting C peptide, average daily insulin dose, fasting glucose, glycosylated hemoglobin (Hb A1c), and AEs","Exsulin Corporation","All","18 Years to 65 Years (Adult, Older Adult)","Phase 2","63","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2003068","October 2003","May 2004","May 2004","October 23, 2003",,"July 11, 2014","Radiant Research, Irvine, California, United States|VA Hospital UCSD, San Diego, California, United States|Diablo Clinical Research, Walnut Creek, California, United States|MedStar Clinical Research Center, Washington, District of Columbia, United States|Springfield Diabetes and Endocrine Center, Springfield, Illinois, United States|Mercury Street Medical, Butte, Montana, United States|UNC Diabetes Care Center, Durham, North Carolina, United States|Clinical Research Institute of Southern Oregon, Medford, Oregon, United States|University of Texas Health Science Center - Texas Diabetes Institute, San Antonio, Texas, United States|DGD Research Associates, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00071409" | |
| 431,"NCT04650646","Cardiovascular Effects of Exercise-related Hypoglycaemia in Patients With Type 1 Diabetes (Hypo Heart Exercise)",,"Completed","No Results Available","Diabetes Mellitus, Type 1|Arrhythmia","Other: Exercise-related hypoglycaemia|Other: Hypoglycaemia under resting conditions","Hypoglycaemia and QTc interval prolongation|Key secondary outcome: Hypoglycaemia and coagulation and fibrinolysis|Hypoglycaemia and QT dispersion (QTd)|Hypoglycaemia and heart rate variability (HRV)|Hypoglycaemia and bradycardia|Hypoglycaemia and ectopic beats|Hypoglycaemia and endothelial activation and damage|Hypoglycaemia and vascular oxidative stress|Hypoglycaemia and electrolytes|Hypoglycaemia and counterregulatory hormonal response|Hypoglycaemia and markers of inflammation|Hypoglycaemia and inflammation|Hypoglycaemia and continuous glucose monitoring (CGM) accuracy|Type 1 diabetes, healthy controls and coagulability","Steno Diabetes Center Copenhagen","Male","18 Years and older (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","H-20023688","September 1, 2020","June 3, 2021","December 1, 2021","December 2, 2020",,"January 21, 2022","Clinical Research, Steno Diabetes Center Copenhagen-Gentofte, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT04650646" | |
| 432,"NCT01559181","Study of Offspring of Women With Type 1 Diabetes","EPICOM","Completed","No Results Available","Type 1 Diabetes",,"Overweight|Diabetes/prediabetes|Cognitive functions|Pubertal development|BMI|Body composition|Blood pressure|Dyslipidemia|Insulin levels|Markers of endothelial function|Markers of autoimmunity|PCOS","Odense University Hospital|University of Copenhagen|Department of Gynaecology and Obstetrics, Rigshospitalet, Copenhagen|Rigshospitalet, Denmark|University of Southern Denmark|University of Aarhus|Aarhus University Hospital","All","13 Years to 19 Years (Child, Adult)",,"584","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2011-41-6044","April 2012","November 2017","December 2017","March 21, 2012",,"May 24, 2018","Aarhus Universitetshospital, Aarhus, Denmark|Department of Gynaecology and Obstetrics, Rigshospitalet, Copenhagen, Denmark|Odense University Hospital, Diabetes Research Center, Odense, Denmark",,"https://ClinicalTrials.gov/show/NCT01559181" | |
| 433,"NCT02490124","The Effect of Type 1 Diabetes on Pan-Arterial Vascular Function and Insulin Sensitivity in Humans","EJB046","Completed","No Results Available","Diabetes Type 1",,"Augmentation Index|Pulse Wave Velocity|Flow Mediated Dilation|Contrast Enhanced Ultrasound","University of Virginia","All","18 Years to 40 Years (Adult)",,"7","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","17099","December 2014","June 2015","June 2015","July 3, 2015",,"January 13, 2016","University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02490124" | |
| 434,"NCT03761251","Pet Ownership and Glucose Control in Early Adolescents With Type 1 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 1|Adolescent Behavior","Behavioral: Pet Fish","Hemoglobin A1c","University of Texas Southwestern Medical Center","All","10 Years to 13 Years (Child)","Not Applicable","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-0044","October 31, 2018","July 9, 2019","September 25, 2019","December 3, 2018",,"October 2, 2019","University of Texas Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03761251" | |
| 435,"NCT01425255","The Impact of Continuous Glucose Monitoring Use on Sleep in Parents of Children With Type 1 Diabetes Mellitus",,"Withdrawn","No Results Available","Type 1 Diabetes",,"sleep quality|Glycemic control","Wolfson Medical Center|Tel Aviv Medical Center|Sheba Medical Center","All","20 Years to 70 Years (Adult, Older Adult)",,"0","Other","Observational","Observational Model: Case-Crossover|Time Perspective: Prospective","0077-11-WOMC","August 2011","August 2012","August 2012","August 29, 2011",,"June 21, 2016","E. Wolfson Medical Center, Holon, Israel",,"https://ClinicalTrials.gov/show/NCT01425255" | |
| 436,"NCT01424046","Health Care for Type 1 Diabetes in Developing World",,"Completed","No Results Available","Type 1 Diabetes","Drug: basal insulin glargine|Drug: standard therapy","HbA1c|Microalbuminuria","University of Pittsburgh|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National University, Rwanda|Association Rwandaise des Diabetiques","All","1 Year to 24 Years (Child, Adult)","Not Applicable","50","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RC4 pitt 1|RC4DK090809","May 2011","June 2014","November 2014","August 26, 2011",,"December 5, 2014","Association Rwandese des Diabetiques, Kigali, Kigali Provence, Rwanda",,"https://ClinicalTrials.gov/show/NCT01424046" | |
| 437,"NCT00273286","Family Management of Type 1 Diabetes in Children",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Behavioral: family diabetes management intervention","glycemic control|treatment adherence|quality of life","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","108 Months to 174 Months (Child)","Phase 2","422","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","FMOD","January 2006","March 2009","March 2009","January 9, 2006",,"May 13, 2011","Nemours Children's Clinic, Jacksonville, Florida, United States|Children's Memorial Hospital, Chicago, Illinois, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|Texas Children's Hospital, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00273286" | |
| 438,"NCT03734367","Evaluation of the Effectiveness of a Program of Emotional Intelligence in Adolescents With Type 1 Diabetes (INTEDI)","INTEDI","Unknown status","No Results Available","Type1 Diabetes Mellitus","Behavioral: Emotional abilities training program","Change in emotional skills of adolescents with type 1 diabetes related to a greater emotional regulation|Change in emotional skills of adolescents with type 1 diabetes related to less stress levels|Change in emotional skills of adolescents with type 1 diabetes related to a greater positive affect|Change in emotional skills of adolescents with type 1 diabetes related to an increase in healthy life habits|Change in emotional skills of adolescents with type 1 diabetes related to a greater perception of quality of life|Change in the emotional skills of adolescents with type 1 diabetes that will be related to a glycosylated index between normal values","Universidad Loyola Andalucia","All","12 Years to 18 Years (Child, Adult)","Not Applicable","62","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","ULoyolaAndalucia","January 2019","May 2019","December 2021","November 8, 2018",,"November 8, 2018","Hospital Universitario Virgen Macarena, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT03734367" | |
| 439,"NCT02898506","Incretin-based Therapy in Late Preclinical Type 1 Diabetes",,"Completed","No Results Available","Type 1 Diabetes","Drug: Victoza®|Drug: Placebo","FPIR (1+3min serum insulin level after iv glucose infusion)|Safety: serum and urine amylase, serum lipase, serum calcitonin, hypoglycemia|Tolerability|Serum C-peptide AUC","University of Oulu|Oulu University Hospital|Tampere University Hospital|Turku University Hospital|Skane University Hospital","All","10 Years to 30 Years (Child, Adult)","Phase 2","13","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","LiraAABDG10-30|2014-004761-25|U1111-1177-0704|3-SRA-2014-301-M-R","March 2016","June 2021","June 2021","September 13, 2016",,"January 25, 2022","University of Oulu and Oulu University Hospital, Dept of Children and Adolescents, Oulu, Finland|University of Tampere and Tampere University Hospital, Tampere, Finland|University of Turku and Turku University Hospital, Turku, Finland|Lund University and Skåne University Hospital, Malmö, Sweden",,"https://ClinicalTrials.gov/show/NCT02898506" | |
| 440,"NCT00891995","Effect of Metabolic Control at Onset of Diabetes on Progression of Type 1 Diabetes",,"Terminated","Has Results","Type 1 Diabetes","Device: Closed loop|Device: Home glucose monitoring|Device: Insulin pump|Device: Continuous glucose monitor","C-peptide Average Area Under the Curve (AUC) in Response to a Mixed Meal at 1 Year Following Enrollment.|Peak C-peptide in Response to a Mixed Meal at 1 Year Following Enrollment|Incidence of the Loss of the 2 Hour Peak C-peptide < 0.2 Pmol/ml on a Semi-annual MMTT|HbA1c|Adverse Events (Severe Hypoglycemia)|CGM Mean Glucose|CGM Measured Glucose Outcomes|Daily Insulin Dose|BMI Percentile","Jaeb Center for Health Research","All","6 Years to 45 Years (Child, Adult)","Phase 2|Phase 3","71","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DirecNet 012","September 2010","October 2013","October 2013","May 1, 2009","October 27, 2016","December 30, 2016","Stanford University, Stanford, California, United States|Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|Indiana University, Indianapolis, Indiana, United States|Vanderbilt University, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00891995" | |
| 441,"NCT03642470","Risk Factors of Metabolic Control in Children and Adolescents With Type 1 Diabetes",,"Completed","No Results Available","Type 1 Diabetes",,"HbA1c|health-related quality of life (Chronic generic measure)|health-related quality of life (diabetes module)|psychological health (Depression)|psychological health (Trait-Anxiety)|psychological health (Child Behavior)","University Children's Hospital, Zurich","All","7 Years to 18 Years (Child, Adult)",,"197","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","2018-00374-G2","June 5, 2018","June 22, 2020","June 22, 2020","August 22, 2018",,"June 3, 2021","University Children's Hospital Zurich, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT03642470" | |
| 442,"NCT03794934","Structured Education Based on New Glucose Management Devices in Patients With Type 1 Diabetes Mellitus","Education","Unknown status","No Results Available","Type 1 Diabetes Mellitus","Behavioral: Structured Education for new glucose management devices","Percentage of time in target range 70-180 mg/dL|Percentage of time in level 2 hypoglycemia (<54mg/dL)|Percentage of time in level 1 hypoglycemia (<70-54mg/dL)|Percentage of time in level 1 hyperglycemia (>180mg/dL)|Percentage of time in level 2 hyperglycemia (>250mg/dL)|Glycemic variability, reported as coefficient of variance (CV)|Glycemic variability, reported as standard deviation (SD)|Mean glucose by continuous glucose monitoring system|HbA1C|glycated albumin|Personalized education time for each patient|Frequency of hypoglycemia|Adverse event","Samsung Medical Center","All","18 Years to 70 Years (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-12-108","February 26, 2019","December 31, 2019","December 31, 2020","January 7, 2019",,"March 25, 2019","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03794934" | |
| 443,"NCT03501511","Health Education During Ramadan Fasting in Type 1 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 1|Fasting","Behavioral: IDF modules|Behavioral: Conversational Maps","Hypoglycemia|Insulin Dose Adjustment|Body Weight Change|Number of successful fasting days","Ain Shams University","All","16 Years to 35 Years (Child, Adult)","Not Applicable","53","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","FMASU/MS 20/2017","April 7, 2018","June 28, 2018","June 28, 2018","April 18, 2018",,"June 29, 2018","Ain-Shams University-Faculty of Medicine- Ain-Shams University Hospitals -Internal Medicine Department -Endocrinology and Metabolism Unit, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT03501511" | |
| 444,"NCT00978796","Assessing Glucose Effects of Sitagliptin (Januvia) in Adult Patients With Type 1 Diabetes",,"Completed","No Results Available","Type 1 Diabetes","Drug: Sitagliptin|Drug: Sugar Pill","The primary objective of this pilot study is to compare 24-hour blood glucose values (overnight and pre- and post- prandial glucoses) in adult subjects with type 1 diabetes receiving either sitagliptin or placebo|Determine differences in fructosamine values|Time spent in hypoglycemic and hyperglycemic excursions recorded on the DexCom STS continuous glucose monitor (CGM) at 3 time periods throughout the study","University of Colorado, Denver","All","18 Years to 70 Years (Adult, Older Adult)","Phase 4","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Merck IISP-32888","September 2009","January 2010","March 2010","September 17, 2009",,"March 30, 2010","Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT00978796" | |
| 445,"NCT05594563","TArgeting Type 1 Diabetes Using POLyamines (TADPOL)","TADPOL","Not yet recruiting","No Results Available","Type 1 Diabetes","Drug: DFMO|Drug: Placebo","Clinical efficacy of 1000 mg/m2/day of oral DFMO after 6 months of treatment|Number of participants with treatment-related adverse events as assessed by CTCAE v5|Clinical efficacy of 1000 mg/m2/day of oral DFMO after 3 months of treatment, 9 months after treatment (or 3 months after treatment end), and 12 months after treatment (or 6 months after treatment end).|Decrease in urinary polyamides after 6 months of DFMO treatment.|Biomarkers of β cell stress at 3, 6, 9, and 12 months after treatment.","Emily K. Sims|Juvenile Diabetes Research Foundation|Cancer Prevention Pharmaceuticals, Inc.|Indiana University","All","6 Years to 40 Years (Child, Adult)","Phase 2","70","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","4-SRA-2022-1205-M-B","December 2022","December 2026","December 2027","October 26, 2022",,"October 26, 2022","Barbara Davis Center, Aurora, Colorado, United States|University of Chicago, Chicago, Illinois, United States|IU Health Riley Hospital for Children, Indianapolis, Indiana, United States|Children's Mercy Hospital, Kansas City, Kansas, United States|University of Michigan, Ann Arbor, Michigan, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT05594563" | |
| 446,"NCT01068951","Treatment of Patients With Newly Onset of Type 1 Diabetes With Mesenchymal Stem Cells",,"Completed","No Results Available","Type 1 Diabetes","Biological: Mesenchymal stem cells","The concentration of stimulated c-peptide at 90 minutes after the start of a mixed meal tolerance test at 365+/-10 days following the infusion or not with mesenchymal stem cells","Uppsala University Hospital","All","18 Years to 40 Years (Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","AS2010-0180","June 2010","September 2013","September 2013","February 17, 2010",,"February 5, 2014","Uppsala University Hospital, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT01068951" | |
| 447,"NCT04233034","Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes","CLVer","Completed","No Results Available","Type1 Diabetes","Device: HCL|Drug: verapamil 120mg tablet|Device: non-HCL|Drug: placebo","C-peptide|C-peptide AUC|Peak C-peptide|Peak C-peptide >= 0.2 pmol/ml|CGM Mean Glucose|CGM time in range (70-180 mg/dL)|CGM time 70-140 mg/dL|>=70% CGM time in range|CGM time >140 mg/dL|CGM time >180 mg/dL|CGM time >250 mg/dL|CGM time <54 mg/dL|CGM time <70 mg/dL|CGM coefficient of variation|HbA1c|HbA1c <7.0%|HbA1c <6.5%|Total daily insulin per kg|Basal:Bolus ratio|Severe Hypoglycemia|DKA","Jaeb Center for Health Research|Juvenile Diabetes Research Foundation|University of Minnesota|DexCom, Inc.|Medtronic|Tandem Diabetes Care, Inc.","All","7 Years to 17 Years (Child)","Phase 3","113","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CLVer","July 9, 2020","September 15, 2022","September 30, 2022","January 18, 2020",,"November 3, 2022","Stanford University, Palo Alto, California, United States|Barbara Davis Center, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|Indiana University, Indianapolis, Indiana, United States|University of Minnesota, Minneapolis, Minnesota, United States|Children's Mercy Hospital, Kansas City, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT04233034" | |
| 448,"NCT02801942","Immune Profile in Subjects With New Onset Type 1 Diabetes",,"Completed","Has Results","Diabetes Mellitus, Type 1","Procedure: Inguinal lymph node fine needle aspirate biopsy|Procedure: Inguinal lymph node core biopsy|Procedure: Peripheral blood collection|Other: Pre- and post-biopsy questionnaire","Percentage of Leukocyte Subsets Including B Lymphocytes, Classical B Lymphocytes, Double Negative B Lymphocytes, Naive B Lymphocytes, Plasmablast and Transitional B Lymphocytes in Blood|Percentage of Leukocyte Subsets Including B Lymphocytes, Classical B Lymphocytes, Double Negative B Lymphocytes, Naive B Lymphocytes, Plasmablast and Transitional B Lymphocytes in iLN|Percentage of Leukocyte Subsets Including B-cells, Clusters of Differentiation 56 Positive (CD56+) CD16+ , CD56bright Natural Killer (NK) Cells, CD56lo CD16+, CD56lo CD16 Negative (CD56lo CD16-), Dendritic Cells, NK Cells in Blood|Percentage of Leukocyte Subsets Including B-cells, CD56+ CD16+, CD56bright NK Cells, CD56lo CD16+, CD56lo CD16-, Dendritic Cells, NK Cells in iLN|Percentage of Leukocyte Subsets Including CD56+CD16+, CD56bright NK Cells, CD56lo CD16+ and CD56lo CD16- in Blood|Percentage of Leukocyte Subsets Including CD56+CD16+, CD56bright NK Cells CD56lo CD16+ and CD56lo CD16- in iLN|Percentage of Leukocyte Subsets Including Myeloid Dendritic Cells and Plasmacytoid Dendritic Cells in Blood|Percentage of Leukocyte Subsets Including Myeloid Dendritic Cells and Plasmacytoid Dendritic Cells in iLN|Percentage of Leukocyte Subsets Including CD14+ CD16+ Monocytes, CD14+ Monocytes, and CD16+ Monocytes in Blood|Percentage of Leukocyte Subsets Including CD14+ CD16+ Monocytes, CD14+ Monocytes and CD16+ Monocytes in iLN|Percentage of Leukocyte Subsets Including CD45RA+ Effector Memory CD8, Central Memory CD8, Effector Memory CD8, Naive CD8 and Stem Cell Memory-like CD8 Cells in Blood|Percentage of Leukocyte Subsets Including CD45RA+ Effector Memory CD8, Central Memory CD8, Effector Memory CD8, Naive CD8 and Stem Cell Memory-like CD8 Cells in iLN|Percentage of Leukocyte Subsets Including Programmed Death 1 (PD-1)+ Inducible Costimulator (ICOS)+ Follicular Helper T (TFH) Cell-like Regulatory (Reg) T Cells in Blood|Percentage of Leukocyte Subsets Including PD-1+ ICOS+ TFH Cell-like Reg T Cells in iLN|Percentage of Leukocyte Subsets Including PD-1+ ICOS+ TFH Cells in Blood|Percentage of Leukocyte Subsets Including PD-1+ ICOS+ TFH Cells in iLN|Percentage of Leukocyte Subsets Including Central Memory Conventional (Conv) T Cells, Effector Memory Conv T Cells, Naive Conv T Cells and Stem Cell Memory-like Conv T Cells in Blood|Percentage of Leukocyte Subsets Including Central Memory Conv T Cells, Effector Memory Conv T Cells, Naive Conv T Cells and Stem Cell Memory-like Conv T Cells in iLN|Percentage of Leukocyte Subsets Including TFH Cells, PD-1+ ICOS+ TFH Cells, Type 17 T Helper (TH17) Cells, TH1 Cells, TH1 TH17 Cells, TH1 TH17 TH2 T Cells, TH1 TH2 Cells, TH2 Cells, and TH22 Cells in Blood|Percentage of Leukocyte Subsets Including TFH Cells, PD-1+ ICOS+ TFH Cells, Type 17 T Helper (TH17) Cells, TH1 Cells, TH1 TH17 Cells, TH1 TH17 TH2 T Cells, TH1 TH2 Cells, TH2 Cells, and TH22 Cells in iLN|Percentage of Leukocyte Subsets Including TFH Cells, PD-1+ ICOS+ TFH Cells, TH1 Cells, TH1 TH17 Cells, TH1 TH17 TH2 Cells, TH1 TH2 Cells, TH17 Cells, TH2 Cells and TH22 Cells-like Reg T Cells in Blood|Percentage of Leukocyte Subsets Including TFH Cells, PD-1+ ICOS+ TFH Cells, TH1 Cells, TH1 TH17 Cells, TH1 TH17 TH2 Cells, TH1 TH2 Cells, TH17 Cells, TH2 Cells and TH22 Cells-like Reg T Cells in iLN|Percentage of Leukocyte Subsets Including Reg T Cells in Blood|Percentage of Leukocyte Subsets Including Reg T Cells in iLN|Percentage of Leukocyte Subsets Including CD69+ CD8 and Antigen Ki67 (Ki67)+ CD8 in Blood|Percentage of Leukocyte Subsets Including CD69+ CD8 and Antigen Ki67 (Ki67)+ CD8 in iLN|Percentage of Leukocyte Subsets Including CD15s+ Reg T Cells, CD69+ Reg T Cells, Helios+ Reg T Cells, Ki67+ T Reg Cells, Memory Reg T Cells and Resting Reg T Cells in Blood|Percentage of Leukocyte Subsets Including CD15s+ Reg T Cells, CD69+ Reg T Cells, Helios+ Reg T Cells, Ki67+ T Reg Cells, Memory Reg T Cells and Resting Reg T Cells in iLN|Percentage of Leukocyte Subsets Including CD15s+ Conv T Cells, CD69+ Conv T Cells, Helios+ Conv T Cells and Ki67+ Conv T Cells in Blood|Percentage of Leukocyte Subsets Including CD15s+ Conv T Cells, CD69+ Conv T Cells, Helios+ Conv T Cells and Ki67+ Conv T Cells in iLN|Percentage of Leukocyte Subsets Including CD15s+ Memory Conv T Cells, CD69+ Memory Conv T Cells, Helios+ Memory Conv T Cells and Ki67+ Memory Conv T Cells in Blood|Percentage of Leukocyte Subsets Including CD15s+ Memory Conv T Cells, CD69+ Memory Conv T Cells, Helios+ Memory Conv T Cells and Ki67+ Memory Conv T Cells in iLN|Percentage of Leukocyte Subsets Including B Lymphocytes, Classical B Lymphocytes, Double Negative B Lymphocytes, Naive B Lymphocytes, Plasmablast and Transitional B Lymphocytes in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including B-cells, CD56+ CD16+, CD56bright NK Cells, CD56lo CD16+, CD56lo CD16, Dendritic Cells, NK Cells in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including CD56+CD16+, CD56br NK Cells CD56lo CD16+ and CD56lo CD16- in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including Myeloid Dendritic Cells and Plasmacytoid Dendritic Cells in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including CD14+ CD16+ Monocytes, CD14+ Monocytes and CD16+ Monocytes in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including CD45RA+ Effector Memory CD8, Central Memory CD8, Effector Memory CD8, Naive CD8 and Stem Cell Memory-like CD8 in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including PD-1+ ICOS+ TFH Cell-like Reg T Cells in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including PD-1+ ICOS+ TFH Cells in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including Central Memory Conv T Cells, Effector Memory Conv T Cells, Naive Conv T Cells and Stem Cell Memory-like Conv T Cells in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including TFH Cells, PD-1+ ICOS+ TFH Cells, TH17 Cells, TH1 Cells, TH1 TH17 Cells, TH1 TH17 TH2 T Cells, TH1 TH2 Cells, TH2 Cells, and TH22 Cells in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including TFH Cells, PD-1+ ICOS+ TFH Cells, TH1 Cells, TH1 TH17 Cells, TH1 TH17 TH2 Cells, TH1 TH2 Cells, TH17 Cells, TH2 Cells and TH22 Cells-like Reg T Cells in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including Reg T Cells in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including CD69+ CD8 and Antigen Ki67 (Ki67)+ CD8 in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including CD15s+ Reg T Cells, CD69+ Reg T Cells, Helios+ Reg T Cells, Ki67+ T Reg Cells, Memory Reg T Cells and Resting Reg T Cells in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including CD15s+ Conv T Cells, CD69+ Conv T Cells, Helios+ Conv T Cells and Ki67+ Conv T Cells in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including CD15s+ Memory Conv T Cells, CD69+ Memory Conv T Cells, Helios+ Memory Conv T Cells and Ki67+ Memory Conv T Cells in iLN Core Biopsies and iLN FNA|Number of Participants With Serious Adverse Events (SAEs) and Non-SAEs|Number of Participants Undergoing Procedure Under Local Anesthetics|Number of Participants Undergoing iLN Biopsy Under Local Anesthetics|Number of Participants With Different Reasons for Participating in the Study|Number of Participants With Extreme Anxiety Towards the Lymph Node Biopsy|Number of Participants Looking Forward to Undergo the Procedure|Number of Participants With Aspects Better Explained About the Lymph Node Biopsy Procedure|Number of Participants Who Considered to Undergo Lymph Node Biopsy Procedure Another Time|Number of Participants Who Were Encouraged to be Included in Study for iLN Biopsy|Number of Participants Who Appreciated Receiving Study Feedback","GlaxoSmithKline","All","18 Years to 40 Years (Adult)","Not Applicable","22","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","203158","July 25, 2016","December 21, 2017","December 21, 2017","June 16, 2016","February 27, 2019","February 27, 2019","GSK Investigational Site, Cambridge, United Kingdom|GSK Investigational Site, Cardiff, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02801942/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02801942/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02801942" | |
| 449,"NCT04876079","Prevention of Mild-to-moderate Hypoglycemia in Type 1 Diabetes","REVERSIBLE","Recruiting","No Results Available","Type 1 Diabetes","Other: Test to induce a decline in plasma glucose|Device: Dexcom G6|Other: Dex4|Drug: Insulin","Time spent of glucose levels < 4.0 mmol/L|Plasma glucose levels at 5 minutes after carbohydrates consumption|Plasma glucose levels at 10 minutes after carbohydrates consumption|Plasma glucose levels at 15 minutes after carbohydrates consumption|Plasma glucose levels at 20 minutes after carbohydrates consumption|Plasma glucose levels at 30 minutes after carbohydrates consumption|Plasma glucose levels at 45 minutes after carbohydrates consumption|Plasma glucose levels at 60 minutes after carbohydrates consumption|Lowest plasma glucose level eached after CHO consumption|Time from CHO consumption to the lowest plasma glucose level reached|Time from CHO consumption to plasma glucose < 3.5 mmol/L|Percentage of participants reaching hypoglycemia (< 4.0 mmol/L) after CHO consumption|Percentage of participants for whom hypoglycemia was corrected at 10 minutes after CHO consumption|Percentage of participants for whom hypoglycemia was corrected at 15 minutes after CHO consumption|Percentage of participants for whom hypoglycemia was corrected at 20 minutes after CHO consumption|Percentage of participants for whom hypoglycemia was corrected at 25 minutes after CHO consumption|Percentage of participants for whom hypoglycemia was corrected at 30 minutes after CHO consumption|Percentage of participants for whom hypoglycemia was corrected at 35 minutes after CHO consumption|Percentage of hypoglycemic events that were corrected at 10 minutes after CHO consumption|Percentage of hypoglycemic events that were corrected at 15 minutes after CHO consumption|Percentage of hypoglycemic events that were corrected at 20 minutes after CHO consumption|Percentage of hypoglycemic events that were corrected at 25 minutes after CHO consumption|Percentage of hypoglycemic events that were corrected at 30 minutes after CHO consumption|Percentage of hypoglycemic events that were corrected at 35 minutes after CHO consumption|Percentage of participants requiring a second treatment with carbohydrates at 20 minutes after the first CHO consumption|Percentage of participants requiring a second treatment with carbohydrates at 40 minutes after the first CHO consumption|Percentage of participants requiring a second treatment with carbohydrates at 60 minutes after the first CHO consumption|Percentage of participants experiencing a rebound hyperglycemia (≥ 10.0 mmol/L) within the first hour following the first carbobydrates consumption","Institut de Recherches Cliniques de Montreal","All","18 Years and older (Adult, Older Adult)","Not Applicable","29","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2022-1119","June 1, 2021","June 1, 2023","December 31, 2023","May 6, 2021",,"October 10, 2022","Montreal Clinical Research Institute, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT04876079" | |
| 450,"NCT04608058","Promoting Self-management Behaviors in Adolescents With Type 1 Diabetes, Using Digital Storytelling",,"Completed","No Results Available","Diabetes Mellitus, Type 1|Self-Management","Behavioral: Digital storytelling training|Behavioral: Routine training","Change in Self-management behavior|Change in Glycated hemoglobin A1c","Nahid Zarifsanaiey|Shiraz University of Medical Sciences","All","12 Years to 18 Years (Child, Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","1398.244","July 30, 2019","March 30, 2020","April 30, 2020","October 29, 2020",,"November 2, 2020","Shiraz University of Medical Sciences, Shiraz, Fars, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04608058" | |
| 451,"NCT02218619","Tauroursodeoxycholic Acid (TUDCA) in New-Onset Type 1 Diabetes",,"Unknown status","No Results Available","Type 1 Diabetes","Drug: Tauroursodeoxycholic Acid (TUDCA)|Drug: Sugar Pill (placebo)","C-peptide measurement as reflection of insulin secretion|Endoplasmic reticulum stress|liver function tests","Robin Goland, MD|Juvenile Diabetes Research Foundation|Columbia University","All","18 Years to 45 Years (Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","AAAN2402","August 2015","October 1, 2019","October 1, 2019","August 18, 2014",,"December 4, 2018","Naomi Berrie Diabetes Center, Columbia University, 1150 St. Nicholas Ave., New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02218619" | |
| 452,"NCT05473364","Acetazolamide in Persons With Type 1 Diabetes",,"Not yet recruiting","No Results Available","Type 1 Diabetes","Drug: Acetazolamide","Change in mGFR percent|Preservation of Serum Bicarbonate|Preservation of Serum Potassium","University of California, San Diego|Juvenile Diabetes Research Foundation|The Leona M. and Harry B. Helmsley Charitable Trust","All","18 Years and older (Adult, Older Adult)","Phase 1|Phase 2","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UC-MEDJP-05","December 1, 2022","April 30, 2025","July 31, 2026","July 25, 2022",,"November 10, 2022","UC San Diego Altman Clinical & Translational Research Institute, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT05473364" | |
| 453,"NCT01586065","Continuous Glucose Monitoring in Adolescents With Poorly Controlled Type 1 Diabetes",,"Completed","No Results Available","Type 1 Diabetes","Device: Continuous Glucose Monitor (CGM)|Other: Fingerstick BGs only","A1c|Frequency of hypoglycemia","Nemours Children's Clinic","All","12 Years to 18 Years (Child, Adult)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R03HD067329-01A1","February 2012","June 2014","June 2014","April 26, 2012",,"June 14, 2016","Nemours Children's Clinic, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01586065" | |
| 454,"NCT05180591","Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes",,"Recruiting","No Results Available","Diabetes Mellitus, Type 1|Diabetes type1|Autoimmune Diabetes","Biological: Bacillus Calmette-Guérin|Biological: Saline Injection","Change in HbA1c values|Change in hypoglycemia|Change in C-peptide|Change in insulin usage|Change in adjusted HbA1c","Massachusetts General Hospital|NYU Langone Health","All","12 Years to 17 Years (Child)","Phase 2","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2019P002835","March 22, 2022","March 2027","March 2027","January 6, 2022",,"November 3, 2022","Immunobiology Labs CNY 149, Charlestown, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT05180591" | |
| 455,"NCT05463874","Teaching Adolescents With Type 1 Diabetes Self-compassion","TADS","Recruiting","No Results Available","Type 1 Diabetes","Behavioral: Mindful Self-Compassion Program","Diabetes Distress as measured by the Problem Areas in Diabetes - Teen Version (PAID-T)|Anxiety as measured by the Generalized Anxiety 7-item scale (GAD-7)|Depression as measured by the Patient Health Questionnaire (PHQ-9)|Disordered eating as measured by the Diabetes Eating Problem Survey, revised version (DEPS-R)|Suicidal ideation as measured by the Patient Health Questionnaire (PHQ-9)|Diabetes distress as measured by the Problem Areas in Diabetes - Teen version (PAID-T)","Children's Hospital of Eastern Ontario|Juvenile Diabetes Research Foundation|Brain Canada","All","12 Years to 17 Years (Child)","Not Applicable","122","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","22/08E","October 4, 2022","July 2024","July 2024","July 19, 2022",,"October 13, 2022","Children's Hospital of Eastern Ontario, Ottawa, Ontatrio, Canada",,"https://ClinicalTrials.gov/show/NCT05463874" | |
| 456,"NCT05163912","Virtual Physical Activity for Type 1 Diabetes",,"Active, not recruiting","No Results Available","Type 1 Diabetes","Behavioral: Virtual home intervention","Adherence|Acceptability","Yale University|Robert E. Leet and Clara Guthrie Patterson Trust","All","14 Years to 19 Years (Child, Adult)","Not Applicable","48","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2000030105","January 4, 2022","June 2023","June 2023","December 20, 2021",,"October 25, 2022","Yale University, New Haven, Connecticut, United States|Yale-New Haven Hospital, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT05163912" | |
| 457,"NCT03965013","A Study to Look at How Safe NNC0268-0965 is in Healthy People and People With Type 1 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 1|Healthy Volunteers","Drug: NNC0268-0965|Drug: Placebo|Drug: insulin glargine","Number of treatment-emergent adverse events|Number of treatment-emergent hypoglycaemic episodes|Area under the serum NNC0268-0965 concentration-time curve after a single dose|Maximum observed serum NNC0268-0965 concentration after a single dose","Novo Nordisk A/S","All","18 Years to 55 Years (Adult)","Phase 1","78","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NN1965-4456|2018-003922-98|U1111-1221-9696","June 5, 2019","December 14, 2019","December 14, 2019","May 28, 2019",,"January 14, 2021","Novo Nordisk Investigational Site, Neuss, Germany",,"https://ClinicalTrials.gov/show/NCT03965013" | |
| 458,"NCT02644590","The Effect of Melatonin on Early Signs of Hypertension in Teenagers With Diabetes Mellitus Type 1",,"Unknown status","No Results Available","Diabetes Mellitus, Type 1|Hypertension","Drug: Melatonin","blood pressure monitoring , pre and post treatment with melatonin","Sheba Medical Center","All","12 Years to 21 Years (Child, Adult)","Early Phase 1","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","311080","February 2016","September 2016","February 2017","January 1, 2016",,"January 1, 2016",,,"https://ClinicalTrials.gov/show/NCT02644590" | |
| 459,"NCT04449198","Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1","T-St1M","Recruiting","No Results Available","Type 1 Diabetes","Drug: Resveratrol|Other: Placebo","Change in AUC for ET-1 + BQ-123|Skeletal Muscle Mitochondrial Function|Change in Percentage Flow-Mediated Dilation (FMD)|Change in Pulse Wave Velocity (PWV)|Change in Post Occlusive Reactive Hyperemia (PORH)","Augusta University","All","18 Years and older (Adult, Older Adult)","Early Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1595933","October 14, 2020","January 1, 2023","July 1, 2023","June 26, 2020",,"July 20, 2022","Augusta University/Georgia Prevention Institute/ Laboratory of Integrative and Exercise Physiology, Augusta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04449198" | |
| 460,"NCT03179423","Clinical Trial Assessing the GNbAC1 in Patients With Onset of Type 1 Diabetes Within 4 Years","RAINBOW-T1D","Completed","No Results Available","Diabetes Mellitus Type 1","Drug: GNbAC1|Drug: Placebo","Safety and tolerability of GNbAC1 in patients with recent onset type 1 diabetes: Serious Adverse Events (SAE) and Adverse Events (AE)","GeNeuro Australia PTY Ltd|Southern Star Research Pty Ltd.|GeNeuro SA","All","18 Years to 55 Years (Adult)","Phase 2","64","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GNC-301","June 14, 2017","September 1, 2018","May 7, 2019","June 7, 2017",,"October 20, 2020","Macquarie University Hospital, Macquarie University, New South Wales, Australia|AIM Centre, Merewether, New South Wales, Australia|Northern Sydney Local Health District - Royal North Shore Hospital, St Leonards, New South Wales, Australia|Ipswich Research Centre, Ipswich, Queensland, Australia|Mater Misericordiae Ltd and Mater Medical Research Institute Limited, South Brisbane, Queensland, Australia|Gold Coast Hospital and Health Service, Southport, Queensland, Australia|Southern Adelaide Local Health Network - Repatriation General Hospital, Adelaide, South Australia, Australia|Northern Adelaide Local Health Network Incorporated, operating as Lyell McEwin Hospital, Elizabeth Vale, South Australia, Australia|Eastern Health, Box Hill, Victoria, Australia|St Vincent's Hospital (Melbourne) Limited, Fitzroy, Victoria, Australia|Barwon Health - University of Geelong, Geelong, Victoria, Australia|Heidelberg Repatriation Hospital, Heidelberg, Victoria, Australia|Keogh Institute of Medical Research, Nedlands, Western Australia, Australia",,"https://ClinicalTrials.gov/show/NCT03179423" | |
| 461,"NCT02746627","Check It! Positive Psychology Intervention to Improve Adherence in Adolescents With T1D",,"Completed","Has Results","Type 1 Diabetes Mellitus","Behavioral: Positive Affect|Behavioral: Education","Glycemic Control (HbA1c)|Frequency of Blood Glucose Monitoring|Diabetes-Related Quality of Life|Family Conflict|Positive Affect|Coping","Vanderbilt University Medical Center","All","13 Years to 17 Years (Child)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","131384","January 2014","February 2016","February 2016","April 21, 2016","February 11, 2019","March 13, 2019","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02746627" | |
| 462,"NCT02131896","The Effects of Mediterranean Diet on Remission, Lipid Profile, Weight and Body Composition in Children and Adolescents With Newly Diagnosed Type 1 Diabetes",,"Terminated","No Results Available","Type 1 Diabetes","Other: Interventional arm-Mediterranean diet|Other: Control Arm- regular nutritional instructions in accordance with the accepted nutritional guidelines","lipid profile|Metabolic control|mean and SD of blood glucose|Peak stimulated C peptide|Daily insulin dose|Percent of subjects who require a daily insulin dose < o,5 IU/kg|Frequency and severity of hypoglycemic episodes|Anthropometric parameters|weight change from at least 1 year before diagnosis to 12 months after diagnosis|Inflammatory parameters|Endothelial function","Rabin Medical Center","All","5 Years to 18 Years (Child, Adult)","Not Applicable","4","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","rmc7800ctil","December 1, 2014","June 2016","June 2016","May 6, 2014",,"October 20, 2017","Schneider Children's Medical Center, Petah-Tikva, Israel",,"https://ClinicalTrials.gov/show/NCT02131896" | |
| 463,"NCT04569994","A Study to Look at the Safety of NNC0363-0845 in Healthy People and People With Type 1 Diabetes",,"Completed","No Results Available","Healthy Volunteers|Diabetes Mellitus, Type 1","Drug: NNC0363-0845|Drug: Placebo (NNC0363-0845)|Drug: Insulin degludec","Number of treatment-emergent adverse events (AEs)|Number of treatment-emergent hypoglycaemic episodes|Area under the serum NNC0363-0845 concentration-time curve from 0 to infinity after a single dose|Maximum observed serum NNC0363-0845 concentration after a single dose","Novo Nordisk A/S","All","18 Years to 55 Years (Adult)","Phase 1","68","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NN1845-4598|U1111-1244-4315|2019-004658-27","September 30, 2020","June 23, 2021","June 23, 2021","September 30, 2020",,"June 24, 2022","Novo Nordisk Investigational Site, Mainz, Germany",,"https://ClinicalTrials.gov/show/NCT04569994" | |
| 464,"NCT03710928","Type 1 Diabetes Management Using a Very Low Carbohydrate Versus Standard Diet",,"Recruiting","No Results Available","Type1diabetes","Other: very low carbohydrate diet|Other: standard carbohydrate diet","Hemoglobin A1C change|total daily insulin dose|percent time spent in the glycemic target range of 70-140 mg/dl|percent time spent below the glycemic target of 70 mg/dl|percent time in hypoglycemia below 54 mg/dl|percent time spent above the glycemic target of 140 mg/dl|percent time spent in hyperglycemia|blood glucose average|blood glucose standard deviation|Glycemic Variability Index, a measure for glycemic variability normalized to mean blood glucose level|Mean Amplitude of Glycemic Excursions (MAGE), a measure for postprandial glycemic variability|fasting total cholesterol|fasting high density lipoprotein cholesterol|fasting low density lipoprotein cholesterol|fasting triglycerides|fasting beta hydroxybutyrate|fasting high-sensitivity c-reactive protein|Self-reported quality of life assessed per self-report by The Problem Areas in Diabetes Scale (PAID)|Becks Depression Inventory II (BDI II) less suicidality|Yale Food Addiction Scale 2.0 (YFAS 2.0)|Highly Processed Food Withdrawal Scale (ProWS)","Boston Children's Hospital","All","18 Years to 40 Years (Adult)","Not Applicable","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB-P00030039","January 3, 2020","December 31, 2022","December 31, 2022","October 18, 2018",,"March 21, 2022","Boston Children's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03710928" | |
| 465,"NCT04758858","Carbohydrates Under Target for Type 1 Diabetes Management",,"Withdrawn","No Results Available","Type 1 Diabetes","Other: Insulin treatment optimization with participant's usual diet|Device: Abbott's FreeStyle Libre|Other: Three-day food journal|Other: Medical visit|Other: Blood pressure measurements|Other: Anthropometric parameters measurements|Other: Indirect calorimetry test|Other: Well-being questionnaire|Other: Diet appreciation questionnaire|Device: Pedometer (PiezoRxD)|Other: Hepatic imaging (MRI)|Other: Glucagon efficiency test|Other: Body composition : Dual Energy X-ray absorptiometry (DEXA)|Other: Blood tests|Other: Stool sample collections (optional)|Other: Hypoglycemia journal|Other: Ketone journal|Other: Adherence to the diet (Keenoa)","Percentage of time-in-target (range of 4-10 mmol/L)|Time to resolve an induced hypoglycemia (>4 mmol/L)|Peak plasma glucose level two hours after glucagon administration|Glycated hemoglobin (HbA1c)|Fructosamine|Fasting blood glucose|Post-prandial blood glucose|Coefficient of glucose variation (%)|Insulin daily dose|Basal insulin doses|Insulin-to-CHO ratio|Percentage of time spent in hypoglycemia ranges < 4 mmol/L|Percentage of time spent in significant hypoglycemia ranges < 3 mmol/L|Weight (kg)|Height (cm)|Waist circumference (cm)|Total cholesterol|HDL-cholesterol|LDL-cholesterol|Triglycerides|Apo-B|Apo-A1|Total lean mass (kg)|Total lean mass (%)|Truncal lean mass (kg)|Truncal lean mass (%)|Total fat mass (kg)|Total fat mass (%)|Truncal fat mass (kg)|Truncal fat mass (%)|Systolic blood pressure (mmHg)|Diastolic blood pressure (mmHg)|Aminotransferases|Alkaline phosphatase|Gamma-glutamyl transpeptidase|Bilirubin|Albumin|High sensitivity CRP|Resting metabolic rate (kcal/day)|Respiratory quotient|Liver proton density fat fraction|Mean liver PDFF|Total liver volume|Total liver fat index|Well-being score|Visual Analog Score for fatigue (none to intolerable)|Visual Analog Score for nausea (none to intolerable)|Visual Analog Score for abdominal cramp/pain (none to intolerable)|Visual Analog Score for headache (none to intolerable)|Visual Analog Score for hunger (none to intolerable)|Visual Analog Score for diet satisfaction (not appreciated to very appreciated)|Visual Analog Score for difficulty to follow the diet (no difficulty to extreme difficulty)|Visual Analog Score for difficulty for meal preparation (no difficulty to extreme difficulty)|Steps/day (physical activity)|Number hypoglycemia episodes|Severity of hypoglycemia episodes (mild or severe)|Capillary ketone body levels|Alpha diversity (optional)|Beta diversity (optional)|Daily caloric intake (kcal/day)|Lipids composition|Carbohydrates composition|Proteins composition|Self-reported symptoms","Institut de Recherches Cliniques de Montreal|McGill University","All","18 Years and older (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CUT-1","March 2021","March 2023","March 2023","February 17, 2021",,"July 13, 2021","Institut de recherches cliniques de Montréal, Montréal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT04758858" | |
| 466,"NCT03961854","Lactobacillus Johnsonii in Children and Adolescents With T1D",,"Recruiting","No Results Available","Type 1 Diabetes (T1D)","Drug: L. johnsonii Probiotic|Drug: Placebo Capsule","Safety will be evaluated according to complete blood count (CBC) and complete comprehensive metabolic panel (CMP)|Tolerance will be evaluated according to their responses on weekly questionnaires|Adverse Event and/or Serious Adverse Event","University of Florida|Juvenile Diabetes Research Foundation","All","8 Years to 18 Years (Child, Adult)","Phase 2","57","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IRB201901369|2-SRA-2019-811-M-B|OCR22462","October 10, 2019","May 18, 2023","May 18, 2023","May 23, 2019",,"September 27, 2022","UF Clinical Research Center, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03961854" | |
| 467,"NCT03961347","Lactobacillus Johnsonii Supplementation in Adults With T1D",,"Recruiting","No Results Available","Type 1 Diabetes (T1D)","Drug: L. johnsonii Probiotic|Drug: Placebo Capsule","Safety will be evaluated according to complete blood count (CBC) and complete comprehensive metabolic panel (CMP)|Tolerance will be evaluated according to their responses on weekly questionnaires|Adverse Event and/or Serious Adverse Event","University of Florida|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 45 Years (Adult)","Phase 2","57","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","IRB201901428 -N|OCR22502|1R01DK121130-01A1","February 1, 2020","June 1, 2026","June 1, 2026","May 23, 2019",,"July 8, 2022","UF Clinical Research Center, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03961347" | |
| 468,"NCT01269034","New Onset Type 1 Diabetes: Role of Exenatide",,"Completed","Has Results","Type 1 Diabetes","Drug: Exenatide|Drug: Rapid and long acting insulin|Drug: long acting insulin + rapid acting + 1.25 mcg Exenatide","The Role of Exenatide as Compared to Insulin Monotherapy in Reducing Postprandial Hyperglycemia.|The Role of Exenatide on Postprandial Glucagon and Gastric Emptying.|Postprandial Glucose Excursions, Glucagon Concentrations and Gastric Emptying in Normal Healthy Controls.","Albert Einstein College of Medicine|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","12 Years to 18 Years (Child, Adult)","Phase 4","13","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2010-435|3R01DK077166-05S1","December 2010","January 31, 2017","January 31, 2017","January 4, 2011","August 4, 2021","August 4, 2021","Albert Einstein CRC- West Campus, Bronx, New York, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT01269034/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT01269034" | |
| 469,"NCT04190277","Safety Assessment of DBLUS System in Adolescent and Adult Patients With Type 1 Diabetes and Assessment of Its Clinical Efficacy (DIABELOOP SP8)","DIABELOOP SP8","Terminated","No Results Available","Diabetes Mellitus, Type 1|Closed-Loop","Device: Open-loop condition|Device: Closed-loop condition","Incidence rate of Serious Adverse Device Effect occuring during the 12-week closed-loop period|Percentage of time spent in hypoglycemia (glucose level below 70mg/dL (3.9 mmol/L)) between baseline period (2-week period) and in-home study phase in closed-loop (12-week period) for the whole patients of the ""single-arm"" part|Difference in percentage of time spent in hypoglycemia (<70mg/dL) during 12 weeks between closed-loop and open-loop|Percentage of sensor time in glucose level o < 50mg/dL (2.8 mmol/L) o < 60 mg/dL (3.3 mmol/L) o < 70mg/dL (3.9 mmol/L)|Number of hypoglycemic episodes with beginning and end of episode o < 70 mg/dL (3.9 mmol/L) o ≤ 54 mg/dL (3 mmol/L)|Incidence of severe hypoglycemia: o Number of severe hypoglycemic episodes needing a third-party intervention o Number of severe hypoglycemic episodes with loss of consciousness o Number of hospitalizations because of a severe hypoglycemia episode|Number of severe hyperglycemia episodes with beginning and end of episode : o > 350 mg/dL (19.4 mmol/L) o > 360 mg/dL (20 mmol/L) or significant ketosis (plasmatic ketones > 3 mmol/L) as defined by the ADA.|Incidence of severe hyperglycemia: o Number of hospitalizations because of ketoacidosis (i.e. incidence of DKA)|Number of technical incidents leading to the interruption of the closed loop|Number of serious adverse events, serious adverse device events, unanticipated adverse device effects|Area under the curve (AUC) from CGM analysis|Risk of hypoglycemia and hyperglycemia (LBGI/HBGI)|Percentage of time spent in the 70-180 mg/dL target range|Percentage of sensor time in glucose level : o < 50 mg/dL (2.8 mmol/L), o < 54 mg/dL (3.0 mmol/L) o < 60 mg/dL (3.3 mmol/L), o < 70 mg/dL (3.9 mmol/L)|Percentage of sensor time in glucose range 54-70 mg/dL (3.0 - 3.9 mmol/L)|Percentage of sensor time in glucose range 70-140 mg/dL (3.9 - 7.8 mmol/L)|Percentage of sensor time in glucose level o > 180 mg/dL (10.0 mmol/L), o > 250 mg/dL (13.9 mmol/L), o > 300 mg/dL (16.7 mmol/L) o > 350 mg/dL (19.4 mmol/L)|Evolution of glycosylated hemoglobin between inclusion and end of study|Average glycemia level during the entire period|Average fasting glycemia level at 6:00 am|Variability of the glycemia level measured by o the glycemic variation coefficient (CV) intra patient: • CV < 36% • CV ≥ 36% o Standard deviation (SD)|Average dose of insulin used & its daily evolution during the entire study duration|Evolution over time of the DBLUS system's performance on a day-to-day and determination of the optimization delay of glycemic control|Percentage of time spent in closed loop mode (i.e. DBLUS System with loop mode operating)|Percentage of time spent in operating mode for the Dexcom G6 CGM|Scoring of the Diabetes Treatment Satisfaction Questionnaire (DTSQ) to evaluate the acceptance|Scoring of the Diabetes Quality of Life (DQOL) questionnaire to evaluate the acceptance|Scoring of the Hypoglycemia Fear Survey (HFS) questionnaire to evaluate the acceptance|Evolution of the weekly average number of CHO intake (for patient with closed-loop)|Questionnaire of usability (for 50 subjects from Arm 1, including 15 adolescents and 35 adults)","Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète","All","14 Years to 75 Years (Child, Adult, Older Adult)","Not Applicable","184","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","2019-A01975-52","January 7, 2020","March 16, 2020","June 16, 2020","December 9, 2019",,"April 8, 2021","Caen University Hospital, Caen, France|Sud Francilien Hospital, Corbeil-Essonnes, France|Grenoble University Hospital, Grenoble, France|Marseille - La Conception University Hospital, Marseille, France|Necker-Enfants Malades University Hospital, Paris, France|Reims University Hospital, Reims, France|Strasbourg University Hospital, Strasbourg, France|Toulouse - Purpan University Hospital, Toulouse, France|Toulouse - Rangueil University Hospital, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT04190277" | |
| 470,"NCT05300022","Technology Knowledge Optimization in Type 1 Diabetes (TeKnO T1D): Parents","TeKnO T1D","Recruiting","No Results Available","Type 1 Diabetes","Other: TeKnO T1D: Parents","Study Recruitment|Intervention Satisfaction|Perceived Intervention Utility|Intervention Completion|Intervention Retention|Hemoglobin A1c|CGM Mean Sensor Glucose|CGM Glucose Management Indicator|CGM Coefficient of Variation of the Mean|CGM Time in Range (70-180 mg/dL)|CGM Time Below Range (<70 mg/dL)|CGM Time Above Range (<180 mg/dL)|CGM Wear Time|Total Daily Insulin Dose|Total Daily Basal Insulin Dose|Percent Basal Insulin Dose|Number of boluses per day|Carbohydrate intake logged on insulin pump|Episodes of Severe Hypoglycemia|Emergency Department Visits|Hospital Admissions|Episodes of Diabetic Ketoacidosis|Parent Diabetes-Specific Quality of Life|Parent Emotional Distress Related to T1D|Parent Diabetes Self-Management|Parent Perceived CGM Benefits and Burdens|Parent Diabetes Technology Knowledge|Child Diabetes-Specific Quality of Life|Child Emotional Distress Related to T1D|Child Diabetes Self-Management|Child Perceived CGM Benefits and Burdens","Children's Hospital of Philadelphia","All","8 Years to 12 Years (Child)","Not Applicable","170","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","22-019791","November 10, 2022","July 2027","July 2027","March 29, 2022",,"November 14, 2022","Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT05300022" | |
| 471,"NCT04204733","Mobile Physical Activity for Type 1 Diabetes",,"Completed","No Results Available","Type1diabetes","Behavioral: Mobile application","Moderate to vigorous physical activity (objective)|Moderate to vigorous physical activity (subjective)","Yale University","All","18 Years to 65 Years (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2000025992","January 6, 2020","November 12, 2020","November 12, 2020","December 19, 2019",,"May 6, 2021","Yale University, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT04204733" | |
| 472,"NCT00579371","Cadaveric Islet Transplantation in Patients With Insulin-Dependent Diabetes Mellitus",,"Terminated","No Results Available","Islets of Langerhans Transplantation|Diabetes Mellitus, Type 1","Drug: Islets of Langerhans","Incidence of insulin independence with a single islet transplant|Islet mass resulting in insulin independence/reduced exogenous insulin requirement|Graft survival|Metabolic functional assessments of the islet graft","University of Nebraska","All","19 Years to 70 Years (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","149-03-FB|BB IND 11397","March 17, 2004","March 2011","March 2011","December 24, 2007",,"June 15, 2018","The Nebraska Medical Center, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT00579371" | |
| 473,"NCT01722240","Liraglutide in Type 1 Diabetes","1966","Completed","No Results Available","Type 1 Diabetes","Drug: Liraglutide 1.8mg|Drug: Placebo","HbA1c|Mean weekly glucose concentrations.","University at Buffalo|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 75 Years (Adult, Older Adult)","Phase 3","96","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","1966","November 2012","March 2019","November 2019","November 6, 2012",,"November 3, 2022","Diabetes-Endocrinology Center of WNY, Buffalo, New York, United States",,"https://ClinicalTrials.gov/show/NCT01722240" | |
| 474,"NCT01337947","The Impact of Fitness on Vascular Dysfunction in Adolescents With Type 1 Diabetes",,"Completed","No Results Available","Type 1 Diabetes","Drug: Definity microbubbles","arterial vascular stiffness|nitric oxide dependent vasodilation","University of Virginia","All","12 Years to 18 Years (Child, Adult)",,"32","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB- HSR #15312","April 2011","November 2013","November 2013","April 19, 2011",,"September 29, 2014","University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01337947" | |
| 475,"NCT02117518","Selective Immunotargeting of Pathogenic CD8 T Cells of Type 1 Diabetes Patients",,"Unknown status","No Results Available","Type I Diabetes","Other: blood drawing","Identification, isolation, propagation and targeting of autoreactive T cells from T1D patients","Migal Galilee Research Institute|Ziv Medical Center","All","up to 25 Years (Child, Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","0063-13","May 2014","December 2015","May 2016","April 21, 2014",,"April 23, 2014","Ziv Medical Center, Safed, Israel",,"https://ClinicalTrials.gov/show/NCT02117518" | |
| 476,"NCT05431686","Group Visits for High Risk Type 1 Diabetes (T1D)",,"Recruiting","No Results Available","Type 1 Diabetes","Behavioral: SMA visits","Percentage of eligible participants who agreed to participate as assessed by tracking those who were approached to participate and those who agreed to participate|Percentage of participants with CGM use, as assessed by tracking CGM use status from enrollment to the end of the study.|Frequency of SMA sessions attended, as assessed by tracking study visit attendance.|Perceived satisfaction of SMA intervention as assessed by user satisfaction surveys summary statistics (mean and standard deviation as well as percent answering a specific Likert level), and semi-structured interviews.|Perceived utility of the SMA intervention content, as measured by user satisfaction surveys summary statistics (mean and standard deviation as well as percent answering a specific Likert level)|Perceived benefit of the SMA intervention content, as measured by user satisfaction surveys summary statistics (mean and standard deviation as well as percent answering a specific Likert level)|continuous glucose monitor time in range from 70-180 mg/dL|continuous glucose monitor time below range (<70 mg/dL)|continuous glucose monitor time above range (>180 mg/dL)|continuous glucose monitor mean sensor glucose|continuous glucose monitor coefficient of variation|continuous glucose monitor wear time|episodes of diabetic ketoacidosis (DKA)|episodes of severe hypoglycemia|number of emergency room visits|number of hospital admissions|hemoglobin A1c|Type 1 Diabetes and Life (T1DAL) survey|Diabetes Self-Management Profile (DSMP) survey|Self-Efficacy for Diabetes Scale (SED) survey|Problem Areas in Diabetes (PAID) scale|CGM Benefits and Burdens scale","Children's National Research Institute|American Diabetes Association|DexCom, Inc.","All","8 Years and older (Child, Adult, Older Adult)","Not Applicable","20","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Pro00016268","February 16, 2022","July 2023","July 2024","June 24, 2022",,"August 31, 2022","Children's National Hospital, Washington, District of Columbia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT05431686/Prot_SAP_003.pdf","https://ClinicalTrials.gov/show/NCT05431686" | |
| 477,"NCT00940173","Open-label Investigation of the Safety and Effectiveness of DIABECELL(R) in Patients With Type I Diabetes Mellitus",,"Completed","No Results Available","Type 1 Diabetes","Device: DIABECELL(R)","To establish the safety of xenotransplantation of DIABECELL(R) [immunoprotected (alginate-encapsulated) porcine islets]|To establish preliminary evidence of the efficacy of DIABECELL(R), as measured by a reduction in serial HbA1C levels|To establish whether DIABECELL(R) causes an improvement in glucose lability determined from continuous glucose monitoring|To determine whether DIABECELL(R) causes a reduction in hypoglycaemia and nocturnal hypoglycaemia|To determine whether DIABECELL(R) causes a reduction in insulin dose|To determine whether DIABECELL(R) causes an improvement in endogenous insulin secretion|To determine whether DIABECELL(R) causes an improvement in quality-of-life","Diatranz Otsuka Limited","All","35 Years to 65 Years (Adult, Older Adult)","Phase 1|Phase 2","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCT/DIA-06","July 2009","October 2013","October 2013","July 15, 2009",,"October 20, 2017","Centre for Clinical Research and Effective Practice, Auckland, New Zealand",,"https://ClinicalTrials.gov/show/NCT00940173" | |
| 478,"NCT03547427","Glucagon Counterregulation in Type 1 Diabetes",,"Terminated","No Results Available","Type 1 Diabetes Mellitus","Other: Basal insulin alone|Other: Basal pramlintide and reduced basal insulin|Other: CGM|Other: Acetaminophen test|Other: Insulin-induced hypoglycemia|Other: Exercise-induced hypoglycemia","Relative glucagon counterregulation (GCR) response|Maximal glucagon counterregulation (GCR) response|Rate of gastric emptying","University of Virginia","All","21 Years to 55 Years (Adult)","Not Applicable","13","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","20364","May 20, 2018","March 11, 2019","March 11, 2019","June 6, 2018",,"March 28, 2022","University of Virginia Center for Diabetes Technology, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03547427" | |
| 479,"NCT04977635","Biomarkers of Heterogeneity in Type 1 Diabetes",,"Completed","No Results Available","Type 1 Diabetes",,"Change from baseline remaining C-peptide production at 1 year and 2 years as measured by the Beckman ultrasensitive C-peptide assay|Change in prevalence of impaired awareness of hypoglycaemia between baseline and 2-year timepoint as measured by adapted Clarke hypoglycaemia awareness survey|Genome-wide Association Study (GWAS) by Illumina 720k chip|Assessment of glucagon response after stimulation with a mixed meal tolerance test as measured by the Mercodia glucagon assay (ELISA)|Change in patient-reported outcomes between baseline and 2 year timepoint as measured by WHO-5, PAID-20 and WHOQOL surveys","Diabeter Nederland BV|University Medical Center Groningen","All","16 Years and older (Child, Adult, Older Adult)",,"611","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NL50314.042.15 / METc 2015/493|3-SRA-2014-291-M-R","June 8, 2016","December 31, 2021","December 31, 2021","July 27, 2021",,"March 23, 2022","University Medical Center Groningen, Groningen, Netherlands|Martine MC de Vries, Rotterdam, Netherlands|Haaglanden Medical Center, The Hague, Netherlands",,"https://ClinicalTrials.gov/show/NCT04977635" | |
| 480,"NCT04774224","Baricitinib in New-onset Type 1 Diabetes","BANDIT","Active, not recruiting","No Results Available","Type 1 Diabetes","Drug: Baricitinib|Drug: Placebo","The primary endpoint of the study is the change from baseline of plasma C-peptide area under the curve (AUC) over 2 hours following a mixed meal.|Change from baseline in plasma C-peptide AUC over 2 hours following a mixed meal.|Change from baseline in mean daily insulin use over 7 consecutive days.|Change from baseline in glycosylated haemoglobin (HbA1c) levels.|Number of participants with responder status. Responder status is defined as glycosylated haemoglobin (HbA1c) less than or equal to 6.5 percent and mean daily insulin use less than 0.5 international units per kilogram per day (IU/kg/day).|Change in estimated C-peptide (CPEST) from baseline. CPEST is calculated based on six variable routine measures: disease duration, BMI, insulin dose, HbA1c, fasting plasma C-peptide and fasting plasma glucose.|Continuous glucose monitoring (CGM).|The composite outcome assessing both the frequency, and when relevant, the severity of all adverse events.","St Vincent's Institute of Medical Research|Juvenile Diabetes Research Foundation|Juvenile Diabetes Research Foundation Australia","All","10 Years to 30 Years (Child, Adult)","Phase 2","91","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SVI-BARI-01","October 30, 2020","October 31, 2023","October 31, 2024","March 1, 2021",,"May 10, 2022","Women's and Children's Hospital Adelaide, North Adelaide, South Australia, Australia|St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Royal Children's Hospital Melbourne, Parkville, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT04774224" | |
| 481,"NCT05359796","Clinical Characteristics of People With Long-term Type 1 Diabetes",,"Recruiting","No Results Available","Type 1 Diabetes","Biological: Chronic hyperglycemia|Biological: Residual islet function|Genetic: Genetic variation|Dietary Supplement: Dietary constitutes|Genetic: Microbiome composition and function|Biological: Metabolome composition|Biological: Composition of peripheral blood immune cells","the development or progression of diabetic nephropathy|the development or progression of diabetic retinopathy|the changes of memory function|the changes of executive function|the changes of language function|the changes on magnetic resonance imaging(MRI)|the changes of bone mineral density(BMD)|the changes of brachial-ankle pulse wave velocity(baPWV)|the changes of carotid intima-media thickness(IMT)","Second Xiangya Hospital of Central South University","All","Child, Adult, Older Adult",,"400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","long-term T1D 2022","May 1, 2022","December 31, 2025","December 31, 2027","May 4, 2022",,"May 4, 2022","Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University, Changsha, Hu Nan, China",,"https://ClinicalTrials.gov/show/NCT05359796" | |
| 482,"NCT04963777","Prebiotics in Newly Diagnosed Type 1 Diabetes",,"Recruiting","No Results Available","Type 1 Diabetes","Dietary Supplement: Prebiotic|Dietary Supplement: Placebo","Change in frequency of hypoglycemia|Change in glycemic control|Change in stimulated C-peptide|Change in Intestinal permeability|Change in Inflammatory marker IL-6|Change in quality of life|Change in dietary intake|Change in gut microbiota composition|Change in gut microbiota function|Change in serum metabolite concentration","University of Calgary","All","8 Years and older (Child, Adult, Older Adult)","Not Applicable","144","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","REB21-0852","March 29, 2022","September 1, 2025","September 1, 2026","July 15, 2021",,"July 6, 2022","University of Calgary, Calgary, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT04963777" | |
| 483,"NCT05078658","Low-carbohydrate Diet in Children With Type 1 Diabetes","Lowca","Recruiting","No Results Available","Type1diabetes","Other: Low-carbohydrate diet|Other: Recommended-carbohydrate diet","Change in continuous glucose monitoring time in target range (3.9-10.0 mmol/l) during the LCD period compared to the RCD period|Changes in mean insulin dose during the LCD period compared to the RCD period|Changes in mean body weight standard deviation score during the LCD period compared to the RCD period|Changes in the lipid spectrum during the LCD period compared to the RCD period|Changes in muscle strength measured by jumping mechanography during the LCD period compared to the RCD period|Changes in lymphocyte subgroup cell counts (flow cytometry) during the LCD period|Differences in faecal microbiome between the LCD and RCD periods|Differences in faecal metabolome between the LCD and RCD periods|Differences in serum metabolome between the LCD and RCD periods|Differences in urine metabolome between the LCD and RCD periods","University Hospital, Motol|Czech Academy of Sciences","All","6 Years to 20 Years (Child, Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NU21-01-00085","September 22, 2021","October 2023","October 2024","October 14, 2021",,"October 14, 2021","University Hospital Motol, Prague, Czechia",,"https://ClinicalTrials.gov/show/NCT05078658" | |
| 484,"NCT03973827","Wharton´s Jelly Derived Mesenchymal Stromal Cell Repeated Treatment of Adult Patients Diagnosed With Type I Diabetes",,"Active, not recruiting","No Results Available","Type1diabetes","Drug: ProTrans","The primary safety endpoint in this study is; safety parameters include adverse events, hypoglycemia and allergic reactions|Delta-change of C-peptide AreaUnder the Curve (AUC) (0-120 min) for Mixed Meal Tolerance Test (MMTT) at day 372 following WJMSC infusion when compared to test performed before start of treatment.|Number of patients insulin independent (ADA criteria) at day 372.|Number of patients with daily insulin needs <0.25U/kg at day 372.|HbA1c at day 372|Glucose variability (mean amplitude of glycaemic excursions and glycaemic lability index) duration derived from the continuous glucose monitoring system® at day 372|Delta change of levels of fasting C-peptide at day 372 when compared to test before start of treatment|Numbers of patients with peak C-peptide >0.20 nmol/l, in response to the MMTT, at day 372.","NextCell Pharma Ab","Male","18 Years to 41 Years (Adult)","Phase 1|Phase 2","15","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ProTrans-Repeat|2018-004158-11","May 17, 2019","December 10, 2020","October 30, 2024","June 4, 2019",,"January 11, 2022","Karolinska Trial Alliance, Fas 1 enheten, Karolinska Universitetssjukhuset Huddinge, Huddinge, Sweden",,"https://ClinicalTrials.gov/show/NCT03973827" | |
| 485,"NCT05481801","Adherence to Guidelines VAccination in Type 1 DIabetes Mellitus Patients (AVADI-2)","AVADI-2","Recruiting","No Results Available","Type 1 Diabetes","Biological: Covid-19 vaccination|Biological: Influenza vaccination|Biological: Pneumococal vaccination|Biological: Hepatitis B Virus (HBV) vaccination","Vaccination adherence|Sick Leaves|Hospital admission|Death","Castilla-La Mancha Health Service","All","18 Years and older (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","C-549","September 1, 2022","December 1, 2022","December 31, 2022","August 1, 2022",,"September 21, 2022","Ciudad Real General University Hospital, Ciudad Real, Spain",,"https://ClinicalTrials.gov/show/NCT05481801" | |
| 486,"NCT05266963","Pancreatic Enzyme Replacement and Glucose Regulation in Type 1 Diabetes","CREON","Enrolling by invitation","No Results Available","Type 1 Diabetes","Drug: CREON|Drug: Placebo","Improvement in glucose regulation|Patient-reported change in pancreatic exocrine insufficiency (PEI) symptoms","Vanderbilt University Medical Center","All","18 Years and older (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","210734","September 2, 2022","August 2023","February 2024","March 4, 2022",,"September 28, 2022","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT05266963" | |
| 487,"NCT04975230","Self-Management in Young Adults With Type 1 Diabetes","SLEEPT1D","Recruiting","No Results Available","Type 1 Diabetes","Behavioral: Sleep Self-Management","Repeated Measures|Non-dominant wrist-worn actigraph to be worn 24/7 (Spectrum Plus)|Continuous Glucose Monitor (CGM) data downloaded directly from each participant's existing or provided blinded Dexcom G6 [trademark]|Self-Care Inventory Revised (15-item)|10-Minute Psychomotor Vigilance Test on a PVT-192 device|Paper-based Trail Making Test parts A and B (Executive Function)|PROMIS v1.0 (8-item general distress-depression)|Diabetes Distress Scale (17-item)|Diabetes Symptom Checklist Revised (34-item)","Case Western Reserve University|National Institute of Nursing Research (NINR)|National Institutes of Health (NIH)","All","18 Years to 25 Years (Adult)","Not Applicable","48","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","STUDY20201829|1K99NR018886-01A1","April 29, 2022","December 2024","December 2025","July 23, 2021",,"December 15, 2022","University Hospitals of Cleveland Medical Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04975230" | |
| 488,"NCT02846831","Closed-loop Control of Glucose Levels (Artificial Pancreas) for 12 Days in Adults With Type 1 Diabetes",,"Completed","No Results Available","Type 1 Diabetes","Other: 12-day intervention with sensor-augmented pump therapy|Other: 12-day intervention with single-hormone closed-loop strategy|Device: Insulin pump|Device: Continuous glucose monitoring system|Drug: Insulin","Percentage of time of glucose levels spent between 3.9 and 10 mmol/L.|Percentage of time of glucose levels spent between 3.9 and 7.8 mmol/L|Percentage of time of glucose levels spent below 3.9 mmol/L|Percentage of time of glucose levels spent below 3.3 mmol/L|Percentage of time of glucose levels spent below 2.8 mmol/L|Percentage of time of glucose levels spent above 10.0 mmol/L|Percentage of time of glucose levels spent above 13.9 mmol/L|Percentage of time of glucose levels spent above 16.7 mmol/L|Percentage of time of overnight glucose levels spent between 3.9 and 7.8 mmol/L|Percentage of time of overnight glucose levels spent between 3.9 and 10.0 mmol/L|Percentage of time of overnight glucose levels spent below 3.9 mmol/L|Percentage of time of overnight glucose levels spent below 3.3 mmol/L|Percentage of time of overnight glucose levels spent below 2.8 mmol/L|Percentage of time of overnight glucose levels spent above 10.0 mmol/L|Percentage of time of overnight glucose levels spent above 13.9 mmol/L|Percentage of time of overnight glucose levels spent above 16.7 mmol/L|Total number of hypoglycemic events below 3.1 mmol/L|Number of nights with hypoglycemic events below 3.1 mmol/L|Number of days with hypoglycemic events below 3.1 mmol/L|Mean glucose levels|Standard deviation of glucose levels|Time between failures due to glucose sensor unavailability|Coefficient of variation of glucose levels|Between-day variability in glucose levels|Total daily insulin dose|Standard deviation of insulin delivery|Coefficient of variation of insulin delivery|Between-day variability in insulin delivery|Total number of hours of glucose sensor availability|Percentage of time of glucose sensor availability|Time between failures due to pump connectivity|Percentage of time when patients switched back to insulin pump therapy|Number of hours when patients switched back to insulin pump therapy|Percentage of time when the closed-loop was automatically switched to insulin pump therapy|Number of hours when the closed-loop was automatically switched to insulin pump therapy|Number of days with at least one technical problem|Number of calls for technical issues related to the closed-loop system|Number of patients calling for technical issues related to the closed-loop system","Institut de Recherches Cliniques de Montreal","All","18 Years and older (Adult, Older Adult)","Phase 2","36","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLASS-14","January 24, 2019","January 27, 2020","January 27, 2020","July 27, 2016",,"June 11, 2020","Institut de recherches cliniques de Montréal, Montreal, Quebec, Canada|McGill University Health Centre, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02846831" | |
| 489,"NCT05422053","Control-IQ Technology for High Insulin Users With Type 1 Diabetes (Higher-IQ)",,"Recruiting","No Results Available","Type 1 Diabetes","Device: t:slim X2 insulin pump with Control-IQ technology 1.5","Severe Hypoglycemic Events|Diabetic ketoacidosis|Adverse device effects|Other serious adverse events|Adverse events|Glucose < 54 mg/dL|Glucose < 70 mg/dL","Tandem Diabetes Care, Inc.","All","18 Years and older (Adult, Older Adult)","Not Applicable","60","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TP-0009856","June 29, 2022","December 30, 2022","February 15, 2023","June 16, 2022",,"August 30, 2022","Barbara Davis Center, Aurora, Colorado, United States|Rocky Mountain Diabetes Center, Idaho Falls, Idaho, United States|International Diabetes Center, Minneapolis, Minnesota, United States|Diabetes & Endocrine Treatment Specialists, Sandy, Utah, United States",,"https://ClinicalTrials.gov/show/NCT05422053" | |
| 490,"NCT03328845","Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. (Ineox Study)","INEOX","Completed","No Results Available","Type 1 Diabetes Mellitus","Drug: Toujeo SoloStar|Drug: Tresiba|Drug: Humalog Kwikpen|Drug: NovoRapid|Drug: Apidra","Oxidative stress markers with the new slow insulin analogues|HbA1c|Mean blood glucose|Standard deviation|Number of mild hypoglycemia|Number of severe hypoglycemia|Number of hyperglycemia|Episodes of ketosis|Number os hospital admissions|Quality of life questionnaire in diabetes (DQOL)|Scale of adherence to treatment in patients with diabetes type 1 (DM1)|Diabetes distress scale. DDS|Fear of hypoglycemia: Questionnaire FH-15|Diabetes treatment satisfaction questionnaire (DTSQ).","Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud","All","18 Years to 65 Years (Adult, Older Adult)","Phase 4","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FIM-EOX-2016-01","January 20, 2017","November 30, 2020","November 20, 2021","November 1, 2017",,"December 6, 2021","Regional University Hospital of Málaga, Málaga, Spain",,"https://ClinicalTrials.gov/show/NCT03328845" | |
| 491,"NCT03139864","Comparison of the Use of Energy Substrates and Hormonal Regulation of Blood Sugar During Exercise of Increasing Intensity Between Children With Type 1 Diabetes and Non-diabetic Control Children.","DIABSPORT","Unknown status","No Results Available","Type 1 Diabetes","Procedure: controlled physical activity","Comparison of substrate utilization between infants with type 1 diabetes and infants without type 1 diabetes during exercise|hormonal regulation of blood glucose|lipoxmax : the intensity for wich lipid oxydation is maximum will be carried out by indirect calorimetry|Comparison between infants during 10 days before and 4 days after exercise of blood glucose modification","University Hospital, Clermont-Ferrand","All","6 Years to 12 Years (Child)","Not Applicable","48","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CHU-0292|2016-A01837-44","April 4, 2017","May 2019","December 2019","May 4, 2017",,"February 4, 2019","CHU Clermont-Ferrand, Clermont-Ferrand, France",,"https://ClinicalTrials.gov/show/NCT03139864" | |
| 492,"NCT00179777","TRIGR - Primary Prevention Study for Type 1 Diabetes in Children at Risk","TRIGR","Completed","Has Results","Diabetes Mellitus, Type 1","Dietary Supplement: Hydrolysed infant formula|Dietary Supplement: Nonhydrolysed infant formula","Number of Participants With Type 1 Diabetes Mellitus|Number of Participants With Diabetes Associated Autoantibodies","University of Helsinki|US Congress|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Canadian Institutes of Health Research (CIHR)|Juvenile Diabetes Research Foundation|European Community (EC)|European Foundation for the Study of Diabetes|Mead Johnson Nutrition|Academy of Finland|Diabetes Research Foundation, Finland|Dutch Diabetes Research Foundation","All","up to 7 Days (Child)","Not Applicable","5156","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","MCT-49395|U01HD040364|U01HD042444","May 6, 2002","March 31, 2017","September 30, 2017","September 16, 2005","July 30, 2021","July 30, 2021","The University of South Florida, Tampa, Florida, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Children's Hospital at Westmead, Westmead, New South Wales, Australia|Robarts Research Institute, London, Ontario, Canada|3rd Faculty of Medicine, Charles University, University Hospital Vinohrady, Prague, Czechia|Tartu University Children's Hospital, Tartu, Estonia|University of Helsinki, Helsinki, Finland|Kinderkrankenhaus auf der Bult, Hannover, Germany|Semmelweis Medical University, Budapest, Hungary|St. Michele Hospital, Cagliari, Sardinia, Italy|University Campus Bio-Medico of Rome, Rome, Italy|Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg|Sophia Children's Hospital, Rotterdam, Netherlands|Medical University of Wroclaw, Wroclaw, Poland|Hospital de Cruces, Barakaldo, Vizcaya, Spain|Hospital Clinico San Carlos, Madrid, Spain|University of Linkoping, Linkoping, Sweden|University Children's Hospital, Zurich, Switzerland","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT00179777/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT00179777" | |
| 493,"NCT03800875","Insulin-plus-pramlintide Closed-loop Strategy to Regulate Glucose Levels Without Carbohydrate Counting","Dual","Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: 27-hour inpatient intervention","Total percentage of time (22:00-22:00) that the glucose concentration remained within 3.9 and 10.0 mmol/L|Total percentage of time (22:00-22:00) that the glucose concentration remained within specified ranges.|Percentage of overnight time (24:00-8:00) that the glucose concentration remained within specified ranges.|Total amount of insulin delivered to the participant|Mean sensor glucose concentration during the overnight stay|Number of participants experiencing hypoglycemia requiring oral treatment during: a. the overall study period; b. the night; c. the day|The number and severity of gastrointestinal sysmptoms experienced by a participant|Mean daytime insulin concentration|Mean daytime concentration of amylin|Total amount of pramlintide delivered to the participant|Mean glucose level","McGill University|Diabetes Canada","All","18 Years and older (Adult, Older Adult)","Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Triple Hormone","February 8, 2019","September 19, 2020","September 19, 2020","January 11, 2019",,"June 8, 2021","McGill University Health Centre, Montréal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03800875" | |
| 494,"NCT01961622","Closing the Loop in Adults With Sub-optimally Controlled Type 1 Diabetes Under Free Living Conditions","AP@home04","Completed","No Results Available","Type 1 Diabetes","Device: Florence D2A or similar closed loop glucose control system|Device: CSII with real-time CGM","Time spent in the target glucose range from 3.9 to 10.0 mmol/l based on subcutaneous glucose monitoring|HbA1c|Insulin dose|Adverse Events|Utility Evaluation|Continuous subcutaneous glucose monitoring (CGM) based outcome|Continuous subcutaneous glucose monitoring (CGM) based outcome during overnight period between 23:00 and 08:00|Continuous subcutaneous glucose monitoring (CGM) based outcome during day period between 08:00 to 23:00","University of Cambridge|Profil Institut für Stoffwechselforschung GmbH|Medical University of Graz","All","18 Years and older (Adult, Older Adult)","Not Applicable","33","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AP@home04","April 2014","May 2015","May 2015","October 11, 2013",,"June 8, 2015","Medical University of Graz, Graz, Austria|Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany|University of Cambridge, Cambridge, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01961622" | |
| 495,"NCT04964128","Evaluation of Meal Gesture Dosing in Adults With Type 1 Diabetes",,"Completed","No Results Available","Type 1 Diabetes","Device: MiniMed™ 780G insulin pump with Klue Health app utilizing meal gesture micro insulin dosing (meal gesture dosing)","Percentage of Time in Range","Medtronic Diabetes","All","18 Years to 75 Years (Adult, Older Adult)","Not Applicable","28","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CIP339","July 22, 2021","June 10, 2022","July 26, 2022","July 15, 2021",,"August 9, 2022","Sheba Medical Center, Tel Hashomer, Israel",,"https://ClinicalTrials.gov/show/NCT04964128" | |
| 496,"NCT05258292","Glycemic Variations During the Menstrual Cycle in Women With Type 1 Diabetes","GLYMETY","Recruiting","No Results Available","Type1diabetes","Device: Continuous glucose monitoring|Drug: Insulin|Other: Premenstrual symptoms|Other: Ovulation kits|Device: Fitbit Inspire 2|Other: Keenoa|Other: Menstrual cycle","Mean glucose levels during the early follicular phase|Mean glucose levels during the mid-late follicular phase|Mean glucose levels during the periovulation phase|Mean glucose levels during the early luteal phase|Mean glucose levels during the mid-luteal phase|Mean glucose levels during the late luteal phase|Percentage of time of glucose levels between 3.9 and 7.8 mmol/L|Percentage of time of glucose levels between 3.9 and 10.0 mmol/L|Percentage of time of glucose levels below 3.9 mmol/L|Percentage of time of glucose levels below 3.0 mmol/L|Percentage of time of glucose levels above 10.0 mmol/L|Percentage of time of glucose levels above 13.9 mmol/L|Standard deviation of glucose levels|Coefficient of variance of glucose levels|Low blood glucose index|High blood glucose index|Standard deviation of insulin delivery|Coefficient of variance of insulin delivery|Total insulin delivery","Institut de Recherches Cliniques de Montreal","Female","18 Years to 50 Years (Adult)",,"86","Other","Observational","Observational Model: Cohort|Time Perspective: Other","2022-1165","May 2, 2022","April 1, 2024","May 31, 2024","February 28, 2022",,"July 28, 2022","Institut de recherches cliniques de Montréal, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT05258292" | |
| 497,"NCT03545802","Home-HIT and Type 1 Diabetes",,"Completed","No Results Available","Type1diabetes","Behavioral: Home-HIT","change in maximal aerobic capacity|adherence over the course of the training programme|Compliance over the course of the training programme|change in insulin sensitivity|change in glycaemic control","Liverpool John Moores University","All","18 Years to 55 Years (Adult)","Not Applicable","11","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","Home-HIT_T1D","May 20, 2017","February 13, 2018","February 13, 2018","June 4, 2018",,"March 2, 2021","Liverpool John Moores University, Liverpool, Merseyside, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03545802" | |
| 498,"NCT05421715","Remote Digital Care Effects in Adolescents With Type 1 Diabetes","TELEDUC-DIAB-1","Not yet recruiting","No Results Available","type1diabetes","Other: TELEDUC-DIAB","Evolution of glycemic control hemoglobin (HbA1c) between inclusion and 6 months|Evolution of adherence to TELEDUC-DIAB management between inclusion and 6 months|Evolution of knowledge about diabetes and glycemic targets between inclusion and T6 months","University Hospital, Toulouse","All","12 Years to 17 Years (Child)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","RC31/21/0617","October 1, 2022","December 1, 2024","December 1, 2024","June 16, 2022",,"August 19, 2022",,,"https://ClinicalTrials.gov/show/NCT05421715" | |
| 499,"NCT04289727","Skeletal Fragility in Type 1 Diabetes: Glycemic Control and Bone Strength",,"Recruiting","No Results Available","Type1diabetes",,"Change in microarchitecture by HR-pQCT|Change in bone mineral density by Dual X-ray Absorptometry (DXA)","Columbia University","All","8 Years to 14 Years (Child)",,"80","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","AAAS5630","January 1, 2020","December 1, 2024","December 1, 2024","February 28, 2020",,"July 28, 2021","Columbia University Medical Center-Harkness Pavillion, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04289727" | |
| 500,"NCT02411578","Mini-Dose Glucagon to Treat Non-Severe Hypoglycemia",,"Completed","Has Results","Diabetes Mellitus, Type 1","Drug: G-Pen Mini™ (glucagon injection)|Other: Glucose Tablets","Number of Hypoglycemic Events ≥50 mg/dl 15 Minutes AND ≥ 70 mg/dl 30 Minutes After Initial Treatment|Continuous Glucose Monitor (CGM) Minimum Glucose, Event Level|CGM Maximum Glucose, Event Level|CGM Mean Glucose, Event Level|CGM Time in Range, Event Level|CGM Time Below 70 mg/dL, Event Level|CGM Minimum Glucose, Event Level|CGM Time Below 70 mg/dL|CGM Mean Glucose|CGM Time in Range|CGM Time Below 70|CGM Coefficient of Variation","Jaeb Center for Health Research|Xeris Pharmaceuticals","All","18 Years to 64 Years (Adult)","Phase 2","26","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","T1DX Mini-dose Non-Severe","September 2015","April 2016","May 2016","April 8, 2015","October 23, 2017","March 3, 2020","University of Colorado/Barbara Davis Center for Diabetes, Aurora, Colorado, United States|Yale University of Medicine, New Haven, Connecticut, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|SUNY Upstate Medical University, Syracuse, New York, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02411578" | |
| 501,"NCT04905823","Effect of SARSCoV2 (COVID-19) Vaccination in Type 1 Diabetes (CoVaxT1D)","CoVaxT1D","Active, not recruiting","No Results Available","Type 1 Diabetes","Diagnostic Test: blood test","Adverse events|Humoral response|Immune cell response|Values of continuous glucose monitoring","Paolo Fiorina, MD|ASST Fatebenefratelli Sacco|University of Milan","All","16 Years and older (Child, Adult, Older Adult)",,"600","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CoVaxT1D","March 31, 2021","October 31, 2021","November 30, 2021","May 28, 2021",,"September 28, 2021","ASST FBF-Sacco P.O. Sacco, Milan, MI, Italy",,"https://ClinicalTrials.gov/show/NCT04905823" | |
| 502,"NCT05639088","Improving Transition Care for Adolescents and Young Adults With Type 1 Diabetes","SHIFT2","Not yet recruiting","No Results Available","Type 1 Diabetes","Behavioral: Transition preparation program|Other: Educational materials","Hemoglobin A1C (HbA1C)|Change in transition readiness|Change in diabetes adherence|Attendance at clinic visits|HbA1C|Diabetes-related events|Change in diabetes support|Change in Diabetes Distress|Change in Self Efficacy|Change in Quality of Life","Virginia Commonwealth University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","16 Years and older (Child, Adult, Older Adult)","Not Applicable","110","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","HM20024552|1K23DK131368","June 2023","June 2025","January 2026","December 6, 2022",,"December 6, 2022","Virginia Commonwealth University, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT05639088" | |
| 503,"NCT04784975","Bone Health and Microbiome in Persons With Type 1 Diabetes",,"Not yet recruiting","No Results Available","Type1diabetes","Other: No intervention","High-resolution peripheral quantitative computed tomography (HRpQCT) strength of cortical and trabecular bone.|Dual-energy x-ray absorptiometry (DXA)|Microbiome|Glycemia","Indiana University","All","12 Years to 20 Years (Child, Adult)",,"40","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","BONE","March 2021","October 2021","October 2021","March 5, 2021",,"March 5, 2021",,,"https://ClinicalTrials.gov/show/NCT04784975" | |
| 504,"NCT03642483","Evaluation of an Early Screener to Identify Long-term Problems With Regard to Metabolic Control and Treatment Adherence Among Children and Adolescents With Type 1 Diabetes",,"Completed","No Results Available","Type 1 Diabetes",,"HbA1c|health-related quality of life (Chronic generic measure)|health-related quality of life (diabetes module)|psychological health (Depression)|psychological health (Trait-Anxiety)|psychological health (Child Behavior)","University Children's Hospital, Zurich","All","5 Years to 18 Years (Child, Adult)",,"61","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2018-00374-G1","June 5, 2018","January 17, 2022","January 17, 2022","August 22, 2018",,"April 21, 2022","University Children's Hospital Zurich, Zürich, Switzerland",,"https://ClinicalTrials.gov/show/NCT03642483" | |
| 505,"NCT04084418","Carbohydrates Under Target for Type 1 Diabetes Management",,"Terminated","No Results Available","Type 1 Diabetes","Other: Control Diet|Other: VLCHF Diet","Daily blood glucose standard deviation|Percentage of time-in-target (range of 4-10 mmol/L)|Coefficient of glucose variation|Mean sensor glucose values (mmol/L)|Glucose area under the curve for 2 hours post-prandial|Number of hypoglycemia episodes necessitating treatment recorded|Percentage of time spent in hypoglycemia ranges (< 4 mmol/L and < 3 mmol/L)|Percentage of time spent in hyperglycemia ranges (>10 mmol/L and > 15 mmol/L)|Daily insulin adjustments required to maintain safe blood glucose|Short-term effects on anthropometric parameters : weight (kg) and height (cm)|Short-term effects on anthropometric parameters : waist circumference (cm)|Short-term effects on blood lipid profiles|Short-term effects on body composition (lean and fat mass)|Short-term effects on inflammatory parameters|Short-term effects on oxidative stress/redox parameters|Short-term effects on blood pressure|Short-term effects on liver function|Short-term effects on resting metabolic rate|Short-term effects on liver proton density fat fraction by MRS (MRS-PDFF) (%)|Short-term effects on mean liver PDFF|Short-term effects on total liver volume (mL)|Short-term effects on total liver fat index (%.ml)|Efficacy of glucagon in correcting hypoglycemia|Modulation of postprandial glycemic response (Standardized meal-tests)|Secretion of key gastrointestinal peptides (Standardized meal-tests)|Questionnaire of well-being (score)|Questionnaire of diet satisfaction (score)|Effects on physical activity (steps/day)","McGill University","All","18 Years and older (Adult, Older Adult)","Not Applicable","8","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CUT-T1D","October 15, 2019","March 23, 2020","March 23, 2020","September 10, 2019",,"February 24, 2021","Institut de recherches cliniques de Montréal, Montréal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT04084418" | |
| 506,"NCT04078308","Mesenchymal Stem Cells Transplantation in Newly Diagnosed Type-1 Diabetes Patients","MSCTXT1DM","Unknown status","No Results Available","Diabetes Mellitus|Diabetes Mellitus, Type 1|Diabetes Mellitus, Insulin-Dependent","Biological: Intravenous Injection of autologous mesenchymal stem cells|Other: Intravenous injection of placebo","Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Change from baseline number of hypoglycemic Unawareness episodes at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Change from Baseline Fasting Blood Sugar (FBS) at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Change from Baseline C-peptide at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Change from Baseline HbA1C at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Change from Baseline 2-hour postprandial blood glucose at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Change from Baseline daily dose of exogenous insulin injected by patients (IU/kg/day) at 12 Months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Change from baseline Lability Index (LI) at 12 Months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Change from Baseline SF-36 Quality of life (QOL) questionnaire score at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Change from Baseline Diabetes Specific Quality of life (DQOL) questionnaire score at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Changes from baseline Autoantibodies levels in patients' blood at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Changes from baseline serum cytokines levels in patients' blood at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells","Royan Institute|Tehran University of Medical Sciences|Iranian Stem Cell Council","All","8 Years to 40 Years (Child, Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","RI-SCBT-94000019|IRCT2016070428786N1|94000019|REP-441","July 6, 2015","September 26, 2019","April 1, 2020","September 6, 2019",,"September 6, 2019","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04078308" | |
| 507,"NCT05347836","Monocyte Soluble Activation Markers sCD14 and sCD163 in Children With Type 1 Diabetes Mellitus",,"Not yet recruiting","No Results Available","Type1diabetes","Diagnostic Test: ELISA","To compare the levels of monocyte soluble activation markers among children with T1DM and healthy controls","Assiut University","All","5 Years to 18 Years (Child, Adult)",,"90","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","Monocyte activation markers","July 1, 2022","July 1, 2023","August 1, 2023","April 26, 2022",,"April 26, 2022",,,"https://ClinicalTrials.gov/show/NCT05347836" | |
| 508,"NCT05495386","Investigation of Hyposafe H02 Device in Patients With Type 1 Diabetes",,"Not yet recruiting","No Results Available","Type 1 Diabetes","Device: Hyposafe hypoglycaemia notification device (H02)","To collect electrocardiogram (EEG) data to develop a hypoglycaemia notification algorithm.|To collect self-measured blood glucose (SMBG) data to develop a hypoglycaemia notification algorithm.|To collect continuous glucose monitoring (CGM) data to develop a hypoglycaemia notification algorithm.|To evaluate the safety of H02 in participants with type 1 diabetes.|To evaluate the performance of H02 in participants with type 1 diabetes.|To evaluate the surgeon satisfaction of H02 in participants with type 1 diabetes.","UNEEG Medical A/S","All","18 Years to 70 Years (Adult, Older Adult)","Not Applicable","25","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","U010","September 1, 2022","January 1, 2024","March 1, 2024","August 10, 2022",,"August 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05495386" | |
| 509,"NCT05449678","Low cArbohydraTe dIeT and aUtomated Insulin Delivery System for Type 1 DiabetEs","LATITUDE","Not yet recruiting","No Results Available","Type 1 Diabetes","Behavioral: Low-carb diet","Time in range (TIR)|Adherence","Institut de Recherches Cliniques de Montreal","All","18 Years and older (Adult, Older Adult)","Not Applicable","38","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2023-1182","September 1, 2022","September 30, 2024","June 30, 2025","July 8, 2022",,"July 28, 2022",,,"https://ClinicalTrials.gov/show/NCT05449678" | |
| 510,"NCT05188014","Exercise and the Menstrual Cycle in Type 1 Diabetes",,"Recruiting","No Results Available","Type 1 Diabetes","Behavioral: Luteal Phase Aerobic Exercise|Behavioral: Follicular Phase Aerobic Exercise","Blood glucose|Interstitial glucose (continuous glucose monitoring)|coefficient of variation (CV)|standard deviation (SD)|frequency of hypoglycemia|frequency of hyperglycemia|percent of time in range|percent of time in hypoglycemia|percent of time in hyperglycemia","University of Alberta|Women and Children's Health Research Institute, Canada","Female","18 Years to 50 Years (Adult)","Not Applicable","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","Pro0083867","March 15, 2022","November 30, 2023","February 28, 2024","January 12, 2022",,"April 4, 2022","Alberta Diabetes Institute, Edmonton, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT05188014" | |
| 511,"NCT04254380","Gan & Lee Evaluation of New Biosimilar for Type 1 Lispro","GENTL 1","Withdrawn","No Results Available","Diabetes Mellitus, Type 1","Biological: Gan & Lee Insulin Lispro Injection|Biological: Humalog","Treatment developed AIAs or important increase in AIA titers|Percentage of subjects with negative AIA at baseline who develop positive AIA after baseline|Percentage of subjects with important increase in titers|Mean change from baseline in AIA titers|Percentage of subjects with confirmed positive AIA who develop anti-insulin NAbs|Percentage of subjects with positive AIA after baseline|Incidence and severity of all treatment-emergent adverse events|Change from baseline in HbA1c at visit Week 26|Percentage of subjects who achieve an HbA1c of ≤ 7.0% at visit Week 26","Gan and Lee Pharmaceuticals, USA","All","18 Years to 75 Years (Adult, Older Adult)","Phase 3","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GL-LSPT1-3003","December 4, 2019","January 27, 2020","January 27, 2020","February 5, 2020",,"February 5, 2020","Advanced Research Center, Anaheim, California, United States|Valley Research, Fresno, California, United States|Angel City Research, Inc., Los Angeles, California, United States|California Medical Research Association, Northridge, California, United States|Mills-Peninsula Health Services, San Mateo, California, United States|Care Access Research - Santa Clarita, Santa Clarita, California, United States|Metabolic Institute of America, Tarzana, California, United States|University of Colorado School of Medicine, Aurora, Colorado, United States|IMMUNOe International Research Centers - Longmont, Longmont, Colorado, United States|Chase Medical Research of Greater New Haven, Hamden, Connecticut, United States|The Center for Diabetes and Endocrine Care, Fort Lauderdale, Florida, United States|M & O Clinical Research, Fort Lauderdale, Florida, United States|Sweet Hope Research Specialty Inc., Hialeah, Florida, United States|Homestead Associates in Research, Homestead, Florida, United States|Med Research of Florida, Miami, Florida, United States|Suncoast Clinical Research - Pasco County, New Port Richey, Florida, United States|Florida Institute for Clinical Research, LLC, Orlando, Florida, United States|Ormond Beach Clinical Research, Ormond Beach, Florida, United States|Suncoast Clinical Research - Pinellas County, Palm Harbor, Florida, United States|Meridien Research - Spring Hill, Spring Hill, Florida, United States|Metabolic Research Institute, West Palm Beach, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|IACT Health - Columbus Regional Medical Group Endocrine Consultants - Columbus, Columbus, Georgia, United States|IACT Health - Columbus Regional Medical Group Endocrine Consultants, Newnan, Georgia, United States|Endocrine Research Solutions, Roswell, Georgia, United States|Cedar Crosse Research Center, Chicago, Illinois, United States|Midwest CRC, Crystal Lake, Illinois, United States|Iowa Diabetes and Endocrinology Research Center, West Des Moines, Iowa, United States|Kentucky Diabetes Endocrinology Center, Lexington, Kentucky, United States|Bay West Endocrinology Associates, Baltimore, Maryland, United States|BTC Network - Capital Diabetes and Endocrine Associates - Camp Springs, Camp Springs, Maryland, United States|Endocrine & Metabolic Consultants, Rockville, Maryland, United States|Quality Clinical Research, Omaha, Nebraska, United States|Palm Research Center, Las Vegas, Nevada, United States|BTC Network - Garden State Endocrinology - Brick, Brick, New Jersey, United States|The Endocrine Group, LLP, Albany, New York, United States|North Shore Diabetes and Endocrine Associates, New Hyde Park, New York, United States|University Physicians Group, Staten Island, New York, United States|PharmQuest, Greensboro, North Carolina, United States|Physicians East - Greenville, Greenville, North Carolina, United States|Carteret Medical Group - Morehead City, Morehead City, North Carolina, United States|Endocrinology Research Associates, Columbus, Ohio, United States|Your Diabetes Endocrine Nutrition Group, Inc., Mentor, Ohio, United States|Intend Research, Norman, Oklahoma, United States|Lynn Institute of Stillwater, Stillwater, Oklahoma, United States|Care Access Research - Warwick, Warwick, Rhode Island, United States|University Diabetes & Endocrine Consultants, Chattanooga, Tennessee, United States|Amarillo Medical Specialists, Amarillo, Texas, United States|Austin Regional Clinic, Austin, Texas, United States|Texas Diabetes & Endocrinology - Central Austin, Austin, Texas, United States|Research Institute of Dallas, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|El Paso Medical Research Institute, El Paso, Texas, United States|Pioneer Research Solutions, Houston, Texas, United States|Austin Regional Clinic - Kelly Lane, Pflugerville, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|Northeast Clinical Research of San Antonio, Schertz, Texas, United States|Crossroads Clinical Research, Victoria, Texas, United States|Diabetologie České Budějovice s.r.o, České Budějovice, Jihocesky KRAJ, Czechia|Diahaza s.r.o., Holešov, Czechia|StefaMed, Hradec Králové, Czechia|Clintrial, Praha 10, Czechia|Milan Kvapil s.r.o, Praha 11, Czechia|Diabeteszentrum DO, Dortmund, Germany|Diabetes Schwerpunktpraxis, Duisburg, Germany|Diabetes-falkensee.de - Zentrum für klinische Studien, Falkensee, Germany|RED-Institut GmbH, Oldenburg, Germany|Diabetologische Praxis, Saarlouis, Germany|Lausmed Egeszsegugyi es Szolgaltato Kft., Baja, Hungary|Dél-pesti Centrumkórház - Országos Hematológiai és Infektológiai Intézet, Budapest, Hungary|Bajcsy-Zsilinszky Kórház és Rendelőintézet, Budapest, Hungary|Trantor 99 Bt Anyagcsere Centrum, Budapest, Hungary|Debreceni Egyetem Kenézy Gyula Egyetemi Kórház, Debrecen, Hungary|Békés Megyei Központi Kórház Pándy Kálmán Tagkórház, Gyula, Hungary|Somogy Megyei Kaposi Mór Oktató Kórház, Kaposvár, Hungary|Kanizsai Dorottya Kórház, Nagykanizsa, Hungary|Markusovszky Egyetemi Oktatokorhaz, Szombathely, Hungary|Medical-Expert Kutatási - Kísérleti és Szolgáltató Kft, Veszprém, Hungary|Zala Megyei Szent Rafael Kórház, Zalaegerszeg, Hungary|Niepubliczny Zaklad Opieki Zdrowotnej Gdanska Poradnia Cukrzycowa, Gdansk, Poland|Centrum Badań Klinicznych PI-House, Gdańsk, Poland|Centrum Medyczne Pratia Gdynia, Gdynia, Poland|Centrum Medyczne Pratia Katowice, Katowice, Poland|Pratia MCM Kraków, Kraków, Poland|NZOZ Medyczne Centrum Diabetologiczno-Endokrynologiczno-Metaboliczne ""Diab-Endo-Met"", Kraków, Poland|CenterMed Lublin Sp. z o.o, Lublin, Poland|KO-MED Centra Kliniczne Lublin - Królewska, Lublin, Poland|Bogdan Walko Niepubliczny Zakład Opieki Zdrowotnej Przychodnia Specjalistyczna MEDICA, Lublin, Poland|Centrum Medyczne Grunwald, Poznan, Poland|Nasz Lekarz Przychodnie Medyczne, Toruń, Poland|AMED Centrum Medyczne, Warszawa, Poland|Centralny Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji w Warszawie, Warszawa, Poland|Centrum Medyczne K2J2, Wołomin, Poland|Regionalna Poradnia Diabetologiczna, Wrocław, Poland|Centrum Medyczne Oporów, Wrocław, Poland|Hospital de la Santa Creu i de Sant Pau, Barcelona, Spain|Hospital Universitari Vall d'Hebrón, Barcelona, Spain|Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain|Complejo Hospitalario Universitario La Coruña (Gerencia de Gestión Integrada de A Coruña), La Coruña, Spain|Hospital Universitari Arnau de Vilanova, Lleida, Spain|Hospital Universitario de La Princesa, Madrid, Spain|Hospital Universitario Ramón Y Cajal, Madrid, Spain|Hospital Universitario Virgen de la Victoria, Málaga, Spain|Fundació Hospital de l'Esperit Sant, Santa Coloma de Gramenet, Spain|Nuevas Tecnologías en Diabetes y Endocrinología, Sevilla, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Universitario Virgen de Valme, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT04254380" | |
| 512,"NCT05619198","The Effects of Different Exercise Modalities in Adolescents With Type 1 Diabetes Using AID Systems","MODE2022","Not yet recruiting","No Results Available","Type 1 Diabetes","Behavioral: High Intensity Interval Exercise|Behavioral: Moderate Intensity Continous Exercise","Percentage of time spent in sensor-derived time in range (3.9-10.0 mmol/L) during and after a bout of exercise|Number of hypo- (<3.9 mmol/L) and hyperglycemic (>10.0 mmol/L) occurrences during exercise session as measured by sensor and plasma sampling|Percentage of time spent below (<3.9 mmol/L), in (3.9-10.0 mmol/L) and above (>10.0 mmol/L) range during in-clinic phase, measured by sensor and plasma sampling|Percentage of time spent below (<3.9 mmol/L), in (3.9-10.0 mmol/L) and above (>10.0 mmol/L) range during home-phase, measured by glucose sensor|Glycemic variability as coefficient of variation, measured by sensor during in-clinic phase|Glycemic variability as coefficient of variation, measured by plasma sampling during in-clinic phase|Glycemic variability as standard deviation, measured by sensor during in-clinic phase|Glycemic variability as standard deviation, measured by plasma sampling during in-clinic phase|Glycemic variability as coefficient of variation measured by glucose sensor during home-phase|Glycemic variability as standard deviation measured by glucose sensor during home-phase|Number of rescue glucose interventions to treat hypoglycemia (<3.9 mmol/L) during in-clinic and home-phase|Area Under the Curve and absolute concentration of serum total insulin during in-clinic phase|Dynamics of plasma glucoregulatory hormone responses during in-clinic phase|Dynamics of plasma metabolites during in-clinic phase|Glucose changes during exercise (delta change expressed as absolute [mmol/L]) during in-clinic phase|Glucose changes during exercise (delta change relativized as a rate of change [mmol/min]) during in-clinic phase|Amount of correction boluses given by each automated insulin delivery system during activation of temporary target and exercise mode|Comparison of heart rate (HR) during high intensity interval exercise and moderate intensity continous exercise session|Comparison of respiratory exchange ratio (RER) during high intensity interval exercise and moderate intensity continous exercise session|Comparison of oxygen consumption (VO2) during high intensity interval exercise and moderate intensity continous exercise session|Comparison of carbon dioxide output (VCO2) during high intensity interval exercise and moderate intensity continous exercise session|Comparison of carbohydrate oxidation during high intensity interval exercise and moderate intensity continous exercise session|Comparison of lipid oxidation during high intensity interval exercise and moderate intensity continous exercise session|Comparison of resting metabolic rate after exercise session|Plasma lactate response before, during and after cardiopulmonary exercise testing|Plasma glucose response before, during and after cardiopulmonary exercise testing|Respiratory exchange ratio (RER) collected continuously during cardiopulmonary exercise testing visit|Oxygen consumption (VO2) collected continuously during cardiopulmonary exercise testing visit|Carbon dioxide output (VCO2) collected continuously during cardiopulmonary exercise testing visit|Sleep efficiency assessed by Actigraph GT3x the night before study visits compared to after study visits.|Wake time after sleep onset assessed by Actigraph GT3x the night before study visits compared to after study visits|Energy expenditure assessed by Actigraph GT3x.|Physical activity level assessed by Actigraph GT3x","Steno Diabetes Center Copenhagen","All","13 Years to 17 Years (Child)","Not Applicable","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","MODE2022","November 2022","November 2024","November 2024","November 16, 2022",,"November 16, 2022","Steno Diabetes Center Copenhagen, Herlev, Denmark",,"https://ClinicalTrials.gov/show/NCT05619198" | |
| 513,"NCT05070949","Self-compassion to Reduce Diabetes Distress in Persons With Type 1 Diabetes",,"Not yet recruiting","No Results Available","Type 1 Diabetes","Behavioral: Mindful Self-Compassion","Diabetes distress|Self-compassion|Diabetes Self-efficacy|Hemoglobin A1C|Sleep quality|Stress and depressive symptoms","Mahidol University|Chulalongkorn University","All","18 Years to 30 Years (Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2933","November 1, 2021","April 1, 2024","September 1, 2024","October 7, 2021",,"October 19, 2021","Faculty of Medicine Ramathibodi Hospital, Bangkok, Ratchatewi, Thailand|Faculty of Medicine Chulalongkorn University, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT05070949" | |
| 514,"NCT05217953","Improving HbA1c Levels Through Behavioural Change of Diabetes Self-management Assisted by the LovedBy Mobile Application for Young Adults and Adolescents With Type 1 Diabetes","LBY-T1","Recruiting","No Results Available","Diabetes Mellitus, Type 1","Device: LovedBy App","Change in HbA1c|Time spent below target glucose (3.9 mmol/l)|Time spent above target glucose (10.0 mmol/l)|Average, standard deviation, and coefficient of variation of glucose levels|The time with glucose levels in hypoglycaemia at <3.5 mmol/l and <2.8 mmol/l|The time with glucose levels in significant hyperglycaemia (>16.7 mmol/l)|Total, basal and bolus insulin dose|AUC of glucose below 3.5 mmol/l","Manchester University NHS Foundation Trust|LovedBy LTD","All","16 Years to 25 Years (Child, Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","B01038","June 30, 2022","February 2, 2023","February 2, 2023","February 1, 2022",,"August 5, 2022","Manchester University NHS Foundation Trust, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05217953" | |
| 515,"NCT05546281","Study of the Characteristics of Orthorexia Nervosa in the Population Living With Type 1 Diabetes","Santal-DT1","Not yet recruiting","No Results Available","Type 1 Diabetes","Other: No intervention","Forced food categorization task according to the categories ""healthy / unhealthy""|Stroop Task|Trail Making Test (TMT)|Age|Gender|Weight|Height|Diabetes Information : Age of appearance and duration|Diabetes Information : How insulin is administered|Diabetes Information : Total dose of insulin|Diabetes Information : Duration of diabetes self-monitoring|Diabetes Information : Severe hypoglycemic episodes|Diabetes Information : Diabetes complications|Eating Habit Questionnaire (EHQ)|Ortho-15 Questionnaire|Eating Disorder Examination Questionnaire (EDE-Q)|Type 1 Diabetes Distress Scale (T1-DDS)","Laval University","All","18 Years to 35 Years (Adult)",,"200","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","2023-3914, 22258","October 2022","December 2022","December 2023","September 19, 2022",,"September 26, 2022",,,"https://ClinicalTrials.gov/show/NCT05546281" | |
| 516,"NCT01374854","Umbilical Mesenchymal Stem Cells and Mononuclear Cells Infusion in Type 1 Diabetes Mellitus",,"Unknown status","No Results Available","Type 1 Diabetes Mellitus","Biological: Umbilical mesenchymal stem cell (UC-MSCs) infusion|Drug: traditional therapy","c-peptide area under the curve during OGTT|The incidence and severity of adverse events related to the stem cell infusion procedure|The reduction in fasting blood glucose (FBG)|The increase in basal C-peptide|The reduction in exogenous insulin requirements|Decrease in HbA1c|insulin area under the curve during OGTT","Fuzhou General Hospital","All","18 Years to 40 Years (Adult)","Phase 1|Phase 2","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCMSC-T1DM","January 2009","December 2010","December 2014","June 16, 2011",,"November 20, 2012","Fuzhou General Hospital, Fuzhou, Fujian, China",,"https://ClinicalTrials.gov/show/NCT01374854" | |
| 517,"NCT02677454","Evaluation of a Flash Glucose Monitoring System in Ambulatory Patients With Type 1 Diabetes",,"Completed","No Results Available","Diabetes Mellitus, Type 1|Diabetes Mellitus","Device: Flash Glucose Monitor","Mean Absolute Relative Difference (MARD)|Mean absolute Difference (MAD)|Pearson Correlation Coefficient|Mean absolute relative difference (MARD)|Mean absolute difference MAD|Pearson Correlation|Mean absolute difference (MAD)|questionnaire","Vastra Gotaland Region","All","18 Years to 74 Years (Adult, Older Adult)","Not Applicable","56","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Libre","June 2015","December 2015","April 2016","February 9, 2016",,"November 15, 2016","NU-Hospital Group, Uddevalla, Sweden",,"https://ClinicalTrials.gov/show/NCT02677454" | |
| 518,"NCT05463744","A Study of LY3209590 Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy","QWINT-5","Recruiting","No Results Available","Type 1 Diabetes|Diabetes","Drug: LY3209590|Drug: Insulin Degludec","Change from Baseline in Hemoglobin A1c (HbA1c)|Time in Glucose Range|Nocturnal Hypoglycemia Event Rate|Change from Baseline in Fasting Glucose|Glucose Variability|Basal Insulin Dose|Bolus Insulin Dose|Total Insulin Dose|Rate of Composite Level 2 and 3 Hypoglycemia Events|Change from Baseline in Body Weight|Time in Hypoglycemia Range|Time in Hyperglycemia Range|Change from Baseline in Diabetes Treatment Satisfaction Questionnaire-Status Version (DTSQ)|Change from Baseline in Short Form-36 Version 2 (SF-36 v2) Acute Form Domain Scores","Eli Lilly and Company","All","18 Years and older (Adult, Older Adult)","Phase 3","670","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18263|I8H-MC-BDCY|2021-005892-38","August 12, 2022","September 15, 2023","April 19, 2024","July 19, 2022",,"December 28, 2022","John Muir Physician Network Research Center, Concord, California, United States|Valley Research, Fresno, California, United States|Catalina Research Institute, LLC, Montclair, California, United States|Sansum Diabetes Research Institute, Santa Barbara, California, United States|University Clinical Investigators, Inc., Tustin, California, United States|University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States|Northeast Research Institute (NERI), Fleming Island, Florida, United States|Jellinger and Lerman, MD PA dba The Center for Diabetes and Endocrine Care, Fort Lauderdale, Florida, United States|Suncoast Clinical Research, Inc., New Port Richey, Florida, United States|Hanson Clinical Research Center, Port Charlotte, Florida, United States|East Coast Institute for Research, LLC, Macon, Georgia, United States|East-West Medical Research Institute, Honolulu, Hawaii, United States|Rocky Mountain Clinical Research, Idaho Falls, Idaho, United States|Iowa Diabetes and Endocrinology Research Center, West Des Moines, Iowa, United States|Cotton O'Neil Clinical Research Center, Topeka, Kansas, United States|MedStar Health Research Institute (MedStar Physician Based Research Network), Hyattsville, Maryland, United States|Endocrine and Metabolic Consultants, Rockville, Maryland, United States|Clinvest Research LLC, Springfield, Missouri, United States|Palm Research Center Tenaya, Las Vegas, Nevada, United States|Palm Research Center Sunset, Las Vegas, Nevada, United States|Research Foundation of SUNY - University of Buffalo, Buffalo, New York, United States|NYU Langone Hospital - Long Island, Mineola, New York, United States|NYC Research, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Thomas Jefferson University - Clinical Research Institute, Philadelphia, Pennsylvania, United States|Texas Diabetes & Endocrinology, P.A., Austin, Texas, United States|Velocity Clinical Research, Dallas, Dallas, Texas, United States|North Texas Endocrine Center, Dallas, Texas, United States|Research Institute of Dallas, Dallas, Texas, United States|Biopharma Informatic, LLC, Houston, Texas, United States|Amir A Hassan, MD, PA, Houston, Texas, United States|Southern Endocrinology Associates, Mesquite, Texas, United States|Texas Diabetes & Endocrinology, P.A., Round Rock, Texas, United States|Rainier Clinical Research Center, Renton, Washington, United States|CEDIC, Caba, Buenos Aires, Argentina|Centro de Investigaciones Metabólicas (CINME), Ciudad Autónoma de Buenos Aire, Buenos Aires, Argentina|Consultorio de Investigación Clínica EMO SRL, Ciudad Autonoma de Buenos Aire, Buenos Air, Argentina|CIAD Moron, Moron, Buenos Air, Argentina|Mautalen Salud e Investigación, Buenos Aires, Ciudad Autónoma De Buenos Aire, Argentina|Investigaciones Medicas Imoba Srl, Buenos Aires, Ciudad Autónoma De Buenos Aire, Argentina|Centro Medico Privado CEMAIC, Capital, Córdoba, Argentina|Centro Medico Privado San Vicente Diabetes, Cordoba, Córdoba, Argentina|Centro de Salud e Investigaciones Médicas, Santa Rosa, La Pampa, Argentina|CIPADI - Centro Integral de Prevencion y Atencion en Diabetes, Godoy Cruz, Mendoza, Argentina|Centro de Investigaciones Médicas Tucuman, SAN M. DE Tucuman, Tucumán, Argentina|Clínica Mayo, San Miguel de Tucuman, Tucumán, Argentina|Instituto Médico Especializado (IME), Buenos Aires, Argentina|Centro Diabetológico Dr. Waitman, Córdoba, Argentina|Nirmal Hospital Pvt Ltd., Surat, Gujarat, India|Victoria Hospital, Bangalore Medical College And Research Institute, Bangalore, Karnataka, India|Kumudini Devi Diabetes Research Center, Hyderabad, Telangana, India|Tosaki Clinic for Diabetes and Endocrinology, Nagoya-shi, Aichi, Japan|Yuri Ono Clinic, Sapporo, Hokkaido, Japan|Manda Memorial Hospital, Sapporo, Hokkaido, Japan|MinamiAkatsukaClinic, Mito, Ibaraki, Japan|Nakakinen clinic, Naka, Ibaraki, Japan|Noritake Clinic, Ushiku, Ibaraki, Japan|Takai Internal Medicine Clinic, Kamakura-shi, Kanagawa, Japan|Takatsuki Red Cross Hospital, Takatsuki, Osaka, Japan|Shimizu Clinic Fusa, Saitama-shi, Saitama, Japan|The Institute of Medical Science, Asahi Life Foundation, Chuo-ku, Tokyo, Japan|Hachioji Diabetes Clinic, Hachioji, Tokyo, Japan|Clinic Masae Minami, Fukuoka, Japan|Jinnouchi Hospital, Kumamoto, Japan|Heiwadai Hospital, Miyazaki, Japan|Abe Clinic, Oita, Japan|Gabinety TERPA, Lublin, Lubelskie, Poland|NZOZ Medica, Lublin, Lubelskie, Poland|Centrum Medyczne ""Diabetika"", Radom, Mazowieckie, Poland|NBR Polska, Warszawa, Mazowieckie, Poland|Centralny Szpital Kliniczny MSWiA w Warszawie, Warszawa, Mazowieckie, Poland|Medyczne Centrum Diabetologiczno Endokrynologiczno Metaboliczne DIAB-ENDO-MET, Krakow, Małopolskie, Poland|SN ZOZ Lege Artis Poradnia Diabetologiczna, Bialystok, Podlaskie, Poland|NZOZ Specjalistyczny Ośrodek Internistyczno-Diabetologiczny, Bialystok, Podlaskie, Poland|Centrum Badan Klinicznych PI-House sp. z o.o., Gdansk, Pomorskie, Poland|Private Practice - Dr. Janusz Gumprecht, Zabrze, Śląskie, Poland|Advanced Clinical Research, LLC, Bayamon, Puerto Rico|Mgcendo Llc, San Juan, Puerto Rico|Tatratrial s.r.o., Rožňava, Košický Kraj, Slovakia|FUNKYSTUFF s.r.o., Nove Zamky, Nitriansky Kraj, Slovakia|ENDIAMED s.r.o, Dolny Kubin, Žilinský Kraj, Slovakia|Changhua Christian Hospital, Changhua County, Changhua, Taiwan|Chung Shan Medical University Hospital, Taichung City, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung City, Taichung, Taiwan|Chi Mei Medical Center, Tainan City, Tainan, Taiwan|Taipei Veterans General Hospital, Taipei City, Taipei, Taiwan|National Cheng-Kung Uni. Hosp., Tainan, Taiwan",,"https://ClinicalTrials.gov/show/NCT05463744" | |
| 519,"NCT00223613","Intranasal Insulin for Prevention of Type 1 Diabetes",,"Unknown status","No Results Available","Type 1 Diabetes","Drug: daily intranasal administration of insulin","Development of clinical type 1 diabetes|Number and concentration in serum of diabetes-associated autoantibodies (ICA, IAA, GADA and IA-2A)|Responses to intravenous glucose tolerance test|Possible side effects of therapy including hypoglycemia|Changes in serum metabolite patterns (metabolomics)","University of Turku|Oulu University Hospital|Tampere University|University of Helsinki","All","1 Year to 15 Years (Child)","Phase 3","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention","DIPP19942014|JDRF File # 4-1999-731","August 1997",,"August 2005","September 22, 2005",,"September 19, 2006","Department of Pediatrics, University of Turku, Turku, Finland",,"https://ClinicalTrials.gov/show/NCT00223613" | |
| 520,"NCT01996228","Reversal of Type 1 Diabetes in Children by Stem Cell Educator Therapy",,"Unknown status","No Results Available","Type 1 Diabetes","Device: Stem Cell Educator","Autoimmune control|Metabolic control","Throne Biotechnologies Inc.|Second Xiangya Hospital of Central South University","All","6 Years to 14 Years (Child)","Phase 1|Phase 2","20","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2013-0002","November 2013","October 2019","October 2019","November 27, 2013",,"February 5, 2019","The Second Xiangya Hospital, Changsha, Hunan, China",,"https://ClinicalTrials.gov/show/NCT01996228" | |
| 521,"NCT01341899","Efficacy and Safety Study of Autologous Hematopoietic Stem Cell Transplantation to Treat New Onset Type 1 Diabetes",,"Completed","No Results Available","Type 1 Diabetes","Procedure: immunosuppression and stem cell transplantation","Changes in C-peptide levels during standard-meal tolerance test from baseline to different time points after transplantation|Changes in serum levels of HbA1c from baseline to different time points after transplantation|Temporal changes of exogenous insulin requirement from baseline to different time points after transplantation|Dynamic changes in islet antibody status from baseline to different time points after transplantation|Dynamic changes in lymphocyte immunophenotyping and cytokine profiles from baseline to different time points after transplantation|mortality and dysfunction of other endocrine glands","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","All","8 Years to 35 Years (Child, Adult)","Phase 2","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ZKX07012","June 2006","December 2012","December 2015","April 26, 2011",,"November 1, 2016","at Division of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT01341899" | |
| 522,"NCT04079413","Efficacy and Safety of GP40071 Compared to NovoRapid® Penfill® in Type 1 Diabetes Mellitus Patients",,"Completed","No Results Available","Diabetes|Diabetes Mellitus, Type 1","Drug: GP40071|Drug: NovoRapid® Penfill®","Immunogenicity|Glycated hemoglobin|Adverse Events frequency and degree|Fasting Plasma Glucose Level|Seven-Point Glucose Testing|Total Insulin Dose|Body Mass Index|Treatment Satisfaction|Achievement of Glycated Hemoglobin Goals|Achievement of Glycated Hemoglobin < 7%","Geropharm","All","18 Years to 65 Years (Adult, Older Adult)","Phase 3","264","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GP40071-P4-31","June 3, 2019","January 21, 2020","January 21, 2020","September 6, 2019",,"July 23, 2020","Arkhangelsk Regional Clinical Hospital, Arkhangel'sk, Russian Federation|Kazan Endocrinology Dispensary, Kazan, Russian Federation|Krasnoyarsk State Medical University named after Professor V.F. Voino-Yasenetsky, Krasnoyarsk, Russian Federation|Endocrinology Research Centre (Moscow), Moscow, Russian Federation|Rostov State Medical University, Rostov-on-Don, Russian Federation|Polyclinic Сomplex, Saint Petersburg, Russian Federation|City Diagnostic Center № 1, Saint Petersburg, Russian Federation|City Polyclinic № 117, Saint Petersburg, Russian Federation|EosMed, Saint Petersburg, Russian Federation|Institute of Medical Research, Saint Petersburg, Russian Federation|Almazov National Medical Research Centre, Saint Petersburg, Russian Federation|Pokrovskaya Municipal Hospital, Saint Petersburg, Russian Federation|Diabetes Center, Samara, Russian Federation|Clinical City Hospital № 9, Saratov, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04079413" | |
| 523,"NCT04812782","Dietary Fat and Endothelial Function in Type 1 Diabetes",,"Completed","No Results Available","Type 1 Diabetes","Dietary Supplement: EVOO supplementation|Dietary Supplement: Butter supplementation","Change of Endothelial function from pre meal to post meal period|Serum glucose|Gastric emptying rate","University Magna Graecia","All","18 Years and older (Adult, Older Adult)","Not Applicable","16","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Dietary Fat in Type 1 Diabetes","February 12, 2018","October 16, 2019","October 16, 2019","March 24, 2021",,"March 24, 2021","University Magna Graecia, Catanzaro, Italy",,"https://ClinicalTrials.gov/show/NCT04812782" | |
| 524,"NCT05298735","Pancreatic Calcium Handling in Islet Beta Cells in Patients With Type 1 Diabetes Mellitus","Pancreas MEMRI","Completed","No Results Available","Type 1 Diabetes",,"Pancreatic calcium-handling: Rate of change of pancreatic T1 values with manganese-enhanced magnetic resonance imaging","University of Edinburgh","All","18 Years and older (Adult, Older Adult)",,"35","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","AC20142","March 1, 2021","January 31, 2022","January 31, 2022","March 28, 2022",,"March 28, 2022","University of Edinburgh, Edinburgh, Scotland, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05298735" | |
| 525,"NCT05653050","Closing the Loop in People With Type 1 Diabetes","CLEAR Phase 2","Not yet recruiting","No Results Available","Type 1 Diabetes","Device: CamAPS HX|Device: Standard insulin pump therapy with CGM","Time in target glucose range|Time spent above the target glucose range|Time spent below the target glucose range|Mean glucose|Standard deviation and coefficient of variation of glucose|Time spent in hypoglycaemia|Time spent in hyperglycaemia|HbA1c|Total, basal, and bolus insulin dose","University of Cambridge|Manchester University NHS Foundation Trust|Barts & The London NHS Trust","All","13 Years to 19 Years (Child, Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLEAR Phase 2","January 4, 2023","January 4, 2024","June 1, 2024","December 16, 2022",,"December 16, 2022",,,"https://ClinicalTrials.gov/show/NCT05653050" | |
| 526,"NCT04949867","Dual-Hormone Closed-Loop Glucose Control in Adolescents With Type 1 Diabetes","DHCL2021","Completed","No Results Available","Type 1 Diabetes","Drug: Glucagon|Device: Closed-loop System","Percentage of time with glucose values < 3.9 mmol/l as measured by the continuous glucose monitor|Number of carbohydrate interventions to treat hypoglycemia|Percentage of time with glucose values in the range 3.9-10.0 mmol/l measured by continuous glucose monitor and plasma glucose|Percentage of time with glucose values < 3.9 mmol/l as measured by plasma glucose|Percentage of time with glucose values in the range > 13.9 mmol/l measured by continuous glucose monitor and plasma glucose|Percentage of time with glucose values < 3.0 mmol/l as measured by continuous glucose monitor and plasma glucose|Mean blood glucose value measured by continuous glucose monitor and plasma glucose|Number of hypoglycemic episodes < 3.9 mmol/l on continuous glucose monitor and plasma glucose|Continuous glucose monitored glycemic variability measured as SD|Continuous glucose monitored glycemic variability measured as CV|Composite outcome: Percentage of participants achieving (1) time in range (3.9-10) > 70 %, (2) time in alert hypoglycemia (<3.9 mmol/l) < 4 %, and (3) time in clinical hypoglycemia (<3.0 mmol) < 1% as measured by CGM and YSI|Total insulin dose|Total glucagon dose|Number of manual insulin boluses|Number of adverse events - Nausea|Number of adverse events - Headache|Number of adverse events - Palpitation|Number of vomits|Difference between actual and participant-estimated carbohydrate content in meals|Mean Borg scale|Physical activity intensity measured by ActiGraph GT9X Link|Sleep efficiency measured by ActiGraph GT9X Link","Steno Diabetes Center Copenhagen|Technical University of Denmark|Herlev Hospital","All","13 Years to 17 Years (Child)","Phase 4","11","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","H-21000207|2020-005836-31|2021-0409-34|PD002-19","May 20, 2021","April 26, 2022","April 26, 2022","July 2, 2021",,"August 18, 2022","Steno Diabetes Center Copenhagen, Gentofte, Denmark|Herlev Hospital, Herlev, Denmark","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT04949867/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04949867" | |
| 527,"NCT01834144","The VIGORous Physical Activity for Glycaemic Control in Type 1 Diabetes (VIGOR) Trial","VIGOR","Terminated","Has Results","Type 1 Diabetes","Other: Exercise Training","Time Spent in Hypoglycaemia in the 12-hour Period Following Exercise, Defined as an Interstitial Glucose Reading <4.0mmol/L and Measured by Continuous Glucose Monitor.|Glycaemic Variability, Measured by the Mean Amplitude of Glycaemic Excursions (MAGE), in the 12-hour Period Following Exercise. This is Calculated From the Same Continuous Glucose Monitor Data as the Primary Outcome.","University of Manitoba|Manitoba Institute of Child Health","All","15 Years to 45 Years (Child, Adult)","Not Applicable","4","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","B2012:136","May 2013","June 15, 2015","June 15, 2015","April 17, 2013","September 20, 2018","September 20, 2018","University of Calgary, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|Manitoba Institute of Child Health, WInnipeg, Manitoba, Canada|McMaster University, Hamilton, Ontario, Canada|University of Ottawa, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01834144" | |
| 528,"NCT03999853","Butyrate Adjuvant Therapy for Type 1 Diabetes",,"Recruiting","No Results Available","Type1diabetes","Drug: BKR-017","Insulin sensitivity|Glucose Variability and Triglycerides","Mayo Clinic|BioKier Inc.|Juvenile Diabetes Research Foundation","All","20 Years to 80 Years (Adult, Older Adult)","Phase 1|Phase 2","20","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BIOKIER PROTOCOL CL-301-00","July 28, 2022","September 2023","September 2023","June 27, 2019",,"October 5, 2022","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03999853" | |
| 529,"NCT04124302","The Impact of Two Different Insulin Dose Calculation on Postprandial Glycemia After Mixed Meal.",,"Not yet recruiting","No Results Available","Diabetes Mellitus, Type 1","Drug: Insulin Glulisine|Drug: Insulin Aspart|Drug: Insulin Lispro","Postprandial glycemia|Glucose Area Under the Curve (AUC)|The Difference Between The Maximum and Baseline Glucose Level - mean amplitude of glycaemic excursion (MAGE)|Hypoglycemia Episodes","Medical University of Warsaw","All","10 Years to 18 Years (Child, Adult)","Phase 4","70","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Mixed Meal Bolus","November 2019","August 2021","August 2023","October 11, 2019",,"October 11, 2019",,,"https://ClinicalTrials.gov/show/NCT04124302" | |
| 530,"NCT04807374","Hybrid Closed Loop in High Risk Youth With Type 1 Diabetes",,"Recruiting","No Results Available","Type 1 Diabetes","Device: Control IQ","Change in CGM Time in Range (TIR)|Changes in mean CGM glucose|Changes in glycemic management indicator (GMI)|Changes in coefficient of variation of mean glucose|Changes in CGM time in hypoglycemia (<70 mg/dL)|Changes in CGM time in hyperglycemia (>180 mg/dL)|Glycemic control as measured by hemoglobin A1c|Incidence of diabetic ketoacidosis (DKA)|Incidence of severe hypoglycemia|Incidence of emergency department visits and hospital admissions|Changes in youth perceptions of diabetes-specific quality of life|Changes in youth perceptions of diabetes distress|Changes in youth perceptions of automated insulin delivery systems|Changes in youth perceptions diabetes self-management|Changes in youth attitudes about diabetes technologies|Changes in parental perceptions of the youth's diabetes-specific quality of life|Changes in parental perceptions of the youth's diabetes distress|Changes in parental perceptions of the youth's perceptions of automated insulin delivery systems|Changes in parental perceptions of the youth's diabetes management|Changes in parental perceptions of the youth's attitudes about diabetes technologies|Semi-structured interviews with youth and parents exploring the overall experience and barriers to expanding access to hybrid closed loop technology","Children's National Research Institute|Tandem Diabetes Care, Inc.|DexCom, Inc.","All","6 Years to 21 Years (Child, Adult)","Not Applicable","30","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00013963","June 1, 2021","March 22, 2023","June 22, 2023","March 19, 2021",,"September 6, 2022","Children's National, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT04807374" | |
| 531,"NCT00784966","Islet After Kidney Transplant for Type 1 Diabetes",,"Withdrawn","No Results Available","Type 1 Diabetes Mellitus","Drug: etanercept","The functional capability of the islet allograft to normalize glucose metabolism in the absence of insulin therapy.|Reduction in insulin requirements in those patients who do not achieve insulin independence with improved metabolic control.","Virginia Commonwealth University|University of Miami","All","18 Years to 60 Years (Adult)","Phase 1|Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VCU IRB 4196","August 2011","September 2015","September 2017","November 5, 2008",,"September 16, 2014","Virginia Commonwealth University Health System, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00784966" | |
| 532,"NCT04073914","Type 1 Teamwork: A Tool for Parents of Adolescents With Type 1 Diabetes","Type1","Completed","No Results Available","Type1diabetes|Type1 Diabetes Mellitus","Behavioral: Type 1 Teamwork Program","Change in Parent Stress using the Perceived Stress Scale (PSS)","HealthCore-NERI|Yale University","All","Child, Adult, Older Adult","Not Applicable","158","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","5R44DK098857","June 29, 2017","March 26, 2018","March 26, 2018","August 29, 2019",,"August 29, 2019","Yale University, New Haven, Connecticut, United States|New England Research Institutes, Watertown, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04073914" | |
| 533,"NCT04847778","Assess the Impact of Insulclock on Glycemic Variability and Treatment Compliance in Uncontrolled DM1 Patients","Segoclock2","Completed","No Results Available","Diabetes Mellitus, Type 1","Device: Use of Insulclock system, both Insulclock device and Insulclock 360 app.|Device: Use of Insulclock system, both Insulclock device and Insulclock app on masked mode.","Change in ""Time In Range"" (TIR)|Number of daily insulin injections irregularities|Change in Mean glucose|Change in Diabetes Treatment Satisfaction Questionnaire (DTSQc-change) Score.|Change in Insulin Treatment Satisfaction Questionnaire (ITSQ-change) Score.","Hospital General de Segovia|Insulcloud S.L.","All","14 Years to 80 Years (Child, Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","INSULCLOCK2018","March 1, 2021","June 30, 2021","July 31, 2021","April 19, 2021",,"March 11, 2022","Endocrinology and Nutrition Unit, Arquitecto Marcide Hospital, Ferrol, A Coruña, Spain|Endocrinology and Nutrition Service, Hospital de Cruces., Bilbao, Spain|Endocrinology and Nutrition Service, Hospital Central de Asturias, Oviedo, Spain|Endocrinology and Nutrition Unit /Diabetes Unit, Hospital General de Segovia, Segovia, Spain","""Study Protocol and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT04847778/Prot_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04847778" | |
| 534,"NCT05203640","Effects of Resistance Exercise on Blood Glucose in Post-menopausal Women With Type 1 Diabetes",,"Recruiting","No Results Available","Type 1 Diabetes","Behavioral: High repetition (HI)|Behavioral: Moderate repetition (MOD)","Blood glucose|Mean continuous glucose monitoring (CGM) glucose|coefficient of variation (CV)|standard deviation (SD)|frequency of hypoglycemia|frequency of hyperglycemia|percent time in range|percent time in hypoglycemia|percent time in hyperglycemia|carbohydrate supplementation","University of Alberta","Female","45 Years to 75 Years (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00112972","April 1, 2022","December 30, 2022","June 30, 2023","January 24, 2022",,"April 4, 2022","Alberta Diabetes Institute, Edmonton, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT05203640" | |
| 535,"NCT05201846","Comparison of CSII and MDI in Pediatric Patients With Type 1 Diabetes",,"Recruiting","No Results Available","Type 1 Diabetes","Device: DIA:CONN G8 insulin pump|Other: Multiple daily insulin injection","Time in range|Time above range|Time below range|Mean sensor glucose|Coefficient of variation|Glucose management indicator|Glycated albumin|Quality of life measurements (general) of patients and parents|Quality of life measurements (diabetes-specific) of patients and parents|Children's Depression inventory of patients|Perceived stress scale of parents","Seoul National University Hospital","All","2 Years to 17 Years (Child)","Not Applicable","66","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","21111431275","January 18, 2022","March 31, 2023","March 31, 2023","January 21, 2022",,"March 3, 2022","Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT05201846" | |
| 536,"NCT05610722","Use of Insulin Adjustment Device DreaMed Endo Digital During Routine Clinical Use for Subjects With Diabetes Type 1","Endo digital","Not yet recruiting","No Results Available","Type 1 Diabetes","Device: DreaMed Endo Digital","HbA1c|Percentage of sensor readings below 54 mg/dl","Rabin Medical Center|DreaMed Diabetes","All","6 Years to 30 Years (Child, Adult)","Not Applicable","500","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RMC057522CTIL","November 6, 2022","November 1, 2024","November 1, 2024","November 9, 2022",,"November 9, 2022","schneider children medical center of Israel, Petach Tikva, Israel",,"https://ClinicalTrials.gov/show/NCT05610722" | |
| 537,"NCT00141986","Feasibility Study of 2000 IU Per Day of Vitamin D for the Primary Prevention of Type 1 Diabetes",,"Completed","No Results Available","Type 1 Diabetes","Dietary Supplement: vitamin D3","change in 25(OH)D from baseline|renal ultrasound|bone densitometry|diabetes autoantibody levels|recruitment and retention rates|Change from baseline in serum calcium levels|changes in urine calcium:creatinine ratio","Canadian Diabetes Association|Manitoba Medical Service Foundation|Manitoba Institute of Child Health|The Health Sciences Centre Medical Staff Council","All","up to 4 Weeks (Child)","Phase 1","9","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","1622","November 2003","March 2007","March 2007","September 2, 2005",,"April 26, 2011","Manitoba Institute of Child Health, Winnipeg, Manitoba, Canada",,"https://ClinicalTrials.gov/show/NCT00141986" | |
| 538,"NCT02488616","Closed-loop Control of Glucose Levels (Artificial Pancreas) for 5 Days in Adults With Type 1 Diabetes",,"Withdrawn","No Results Available","Type 1 Diabetes","Other: 5-day intervention with single-hormone closed-loop strategy|Other: 5-day intervention with sensor-augmented pump therapy|Device: Insulin pump|Device: Continuous glucose monitoring system|Drug: Insulin","Percentage of time of glucose levels spent between 3.9 and 10.0 mmol/L|Percentage of time of glucose levels spent between 3.9 and 7.8 mmol/L|Percentage of time of glucose levels spent below 3.9 mmol/L|Percentage of time of glucose levels spent below 3.3 mmol/L|Percentage of time of glucose levels spent below 2.8 mmol/L|Percentage of time of glucose levels spent above 10 mmol/L|Percentage of time of glucose levels spent above 13.9 mmol/L|Percentage of time of glucose levels spent above 16.7 mmol/L|Percentage of time of overnight glucose levels spent below 3.9 mmol/L|Percentage of time of overnight glucose levels spent between 3.9 and 7.8 mmol/L|Percentage of time of overnight glucose levels spent between 3.9 and 10.0 mmol/L|Percentage of time of overnight glucose levels spent below 3.3 mmol/L|Percentage of time of overnight glucose levels spent below 2.8 mmol/L|Percentage of time of overnight glucose levels spent above 10 mmol/L|Percentage of time of overnight glucose levels spent above 13.9 mmol/L|Percentage of time of overnight glucose levels spent above 16.7 mmol/L|Area under the curve of glucose levels below 3.9 mmol/L|Area under the curve of glucose levels below 3.3 mmol/L|Area under the curve of glucose levels below 2.8 mmol/L|Area under the curve of glucose levels above 10 mmol/L|Area under the curve of glucose levels above 13.9 mmol/L|Area under the curve of glucose levels above 16.7 mmol/L|Area under the curve of overnight glucose levels below 3.9 mmol/L|Area under the curve of overnight glucose levels below 3.3 mmol/L|Area under the curve of overnight glucose levels below 2.8 mmol/L|Area under the curve of overnight glucose levels above 10 mmol/L|Area under the curve of overnight glucose levels above 13.9 mmol/L|Area under the curve of overnight glucose levels above 16.7 mmol/L|Mean glucose levels|Standard deviation of glucose levels|Standard deviation of insulin delivery|Coefficient of variance of glucose levels|Coefficient of variance of insulin delivery|Between-day variability in glucose levels|Between-day variability in insulin delivery|Total insulin delivery|Percentage of time of closed-loop operation|Percentage of time of glucose sensor availability|Time between failures|Number of hypoglycemic events less than 3.1 mmol/L|Number of nights with hypoglycemic events less than 3.1 mmol/L|Number of days with hypoglycemic events less than 3.1 mmol/L","Institut de Recherches Cliniques de Montreal","All","18 Years and older (Adult, Older Adult)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLASS-11","March 2018","November 2018","November 2018","July 2, 2015",,"January 31, 2018","Institut de recherches cliniques de Montréal, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02488616" | |
| 539,"NCT05508061","Ultrarapid Insulin Administered by a Bihormonal Closed Loop System in Patients With Type 1 Diabetes","FAST 1","Recruiting","No Results Available","Type 1 Diabetes","Drug: Insulin Lispro Cartridge [Lyumjev]|Drug: Insulin Lispro Cartridge","Percentage of time the glucose level is above 10 mmol/l for the study participants|Safety parameters|Pharmacodynamic parameters: euglycemia|Pharmacodynamic parameters: hypoglycemia|Pharmacodynamic parameters: median glucose value|Pharmacodynamic parameters: standard deviation of glucose value|Pharmacodynamic parameters: mean glucose value|Pharmacodynamic parameters: glycemic variability (CoV)|Pharmacodynamic parameters: glycemic variability (IQR)|AP-related parameters: insulin usage|AP-related parameters: glucagon usage|AP-related parameters: algorithm activity","Inreda Diabetic B.V.","All","18 Years to 75 Years (Adult, Older Adult)","Not Applicable","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NL79588.091.22","October 19, 2022","December 30, 2022","December 30, 2022","August 19, 2022",,"November 25, 2022","Rijnstate Hospital, Arnhem, Gelderland, Netherlands|Slingeland Hospital, Doetinchem, Gelderland, Netherlands|Hospital Gelderse Vallei, Ede, Gelderland, Netherlands",,"https://ClinicalTrials.gov/show/NCT05508061" | |
| 540,"NCT05434559","Evaluation of Glycemic Control in Adults With Type 1 Diabetes When Switching to Insulin Degludec","GLADE","Completed","No Results Available","Type 1 Diabetes","Drug: Insulin Degludec","Time in range|HbA1c|Time below 54 mg/dL|Time below 70 mg/dL|Time above 180 mg/dL|Time above 250 mg/dL|Mean glucose|Glycemic variability|Insulin dose|Body mass index","prof dr Pieter Gillard|University Hospital, Antwerp|Universitaire Ziekenhuizen KU Leuven","All","18 Years and older (Adult, Older Adult)",,"475","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","S66239","February 20, 2022","October 31, 2022","October 31, 2022","June 28, 2022",,"December 21, 2022","Universitaire Ziekenhuizen Leuven, Leuven, Belgium|University Hospital Antwerp, Wilrijk, Belgium",,"https://ClinicalTrials.gov/show/NCT05434559" | |
| 541,"NCT03394352","Exercise Activity-Based Bolus Decisions in Type 1 Diabetes",,"Completed","No Results Available","Type 1 Diabetes Mellitus","Other: Activity on Board|Other: Usual Diabetes Care","Continuous Glucose Monitor metrics","University of Virginia|DexCom, Inc.|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 65 Years (Adult, Older Adult)","Not Applicable","15","Other|Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","20319|DP3DK106826","January 17, 2018","May 11, 2018","May 11, 2018","January 9, 2018",,"May 23, 2018","University of Virginia Center for Diabetes Technology, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03394352" | |
| 542,"NCT03182322","PINIT Study: Primary Intranasal Insulin Trial",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: intranasal insulin|Other: Placebo","The activation of an immune response (antibody or CD4+ T cell) against insulin.","Technical University of Munich|Technische Universität Dresden|Ludwig-Maximilians - University of Munich|Helmholtz Zentrum München|University Hospital Carl Gustav Carus","All","1 Year to 7 Years (Child)","Phase 2","38","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","808040015","May 25, 2018","June 7, 2021","June 7, 2021","June 9, 2017",,"June 22, 2021","Klinik und Poliklinik für Kinder und Jugendmedizin, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, 01307 Dresden, Germany, Dresden, Germany|Forschergruppe Diabetes, Klinikum rechts der Isar, Technische Universität München, Lehrstuhl für Diabetes und Gestationsdiabetes der Technischen Universität München, München, Germany",,"https://ClinicalTrials.gov/show/NCT03182322" | |
| 543,"NCT05168488","Repeatability of Blood Glucose Responses to Resistance Exercise in Type 1 Diabetes",,"Recruiting","No Results Available","Type 1 Diabetes","Behavioral: Fasted morning resistance exercise|Behavioral: Afternoon resistance exercise","Capillary glucose (change during exercise)|Mean CGM glucose|CGM coefficient of variation (CV)|CGM standard deviation (SD)|frequency of hypoglycemia|frequency of hyperglycemia|percent time in range|percent time in hyperglycemia|percent time in hypoglycemia","University of Alberta|DexCom, Inc.","All","18 Years to 55 Years (Adult)","Not Applicable","15","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","Pro00082031","November 16, 2021","December 16, 2022","February 28, 2023","December 23, 2021",,"January 26, 2022","Alberta Diabetes Institute, Edmonton, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT05168488" | |
| 544,"NCT00117026","Effects of Vitamin B1 in Type 1 Diabetic Patients",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: Placebo|Drug: Benfotiamine","Lower-limb nerve conduction velocity|Serum advanced glycation end products (AGEs) and markers of inflammation (CRP, IL-6, VCAM-1)","University Hospital, Aker|The Research Council of Norway|Oslo University Hospital","All","18 Years to 60 Years (Adult)","Phase 1|Phase 2","67","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","AkerU","August 2005","June 2010","February 2011","July 4, 2005",,"May 10, 2013","Aker University Hospital, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT00117026" | |
| 545,"NCT04135365","Pediatric Type 1 Diabetes and Neurocognitive Complications Cohort Study",,"Completed","No Results Available","Type 1 Diabetes","Behavioral: neurocognitive assessment|Behavioral: neuroimaging assessment","Cognitive Function: Full-scale IQ|Cognitive Function: Executive Function|Cognitive Function: Behavior Rating Inventory of Executive Function, Second Edition|Imaging","Vanderbilt University Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","6 Years to 11 Years (Child)",,"12","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","T1DCohortStudy|1U34DK123895-01","January 18, 2021","October 31, 2022","October 31, 2022","October 22, 2019",,"November 1, 2022","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04135365" | |
| 546,"NCT05574023","Effect of CGM With Predictive Alarm on Hypoglycemia in Young Patients With T1D.","CGMHYPO","Completed","No Results Available","Type 1 Diabetes","Device: Use of Predictive Alarm for hypoglycaemia or hyperglycaemia|Device: Use of Alarm on Threshold for hypoglycaemia or hyperglycaemia","Less time spent in hypoglycaemia using Predictive Alarm vs Alarm on Threshold|Better glycemic metrics using Predictive Alarm vs Alarm on Threshold","Azienda Ospedaliera Universitaria Integrata Verona","All","12 Years to 17 Years (Child)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3142CESC","May 10, 2021","March 28, 2022","June 10, 2022","October 10, 2022",,"October 10, 2022","Pediatric Diabetes and Metabolic Disorders Unit, Surgery, Dentistry, Paediatrics and Gynaecology, University of Verona, 1 Piazzale Stefani, Verona, Italy",,"https://ClinicalTrials.gov/show/NCT05574023" | |
| 547,"NCT04124211","Fecal Microbiome Transplantation (FMT) for Type 1 Diabetes",,"Unknown status","No Results Available","Type 1 Diabetes","Biological: Fecal Microbiota Transplantation (FMT)","Changes in mean amplitude of glycemic excursion (MAGE)|Changes in standard deviation of blood glucose (SDBG)|Changes in hemoglobin A1c (HbA1c)|Safety of FMT|Changes in 24h mean blood glucose(MBG)|Changes in percentage of time of blood glucose(PT)|Changes in mean absolute glucose(MAG)|Changes in standard deviation of blood glucose(SDBG)|Changes in coefficient of variation(CV)|Changes in high blood glucose index(HBGI)|Changes in low blood glucose index(LBGI)|Changes in effective blood glucose fluctuations in frequency(NGE)|Changes in glycated albumin (GA)|Changes of serum C-peptide (fasting, 30min after meal, 120min after meal)|Assessment of diabetes antibodies|Changes in intestinal microbiome profile|Changes in Peripheral Blood Stem Cell (PBMC)|Changes in body weight to calculate body mass index (BMI)|Pathological changes of intestinal mucosa|Changes in blood pressure|Changes in oral mucosal bacteria colonization|Changes in urine microalbumin|Blood chemistry panel","The Third Affiliated Hospital of Southern Medical University|Southern Medical University, China","All","18 Years to 65 Years (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NYSY-NFM|2018-lunshen-017","August 25, 2019","March 10, 2020","March 10, 2020","October 11, 2019",,"October 11, 2019","The third affiliated hospital of Southern Medical University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04124211" | |
| 548,"NCT05437913","Protocol for Self-Compassion Intervention for Teens With Diabetes Type 1 and Their Caregivers","SWEET","Active, not recruiting","No Results Available","Diabetes type1","Other: Psychological intervention (self-compassion based)","Change in Self-report psychological variables: depression (caregivers )|Change in Self-report psychological variables: depression ( teens)|Change in Self-report psychological variables: self-compassion (caregivers)|Change in Self-report psychological variables: self-compassion (teens)|change in Self-report psychological variables: self-criticism (caregivers)|Change in Self-report psychological variables: self-criticism (teens)|Change in Self-report psychological variables: self care (caregivers)|Change in Self-report psychological variables: self care (teens)|Change in Self-report psychological variables: interoceptive awareness (caregivers)|Change in Self-report psychological variables: interoceptive awareness (teens)|change in metabolic outcome 1 (only teens)|change in metabolic outcome 2 (only teens)|Change in Self-report diabetes-related variables: diabetes-specific emotional distress (caregivers)|Change in Self-report diabetes-related variables: diabetes-specific emotional distress (teens)|Change in Self-report diabetes-related variables: the diabetes family conflict scale (caregivers)|Change in Self-report diabetes-related variables: the diabetes family conflict scale (teens)|Change in Self-report diabetes-related variables: parental report on teen's health-related quality of life|Change in observational behavioural variable (caregiver-teen dyad)|Change in ecological momentary assessment: affect (caregivers)|Change in ecological momentary assessment: affect (teens)|Change in ecological momentary assessment self kindness (caregivers )|Change in ecological momentary assessment self kindness (teens)|Change in ecological momentary assessment: self criticism (caregivers)|Change in ecological momentary assessment: self criticism (teens)|Change in ecological momentary assessment: triggering event (caregivers)|Change in ecological momentary assessment: triggering event (teens)|Change in ecological momentary assessment: emotion regulation (caregivers )|Change in ecological momentary assessment: emotion regulation (teens)|change in ecological momentary assessment: positive impact on caregiver-teen interactions (caregivers and teens)|change in ecological momentary assessment: negative impact on caregiver-teen interactions (caregivers and teens)|Practice frequency|Possible adverse effects","University of Valencia","All","12 Years to 15 Years (Child)","Not Applicable","8","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","SWEET2021","September 6, 2021","March 15, 2022","September 15, 2022","June 29, 2022",,"June 29, 2022","University of Valencia, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT05437913" | |
| 549,"NCT05319600","Technology-delivered Physical Activity Program for Adolescents With Type 1 Diabetes","Activate","Recruiting","No Results Available","Type 1 Diabetes","Behavioral: Diabetes behavior change skills training|Behavioral: Physical activity promotion program","Change from Baseline in Coping Skills Assessed by the Coping Self-Efficacy Scale|Change from Baseline in Goal Setting Assessed by Goal-Directed Planning|Change from Baseline in Physical Activity|Change from Baseline in Self-Regulation Assessed by The Functional Assessment of Maladaptive Behaviors|Change from Baseline in Self-Regulation Assessed by the Diabetes Habit Strength (DHS) Measure|Change from Baseline in Self-Regulation Assessed by the Self Care Inventory (SCI)|Change from Baseline in Self-Regulation Assessed by the Effortful Control Scale Short|Change from Baseline in Self-Regulation Assessed by the Delay Discounting Task|Change from Baseline in Diet and Physical Activity Habit Strength Assessed by the Eating and Activity Behavioral Automaticity Scale (EABA)|Change from Baseline in Distress Assessed by the Patient Health Questionnaire for Adolescents (PHQ-A)|Change from Baseline in Distress Assessed by the Pediatric Symptom Checklist (PSC-17)|Change from Baseline in Distress Assessed by the Motivation and Energy Inventory (MEI)|Change from Baseline in Distress Assessed by the Perceived Stress Scale (PSS)|Change from Baseline in Distress Assessed by the Diabetes Stress Questionnaire - Short Form (DSQ)|Change from Baseline in Distress Assessed by the Type 1 Diabetes Quality of Life (T1DAL) Measure|Change from Baseline in Inflammation Assessed by C-Reactive Protein|Change from Baseline in Glycosylated Hemoglobin (HbA1c) Percentage|Change from Baseline in Mean Daily Blood Glucose (MBG)|Change from Baseline in Mean Variability in Blood Glucose|Change from Baseline in Cardiovascular Disease Risk Score Assessed by Weight|Change from Baseline in Cardiovascular Disease Risk Score Assessed by Blood Pressure|Change from Baseline in Cardiovascular Disease Risk Score Assessed by Diet|Change from Baseline in Cardiovascular Disease Risk Score Assessed by Physical Activity|Change from Baseline in Cardiovascular Disease Risk Score Assessed by Blood Sugar|Change from Baseline in Cardiovascular Disease Risk Score Assessed by Total Cholesterol|Change in insulin requirements","University of Vermont","All","13 Years to 17 Years (Child)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00001482","March 23, 2022","July 2023","December 2023","April 8, 2022",,"April 8, 2022","University of Vermont, Burlington, Vermont, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT05319600/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT05319600" | |
| 550,"NCT01713023","Fructose and Glucose and TAS1R2 in Type 1 Diabetes","TAS1R2","Completed","No Results Available","Type 1 Diabetes","Dietary Supplement: Glucose|Dietary Supplement: Fructose","Compare the effects of fructose and glucose and TAS1R2 in postprandial metabolism of individuals with type 1 diabetes|Effect of fructose or glucose on blood glucose|Effect of fructose or glucose on triglycerides levels|Effect of fructose or glucose on uric acid, pyruvic acid, and lactate|Effect of fructose or glucose on oxidative stress|Effect of two polymorphisms in the gene TAS1R2 in the sweet taste perception|Effect of fructose or glucose on appetite and palatability|Effect of fructose or glucose on glucagon levels|Effect of fructose or glucose on leptin levels","Universidade Federal do Rio de Janeiro|Rio de Janeiro State Research Supporting Foundation (FAPERJ)","All","18 Years to 50 Years (Adult)","Not Applicable","16","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research","Debora-TAS1R2|CEP-151/2011","March 2013","December 2014","January 2016","October 24, 2012",,"April 15, 2016","University Hospital of Rio de Janeiro, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil",,"https://ClinicalTrials.gov/show/NCT01713023" | |
| 551,"NCT03369821","EXtremely Early-onset Type 1 Diabetes EXtremely Early-onset Type 1 Diabetes (A Musketeers' Memorandum Study)","EXE-T1D","Recruiting","No Results Available","Type1 Diabetes Mellitus","Diagnostic Test: Beta Cell Loss and Immune Function|Other: Immune Function with RNAseq","Measure beta cell function in EET1D compared to T1D, NDM and non-diabetic controls.|Immune phenotyping in EET1D compared to T1D, NDM and non-diabetic controls.|Difference in immune gene expression|Association of maternal and paternal non-inherited HLA alleles with EET1D","University of Exeter|Royal Devon and Exeter NHS Foundation Trust|King's College London|City of Hope National Medical Center|Benaroya Research Institute","All","up to 70 Years (Child, Adult, Older Adult)",,"240","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","CRF 228|17/EM/0255|1617/023|1706443|228082|50793","September 1, 2017","November 30, 2024","March 31, 2025","December 12, 2017",,"June 6, 2022","Diabetes and Metabolism Institute, Hope, California, United States|Benaroya Research Institute, Seattle, Washington, United States|Royal Devon & Exeter NHS Foundation Trust, Exeter, Devon, United Kingdom|King's College London, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03369821" | |
| 552,"NCT05270343","Early High-Dose Vitamin D and Residual β-Cell Function in Pediatric Type 1 Diabetes",,"Not yet recruiting","No Results Available","Type 1 Diabetes","Drug: Cholecalciferol (Vit D3) 400Unit Cap","Residual β-Cell function (RBCF)|Glycemic control (HbA1c)|Glycemic control (free blood glucose)|Glycemic control (postprandial blood glucose)|Islet Function (stimulated C-peptide)|Daily Insulin Dosage","Shanghai Jiao Tong University School of Medicine","All","3 Years to 18 Years (Child, Adult)","Phase 3","198","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","YZhang","June 1, 2022","January 1, 2023","December 30, 2024","March 8, 2022",,"May 23, 2022","Department of Pediatrics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05270343" | |
| 553,"NCT05413239","Healthy And Positive Pathways for Young People With Type 1 Diabetes (HAPPY T1D)",,"Recruiting","No Results Available","Type 1 Diabetes","Behavioral: Psychoeducation to reduce diabetes distress and improve glycemic outcomes","Time in Range (TIR)|A1c|Diabetes distress|Attitudes toward diabetes device use","Joslin Diabetes Center|Stanford University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","14 Years to 25 Years (Child, Adult)","Not Applicable","180","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","STUDY00000154|R01DK129479","July 26, 2022","May 2024","May 2025","June 9, 2022",,"July 29, 2022","Stanford University, Palo Alto, California, United States|Joslin Diabetes Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT05413239" | |
| 554,"NCT03423589","Modulation of Type 1 Diabetes Susceptibility Through the Use of Probiotics",,"Completed","No Results Available","Type1diabetes|Type1 Diabetes Mellitus","Dietary Supplement: VSL#3","Alterations in Plasma-Induced Transcriptional Analysis|Intestinal Microbiota","Medical College of Wisconsin","All","5 Years to 17 Years (Child)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","1171017","April 23, 2018","December 18, 2018","December 31, 2018","February 6, 2018",,"November 30, 2021","Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03423589" | |
| 555,"NCT05653518","Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes","WBH002","Not yet recruiting","No Results Available","Type 1 Diabetes","Device: Tandem t:slim X2 with Control-IQ Technology|Device: Sensor augmented pump (SAP) therapy","Glucose Time-in-Range|High-sensitivity C-reactive protein (hs-CRP)|TNF-alpha|Interleukin-6 (IL-6)|E-selectin|Intracellular adhesion molecule 1 (ICAM-1)|Malondialdehyde (MDA)|Asymmetric Dimethylarginine (ADMA)","University of Virginia","All","18 Years to 40 Years (Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","220180|941481|3-SRA-2023-1236-M-B","January 15, 2023","November 30, 2025","November 30, 2025","December 16, 2022",,"December 20, 2022",,,"https://ClinicalTrials.gov/show/NCT05653518" | |
| 556,"NCT04288063","Skeletal Muscle Health in Children With Type 1 Diabetes",,"Active, not recruiting","No Results Available","Type 1 Diabetes",,"Change in muscle mass as measured by D3 creatinine dilution method|Physical Activity|Endurance|Muscle Strength","Duke University","All","6 Years to 11 Years (Child)",,"29","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Pro00104288","September 18, 2020","October 31, 2022","January 2023","February 27, 2020",,"December 21, 2022","Duke University, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04288063" | |
| 557,"NCT04950634","Sexual Dimorphism in Cardiovascular Autonomic Neuropathy in Patients With Type 1 Diabetes",,"Recruiting","No Results Available","type1diabetes",,"To address sexual dimorphism in the prevalence of CAN in patients with T1D.|To address sexual dimorphism in subclinical atherosclerosis in patients with T1D.|To assess the role of sex on the progression of cardiovascular dysautonomy in patients with T1D.|To assess the role of sex on the progression of subclinical atherosclerosis in patients with T1D.|To identify the influence of sex steroids on the evolution of cardiac autonomic dysfunction.|To identify the influence of sex steroids on the evolution of subclinical atherosclerosis|To identify novel circulating markers of CAN|To identify novel circulating markers of subclinical atherosclerosis","Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal","All","18 Years and older (Adult, Older Adult)",,"320","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","189/17","September 1, 2018","December 2025","December 2025","July 6, 2021",,"June 28, 2022","Lía Nattero Chávez, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04950634" | |
| 558,"NCT04545567","Fully Automated Closed Loop Control in Adolescents With Type 1 Diabetes","RocketAP","Completed","Has Results","Type 1 Diabetes","Device: RocketAP|Device: USS Virginia","Percentage of Time From Dinner Time Until Midnight With Blood Glucose in Range 70-180 mg/dL in the Unannounced Meal|Number of Hypoglycemia Events From Dinner Time Until Midnight|Percentage of Time From Dinner Time Until Midnight With Blood Glucose in Range < 70 mg/dL|Percentage of Time From Dinner Time Until Midnight With Blood Glucose in Range >180 mg/dL|Percentage of Time From Dinner Time Until Midnight With Blood Glucose in Range >250 mg/dL|Units of Insulin Injected From Dinner Time Until Midnight|The Blood Glucose Area Under the Curve (AUC) From Dinner Until Midnight, Accounting for the Initial Blood Glucose Value|Percentage of Time From Dinner Time Until Dinner Time + 12h With Blood Glucose in Range 70-180 mg/dL|Number of Hypoglycemia Events From Dinner Time Until Dinner Time + 12h|Percentage of Time From Dinner Time Until Dinner Time + 12h With Blood Glucose in Range <70 mg/dL|Percentage of Time From Dinner Time Until Dinner Time + 12h With Blood Glucose >180 mg/dL|Percentage of Time From Dinner Time Until Dinner Time + 12h With Blood Glucose >250 mg/dL|Units of Insulin Injected From Dinner Time Until Dinner Time + 12h|The Blood Glucose Area Under the Curve (AUC) From Dinner Until Dinner + 12h, Accounting for the Initial Blood Glucose Value|Percentage of Time Outside the Dinner Sessions With Blood Glucose in Range 70-180 mg/dL|Number of Hypoglycemia Events Outside of the Study Dinner Sessions|Percentage of Time Outside of the Study Dinner Sessions With Blood Glucose <70 mg/dL|Percent of Time Outside of the Study Dinner Sessions With Blood Glucose >180 mg/dL|Percent Time Outside of the Study Dinner Sessions With Blood Glucose >250 mg/dL|Units of Insulin Injected Outside of the Study Dinner Sessions","University of Virginia","All","12 Years to 25 Years (Child, Adult)","Not Applicable","21","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","200235","December 16, 2020","January 18, 2021","January 21, 2021","September 11, 2020","March 31, 2022","April 20, 2022","University of Virginia Center for Diabetes Technology, Charlottesville, Virginia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT04545567/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT04545567/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT04545567" | |
| 559,"NCT05487534","Do ""Sugar Swings"" Impact the Brain Function and the Eating Behaviors of People With Type 1 Diabetes",,"Not yet recruiting","No Results Available","Type 1 Diabetes","Other: Observational","Eating Disorder examination (EDE-Q)|Glucose variability and insulin resistance (CGMS - 10 days)|Distress Diabetes Scale (T1-DDS)|Diabetes Behavior Ratting Scale (DBRS)|Generalized Anxiety Disorder (GAD-7)|Patient Health Questionnaire (PHQ-9)|Diabetes Numeracy Test (DNT-15)|Physical and psychological comorbidities|Diabetes Information : Duration|Diabetes Information : Modality of insulin delivery|Diabetes Information : Total daily insulin dose|Diabetes Information : Duration of diabetes self-monitoring|Diabetes Information : Severe hypoglycemic episodes|Diabetes Information : Medication|Diabetes Information : Diabetes complications|Diabetes Information : Coefficient of variation|Anthropometric markers : BMI|Anthropometric markers : Waist, hips and neck circumferences|Biological information : Cholesterol and triglycerides|Biological information : Fasting blood glucose|Biological information : C-peptide|Biological information : Triglycerides|Biological information : Ghrelin fasting and C-Reactive protein (CRP)|Detail and Flexibility Questionnaire (DFQ)|Adult ADHD Self-Report Scale (ASRS)|Category Switch Task|Multidimensional Assessment of Interoceptive Awareness Version 2 (MAIA)|Binge Eating Scale (BES)|Tower of London Task|Stop Signal Task|5-Trial Adjusting Delay Discounting|Short UPPS-P Impulsive Behavior Scale|Modified Yale Food Addiction Scale 2.0 (mYFAS 2.0)|Emotional Go/No-Go Task|Attentional Cueing Procedure","Laval University|CHU de Quebec-Universite Laval|Institut de Recherches Cliniques de Montreal|Centre d'expertise Poids, Image et Alimentation (CEPIA)|Institut universitaire de cardiologie et de pneumologie de Québec, University Laval","All","18 Years to 65 Years (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","MP-20-2023-6466","September 2022","September 2025","September 2025","August 4, 2022",,"August 4, 2022",,,"https://ClinicalTrials.gov/show/NCT05487534" | |
| 560,"NCT01939834","Early Feasibility Study of Adaptive Advisory/Automated (AAA) Control of Type 1 Diabetes",,"Terminated","No Results Available","Type 1 Diabetes Mellitus","Device: AAA control|Other: CGM + insulin pump at home","Evaluating the risk for hypoglycemia as measured by the Low Blood Glucose Index|Time in range overnight|Time within target range","Sue Brown|DexCom, Inc.|Roche Diagnostics|University of Virginia","All","21 Years to 64 Years (Adult)","Not Applicable","6","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","16930","December 2013","January 2014","January 2014","September 11, 2013",,"April 1, 2015","University of Virginia Center for Diabetes Technology, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01939834" | |
| 561,"NCT05570162","Clinical Efficacy of a Diabetes Educational Program to Improve Flash Adherence in Type 1 Diabetes Patients",,"Recruiting","No Results Available","Type 1 Diabetes","Other: Diabetes educational program","Adherence to Flash 1|Time in range|Adherence to Flash 2|Time below range 1 (TBR1)|Time below range 2 (TBR2)|Time above range 1 (TAR1)|Time above range 2 (TAR2)|Coefficient of variation percentage (CV)|Glucose management index|Time in hypoglycemia|Hypoglycemia frequency|Percentage of patients attaining the the International Consensus on Time in Range (ICTR)","Castilla-La Mancha Health Service","All","18 Years to 99 Years (Adult, Older Adult)","Not Applicable","41","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C-558","November 1, 2022","December 31, 2022","January 1, 2023","October 6, 2022",,"November 30, 2022","Ciudad Real General University Hospital, Ciudad Real, Spain",,"https://ClinicalTrials.gov/show/NCT05570162" | |
| 562,"NCT00545857","Effect of Pioglitazone on the Course of New Onset Type 1 Diabetes Mellitus",,"Completed","No Results Available","Type 1 Diabetes Mellitus","Drug: pioglitazone|Drug: Placebo control","C-peptide response to a Sustacal meal|Insulin requirement|Hemoglobin A1c","Stony Brook University","All","6 Years to 18 Years (Child, Adult)","Phase 1","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20064114","June 2002","May 2012","May 2012","October 17, 2007",,"May 31, 2012","Thomas A. Wilson, MD, Stony Brook, New York, United States",,"https://ClinicalTrials.gov/show/NCT00545857" | |
| 563,"NCT05061030","Mesenchymal Stromal Cells to Treat Type 1 Diabetes in Children and Adolescents",,"Recruiting","No Results Available","Type1diabetes","Biological: the ATMP Protrans","Safety at one year evaluated as adverse events|Safety at five years evaluated as adverse events|Efficacy measured as change in C-peptide Area under the curve to a mixed mealtolerance test.|Insulin independency|Low insulin needs|Insulin needs|HbA1c|Time in target|Time in range|C-peptide|Change in peak C-peptide","Uppsala University Hospital","All","7 Years to 21 Years (Child, Adult)","Phase 1|Phase 2","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","WJMSC-P01","January 14, 2022","September 2028","December 2028","September 29, 2021",,"May 23, 2022","Uppsala University Hospital, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT05061030" | |
| 564,"NCT04601519","Effect of Type 1 Diabetes on Sleep Fragmentation","DIAPASOM5","Unknown status","No Results Available","Type 1 Diabetes","Other: Cross-sectional observational study","Objective sleep fragmentation|Subjective sleep fragmentation|Subjective sleep quality|Subjective impact of type 1 diabetes on sleep quality.|Sleep fragmentation by subgroups","University Hospital, Grenoble","All","18 Years and older (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","38RC18.271|2018-A02474-51","July 1, 2021","November 1, 2021","May 1, 2022","October 23, 2020",,"August 2, 2021","Grenoble Alpes university hospital, Grenoble, France",,"https://ClinicalTrials.gov/show/NCT04601519" | |
| 565,"NCT04428645","Assessment of a Decision Support Tool in Participants With Type 1 Diabetes",,"Completed","Has Results","Type 1 Diabetes","Device: DailyDose Decision Support","Mean Change in the Percent of Time With Sensed Glucose Between 70 - 180 mg/dl|Mean Change in Sensed Glucose|Mean Change in the Percent of Time With Sensed Glucose <70 mg/dl|Mean Change in the Percent of Time With Sensed Glucose <54 mg/dl|Mean Change in the Percent of Time With Sensed Glucose >180 mg/dl|Mean Change in the Percent of Time With Sensed Glucose >250 mg/dl|Change in Coefficient of Variation of Sensor Glucose Based on the Dexcom G6 CGM Data.","Oregon Health and Science University","All","18 Years to 60 Years (Adult)","Not Applicable","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19950","July 21, 2020","November 15, 2021","November 15, 2021","June 11, 2020","May 13, 2022","July 19, 2022","Oregon Health and Science University, Portland, Oregon, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04428645/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04428645" | |
| 566,"NCT04506151","Sleep Optimization to Improve Glycemic Control in Adults With Type 1 Diabetes",,"Recruiting","No Results Available","Type 1 Diabetes","Behavioral: Sleep-Opt|Behavioral: Healthy Living","Sleep variability|Sleep duration|Glycemic control|Diabetes distress|Self-management behavior|Fatigue|Mood","University of Illinois at Chicago|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 65 Years (Adult, Older Adult)","Not Applicable","144","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2020-0374|1R01DK121726","January 19, 2021","April 30, 2025","April 30, 2025","August 10, 2020",,"March 15, 2022","University of Illinois Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04506151" | |
| 567,"NCT05000021","Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes","ReDUCe","Recruiting","No Results Available","Type 1 Diabetes","Behavioral: Telemedicine-Delivered Cognitive Behavioral Therapy","Diabetes Distress Levels|Hemoglobin A1c","Albert Einstein College of Medicine|Juvenile Diabetes Research Foundation|DexCom, Inc.","All","18 Years to 30 Years (Adult)","Not Applicable","150","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","2021-12789","June 27, 2022","March 31, 2025","March 31, 2025","August 11, 2021",,"December 2, 2022","Albert Einstein College of Medicine, Bronx, New York, United States|Yeshiva University, New York, New York, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT05000021/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT05000021" | |
| 568,"NCT05431140","Evaluation of CloudCare in the Treatment of Type 1 Diabetes",,"Recruiting","No Results Available","Type 1 Diabetes","Device: CloudCare","Diabetes Treatment Satisfaction Questionnaire (DTSQc)|% HbA1c|Time in Range (TIR)|Time above Range (TAR)|Time below Range (TBR)|Problem Areas In Diabetes (PAID-5) questionnaire score|Change in mean treatment satisfaction score of the HCP satisfaction Questionnaire|Number of reported complications requiring hospitalizations|Treatment costs of complications requiring hospitalizations|Number of contacts with HCP|Type of contacts with HCP|Time spent by the HCP","Diabeter Nederland BV","All","16 Years to 75 Years (Child, Adult, Older Adult)",,"194","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","DIA-2022-01","June 20, 2022","December 2022","December 2022","June 24, 2022",,"June 29, 2022","Diabeter, Rotterdam, Zuid-Holland, Netherlands",,"https://ClinicalTrials.gov/show/NCT05431140" | |
| 569,"NCT01490619","Resilience Promotion in Teens With Type 1 Diabetes: Preventing Negative Outcomes",,"Completed","No Results Available","Type 1 Diabetes","Behavioral: Healthy Thinking In Teens|Other: Advanced Diabetes Education.","Change in Depressive symptoms from baseline to post intervention and change in Depressive symptoms over the two year study period.|Change in Glycemic Control from baseline to post-intervention and change in Glycemic Control over time during the two year study period.","Ann & Robert H Lurie Children's Hospital of Chicago","All","14 Years to 18 Years (Child, Adult)","Not Applicable","280","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","R01DK090030-01A1","October 2011","September 2016","March 30, 2018","December 13, 2011",,"January 27, 2020","Ann and Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01490619" | |
| 570,"NCT00308256","Effects of Nurse-counselling in the Improvement of the type1 Diabetes Control in Adolescents",,"Completed","No Results Available","Type 1 Diabetes","Behavioral: nurse-counselling","Patient's acceptance of the disease evaluated by an analogical visual scale rating|Glycaemic equilibrium by measuring the rate of glycosylated haemoglobin|Number of diabetic acidosis having required hospitalization,|Episodes number of severe hypoglycaemia having required an intervention of a third party or a hospitalization.","Hospices Civils de Lyon","All","13 Years to 18 Years (Child, Adult)","Not Applicable","77","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","2005.395","March 2006","August 2011","August 2011","March 29, 2006",,"December 30, 2011","Marc Nicolino, Lyon, France",,"https://ClinicalTrials.gov/show/NCT00308256" | |
| 571,"NCT04696640","Pilot Study of Remote Glucose Monitoring Among Pediatric Patients With Type 1 Diabetes",,"Completed","No Results Available","Type 1 Diabetes","Behavioral: Remote Patient Monitoring","Feasibility of remote glucose monitoring for pediatric T1D patients who receive care at UC Davis Health|Change in hemoglobin A1c (HbA1c)|Data-sharing experience survey|Target Glucose Range|Hyperglycemic range|Hypoglycemic range|Overall continuous glucose monitor (CGM) wear time|Remote patient monitoring survey","University of California, Davis","All","1 Year to 20 Years (Child, Adult)","Not Applicable","39","Other","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","1638182","June 3, 2021","April 18, 2022","May 25, 2022","January 6, 2021",,"June 2, 2022","University of California-Davis, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT04696640" | |
| 572,"NCT04800536","Cardiovascular Effects of Rapidly Declining Plasma Glucose in Patients With Type 1 Diabetes",,"Active, not recruiting","No Results Available","Type 1 Diabetes","Other: Rapidly declining plasma glucose|Other: Slowly declining plasma glucose","QTc interval|Cardiac function|Heart rate variability|Haemostatic balance|Endothelial activation and damage|Plasma glucose decline rate and counterregulatory hormonal response|Plasma glucose decline rate and oxidative stress|Plasma glucose decline rate and potassium|Plasma glucose decline rate and symptomatic response","Steno Diabetes Center Copenhagen|University Hospital, Gentofte, Copenhagen|Rigshospitalet, Denmark","All","18 Years and older (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Other","H-20033627","June 1, 2021","December 16, 2021","April 1, 2023","March 16, 2021",,"May 13, 2022","Steno Diabetes Center Copenhagen - Gentofte Hospital, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT04800536" | |
| 573,"NCT05308836","Evaluate Safety of Adipose Derived Mesenchymal Stem Cell Transplantation for Type 1 Diabetes Treatment",,"Recruiting","No Results Available","Type 1 Diabetes","Combination Product: adipose-derived messenchymal stem cell","Safety measure|HbA1c|Fasting blood glucose (FPG)|C-peptide levels|Blood insulin|Insulin dose","Vinmec Research Institute of Stem Cell and Gene Technology|Gwoxi Stem cell applied technology Company","All","5 Years and older (Child, Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ISC20.01","October 4, 2021","October 30, 2022","October 30, 2023","April 4, 2022",,"April 4, 2022","Vinmec Research Institute of Stem Cell and Gene Technology, Hanoi, Vietnam",,"https://ClinicalTrials.gov/show/NCT05308836" | |
| 574,"NCT02518945","Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes",,"Completed","No Results Available","Type 1 Diabetes Mellitus","Drug: Dapagliflozin|Drug: Insulin|Drug: Liraglutide|Drug: Dapagliflozin placebo","To detect a difference from baseline in mean HbA1c before and after 12 weeks of addition of dapagliflozin compared to placebo.|Comparison of the time spent at glucose concentrations between 70-160; 160-240; 240--401; 55-70; <55 mg/dl before and after treatment with 12 weeks of dapagliflozin in addition to liraglutide and insulin.|Comparison of 24-hour urine glucose excretion before and after 12 weeks of treatment of dapagliflozin in addition to liraglutide and insulin.|Comparison of the total daily insulin requirements in units and units per kilogram before and after treatment 12 weeks of dapagliflozin in addition to liraglutide and insulin.|Comparison of Body weight in Kilograms before and after 12 weeks treatment with dapagliflozin in addition to liraglutide and insulin.|Comparison of Systolic and diastolic blood pressure in mm Hg before and after 12 weeks treatment with dapagliflozin in addition to liraglutide and insulin.|Comparison of Postprandial glucose concentrations following a test meal as areas under the curve for the data obtained from the meal challenge. before and after 12 weeks treatment with dapagliflozin in addition to liraglutide and insulin.|Comparison of Carbohydrate intake in grams and in terms of carbohydrate helpings(frequency) before and after 12 weeks treatment with dapagliflozin in addition to liraglutide and insulin.|Comparison of quality of life measures using Diabetes Specific Quality of Life Scale (DSQOLS) and problem areas in Diabetes survey (PAID) scores before and after 12 weeks treatment with dapagliflozin in addition to liraglutide and insulin.","University at Buffalo","All","18 Years to 80 Years (Adult, Older Adult)","Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1969","August 2015","December 2015","February 2016","August 10, 2015",,"August 29, 2022","ECMC Ambulatory Center, 3rd Floor, Buffalo, New York, United States",,"https://ClinicalTrials.gov/show/NCT02518945" | |
| 575,"NCT01220479","Exercise Training Intervention in Children With Type 1 Diabetes","Diabex","Completed","No Results Available","Type 1 Diabetes Mellitus","Behavioral: Exercise training program","Bone mineral density and content|Anthropometrics|Blood lipids levels|Physical activity|Nutrition|Circulating bone biomarkers levels|Glycated Haemoglobin|Systemic blood pressure|Body composition","University Hospital, Geneva|Swiss National Science Foundation","All","8 Years to 16 Years (Child)","Not Applicable","59","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","snf n°63164","September 2001","December 2008","June 2009","October 14, 2010",,"October 14, 2010","University Hospital of Geneva, Geneva, Switzerland",,"https://ClinicalTrials.gov/show/NCT01220479" | |
| 576,"NCT04520971","Closed-loop Insulin Delivery in Pregnant Women With Type 1 Diabetes","CRISTAL","Recruiting","No Results Available","Type1 Diabetes","Device: 780G|Device: standard of care","time in range|time in range during the night|time below low day and night|overnight time low|time in range during the day|time in range early pregnancy|time in range during each trimester|HbA1c during each trimester|mean glucose|time above target (140mg/dl)|time above target (180mg/dl)|time below target (50mg/dl)|time below target (54mg/dl)|duration of hypoglycemia|time in nonpregnant target range|CGM compliance|insulin dose|glycemic variability|variation glucose values|MAGE|nocturnal hypoglycemia|severe hypoglycemia|rate of diabetic keto-acidosis|gestational duration|duration hospitalization delivery|type of labor|type of delivery|rate of preterm delivery|rate of gestational hypertension|rate of worsening of chronic hypertension|rate of preeclampsia|rate of eclampsia|rate of HELLP syndrome|rate of IUGR|rate of fetal malformation|rate of miscarriage|rate of termination of pregnancy|rate of stillbirth|rate of neonatal death|sex of infant|birth weight|rate of shoulder dystocia|rate of birth trauma|rate of respiratory distress|rate of hyperbilirubinaemia|rate of macrosomia|rate with high birth weight|rate of LGA infant (lage for gestational age)|rate of SGA infant (small for gestational age)|number with very large gestational age infants|cord blood ph|rate of neonatal hypoglycemia|rate of NICU admission|duration NICU admission|rate of fetal hyperinsulinemia|skinfolds newborn|neonatal fat mass|number with composite neonatal outcome","Universitaire Ziekenhuizen KU Leuven|University Hospital, Ghent|Universitair Ziekenhuis Brussel|University Hospital, Antwerp|Imelda Hospital, Bonheiden|AZ Sint-Jan AV|AZ Delta|Onze Lieve Vrouw Hospital|General Hospital Groeninge|AZ Nikolaas|AZ Turnhout|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","Female","18 Years to 45 Years (Adult)","Not Applicable","95","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","S64308","January 15, 2021","May 2023","June 2023","August 20, 2020",,"October 12, 2022","OLV Aalst-Asse, Aalst, Oost-Vlaanderen, Belgium|Imelda Bonheiden, Bonheiden, Belgium|AZ St Jan Brugge, Brugge, Belgium|UCLouvain, Brussels, Belgium|UZ Brussel, Brussel, Belgium|UZ Gent, Gent, Belgium|AZ Groeninge Kortrijk, Kortrijk, Belgium|UZ Leuven, Leuven, Belgium|AZ Roeselare, Roeselare, Belgium|AZ Nikolaas, Sint-Niklaas, Belgium|AZ Turnhout, Turnhout, Belgium|Amsterdam UMC, Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT04520971" | |
| 577,"NCT03407599","A Trial Comparing the Pharmacokinetic Properties of Fast-acting Insulin Aspart Between Children, Adolescents and Adults With Type 1 Diabetes",,"Completed","No Results Available","Diabetes|Diabetes Mellitus, Type 1","Drug: Faster aspart|Drug: Insulin aspart (NovoRapid®)","AUC(IAsp),0-12h, area under the serum insulin aspart concentration-time curve from 0 to 12 hours|AUCIAsp,0-15min, area under the serum insulin aspart concentration-time curve 0 to 15 minutes|AUCIAsp,0-30min, area under the serum insulin aspart concentration-time curve from 0 to 30 minutes|AUCIAsp,0-1hr, area under the serum insulin aspart concentration-time curve from 0 to 1 hour|AUCIAsp,0-1½hr, area under the serum insulin aspart concentration-time curve from 0 to 1½ hour|AUCIAsp,0-2hr, area under the serum insulin aspart concentration-time curve from 0 to 2 hours|Cmax,IAsp, maximum observed serum insulin aspart concentration|tmax,IAsp, time to maximum observed serum insulin aspart concentration|Onset of appearanceIAsp, time from trial product administration until the first time serum insulinaspart concentration greater than or equal to Lower Limit Of Quantitation (LLOQ)|Duration of exposureIAsp, time from trial product administration until the first time serum insulin aspart concentration is equal to LLOQ in the terminal part of the curve|Time to 50% Cmax, IAsp, the first time point where the insulin aspart concentration equals 50% of Cmax,IAsp|Time to late 50% Cmax,IAsp, the last time point where the insulin aspart concentration equals 50% of Cmax,IAsp|Mean change in plasma glucose concentration from 0-1 hour after administration|Mean change in plasma glucose concentration from 0-2 hours after administration|Mean change in plasma glucose concentration from 0-6 hours after administration|Change from baseline in plasma glucose concentration 1 hour after administration|Change from baseline in plasma glucose concentration 2 hours after administration|Plasma glucose concentration 1 hour after administration|Plasma glucose concentration 2 hours after administration|Maximum plasma glucose excursion after administration|Maximum plasma glucose concentration after administration|Time to maximum plasma glucose concentration after administration|Minimum plasma glucose concentration after administration|Number of adverse events|Number of hypoglycaemic episodes","Novo Nordisk A/S","All","6 Years to 64 Years (Child, Adult)","Phase 1","46","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NN1218-4371|2017-002014-31|U1111-1197-0428","January 8, 2018","July 5, 2018","July 5, 2018","January 23, 2018",,"June 19, 2019","Novo Nordisk Investigational Site, Hannover, Germany",,"https://ClinicalTrials.gov/show/NCT03407599" | |
| 578,"NCT04949022","Glycemic Outcomes and Safety With Minimed 780G System in Children With Type 1 Diabetes Aged 2-6 Years",,"Recruiting","No Results Available","Type 1 Diabetes","Device: Medronic 780G insulin pump","Time in range (glucose between 3.9-10 mmol/l) before and during hybrid close loop insulin pump treatment|The number of severe hypoglycemia before and during hybrid close loop insulin pump treatment|Number of diabetic ketoacidosis in participant before and during hybrid close loop insulin pump treatment|Diabetes distress before and during hybrid close loop insulin pump treatment|HbA1c before and during hybrid close loop insulin pump treatment","Helsinki University Central Hospital|Medtronic International Trading Sarl","All","2 Years to 6 Years (Child)","Not Applicable","38","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ERP-2020-12544","August 23, 2021","October 1, 2022","December 31, 2023","July 2, 2021",,"January 25, 2022","Helsinki University Hospital, New Children's Hospital and Jorvi Hospital, Helsinki, Finland",,"https://ClinicalTrials.gov/show/NCT04949022" | |
| 579,"NCT01899872","Effect of Acute Exercise on Endothelial Function in Patients With Type 1 Diabetes.","EAEEFD","Unknown status","No Results Available","Type 1 Diabetes Mellitus","Behavioral: Resistance exercise session|Behavioral: Aerobic exercise session","Circulating endothelial progenitor cells|Forearm vascular reactivity","Hospital de Clinicas de Porto Alegre","Male","18 Years to 45 Years (Adult)","Not Applicable","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","100400","December 2011","November 2013","December 2013","July 16, 2013",,"July 16, 2013","Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil",,"https://ClinicalTrials.gov/show/NCT01899872" | |
| 580,"NCT05153070","Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes","DF-IL2-REP","Recruiting","No Results Available","Type 1 Diabetes","Drug: Cyclosporin|Drug: ILT101|Drug: Placebo","Treg variation|Change in Area under curve (AUC (T0-T120) of serum C-peptide at month 6|Change in Area under curve (AUC (T0-T120) of serum C-peptide at month 12|Change in Area under curve (AUC (T0-T120) of serum C-peptide at month 24|Variation in HbA1c value (in %) during the treatment period and during the 1-year follow-up period compared to Baseline at day 63,|Variation in HbA1c value (in %) during the treatment period and during the 1-year follow-up period compared to Baseline at month 3|Variation in HbA1c value (in %) during the treatment period and during the 1-year follow-up period compared to Baseline at month 6|Variation in HbA1c value (in %) during the treatment period and during the 1-year follow-up period compared to Baseline at month 9|Variation in HbA1c value (in %) during the treatment period and during the 1-year follow-up period compared to Baseline at month 12|Variation in HbA1c value (in %) during the treatment period and during the 1-year follow-up period compared to Baseline at month 18|Variation in HbA1c value (in %) during the treatment period and during the 1-year follow-up period compared to Baseline at month 24|Variation in IDAA1c scoreduring the treatment period and during the 1 year follow-up period at day 63|Variation in IDAA1c scoreduring the treatment period and during the 1 year follow-up period up to month 3|Variation in IDAA1c scoreduring the treatment period and during the 1 year follow-up period at month 6|Variation in IDAA1c scoreduring the treatment period and during the 1 year follow-up period at month 9|Variation in IDAA1c scoreduring the treatment period and during the 1 year follow-up period at month 12|Variation in IDAA1c scoreduring the treatment period and during the 1 year follow-up period at day month 18|Variation in IDAA1c scoreduring the treatment period and during the 1 year follow-up period at month 24|Change in Insulin requirement (insulin dose in international units per kilogram per 24 h) during the treatment period and during the 1 year follow-up period at day 30|Change in Insulin requirement (insulin dose in international units per kilogram per 24 h) during the treatment period and during the 1 year follow-up period at day 63|Change in Insulin requirement (insulin dose in international units per kilogram per 24 h) during the treatment period and during the 1 year follow-up period at month 3|Change in Insulin requirement (insulin dose in international units per kilogram per 24 h) during the treatment period and during the 1 year follow-up period at month 6|Change in Insulin requirement (insulin dose in international units per kilogram per 24 h) during the treatment period and during the 1 year follow-up period at month 9|Change in Insulin requirement (insulin dose in international units per kilogram per 24 h) during the treatment period and during the 1 year follow-up period at month 12|Change in Insulin requirement (insulin dose in international units per kilogram per 24 h) during the treatment period and during the 1 year follow-up period at month 18|Change in Insulin requirement (insulin dose in international units per kilogram per 24 h) during the treatment period and during the 1 year follow-up period at month 24|Change in Tregs values (in %/CD4+) after treatment interruption and post-cyclosporin values at day 30|Change in Tregs values (in %/CD4+) after treatment interruption and post-cyclosporin values at day 63|Change in Tregs values (in %/CD4+) after treatment interruption and post-cyclosporin values at month 3|Change in Tregs values (in %/CD4+) after treatment interruption and post-cyclosporin values at month 6|Change in Tregs values (in %/CD4+) after treatment interruption and post-cyclosporin values at month 9|Change in Tregs values (in %/CD4+) after treatment interruption and post-cyclosporin values at month 12|Change in Tregs values (in %/CD4+) after treatment interruption and post-cyclosporin values at month 18|Change in Tregs values (in %/CD4+) after treatment interruption and post-cyclosporin values at month 24|incidence of adverse events at day 30|incidence of adverse events at day 63|incidence of adverse events at month 3|incidence of adverse events at month 6|incidence of adverse events at month 9|incidence of adverse events at month 12|incidence of adverse events at month 18|incidence of adverse events at month 24","Assistance Publique - Hôpitaux de Paris|Iltoo Pharma","All","16 Years to 45 Years (Child, Adult)","Phase 2","24","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","P120142","September 21, 2022","October 2023","July 2025","December 10, 2021",,"November 7, 2022","Lorenzon Roberta, Paris, France",,"https://ClinicalTrials.gov/show/NCT05153070" | |
| 581,"NCT04439903","Web-Based Simulation Tool For Self-Management Support In Type 1 Diabetes Mellitus","WST","Completed","No Results Available","Type 1 Diabetes","Other: Web-based Simulation Tool","Technology Expectation and Technology Acceptance Questionnaires|Diabetes Distress Scale","University of Virginia|Juvenile Diabetes Research Foundation|Tandem Diabetes Care, Inc.","All","21 Years to 65 Years (Adult, Older Adult)","Not Applicable","15","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","200157","October 12, 2020","February 22, 2021","February 22, 2021","June 19, 2020",,"March 12, 2021","University of Virginia - Center for Diabetes Technology, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT04439903" | |
| 582,"NCT03202732","DiabetesFlex - Patient Involvement and Patient-reported Outcome Measures in Type 1 Diabetes",,"Completed","No Results Available","Type1 Diabetes Mellitus","Other: DiabetesFlex","HbA1c|General health will be assessed by items from the SF-36 questionnaire|Health literacy will be assessed by The Health Literacy Questionnaire (sub scale 6 and 9)|Well-being will be assessed by the WHO-5 Well-being Index|Patient Activated Measure (PAM)|""Generic questions concerning patient involvement"" is validate by ""DEFACTUM""|The problem Areas In Diabetes Scale (PAID)|Blood pressure|Urine albumine/creatinine ratio|Number and type consultations|Mortality","Annesofie Lunde Jensen|Aarhus University Hospital","All","18 Years and older (Adult, Older Adult)","Not Applicable","344","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","DiabetesFlex2017","October 9, 2017","August 20, 2020","August 25, 2020","June 29, 2017",,"November 6, 2020","Aahurs University Hospital, Aarhus, Denmark",,"https://ClinicalTrials.gov/show/NCT03202732" | |
| 583,"NCT04019821","Super-Bolus: Effects on Postprandial Glycemia After High Glycemic Index Meal",,"Recruiting","No Results Available","Diabetes Mellitus, Type 1","Drug: Insulin Glulisine|Drug: Insulin Aspart|Drug: Insulin Lispro","Postprandial Glycemia|Hypoglycemia Episodes|Glucose Area Under the Curve (AUC)|Mean amplitude of glycaemic excursion (MAGE)|Capillary blood glucose level 30,60,120,150,180 min after administration of the prandial bolus|Glycemic rise (GR)|Peak glucose level (PG)|Time to glucose peak|Time in postprandial glucose range between 70 to 180 mg/dl (4.0-10.0 mmol/L)","Medical University of Warsaw","All","10 Years to 18 Years (Child, Adult)","Phase 4","72","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","SuperBolus","January 1, 2020","July 2022","January 2023","July 15, 2019",,"January 28, 2022","Department of Pediatric Diabetology and Pediatrics, Pediatric Teaching Clinical Hospital, Warsaw, Poland",,"https://ClinicalTrials.gov/show/NCT04019821" | |
| 584,"NCT01157611","The Effect of Online Based Mentoring Program on the Blood Glucose and Satisfaction Score in Type 1 Diabetes Patients",,"Completed","No Results Available","Type 1 Diabetes","Behavioral: Mentoring program","change of the blood glucose|satisfaction score","Samsung Medical Center","All","18 Years and older (Adult, Older Adult)","Not Applicable","57","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2010-05-065","July 2010","August 2013","August 2013","July 7, 2010",,"November 17, 2015","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01157611" | |
| 585,"NCT04235504","ADvanced Hybrid Closed Loop Study in Adult Population With Type 1 Diabetes","ADAPT","Active, not recruiting","No Results Available","Type 1 Diabetes","Other: MDI|Device: AHCL","HbA1c 6 months change between AHCL and MDI|TIR between 70-180 mg/dL|Time in Hyperglycemic range|Hypoglycemic events","Medtronic Diabetes","All","18 Years and older (Adult, Older Adult)","Not Applicable","124","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CIP327","July 13, 2020","December 2, 2021","July 30, 2022","January 22, 2020",,"December 20, 2021","Centre Hospitalier Universitaire Besancon - Hôpital Jean Minjoz, Besançon, France|CHU de Bordeaux - Hôpital Saint André, Bordeaux, France|CHU Caen, Caen, France|Hospices Civils de Lyon (DIAB-e CARE), Lyon, France|APM - Hôpital de la Conception, Marseille, France|Hospital Civil, Strasbourg, France|Diabetologische Schwerpunktpraxis Dr. Ralf Kolassa, Bergheim, Germany|Zentrum für Diabetologie Bergedorf, Hamburg, Germany|Gemeinschaftspraxis im Westtor Hausarztpraxis & Diabetologische Schwerpunktpraxis, Lage, Germany|Medical Center am Clemenshospital Dr. Winfried Keuthage, Münster, Germany|Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital, Cambridge, United Kingdom|Harrogate and District Hospital - NHS Foundation Trust, Harrogate, United Kingdom|University Hospitals of Leicester NHS Trust Leicester General Hospital, Leicester, United Kingdom|King's College Hospital NHS Foundation Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04235504" | |
| 586,"NCT04247620","DiaBetter Together for Young Adults With Type 1 Diabetes","DiaBetter","Enrolling by invitation","No Results Available","Type 1 Diabetes","Behavioral: DiaBetter Together|Behavioral: Peer Mentor Delivery","Glycemic Control (HbA1c)|Time to First Adult Care Visit|Diabetes Self-Management/Adherence (Self-Care Inventory-Revised, Short Form)|Health-Related Quality of Life (Type 1 Diabetes and Life)|Diabetes Strengths (Diabetes Strengths and Resilience measure)|Social Support (Brief 2-Way Social Support Scale)|Diabetes Distress (Diabetes Distress Scale for Adults with T1D)|Depressive Symptoms (PROMIS Short Form Depression 4a)|Emotional Support (PROMIS Short Form Emotional Support 4a)|Informational Support (PROMIS Short Form Informational Support 4a)|Social Isolation (PROMIS Short Form Social Isolation item)|Transition Readiness (Readiness Assessment of Emerging Adults With Type 1 Diabetes Diagnosed in Youth)|General Quality of Life (Satisfaction with Life Scale)|Subjective Sleep Experiences (Pittsburgh Sleep Quality Index - Revised)|COVID-19 Protective Behaviors (Oelsner MESA COVID-19 - Revised)|COVID-19 Experiences (COVID-19 Experiences Questionnaire for Young Adults with T1D)|Stressful Events (Stressful Event Questionnaire)|Social Vulnerability (CDC/ATSDR Social Vulnerability Index)","Baylor College of Medicine|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Children's National Research Institute","All","17 Years to 35 Years (Child, Adult)","Phase 2","186","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","H-45360|1R01DK119246","December 15, 2020","April 2025","December 2025","January 30, 2020",,"June 10, 2022","Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04247620" | |
| 587,"NCT05626725","Safety and Effectiveness of Automated Insulin Delivery (AID) Systems in Physically Active Adults With Type 1 Diabetes","AIDE-1","Recruiting","No Results Available","Type 1 Diabetes","Device: Automated insulin delivery system","Change in blood glucose levels from start of exercise to nadir during or up to 30 min post exercise.|Hypoglycemic events (n) 120-min before, during and 120-min after recorded structured PA sessions|Hypoglycemic events (n) during (at least 15-min) of habitual PA and 30-min after|Time in range 120-min before, during and 120-min after recorded structured PA sessions|Time in range during (at least 15-min) of habitual PA and 30-min after|CHO intake 120-min before, during and 120-min after recorded structured PA sessions|CHO intake during (at least 15-min) of habitual PA and 30-min after|Glucose variability 120-min before, during and 120-min after recorded structured PA sessions|Glucose variability during (at least 15-min) of habitual PA and 30-min after|Total insulin delivery 120-min before, during and 120-min after recorded structured PA sessions|Total insulin delivery during (at least 15-min) of habitual PA and 30-min after","Institut de Recherches Cliniques de Montreal|University of Alberta","All","18 Years and older (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2023-1190","December 1, 2022","December 31, 2024","December 31, 2024","November 25, 2022",,"December 5, 2022","Institut de Recherches Cliniques de Montréal (IRCM), Mont |
Sign up for free
to join this conversation on GitHub.
Already have an account?
Sign in to comment